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Thesis Overview 
 
 Breast cancer is the second leading cause of cancer-related mortality in 
women and accounts for 33% of all new malignancies.  As many as 12% of 
breast cancer patients present with locally advanced breast cancer (LABC), 
defined as stage 3 disease, i.e. tumours >5 cm and may involve the skin, chest 
wall, or lymph nodes.  Survival outcomes for LABC are poor; only 50% of 
patients survive five years after diagnosis.    Clinical management involves 
neoadjuvant (i.e. pre-operative) chemotherapy (NAC) and this is recommended 
as first-line treatment to downstage tumours before surgery.  However, a 
variable response to treatment has been shown in patients receiving NAC and 
there is evidence that favourable responses to NAC correlate well with 
improved survival.   
 Understanding the likelihood of treatment efficacy at early stages of NAC 
(i.e. before starting treatment or after one chemotherapy cycle) may inform 
physicians and patients about the tumour’s response; ultimately with the 
potential to adapt treatments and improve patient outcomes. Standard methods 
to assess chemotherapy response use clinical palpation or medical imaging, 
such as magnetic resonance imaging (MRI) to measure the changes in tumour 
size during treatment.  However, the major limitations for current imaging 
techniques include expensive equipment, need for contrast agents, or poor 
sensitivity and specificity of gold-standard pathology.  Also, it may take many 
weeks for tumour size to shrink, despite the biological responses that may occur 
much earlier.    With the limitations of current imaging techniques, the 
motivation for this present study was to investigate quantitative imaging 
methods to evaluate tumour biology during early phases of treatment as early-
response markers for breast tumour response to NAC.   
 In this thesis, it is proposed that quantitative imaging using diffuse optical 
spectroscopy (DOS) and quantitative ultrasound (QUS) can be used to address 
the limitations of conventional imaging in breast cancer.  DOS and QUS can 
measure biological and functional properties in tumours which can 
subsequently be used to characterize tumour response.  Although both DOS 
and QUS parameters have previously been studied individually, further work is 
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needed to explore DOS and QUS imaging biomarkers since there remains an 
opportunity to study the temporal relationships between DOS and QUS 
parameters.   This is because with each modality, one can potentially provide 
tumour markers for vascularity, cellularity, cell death and tumour oxygenation, 
which are important hallmarks for tumour progression and tumour killing.  In 
addition, there are further opportunities to investigate DOS imaging before 
chemotherapy in order to predict the likelihood of tumour response to treatment.   
This thesis has four chapters.  To establish the groundwork for this study, 
the first chapter is presented to illustrate the biologically complex breast tumour 
and to present the treatment and clinical problem associated with locally 
advanced breast cancer.  Additionally, in Chapter 1, a review of the literature 
was conducted to evaluate the status of breast imaging to measure 
chemotherapy response in breast tumours.  Several clinical imaging modalities 
were considered, which included magnetic resonance imaging (MRI), computed 
tomography (CT), positron emission tomography (PET) and technetium 99-m 
(99m-Tc) scintigraphy.  Following this, a systematic review was completed 
which focused on studies for diffuse optical spectroscopy (DOS) and 
quantitative ultrasound spectroscopy (QUS).   
In Chapter 2, the research methods are presented within the framework 
of the research questions in this thesis.  The study was composed of two major 
subprojects; in the first subproject, the overarching research question was, “can 
DOS and QUS imaging biomarkers be modelled temporally to measure 
treatment response at early time intervals (i.e. after one or two cycles of 
chemotherapy)?”. The analysis included clustering DOS and QUS features to 
test the predictive value (sensitivity and specificity) to NAC response.   The 
results of the first subproject raised questions about using new image analysis 
techniques (i.e. texture) for DOS.   Thus, the aim of subproject 2 was to 
investigate if DOS imaging before treatment could predict tumour response to 
chemotherapy.  Here, the overarching question of the second subproject was, 
“can DOS-texture markers predict chemotherapy response prior to starting 
treatment?”.   In this component, DOS images were analysed using texture 
features of DOS parametric maps prior to chemotherapy, which were shown to 
provide an increase in DOS-imaging signatures about the tumour’s biological 
features.  Such DOS-texture markers were used in both univariate and 
multivariate analyses to yield statistical models that correlated DOS-texture 
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features with pathological response, as measured by Miller-Payne pathological 
response criteria.   
 In Chapter 3, the results of the study are presented according to each 
subproject.  For subproject one, the results showed that there was a temporal 
relationship between DOS and QUS imaging markers during early phases of 
chemotherapy.  Statistical models were developed and showed that both 
univariate and multivariate DOS and QUS features were correlated to final 
pathological (Miller-Payne) response with an area under the curve (AUC) of 
0.84-1.00 after one week of chemotherapy.    For subproject two, it was found 
that there were significant differences in DOS texture-based features between 
responsive and non-responsive tumours before NAC.  Statistical models using 
machine learning techniques, found that features of tumour oxygenation and 
tumour haemoglobin could predict pathological treatment response with an 
accuracy of 87.8%. 
 Chapter 4 includes a discussion of the current study’s findings and 
compares to the previous literature as presented in the systematic review.  A 
discussion on the status of DOS and QUS imaging as a clinical decision-making 
tool are presented in terms of the current translational gaps that DOS and QUS 
are required to overcome to achieve robust clinical and scientific validation.  
The thesis concludes with limitations and future directions.   
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Abstract 
 
Purpose: This study comprises two subprojects.  In subproject one, the study 
purpose was to evaluate response to neoadjuvant chemotherapy (NAC) using 
quantitative ultrasound (QUS) and diffuse optical spectroscopy imaging (DOS) 
in locally advanced breast cancer (LABC) during chemotherapy.  In subproject 
two, DOS-based functional maps were analysed with texture-based image 
features to predict breast cancer response before the start of NAC.      
Patients and Measurements:  The institution’s ethics review board approved 
this study.  For subproject one, subjects (n=22) gave written consent before 
participating in the study. Participants underwent non-invasive, DOS and QUS 
imaging.  Data were acquired at weeks 0 (i.e. baseline), 1, 4, 8 and before 
surgical removal of the tumour (mastectomy and/or lumpectomy); 
corresponding to chemotherapy schedules.  QUS parameters including the mid-
band fit (MBF), 0-MHz intercept (SI), and the spectral slope (SS) were 
determined from tumour ultrasound data using spectral analysis.  In the same 
patients, DOS was used to measure parameters relating to tumour haemoglobin 
and tissue composition such as %Water and %Lipids.    Discriminant analysis 
and receiver-operating characteristic (ROC) analyses were used to correlate the 
measured imaging parameters to Miller-Payne pathological response during 
treatment.  Additionally, multivariate analysis was carried out for pairwise DOS 
and QUS parameter combinations to determine if an increase in the 
classification accuracy could be obtained using combination DOS and QUS 
parametric models.   
 For subproject two, 15 additional patients we recruited after first giving 
their written informed consent.  A pooled analysis was completed for all DOS 
baseline data (subproject 1 and subproject 2; n=37 patients).  LABC patients 
planned for NAC had functional DOS maps and associated textural features 
generated.  A grey-level co-occurrence matrix (texture) analysis was completed 
for parameters associated with haemoglobin, tissue composition, and optical 
properties (deoxy-haemoglobin [Hb], oxy-haemoglobin [HbO2], total 
haemoglobin [HbT]), %Lipids, %Water, and scattering power [SP], scattering 
amplitude [SA]) prior to treatment.  Textural features included contrast (con), 
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correlation (cor), energy (ene), and homogeneity (hom).  Patients were 
classified as ‘responders’ or ‘non-responders’ using Miller-Payne pathological 
response criteria after treatment completion.  In order to test if baseline 
univariate texture features could predict treatment response, a receiver 
operating characteristic (ROC) analysis was performed, and the optimal 
sensitivity, specificity and area under the curve (AUC) was calculated using 
Youden’s index (Q-point) from the ROC.  Multivariate analysis was conducted to 
test 40 DOS-texture features and all possible bivariate combinations using a 
naïve Bayes model, and k-nearest neighbour (k-NN) model classifiers were 
included in the analysis.  Using these machine-learning algorithms, the pre-
treatment DOS-texture parameters underwent dataset training, testing, and 
validation and ROC analysis were performed to find the maximum sensitivity 
and specificity of bivariate DOS-texture features.        
Results:  For subproject one, individual DOS and QUS parameters, including 
the spectral intercept (SI), oxy-haemoglobin (HbO2), and total haemoglobin 
(HbT) were significant markers for response outcome after one week of 
treatment (p<0.01).  Multivariate (pairwise) combinations increased the 
sensitivity, specificity and AUC at this time; the SI+HbO2 showed a 
sensitivity/specificity of 100%, and an AUC of 1.0 after one week of treatment.    
 For subproject two, the results indicated that textural characteristics of 
pre-treatment DOS parametric maps can differentiate treatment response 
outcomes.  The HbO2-homogeneity resulted in the highest accuracy amongst 
univariate parameters in predicting response to chemotherapy: sensitivity (%Sn) 
and specificity (%Sp) = 86.5 and 89.0%, respectively and an accuracy of 
87.8%.  The highest predictors using multivariate (binary) combination features 
were the Hb-Contrast + HbO2-Homogeneity which resulted in a %Sn = 78.0, 
a %Sp = 81.0% and an accuracy of 79.5% using the naïve Bayes model. 
Conclusion:   DOS and QUS demonstrated potential as coincident markers for 
treatment response and may potentially facilitate response-guided therapies. 
Also, the results of this study demonstrated that DOS-texture analysis can be 
used to predict breast cancer response groups prior to starting NAC using 
baseline DOS measurements.                 
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Chapter 1 
 
Background and Review of the Literature 
 
 
1.0 Chapter Overview 
 
  This chapter has two major components that begins with background 
information on breast cancer (Section 1.1-Section 1.10), followed by a 
literature review of imaging biomarkers studied to measure breast cancer 
response to chemotherapy (Section 1.11-Section 1.14).     
The first component (i.e. background) describes the biologically complex 
tumour and the driving factors that initiate tumour growth and progression.  This 
section focuses on the incidence of breast cancer, its natural presentation, risk 
factors and the current methods used to screen and diagnose breast cancer.  
Here, a definition of locally advanced breast cancer is presented, which 
includes the disease presentation, treatment, toxicity (i.e. side effects of 
treatments) and survival outcomes, which illustrate the clinical problem.  
 The second major component of this chapter (i.e. review of the literature) 
begins in Section 1.11.  Here, the literature review question is presented.  The 
literature review was structured as a narrative review for general imaging such 
as magnetic resonance imaging, computed tomography, positron emission 
tomography and 99m-Tc-Scintigraphy.  Secondly, a systematic review was 
completed for previous research, with a focus on diffuse optical spectroscopy 
and quantitative ultrasound spectroscopy in locally advanced breast cancer.  
Technical frameworks are presented and a quality assessment of studies was 
performed using the QUADAS-2 tool (Quality Assessment of Diagnostic 
Accuracy) and the STARD tool (Standards for Reporting Diagnostic Accuracy).  
The findings of the literature review were used to provide a framework for the 
current thesis study and presented at the end of this chapter.    
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1.1 Cancer 
 
 Cancer is a disease characterized by uncontrolled and aberrant cell 
division (Harrington, 2016). The World Health Organization (WHO) report in 
2011 presented data which showed that 8.2 million deaths were caused by 
cancer globally (Ferlay et al., 2015).  In the United States (2014) alone, the 
annual incidence was 1.7 million cases for all types of cancer  (Siegel et al., 
2014).   Due to an aging population, cancer incidence in the United States is 
expected to grow to 2.14 million cases by 2030; with breast, prostate and lung 
cancers projected to account for 747,000 of the newly diagnosed malignancies 
(Rahib et al., 2014).  In the United Kingdom, there were 357,000 new cancer 
cases in 2014 and cancer incidence rates have grown 12% since the 1990s. 
(Cancer Research UK, 2017)    
Cancer risk factors are correlated to environmental factors, lifestyle 
habits and genetic causes (Torre et al., 2015).  The societal impact of cancer 
can be measured in terms of its negative effect on population health, quality of 
life, and is associated with significant costs to the health care system (Campbell 
and Ramsey, 2009, Will et al., 2000).  The growing trends in cancer-related 
mortality and morbidity have prompted major efforts to improve diagnosis and 
treatment. Therefore, the examination of the onset, development, progression, 
and optimal treatment of cancer has become the focus of substantial research.    
 
1.1.1 Tumourigenesis and Cancer Progression   
                 
 The onset of tumours, known as tumourigenesis is a multistep process 
that involves transformation of normal cells into cells that exhibit rapid and 
unstable cell growth (Beckmann et al., 1997).  Tumourigenesis is dependent on 
several factors such as the  overexpression of oncogenes, cell signal 
amplification, and angiogenesis (Luo and Elledge, 2008). These factors are 
interdependent for tumour growth; for example, oncogenes such as, ras/MAP-
kinase have been shown to initiate new blood vessels in tumours, promote 
tumour growth rate, increase cell signalling activity and enhance the potential 
for invasion and metastasis.  In contrast, other genes play a role in suppressing 
tumour growth (i.e. tumour suppressor genes) and are also part of the DNA 
repair process; for example, BRCA1 and BRCA2 genes (Rak et al., 1995, 
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Carmeliet and Jain, 2000, Atchley et al., 2008, Eerola et al., 2005, Perou et al., 
2000).   
 Hanahan and Weinberg described tumourigenesis and summarized six 
fundamental and interacting characteristics of cancer (Hanahan and Weinberg, 
2011).  These include: 1) tumour cell immortality through deregulated cell 
senescence; 2) resistance factors to cell death; 3) signalling defects that 
promote tumour cell proliferation; 4) blocking growth suppressors; 5) increase in 
angiogenesis; and 6) establishing mechanisms for invasion and metastatic 
spread (Hanahan and Weinberg, 2011).  Tumour cell immortality is caused by 
deregulated cell division and it has been shown that telomeres play an 
important role in this process and particularly in regulating cell senescence1  
(Kelland, 2005).  Tumour cells are genetically programmed to become 
“immortal” and continue to divide uncontrollably, unlike normal cells that either 
die or enter into a senescence state.  Other mechanisms involve defective cell 
signalling pathways that inhibit apoptotic cell death (Elmore, 2007).  This is 
regulated by anti-apoptotic proteins, which include survivin, caspase, Bcl-2, and 
p53 (Elmore, 2007, Lowe and Lin, 2000).  For example, mutations in the p53 
protein affect cell-cycle checkpoints that are responsible for committing cells 
into apoptosis; whereas other proteins such as survivin have been shown to 
supress signalling pathways in the cytoplasm which can lead to cell immortality 
(Escuin and Rosell, 1999).   
 An important hallmark of cancer involves angiogenesis and 
neovascularization (Nishida et al., 2006). Muthukkaruppan et al. (1982) 
described a critical point, termed the ‘angiogenic switch’ when neoplasms 
switch from passive diffusion to vascular perfusion for nutrient supply 
(Muthukkaruppan et al., 1982).  Beyond 2 mm3 in growth, tumours need a 
vascular supply to provide nutrients, oxygen and transport blood-borne 
biochemical signals for survival  (Muthukkaruppan et al., 1982, Nishida et al., 
2006).  The growing vasculature is also driven by tumour cells that release pro-
angiogenic factors such as VEG-F (vascular endothelial growth factor), 
angiogenin, angiostatin, and transforming growth factor.  Tumour cells also 
down-regulate angiogenesis inhibitors such as angiopoietin-2, angiotensin, and 
                                            
1 Cell senescence is “cell aging”, whereby cells are no longer capable of 
replicating, but are metabolically active (Campisi, 2013).   
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angiostatin-2 which lead to uncontrolled vascular growth.  The dysfunctional 
signalling produces vessels that are immature, “leaky”, and poorly formed 
(Nishida et al., 2006).   Tumour blood vessels also increases the risk for 
malignant cells to spread (i.e. metastasize), as the blood vessels serve as 
channels for circulating tumour cells (Hanahan and Weinberg, 2011).  In 
summary, tumourigenesis and sustaining the tumour’s lifecycle involves 
complex oncogene expression, molecular signalling, and angiogenesis.  The 
tumour relies on these processes in parallel to build a microenvironment that 
promotes cell immortality and tissue invasion.  The processes described above 
are also characteristic of neoplasms of the breast.          
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1.2 Breast Cancer 
 
1.2.1 Natural History and Presentation 
 
 The natural history of breast cancer starts with transformation of 
epithelial cells of the terminal duct lobules units (TDLU) (Logan et al., 2015). 
(Santagata et al., 2014, Ellis et al., 2003, Weigelt and Reis-Filho, 2009).  At the 
time of diagnosis, breast cancers may be classified as either non-invasive (i.e. 
in situ) or invasive breast cancer.  Non-invasive breast cancer are characterized 
by tumours that are confined to the lumens of the mammary duct (Burstein et 
al., 2004).  One example of non-invasive breast cancer is ductal carcinoma in 
situ (DCIS), which accounts for approximately 20% of all newly diagnosed 
breast cancers; whereas a rarer form termed lobular carcinoma in situ (LCIS) 
accounts for a smaller portion (0.5-3.9%) of new diagnoses (Logan et al., 2015, 
Burstein et al., 2004).  Both DCIS and LCIS are thought to be precursors to 
invasive breast cancer and their nomenclature refers to their proximity to the 
mammary ducts (DCIS), or terminal duct lobular units (LCIS) (Figure 1.1) (Hu et 
al., 2008). 
 
Figure 1.1:  Breast cancer arises from the epithelial cells of ducts.  A. In 
situ disease (A) is characterized as lesions contained within the duct itself, such 
as ductal carcinoma in situ (DCIS).  B.  Invasive carcinomas have features that 
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show degradation of the basement membrane (myoepithelium) and invasion 
into the adjacent breast parenchyma. 
 Tumours that spread beyond the luminal ducts of the breast and travel 
into the adjacent parenchyma are termed invasive carcinoma.  There are as 
many as 17 invasive breast cancer subtypes, which are characterized by 
variable histological and molecular features such as hormone receptor status, 
growth hormone amplification, or tumour cell type (Ellis et al., 2003, Weigelt and 
Reis-Filho, 2009) (Table 1.1).  Additionally, as breast cancer progresses, it is 
categorized into stages according to the size of the tumour, its spread into 
lymph nodes and into other parts of the body.  Breast tumour staging is outlined 
in Table 1.2. 
 
 
Histological Classification Prevalence (%) 
(Ellis et al., 2003) 
ICD-O 
Code2 
Invasive Ductal Carcinoma (NOS)1 50-80 8500/3 
Invasive Lobular Carcinoma 5-15 8520/3 
Medullary Carcinoma 1-7 8510/3 
Invasive Cribriform Carcinoma 0.8-3.5 8201/3 
Mucinous Carcinoma 2 8480/3 
Neuroendocrine Tumours 2-5 8249/3 
Invasive Papillary Carcinoma 1-2 8503/3 
Apocrine Carcinoma <4 8401/3 
Lipid-rich Carcinoma 1-6 8314/3 
Metaplastic Carcinoma <1 8575/3 
Pure Tubular Carcinoma <2 8211/3 
Glycogen-rich Clear-cell Carcinoma 1-3 8315/3 
Adenoid Cystic Carcinoma 0.1 8200/3 
Secretory Carcinoma <0.15 8502/3 
Acinic-cell Carcinoma No statistics 8550/3 
Sebaceous Carcinoma No statistics 8410/3 
Table 1.1:  World Health Organization classification of breast cancers.  
1NOS: Not otherwise specified; 2ICD-O Code: International code of diseases-
oncology 
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Stage T N M Description  
Non-Invasive Breast Cancer (In Situ) 
 0 Tis N0 M0 Carcinoma in situ 
Invasive Breast Cancer 
Ea
rly
 B
re
as
t C
an
ce
r 
1 T1 N0 M0 Primary lesion <2 cm 
2A T0 N1 M0 No primary but axillary lesion 
 T1 N1 M0 Primary lesion <2 cm. Involved lymph 
nodes 
 T2 N0 M0 Primary lesion 2 to 5 cm, no node 
involvement 
2B T2 N1 M0 Primary lesion >2 to 5 cm  
Movable axillary lymph nodes 
 T3 N0 M0 Primary lesion > 5cm  
No node involvement 
Ad
va
nc
ed
 B
re
as
t C
an
ce
r  
3A T2 N2 M0 Primary lesion >2 to 5 cm 
Fixed axillary lymph nodes 
 T3 N1, N2 M0 Primary lesion > 5cm  
Movable and/or fixed axillary lymph 
nodes 
3B T4 Any N M0 >5cm, chest wall/skin 
Movable and/or fixed axillary lymph 
nodes 
Internal mammary nodes.   
Includes inflammatory carcinoma 
3C Any T N3 M0 Primary lesion >2 to 5 cm 
Primary lesions >5 cm  
Involvement with chest wall/skin  
Movable and/or fixed axillary lymph 
nodes  
May include internal mammary nodes.   
Includes inflammatory carcinoma 
Metastatic Breast Cancer 
 4 Any T Any N M1 Distant metastasis 
Table 1.2: Clinical presentation and staging for breast cancer, based on TNM 
classification (primary tumour extent [T], nodal Involvement [N], metastatic 
spread [M]).  Note: Stage 2B disease may be considered inoperable in cases 
with chest wall and/or skin involvement  (Hortobagyi et al., 1988). 
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 Other characteristics of breast cancer include differences in tumour-
molecular features such as oestrogen receptor (ER) and progesterone receptor 
(PR) expression, human epidermal growth factor-2 receptor (HER2), and 
proliferative rate (Ki67) (Inic et al., 2014).  These parameters are used to 
classify breast cancer subtypes, as outlined by a consensus guideline at the St. 
Gallen Conference in 2013 (Harbeck et al., 2013, Goldhirsch et al., 2013).  The 
breast tumour subtypes are summarized in Table 1.3.   
 
Breast Cancer 
Subtype 
ER PR HER2 Ki67 (Marker for Proliferation) 
Luminal A + + - Low1 
Luminal B + +/- +/- High1 
Basal-Like - - - n/a 
HER2 Overexpressed - - + n/a 
Table 1.3:  Molecular and cell proliferation characteristics of breast cancer 
according to subtype. 1High and low Ki67 cut-off values were not indicated in 
the St. Gallen consensus statement. 
 
Data from 50,571 women in the United States showed that 72.7% of 
women had luminal A breast cancer; while 12.2% were basal-like.  A smaller 
portion of patients exhibited luminal B breast cancer (10.3%), and only 4.6% of 
all patients demonstrated HER2 overexpressed (HER2+) breast cancer 
(Howlader et al., 2014).   
 
1.2.2 Epidemiology: Incidence and Mortality 
 
 Breast cancer is the second most diagnosed cancer globally (Ferlay et 
al., 2015).  Incidence rates vary among geographic regions; affecting 27 per 
100,000 in Africa and Asia and increasing to 96 per 100,000 in Western Europe 
and 92 per 100,000 in North America (Ferlay et al., 2015).  In terms of mortality 
rates, breast cancer is listed as the fifth leading cause of cancer-related death 
in comparison to other malignancies.  There are 522,000 deaths caused by 
breast cancer each year (Ferlay et al., 2015).  Mortality is also variable between 
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developed and developing countries, and this is caused by differences in 
healthcare infrastructure, ability to access an early diagnosis and treatment. 
 1.2.3 Risk Factors for Developing Breast Cancer 
  
 Race: SEER (Surveillance, Epidemiology, and End Results Program) 
data between 2004-2011 for American women (n= 373,563) indicated that Non-
Hispanic-White and Black women were at highest risk for developing breast 
cancer (Non-Hispanic White women = 71.9% versus Black women = 10.4%) 
(Iqbal et al., 2015).  Incidentally, Stage 3 breast cancer (i.e. locally advanced) 
was indicated as highest (16.6%) in Black women amongst all ethnic groups.  In 
comparison, Asian women demonstrated the lowest incidence of breast cancer 
(range = 0.59%-3.84%) (Newman, 2009, Iqbal et al., 2015) (Figure 1.2).  
 
 
Figure 1.2:  Stage 3 breast cancer incidence according to race. [Adapted from: 
(Iqbal et al., 2015, Newman, 2009)]. Data population: American Women; 
National Cancer Database [NCDB] (2009, n=178,764), SEER (2015, 
n=373,563).    
 
 Gender: Gender is a significant risk factor for new diagnoses; male 
breast cancers are very rare and account for only 1% of all breast cancers 
(Leone et al., 2015). Previous data from 2005 reported 1690 new cases in the 
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United States and of those cases, the mortality rate showed that 460 men died 
of the disease (Jemal et al., 2005).  After a decade, incidence rates have 
increased to 2350 diagnoses in 2015 with a stable mortality rate of 440 deaths 
(18.7%) per year in the United States (Siegel et al., 2015).   
 
 Age: The probability of developing breast cancer over a lifetime is 
12.3%, however there is an increased risk with an increase in age (Siegel et al., 
2015).  The median age for developing breast cancer is 60 years old (Iqbal et 
al., 2015).    Figure 1.3 presents the risk probability in the United States from 
2009 to 2011.  The peak probability is reported in women above 70 years old.  
At this age interval, women demonstrate a 6.7% probability of developing breast 
cancer (i.e., 1 in 15 women) (Siegel et al., 2015).    
 
 
Figure 1.3:  Breast cancer incidence related to age (data on women, 2009-
2011 in the United States).  [Adapted from data obtained by (Siegel et al., 
2015)].  The increased incidence of breast cancer is related to older age.  
Women over the age of 70 show a highest risk of developing breast cancer, 
with a probability of 6.7%, or 1 in 15 women.  The median age for developing 
breast cancer is 60 years old.   Blue dotted line:  Regression line  
 
 Family History and Genetic Conditions:   Hereditary factors account 
for 27% of breast cancer risk; 95% CI [4%, 41%] (Lichtenstein et al., 2000).  
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The risk ratio for breast cancer in women with one first degree relative who has 
breast cancer is 1.8; 95% CI [1.70, 1.91], and increases to 2.93; 95% CI [2.37, 
3.63], when two first degree relatives have breast cancer.  The risk ratio is 3.90; 
95% CI [2.03, 7.49], when three or more relatives have breast cancer 
(Collaborative Group on Hormonal Factors in Breast, 2001).  Women with an 
adoptive parent with breast cancer have not been shown to be at higher risk for 
breast cancer (Zoller et al., 2014).   
 In terms of genetic conditions, women who carry mutations in tumour 
suppressor genes, BRCA-1 (breast cancer susceptibility gene-1) and BRCA-2 
demonstrate a higher risk for breast cancer and this is confounded with age, 
and a family history of breast cancer (King et al., 2003, Antoniou et al., 2003).  It 
should be noted that BRCA mutations are relatively rare in the general 
population; only 0.11%, and 0.12% of the general population express BRCA-1 
and BRCA-2 mutations, respectively.  However, approximately 3.0%-3.1% of 
breast cancer patients under 50 are BRCA-1 and BRCA-2 mutation carriers.    
BRCA-1 or BRCA-2 mutation carriers develop breast cancer earlier in their 
lifetime compared to women who are not carriers (i.e. wild type) (King et al., 
2003).  Each successive year of the carrier’s lifetime confers an increased 
cumulative risk of developing breast cancer.  By 70 years of age the cumulative 
risks are 65% for BRCA-1 mutation carriers and 45% for BRCA-2 mutation 
carriers (Antoniou et al., 2003).   
A family history of breast malignancies elevates breast cancer risk in BRCA 
mutation carriers. Metcalfe et al. (2010) showed that women with BRCA 
mutations whose first-degree relatives are diagnosed with breast cancer by age 
50 or younger demonstrate a hazard ratio of 1.67; 95% CI [1.04, 2.69] for 
BRCA-2 carriers. In comparison, BRCA-1 carriers demonstrate a hazard ratio of 
1.21; 95% CI [0.94,1.57], indicating that there is a weaker familial association to 
breast cancer risk within this group (Metcalfe et al., 2010).  Other genes have 
been suggested in increasing the risk of breast cancer such as TP53 (tumour 
protein-53), ATM (serine/threonine kinase), and CHEK2 (checkpoint kinase-2) 
(Turnbull and Rahman, 2008).  The relative risks associated with gene 
mutations are >10%, 2-3%, and 2-3%, respectively (Turnbull and Rahman, 
2008).  However, the carrier frequency of these gene mutations is very low 
(<0.4%) in the general population (Turnbull and Rahman, 2008).      
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 Gynaecological and obstetric history:  Reproductive factors are linked 
to breast cancer risk and include the age at menarche, age of menopause, and 
parity. Women who reach menarche earlier during adolescence are at an 
increased risk of developing breast cancer (McPherson et al., 2000).  A meta-
analysis which included 117 studies showed that each earlier year at menarche 
corresponded to an increased risk of 1.050-fold; 95% CI [1.044,1.057] 
(Collaborative Group on Hormonal Factors in Breast, 2012).  In the same study, 
the later age of menopause was also linked to an increased risk.  For every 
older year of menopause, the risk factor was 1.029; 95% CI [1.025,1.032].  The 
increased risk may be linked to the lifetime exposure to oestrogens (Yager and 
Davidson, 2006).   Parity has been shown to mitigate breast cancer risk 
(Collaborative Group on Hormonal Factors in Breast, 2002). The relative risk of 
developing breast cancer is reduced by 7% with each childbirth (Collaborative 
Group on Hormonal Factors in Breast, 2002).    Also, having children earlier in 
life reduces the risk; each earlier year reduces the relative risk by 3.0% 
(Collaborative Group on Hormonal Factors in Breast, 2002).  Parity has also 
been linked to certain types of breast cancer such as hormone-sensitive breast 
cancer.  There is also evidence to suggest that parous women were 25% less 
likely to develop hormone-sensitive breast cancer.  Also, women who had 
children at an older age were shown to increase their risk by 15% of developing 
hormone-sensitive breast cancer.   Other reproductive-related factors include 
breastfeeding history, the use of oral contraceptives and hormone replacement 
therapy (HRT).  For every year of breastfeeding, the relative risk of breast 
cancer is decreased by 4.3%; 95% CI [2.9, 5.8] (Collaborative Group on 
Hormonal Factors in Breast, 2002).  Oral contraceptives account for an 
increased risk of 1.1%, and post-menopausal HRT is responsible for 3.2% of 
breast cancer cases in the UK (Parkin, 2011b).     
 
Lifestyle Factors: The patient’s lifestyle history can also provide 
important information for risk factors which include: diet, and weight.  Poor diet 
involving high fat intake, and obesity have been suggested as risk factors for 
breast cancer; the risk is double for obese patients (McPherson et al., 2000).   
Finally, alcohol consumption and smoking status have been correlated to 
increasing the lifetime risk of developing breast cancer. Chen and colleagues 
(2011) observed 105,986 women between 1980 and 2008 and evaluated the 
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link between alcohol consumption and breast cancer risk.  The study showed 
that the relative risk (RR) of developing breast cancer was 1.15 when alcohol 
consumption levels ranged between 5.0-9.9 grams/day, which equates to 3-6 
drinks per week (Chen et al., 2011).  A British study by Parkin (2011) showed 
that 6.4% of breast cancer cases between 2000-2001 were attributable to 
alcohol consumption (Parkin, 2011a).  In terms of smoking, a recent study by 
Gaudet et al. (2013) examined data taken from 73, 388 female participants 
enrolled in the American Cancer Society’s Cancer Prevention Study II (CPS-II) 
(Gaudet et al., 2013).  Breast cancer incidence was higher in current smokers 
(Hazard Ratio=1.24), and former smokers (Hazard Ratio=1.13), compared to 
women who never smoked (Gaudet et al., 2013). 
 
1.2.4 Screening and Diagnosis 
 
 Screening for breast cancer is completed under two major routes:  1) a 
self-breast exam (SBE) or; 2) during a routine or urgent referral from the 
general practitioner (GP).  Practicing and educating SBEs have not been shown 
to improve mortality, although awareness is an important aspect to overall 
breast care (Thomas et al., 2002, Austoker, 2003).   A longitudinal study 
examined 266,064 Chinese women over 10-11 years.   The participants were 
randomized into two groups that received either SBE instructions (i.e. taught 
group) or women who did not receive teaching on SBE (non-taught group).  The 
results of the study showed nearly identical death rates related to breast cancer 
between groups (taught group, n=135 versus non-taught group, n=131) 
(Thomas et al., 2002).     
 In the United Kingdom, 51% of women are diagnosed through the “two-
week wait” NHS policy; 31% through screening; 9% by way of routine or urgent 
referrals from general practitioners; and a smaller percentage (4%) are 
diagnosed in the urgent care unit (Cancer Research UK, 2016d).    Quality 
standards for breast cancer screening and diagnosis in the UK have been 
developed by the National Institute for Health and Care Excellence (National 
Institute for Health and Clinical Excellence (NICE), 2009b).  NICE guideline 
standards recommend a “timely diagnosis” where patients are referred to their 
general practitioner or specialist to carry out a triple-diagnostic assessment 
(National Institute for Health and Clinical Excellence (NICE), 2009b).  Within this 
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recommendation, a single visit for the patient would include: 1) clinical 
assessment; 2) mammography and/or ultrasound examination; and 3) a fine-
needle aspiration (FNA) or core biopsy for histological analysis (National 
Institute for Health and Clinical Excellence (NICE), 2009b).  Magnetic 
resonance imaging (MRI) may be recommended for patients when there is poor 
mammographic quality due to dense breasts, or to assess the tumour’s size if 
breast-conserving surgery is indicated (National Institute for Health and Clinical 
Excellence (NICE), 2009b).  The NICE guideline (algorithm) for screening and 
diagnosis is presented in Figure 1.4.   
 
 
Figure 1.4.  Breast cancer screening and diagnosis guidelines were developed 
by the National Institutes for Health and Care Excellence (2009).  The National 
Institutes for Health and Care Excellence make recommendations for a one-day 
service where patients undergo a triple-diagnostic assessment that involves 
clinical assessment (physical palpation), mammography, followed by a fine-
needle aspiration or core biopsy to confirm malignancies in the breast (National 
Institute for Health and Clinical Excellence (NICE), 2009b).       
 
 Medical imaging has an important role in the detection of benign and 
malignant breast masses (Saslow et al., 2007).  However, routine 
mammography has not shown to decrease mortality in women in recent 
screening trials (Miller et al., 2014).  A study by Miller et al. (2014) compared 
survival data for women (n=89,835) who were randomized into two groups: 
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annual physical breast examinations (i.e. clinical examination) with 
mammography versus a control group (no mammography, but clinical 
examination only).  A hazard ratio (HR) of only 1.05 was observed between the 
two patient groups.  The authors concluded that there is no survival benefit  
when routine mammography is given to women annually (Miller et al., 2014).  
 A diagnosis of breast cancer is determined from a core biopsy of the 
primary lesion.   Histological features of the cancer cells may also be collected, 
such as cellularity, grade, molecular and intrinsic features (ER, PR, HER2) to 
help guide treatments (National Institute for Health and Clinical Excellence 
(NICE), 2009b).  Additionally, current guidelines indicate for a biopsy of axillary 
lymph nodes as part of the cancer staging work-up (National Institute for Health 
and Clinical Excellence (NICE), 2009b).  An ultrasound-guided fine-needle 
aspiration is used to confirm for malignancies histologically (National Institute 
for Health and Clinical Excellence (NICE), 2009b).  In cases where there is no 
evidence of disease in the axilla from biopsy, women with early invasive breast 
cancer are recommended for sentinel lymph node biopsy at surgery (National 
Institute for Health and Clinical Excellence (NICE), 2011).  Additional 
investigations include using computed tomography (CT), MRI, or nuclear 
medicine scans to screen for metastasis in cases where advanced breast 
cancer is suspected (Murray et al., 2009).   These involve examinations of the 
liver, lungs, brain, and bones (Whitman and Strom, 2009).  
 Taken together, breast cancer is initiated by environmental, lifestyle, 
biological, and genetic factors.  The development of breast cancer is reliant on 
physiological processes that form biologically diverse tumours.  A diagnosis of 
breast cancer can be alarming to patients and thus clinical standards have been 
outlined in the UK to provide rapid screening and diagnosis.  Despite the efforts 
for health agencies such as the NHS (UK) and Health Canada to provide 
education, rapid screening and diagnosis, a portion of patients may still present 
with advanced disease, such as locally advanced breast cancer (LABC).  LABC 
carries an especially poor prognosis and the survival for patients is low 
compared to early stage breast cancer.  Since LABC can present itself as a 
clinical challenge, the details of its presentation, treatment and thus providing 
the motivation of the thesis is outlined in the next sections.        
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1.3 Locally Advanced Breast Cancer and Treatment 
 
Locally advanced breast cancer, which is described as stage 3 disease, 
characteristically is a lesion greater than 5 cm and may involve the lymph node, 
skin, and chest wall. There is an especially poor prognosis (Newman, 2009, Lee 
and Newman, 2007); incidence rates of LABC in the United States account for 
12.4% of new breast cancer cases in 2015 and 8.5% of cases in the United 
Kingdom (Iqbal et al., 2015, Cancer Research UK, 2016c).  Survival data for 
patients with LABC in America were reported in 2009 using the SEER registry 
(Statistics, Epidemiology, and End-Results Program) (Newman, 2009, 
Tryfonidis et al., 2015).   Mortality rates for locally advanced breast cancer 
ranged between 48%- 52% (Newman, 2009).   British data showed that 
between 2002-2006, only 55.1% of women with stage 3 breast cancer survived 
beyond 5-years (Cancer Research UK, 2016b).  
 Locally advanced breast cancer requires multimodality treatment to 
address both local (primary) disease and potential distant microscopic spread.  
Studies emerged in the 1970s in Europe and the United States, which showed 
that pre-operative (neoadjuvant) chemotherapy for LABC (stage 3 disease) can 
have significant practical and clinical advantages (Broadwater et al., 1991, 
Alvarado-Cabrero et al., 2009).   These advantages included down-staging 
inoperable breast tumours to facilitate resection and allowing clinicians to 
monitor tumour response during therapy (Cance et al., 2002, Honig et al., 
2005).  However, there is still some debate about its benefit; specifically since 
neoadjuvant chemotherapy has not been associated with increasing survival, 
despite these putative advantages (Lee and Newman, 2007).  The following 
section discusses disease management for locally advanced breast cancer, and 
specifically focus on chemotherapy treatment in the pre-operative setting (i.e. 
neoadjuvant chemotherapy).    
 
1.3.1 Multimodality Treatments:  Historical Perspective 
 
 Treatment for locally advanced breast cancer involves multimodality 
treatments that are loco-regional (i.e. surgery or radiation), or systemic (i.e. 
chemotherapy, endocrine therapy, targeted drug therapy) (El Saghir et al., 
2008).  Multimodality treatments for cancer have only been realized in the past 
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70 years of medicine (Lee and Newman, 2007).  Historically, data from the 
1940s reported low rates of survival for patients with stage three breast cancer 
who received mastectomy alone; only 6% of patients lived beyond five years 
(Haagensen and Stout, 1943, Lee and Newman, 2007).  However, it was during 
the 1940s, and 1950s that chemical agents that were intended for military 
warfare were being tested for cancer therapy (DeVita and Chu, 2008).   This 
was initiated from observations that soldiers who were accidentally exposed to 
mustard sulphurs in World War one, and two demonstrated depleted bone 
marrow and lymph nodes and thus research began to study its potential 
treatment for cancer (Krumbhaar and Krumbhaar, 1919, DeVita and Chu, 
2008).  In the late 1960s multidrug chemotherapy “cocktails” were tested for 
breast cancer (Bagley et al., 1972, Canellos et al., 1974).  Early results in the 
1970s using primary chemotherapy-alone, as well as adjuvant chemotherapy 
(i.e. after mastectomy) showed exciting improvements in survival for patients 
with advanced breast cancer (Canellos et al., 1974, DeVita and Chu, 2008).  
The median survival for responders was 13 months compared to 6 months for 
non-responders (Canellos et al., 1974).     
 At the same time, trials between 1960-1975 in the United States 
investigated radiation-alone for locally advanced breast cancer.  However early 
analysis showed high loco-regional failure rates in 37% of patients treated with 
radiation alone (Bedwinek et al., 1982).  Adjuvant radiation improved survival; 
results indicated a significant reduction of 12% in loco-regional failure rates 
(p<0.001) (Bedwinek et al., 1982).  However, distant metastasis remained as a 
clinical problem despite improved local control using radiation and surgery.  
Table 1.4 shows results of that early study (Bedwinek et al., 1982).  
 
(n=183) Percent Failure (%)  
Site Radiation-alone  Radiation + 
Surgery 
p-value 
Local 61 13 0.0001 
Regional 37 12 0.0007 
Distant Metastasis 65 68 0.7 (NS) 
Table 1.4: Radiation and surgery resulted in improved outcomes.  “Failure” end-
points were defined as disease relapse identified within the site after 5+ years.  
(NS); Not Significant 
 In current oncology practice, it has become widely accepted that 
multimodality therapies that combine surgery, chemotherapy, and radiation 
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improve overall survival compared to regimens that exclude one or more 
modalities within the treatment scheme (Cance et al., 2002, Giordano, 2003).  
Since the 1970s, pre-operative (neoadjuvant) chemotherapy, followed by 
surgery, then radiation have become standard treatment approaches for locally 
advanced breast cancer in North America (Valero et al., 1996) (Figure 1.5).  
Multimodality treatment decisions are dependent on the tumour’s response at 
each phase of the patient’s treatment plan.  
The focus of the thesis will therefore examine breast cancer neoadjuvant 
chemotherapy since it is recommended as first-line treatment for LABC in North 
America, and its effects can influence subsequent surgery and radiation for 
patients.  Neoadjuvant chemotherapy for LABC is described in the subsequent 
sections.  
 
 
Figure 1.5:  Multimodality treatments decision tree.  Neoadjuvant 
chemotherapy is administered to allow tumour surveillance during treatment.  
Approximately 84% of patients will have sufficient tumour down-staging for 
mastectomy, then radiation (Cance et al., 2002).   
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1.4 Study Motivations and Aims 1  
 
Identifying the Target Study Population 
 
The motivation for this thesis is based on studying patients with LABC because:  
1) Breast cancer is a global public health problem. 
2) Approximately 8.5% (i.e. 4,700 cases) of breast cancer is diagnosed as 
LABC (i.e. stage 3) in the United Kingdom which accounts for a 
significant patient population.   
3) LABC has a poor 5-year survival rate (55.1%) compared to early stage 
breast cancer which makes it a clinical problem.  
Therefore, the aim of this study will focus on locally advanced breast cancer 
patients and treatments.  Since neoadjuvant chemotherapy is the primary 
treatment for this patient population, the aim of this thesis is to study locally 
advanced breast cancer patients treated with neoadjuvant chemotherapy.   
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1.5 Breast Cancer Chemotherapy 
 
 Chemotherapy drugs are among many types of cytotoxic agents used to 
treat breast cancer.  Chemotherapy strategies destroy cancer cells by targeting 
the cells’ ability to replicate and function.  In many cases, this is achieved by 
disrupting the DNA of cancer cells.  In contrast to normal cells that are able to 
repair itself from cytotoxic effects, cancer cells lack repair mechanisms and 
undergo various forms of cell death such as apoptosis, oncosis or necrosis 
when exposed to chemotherapy (Okada and Mak, 2004).   
 Chemotherapy is administered intravenously for breast cancer over a 
period of several cycles (6-8 cycles, two to three weeks between cycles).  Drug 
strategies also combine several types of drugs simultaneously to target cancer 
cells (Table 1.5, Figure 1.6).  Drug combinations include anthracyclines, 
taxanes, alkylating agents and antimetabolites (Cancer Research UK, 2016a).  
Anthracyclines interfere with DNA regulation (Thorn et al., 2011); taxanes 
disrupt microtubule “building blocks” that are essential for cell replication 
(Dumontet and Jordan, 2010); alkylating agents interfere with DNA formation 
(Fu et al., 2012); and antimetabolites interfere with molecules required for DNA 
synthesis (Parker, 2009).  Employing multiple drug combinations were shown to 
improve survival by the Aberdeen Trial (UK) (Heys et al., 2002).  Patients who 
were randomized for combination drugs demonstrated a 34% rate in 
pathological complete response (pCR) versus 16% for patients who were 
randomized to fewer chemotherapies (Heys et al., 2002) (Figure 1.7).  
  
Chemotherapy Drug Drug Type Chemotherapy Combination 
Cyclophosphamide [C] Alkylating Agent FEC-D or AC-T 
Epirubicin [E] Anthracycline FEC-D 
Doxorubicin [A] Anthracycline AC-T 
Fluorouracil (5FU) [F] Antimetabolite FEC-D 
Docetaxel  [D] Taxane FEC-D 
Paclitaxel [T] Taxane AC-T 
Table 1.5:  Various chemotherapy drug-types are used to treat breast cancer.  
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Figure 1.6:  Chemotherapy is given in several cycles, over a course of several 
weeks.  In this schematic representation, chemotherapy combinations use 
Fluorouracil, Epirubicin, Cyclophosphamide in the first three cycles followed by 
Docetaxel to complete another three cycles (represented in parenthesis).  The 
time intervals are used to allow patients to recover between cycles and to 
monitor the patient’s wellbeing through blood tests and physical examination 
(Cancer Research UK, 2016a).     
 
 
Figure 1.7: [Adapted from (Heys et al., 2002)].  Breast cancer patients (n=162) 
with large or locally advanced breast cancers were treated with various 
chemotherapy treatment schemes (Phase I).  Responders were randomized 
into two treatment arms (Phase II), and results indicated that patients who were 
treated with more combination drugs demonstrated a higher pathological 
complete response rate (34%) in comparison to patients who received fewer 
chemotherapy combinations (16%).      
 22 
Chemotherapy treatment with surgery and radiation have been shown to 
improve survival for breast cancer; however clinical data collected since the 
1980s have shown that there are no significant differences in survival outcomes 
when chemotherapy is administered pre-operatively (neoadjuvant 
chemotherapy) versus post-operatively (adjuvant chemotherapy) (Wolmark et 
al., 2001, Sachelarie et al., 2006).  Data from the United Kingdom at the Royal 
Marsden Hospital reported equivalent survival in both pre-operative and post-
operative chemotherapy-treated groups (Powles et al., 1995).   Thus, there has 
been some confusion about the primary role of pre-operative, versus post-
operative chemotherapy. Fundamental advantages for pre-operative 
chemotherapy are mostly pragmatic; which include improving resection from 
tumour-size reduction, immediate cancer down-staging (i.e. reducing tumour 
extent), permitting clinical surveillance to gauge tumour behaviour to 
chemotherapy (i.e. chemosensitivity), and assess metastatic risk (Valero et al., 
1996, Cancer Research UK, 2016a).  Anecdotal reports also argue that 
maintaining the tumour intact during chemotherapy may improve drug delivery 
since the tumour vasculature is left intact before surgery (Giordano, 2003).   
Disadvantages to neoadjuvant chemotherapy may include delayed loco-
regional treatment and it may complicate tumour resection if tumour response is 
unfavourable.   For patients, the major disadvantages of delaying surgery in 
favour of giving neoadjuvant chemotherapy is the psychological and physical 
burden of having a tumour in the breast over the course of several months of 
chemotherapy (Walker et al., 1999).    
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1.6 Chemotherapy Side Effects 
 
 Although chemotherapy strategies are intended to damage tumour cells, 
treatments also affect normal cells that result in systemic toxicity and side 
effects.  Complications associated with chemotherapy treatment (i.e. treatment 
morbidity) may present as acute side effects such as nausea, hot flashes, and 
dry mouth.  Chronic (long-term) conditions include cardiac and vascular toxicity 
(Meinardi et al., 2000).  However, morbidities such as cardiac toxicity may also 
have an early onset but continues into chronic conditions in later life (Yeh and 
Bickford, 2009).    The following section will describe common morbidities 
associated with chemotherapy treatment.     
 
1.6.1 Cardiac Complications   
 
 Cardiac complications include heart failure, myocardial ischemia, 
hypertension, thromboembolism, and bradycardia, and have been identified 
during anthracycline use (Yeh and Bickford, 2009, Thorn et al., 2011).  The 
mechanism for cardiac toxicity is poorly understood; although there is evidence 
to suggest that reactive oxygen species from anthracyclines form metabolites 
that interfere with cardiac fibrillation by disrupting iron and calcium regulation 
(Thorn et al., 2011).  Another proposed mechanism for causing cardiotoxicity is 
the disruption of mitochondrial respiration that can initiate apoptosis in cardiac 
cells (Clementi et al., 2003).  Other direct effects on cardiac cells have been 
linked to 5-fluorouracil, which has been shown to cause cell hypoxia and 
interfere with metabolic regulation (Meinardi et al., 2000).  Targeted therapies 
such as Trastuzumab have been shown to cause congestive heart failure and 
compromised left-ventricle ejection fractions (Slamon et al., 2001).  Due to 
these potential hazards, drugs are grouped separately to minimize the additive 
toxic effects; for example, Trastuzumab is not recommended in combination 
with anthracycline chemotherapy.  A higher incidence of cardiotoxic effects 
were observed when anthracyclines were given with Trastuzumab (27%) 
compared to Trastuzumab alone (5%) (Hudis, 2007).        
 The incidence of heart failure was documented to be as high as 45% of 
patients who received anthracycline-based drugs (Yeh and Bickford, 2009).  
Other agents such as antimetabolites can induce myocardial ischemia in up to 
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68% of patients.  Fluorouracil has been associated with cardiotoxicity and 
present as severe chest pain, and the death rate (mortality) for these episodes 
is estimated at 13% (Yeh and Bickford, 2009).  
   
1.6.2 Haematopoietic Toxicity 
 
 Cytotoxic effects can occur in blood cells and lead to neutropenia, which 
is a condition associated with severe neutrophil depletion.  Neutrophils are a 
type of white blood cell that are responsible for host immunity to infectious 
agents.  The risk of developing neutropenia increases with age, and its onset is 
associated with anthracyclines and alkylating chemotherapy treatment 
(Crawford et al., 2004).  Consequences associated with hematopoietic toxicity 
include susceptibility to bacterial infections from Escherichia coli, Klebsiella 
pneumoniae, Staphylococcus, Streptococcus, and Enterococcus, and are most 
commonly observed in the digestive tract, lungs and skin (Crawford et al., 
2004).  Symptoms associated with neutropenia present as fevers and fatigue.  
Mortality from neutropenia-related infections have been reported around 8% 
(Crawford et al., 2004).   
 Other complications include neutropenic sepsis which affect specialized 
immune-producing cells in the bone marrow.  Neutropenic sepsis can be fatal 
and mortality rates range between 2% - 21% (National Institute for Health and 
Clinical Excellence (NICE), 2012).  Symptoms associated with neutropenic 
sepsis are similar to neutropenia and involve fever (pyrexia) and susceptibility to 
infections.  Treatments for both conditions involve antibiotic therapy and a 
temporary suspension of chemotherapy until blood tests indicate a recovery in 
neutrophils (National Institute for Health and Clinical Excellence (NICE), 2012).             
 
1.6.3 Gastrointestinal Toxicity   
 
 Damage to the gastrointestinal (GI) system will present as nausea, 
diarrhoea, esophagitis, stomatitis, and mucositis and are associated with many 
chemotherapeutic agents such as taxanes, platinum compounds, 
anthracyclines, and pyrimidine antimetabolites (Boussios et al., 2012).   The 
gastrointestinal system is especially vulnerable to toxicity from 
chemotherapeutic agents since normal cells of the GI system divide rapidly 
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(Boussios et al., 2012).  The onset of symptoms is typically acute; for example, 
cisplatin doses given between 5-120 mg/m2 trigger vomiting (emesis) within 24 
hours after dose administration.  Similarly, alkylating agents cause nausea and 
vomiting as early as 1-2 hours after treatment administration (Boussios et al., 
2012).  The prevalence of symptoms is dependent on the type of 
chemotherapy;  alkylating agents and platinum based compounds showed the 
highest incidence of GI toxicity of up to 90% of patients (Boussios et al., 2012).   
 
1.6.4 Alopecia   
 
 Chemotherapy-induced alopecia is characterized as hair loss on the 
scalp and other parts of the body, and is associated with high anxiety and 
distress in cancer patients (Trueb, 2009).  Cells of the hair follicles are rapidly 
dividing and therefore are prone to injury from cytotoxic therapy (Trueb, 2009).  
The onset of alopecia often occurs one to three weeks after starting 
chemotherapy and full hair-loss typically takes place between one to two 
months (Trueb, 2009).  Chemotherapy agents associated with high rates of hair 
loss include: anthracyclines, alkylating agents, and pyrimidine antimetabolites 
(Chon et al., 2012).  In contrast, platinum-based drugs such as cisplatin rarely 
cause hair loss (Trueb, 2009).             
 
1.6.5 Neurotoxicity 
 
 Neurotoxicity can present in 30-40% of patients as peripheral 
neuropathy.  This condition is described as extremely painful sensations in the 
toes, fingers, and extremities (Wolf et al., 2008).  Peripheral neuropathy can be 
caused by platinum agents, taxanes, and alkylating agents that damage the 
neural cells of the peripheral nerves (Wolf et al., 2008).  The onset of symptoms 
may occur spontaneously during treatment, and present as “tingling” in the toes 
and fingers. Some reports have indicated that full neuropathic recovery is rarely 
achieved; while others have indicated improvement or resolution within 3-6 
months after completing chemotherapy (Kannarkat et al., 2007, Argyriou et al., 
2005).  Other neurotoxic effects include paclitaxel acute pain syndrome.  This 
condition is characterized as arthralgia and myalgia and is experienced in 
approximately 58% of patients who have received paclitaxel drugs as part of 
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their treatment regimen (Wolf et al., 2008).  Despite symptoms experienced in 
the muscle, the suspected mechanism is believed to be caused by 
hypersensitization of neural fibres of the spinothalamic system (Wolf et al., 
2008).         
  
1.6.6 Anaphylaxis    
 
 Hypersensitivity to chemotherapy agents can lead to anaphylaxis 
reactions which involve the rapid activation of inflammatory signals such as 
histamine, cytokines, and chemokines that result in sudden respiratory 
contraction, and cardiovascular response (Castells et al., 2012).  Taxane-
hypersensitivity reactions are common; approximately 30% of patients develop 
some form of hypersensitivity, however improved pre-treatment protocols such 
as administering antihistamines and corticosteroids prior to taxane-infusion 
have reduced the rate to approximately 10% (Castells et al., 2012, Feldweg et 
al., 2005).  The exact mechanism of chemotherapy-induced hypersensitivity is 
still under investigation, however at extremely high doses of paclitaxel (10-100 
times the dose given clinically), human basophil cells were shown to 
demonstrate elevated histamine production (Essayan et al., 1996).           
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1.7 Mechanisms of Chemotherapy Resistance  
 
1.7.1 Pharmacokinetic Influences 
 
 The variability in tumour response is caused in part by differences in drug 
pharmacokinetics; i.e., how the body processes the drugs based on biological 
and physiological mechanisms.  These mechanisms are described by how 
drugs are handled by the body, which include: absorption, distribution, 
metabolism, and excretion (Garattini, 2007).  
 
Absorption and Distribution 
 
 Drug absorption and distribution are important factors, as this represents 
the delivery of chemotherapeutic agents to the tumour (Figure 1.8).  The 
absorption and distribution of chemotherapy in the body affects the 
chemotherapy concentrations.  It has been shown that patients exhibit a two- to 
ten-fold difference in drug concentrations, which subsequently results in 
variable drug doses that can reach the tumour (Evans and Relling, 1989, 
Masson and Zamboni, 1997).  The absorption and distribution of drugs are 
affected by the route of entry into the body.  Many chemotherapies are 
administered through intravenous injection, and therefore the drug’s 
bioavailability is higher when delivered directly into the blood stream, compared 
to when drugs are given orally.  Oral drug administration inhibits optimal 
absorption and distribution since gastric pH and the intestinal villi can act as 
barriers (Undevia et al., 2005).  By contrast, in the vascular/circulatory system, 
drugs are bound to serum proteins such as albumin, that facilitates transport 
and delivery (Garattini, 2007).  In the tumour itself, drug distribution may be 
blocked by tortuous blood vessels that restrict exchange and transport cross the 
vascular barrier (Goel et al., 2011).       
 
Metabolism and Excretion 
 
 Drug metabolism is an important step for activating drugs into molecular 
forms that are recognizable to tumour cells (Figure 1.8).  For example, the 
alkylating agent, cyclophosphamide is biologically active in the liver, which 
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metabolizes cyclophosphamide into intermediate biochemical products that are 
readily transported into the tumour cell (Garattini, 2007).  Metabolic activation 
relies on enzymes such as Cytochrome P450, CYP2B10, CYP2C29, CYP2C19 
and CYP3A, which is responsible for 45-60% of drug activation (Garattini, 2007, 
Undevia et al., 2005).  For patients who are enzyme-deficient, chemotherapies 
are not activated therefore the drugs remain inactive and ineffective in the 
system (Undevia et al., 2005).  Other metabolic defects are caused by 
dysfunctional drug uptake into the cell itself, which are caused by drug efflux 
mechanisms that pump out the drugs across the cell’s plasma membrane 
(Figure 1.9) (Coley, 2008).  
 Excretion can influence drug clearance and is handled by the kidney, 
and biliary tract.  Renal and hepatic dysfunction may affect drug concentrations 
in the blood by rapidly excreting drugs  (Undevia et al., 2005).      
   
 
Figure 1.8:  Drug pharmacokinetics can influence drug resistance.  
Pharmacokinetics are defined by the drug’s interaction with the body through 
absorption, distribution, metabolism and excretion.  The efficacy of a drug can 
be reliant on its bioavailability and biotransformation that activates the 
mechanism of action on the tumour cells.   
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Figure 1.9:  Chemotherapies are transported into the cell by either active 
transport or passive diffusion across the plasma membrane.  Ineffective 
chemotherapy can occur when drug efflux occurs that result in low drug 
concentrations in the cytoplasm.  This results in inadequate delivery of drugs 
into cell targets, such as the nucleus.   
 
1.7.2 Chemotherapy Resistance in Molecular Subtypes 
 
 Breast cancer molecular subtypes, as described earlier as having 
different ER, PR and HER2 status, demonstrate variable response to 
neoadjuvant chemotherapy (von Minckwitz et al., 2012, Carey et al., 2007, 
Rouzier et al., 2005).  Reports of over 6,000 patients have showed that basal-
type, and HER2+ breast cancers have the highest rate of pathological complete 
response (pCR) to anthracycline- and taxane-based chemotherapies (Table 
1.6). In contrast, luminal A and luminal B breast cancers (i.e. ER+, PR+) are 
highly resistant to chemotherapy.  There is evidence in rodent models that 
luminal breast cancer cells exhibit stem-cell-like behaviours that are genetically 
driven and cause tumour cell immortality, higher rates of differentiation, and 
rapid proliferation (Sims et al., 2007).  Some studies have also suggested that 
basal-type tumours have dysfunctional cell-repair mechanisms in comparison to 
luminal A and luminal B tumours that make it more susceptible to 
chemotherapy-induced DNA damage (Desmedt et al., 2008).  Table 1.6 
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summarizes tumour response rates based on breast cancer molecular 
subtypes.        
Reference n Neoadjuvant 
Chemotherapy 
pCR Rate by 
Molecular Subtype 
(Babyshkina et al., 
2014) 
198 5-FU1 
Doxorubicin 
Cyclophosphamide 
Capecitabine 
Taxotere 
Methotrexate 
Luminal A+B: 2.1% 
Basal-Type: 10.7% 
HER2 +:  0.0% 
(Carey et al., 2007) 107 Doxorubicin 
Cyclophosphamide 
Taxotere 
Luminal A+B: 15.0% 
Basal-Type: 27.0% 
HER2 +:  36.0% 
(Chang et al., 2010) 74 Docetaxel 
Carboplatin 
Luminal A+B:  
No Data 
Basal-Type: 55.0% 
HER2 +:  NS 
(Goldstein et al., 2007) 68 5-FU 
Doxorubicin 
Cyclophosphamide 
Epirubicin 
Taxotere 
Luminal A+B: 19.4% 
Basal-Type: 57.1% 
HER2 +:  62.5% 
 
(Kim et al., 2010) 257 Doxorubicin 
Docetaxel 
Luminal A+B: 8.9% 
Basal-Type: 21.1% 
HER2 +:  21.1% 
(Liedtke et al., 2008) 1118 5-FU 
Doxorubicin 
Cyclophosphamide 
Epirubicin 
Paclitaxel 
Luminal A+B: No 
data 
Basal-Type: 22.0% 
HER2 +: No data 
(Rouzier et al., 2005) 82 5-FU 
Doxorubicin 
Cyclophosphamide 
Paclitaxel 
Luminal A+B: 7.0% 
Basal-Type: 45.0% 
HER2 +: 45.0% 
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(Sanchez-Munoz et 
al., 2008) 
127 Doxorubicin 
Cyclophosphamide 
Gemcitabine 
Epirubicin 
Luminal A+B: 5.4% 
Basal-Type: 58.3% 
HER2 +:  39.5% 
(von Minckwitz et al., 
2012) 
4193 Anthracyclines2 
Taxanes2 
Luminal A+B: 13.9% 
Basal-Type: 35.8% 
HER2 +:  43.0% 
 
Table 1.6:  Comparison of chemotherapy response according to breast cancer 
molecular subtypes.  All values within the 95% confidence interval. 15-
Fluorouracil; 2Anthracycline and Taxane type drugs not specified.  NS: Not 
significant; pCR: Pathological complete response.  Luminal A = ER+, PR+. 
HER2-.  Luminal B = ER+, PR+, HER2+.  Basal-Type= “Triple negative” (ER-, 
PR-, HER2-).   
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1.8 Prognostic Factors  
  
1.8.1 Pathological Response to Neoadjuvant Chemotherapy 
 
 Pathological complete response (pCR) is a prognostic indicator and is 
defined as demonstrating no residual disease following chemotherapy (Ogston 
et al., 2003).  There are several methods previously proposed to measure 
pathological response after neoadjuvant chemotherapy as a treatment endpoint 
that include the following classification systems: Chevalier, Sataloff, Residual 
Cancer Burden Index (RCBI), Miller-Payne, and the National Surgical Adjuvant 
Breast and Bowel Protocol B-18 (NSABP B-18), and Residual Disease in Breast 
and Nodes (RDBN) (Marchio and Sapino, 2011) (Table 1.7).  However, there is 
still no consensus on defining or classifying pathologic response in terms of 
pathological complete response and partial response (Corben et al., 2013).  
Resected breast specimens are analysed microscopically to measure 
residual disease, assess cellularity, and examine if any cancer remains in the 
lymph nodes. The agreement on pathological complete response remains 
undetermined; for example, residual disease from ductal carcinoma in situ is still 
defined as pathological complete response for RCBI and Miller-Payne 
classification.  On the other hand, Chevalier classification define pCR as 
complete disappearance of microscopic cells.  This has led to varying practices 
between clinics and has also posed a challenge in research for correlating 
diagnostic tests to final pathologic endpoints (Symmans et al., 2007).      
 Pathological complete response is an important prognostic factor.  There 
is an association between pCR and longer survival; a meta-analysis on 3,182 
locally advanced breast cancer patients demonstrated a better survival time for 
patients who achieved pCR after neoadjuvant chemotherapy (odds ratio: 3.44 
[95% CI: 2.45,4.84]; overall survival=2.3-7.6 years) (Kong et al., 2011).  Another 
study by Chollet et al. (2002) followed 396 locally advanced breast cancer 
patients for 15 years, following neoadjuvant chemotherapy treatment.  A 
significant difference in the disease-free survival (P=0.039) and overall survival 
(P=0.047) was reported in favour of pCR patients compared to partial 
responders (Chollet et al., 2002).  In another study, 87% of patients who 
achieved pCR survived after 5 years (Kuerer et al., 1999).   The rate of 
pathological complete response ranges between 15.2%-17.4% (Kong et al., 
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2011, Chollet et al., 2002).  Although pCR is the desired treatment outcome, 
patients achieving partial response (defined below in Table 1.7) may still benefit 
from therapy and live beyond five years.  The German Breast Group reported 
that smaller residual tumours after chemotherapy were associated with better 
survival (HR range: 1.53-7.97, p<0.001)) (von Minckwitz et al., 2012).  Also, a 
study by Huang et al. (2015) showed that the 5-year overall survival rate for 
partial responders was 68.5% (Huang et al., 2015).  Poor prognosis and low 
survival rates in this response group are attributed mainly to local recurrence 
and distant metastasis (Huang et al., 2015).     
 
System Characteristics Reference 
 
Chevalier 
 
System Classification Type: 
Categorical 
 
Grade 1: Disappearance of all tumour 
either on macroscopic or microscopic 
assessment.  
Grade 2: Presence of in situ carcinoma 
in the breast, no invasive tumour and no 
tumour found in the lymph nodes. 
Grade 3: Presence of invasive 
carcinoma with stromal alteration, such 
as sclerosis or fibrosis. 
Grade 4: No or few modifications of the 
appearance of the tumour.   
 
 
(Chevallier et al., 
1993) 
Miller-
Payne2 
System Classification Type: 
Categorical 
Grade 1: No change or some alteration 
to individual malignant cells but no 
reduction in overall cellularity. 
(Ogston et al., 2003) 
                                            
2 Miller-Payne pathological grading system is used in this study and described 
later in Chapter 2 (Methods) and Chapter 3 (Results).   
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Grade 2: A minor loss of tumour cells 
but overall cellularity still high; up to 
30% loss. 
Grade 3: Between an estimated 30% 
and 90% reduction in tumour cells. 
Grade 4: A marked disappearance of 
tumour cells such that only small 
clusters or widely dispersed individual 
cells remain; more than 90% loss of 
tumour cells.  
Grade 5: No malignant cells identifiable 
in sections from the site of the tumour; 
only vascular fibroelastotic stroma 
remains often containing macrophages.  
However, ductal carcinoma in situ 
(DCIS) may be present.   
No assessment of lymph nodes.   
 
NSABP B-
18 
System Classification Type: 
Categorical 
Pathological Complete Response 
(pCR):  No presence or recognizable 
presence of invasive tumour cells 
present.  
Pathological Partial Responder 
(pPR):  Presence of scattered individual 
or small clusters of tumour cells in a 
desmoplastic or hyaline stroma. 
No Pathologic Response (pNR): 
Tumours not exhibiting any of the 
changes and characteristics as listed for 
pCR, and pPR.     
No assessment of lymph nodes.   
 
 
(Fisher et al., 1998) 
(Marchio and Sapino, 
2011) 
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RCB Index System Classification Type: 
Continuous 
Parameters used to calculate the RCB 
index:  
Primary Tumour Bed: 
1) Primary tumour bed area (mm) 
2) Overall cancer cellularity (%) 
3) Cancer that is in situ disease (%) 
Lymph Nodes: 
1) Number of positive lymph nodes (n) 
2) Diameter of largest metastasis (mm) 
A Cox-regression model is calculated. 
RCBI indices were classified as:   
RCBI0: Pathological complete response 
RCBI1: Moderate response 
RCBI2: Moderate response (relative 
score) 
RCBI3: Extensive residual disease 
RCBI4: Extensive residual disease 
(relative score) 
 
(Symmans et al., 
2007) 
Sataloff System Classification Type: 
Categorical 
 
Tumour Characteristics Scoring (T) 
T-A: Total or near total therapeutic 
effect.  
T-B: Subjectively >50% therapeutic 
effect, but less than total, or near total 
therapeutic effect. 
T-C: <50% therapeutic effect.   
T-D: No therapeutic effect evident.   
Lymph Node Status (N): 
N-A: Evidence of therapeutic effect, no 
metastatic disease. 
(Sataloff et al., 1995) 
(Marchio and Sapino, 
2011) 
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N-B: No nodal metastasis; no 
therapeutic effect.   
N-C: Nodal metastasis; therapeutic 
effect. 
N-D: Nodal metastasis: no therapeutic 
effect.   
Table 1.7:  Pathological response classification systems use variables such as 
primary tumour dimensions, cellularity, and lymph node status to calculate the 
overall pathological scoring.  Some scores are categorical data versus 
continuous data.  The score/index indicates the relative therapeutic effect.            
 
1.8.2 Molecular Features 
 
 Molecular subtypes in breast cancer are associated with variable 
prognosis and survival outcomes (Smid et al., 2008).  A study examining 3,726 
patients showed that the 10-year overall survival rate was 70% in patients with 
luminal A tumours, 54.4% in luminal B tumours, and 52.6% in basal-like 
tumours.  HER2-overexpressed tumours were associated with 48.1% overall 
survival (Kennecke et al., 2010).  A significant decrease in overall survival was 
indicated when distant metastasis was involved; luminal A tumours were 
associated with a median survival of 2.2 years, while patients with luminal B, 
and basal-like tumours had a median survival of 1.6 and 0.5 years, respectively. 
HER2-positive tumours resulted in a survival duration of 0.7 to 1.3 years 
(Kennecke et al., 2010). Women with HER2-overexpressed (i.e. HER2+) 
tumours also presented with the highest relapse rates in the liver and lung 
(Kennecke et al., 2010, Smid et al., 2008).  Additionally, previous work from the 
German Breast Group (GBG) reported improved disease-free survival for 
Luminal B/HER2-, HER2+ (non-luminal), and triple negative (ER-/PR-/HER2-) 
breast cancers that achieve pCR (von Minckwitz et al., 2012).   
 At first glance, there seems to be conflicting data between survival 
outcomes of cancer subtypes and the rate of pathological complete response.  
For example, HER2-overexpressed tumours demonstrate high pCR but also 
have poor prognosis. This is explained as a proportion of HER2-overexpressed 
tumours demonstrate high relapse rates, and therefore patient deaths are 
caused mainly by metastasis to distant organs (Huber et al., 2009).  Despite the 
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generally favourable response rates in HER2-overexpressed tumours; a large 
majority of HER2+ breast tumours do not achieve pathological complete 
response.    
 
1.8.3 Histological Grade (Nottingham Grade) 
 
 According to the American Pathologists Consensus Statement, histologic 
grade is included as a prognostic indicator (Fitzgibbons et al., 2000).  The 
“Bloom-Richardson-Nottingham” grade is calculated from histological features 
such as tubule formation, nuclear pleomorphism, and mitotic count of tumour 
cells (Elston and Ellis, 1991).  The tubule formation describes the morphological 
characteristics of the cell; nuclear pleomorphism denotes the shape, size and 
structure of the cell’s nuclei; whereas mitotic count represents the number of 
cell divisions that are present within the specimen.   Clinicians interpret the 
Nottingham grade as the degree of cellular abnormalities present in the tumour 
and represents the tumour’s “aggressiveness” (Elston and Ellis, 1991).  Table 
1.8 outlines the scoring algorithm of individual features (Table 1.8A) and the 
resulting Nottingham tumour grade (Table 1.8B).  The Nottingham grade has 
been shown to be reproducible with a low relative disagreement rate (RDR) of 
0.10 (95% confidence interval 0.05-0.19) and kappa [k] statistic of 0.77 (95% 
confidence interval: 0.66-0.88) (Harvey et al., 1995). 
 
Histological Features Measured Score 
Tubule Formation (TF)  
 Majority of tumour (>75%) 1 
 Moderate degree (10-75%) 2 
 Little or none (<10%) 3 
Nuclear Pleomorphism (NP)  
 Small, regular uniform 1 
 Moderate increase in size and variability 2 
 Marked variation 3 
Mitotic Counts (MC)1,2  
 0-9 1 
 10-19 2 
 >20 3 
Table 1.8A: Histological grade as measured by the Nottingham grade system. 
1Mitotic counts are counted per ten fields; 2Mitotic counts are based on Leitz 
Ortholux microscope with an objective of 25x, field diameter of 0.59 mm, and 
field area of 0.274 mm2. (Elston and Ellis, 1991).   
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Nottingham Grade (Modified Bloom-Richardson):  Grade 
3-5 points: well differentiated (low) 1 
6-7: moderately differentiated (intermediate) 2 
8-9: poorly differentiated (high) 3 
Table 1.8B: The Nottingham grade is calculated based on the sum of each 
feature score, and represents the potential aggressiveness of the tumour.    
 
 Previous work by Elston and Ellis (1991) showed that the Nottingham 
grade is associated with recurrence-free intervals and disease-free survival 
(Elston and Ellis, 1991).  In this previous study, 1,830 patients were followed for 
up to 16 years after a mastectomy or local excision and radiotherapy (Elston 
and Ellis, 1991).  The patient cohort comprised of 19% of patients who were 
Nottingham grade one, 34% were Nottingham grade two, and 47% were 
Nottingham grade three.  A 16-year follow-up demonstrated that grade one 
patients were significantly correlated to a longer recurrence-free interval 
compared to grade two and three patients (c2=133.70 d/f; p<0.0001).  Also, a 
greater survival rate was significantly correlated to grade one tumours, 
compared to grade two and three tumours (c2=198.06 d/f; p<0.0001).   
 
1.8.4 Nottingham Prognostic Index 
 
 The Nottingham prognostic index (NPI) is modelled from a multivariate 
Cox regression based on an initial analysis of 387 breast cancer patients.  The 
regression model includes multiple prognostic variables (age, menopausal 
status, tumour size, lymph node stage, tumour grade, cell reaction, sinus 
histiocytosis, oestrogen receptor status, adjuvant chemotherapy) to 
prognosticate patient outcomes  (Haybittle et al., 1982, Blamey, 2002).  The NPI 
is described as: 
    
NPI = Grade [1-3] + LN Stage [1-3] + 0.2(Size) [cm] (Equation 1.1) 
 
The NPI categorizes patients into potential prognostic risk groups based on the 
final index (Table 1.9). 
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Prognostic Group NPI range1 
Excellent  2.08-2.40 
Good  2.42-3.40 
Moderate I  3.42-4.40 
Moderate II  4.42-5.40 
Poor 5.42-6.40 
Very Poor 6.50-6.80 
Table 1.9:  The Nottingham Prognostic Index was developed using a Cox 
regression analysis.  The NPI classifies the patient’s prognostic risk into 
categories that range from “Excellent” to “Very Poor”.  1Note the cut-off points 
between categories is based on the mathematical properties of the regression 
model.   
 
Survival data was collected between 1990-1999 for 2,238 patients at 
Nottingham City Hospital.  Researchers found a significant difference in the 10-
year survival between “Excellent” NPI patients compared to other risk 
categories (p<0.001); for example, the 10-year survival for “Excellent” patients 
was 96%, compared to only 38% in patients who were classified as “Very Poor” 
(Blamey, 2002).  Experimental work has also emerged in recent studies using a 
modified Nottingham prognostic indicator “plus” system (NPI+), which includes 
up to ten biomarkers in the Cox regression model: 1) Oestrogen receptor; 2) 
Progesterone receptor; 3) Cytokeratin 5/6 expression; 4) Cytokeratin 7/8; 5) 
Epidermal growth factor receptor, 6) HER2; 7) HER3; 8) HER4; 9) p53; and 10) 
Mucin 1 (Green et al., 2016, Rakha et al., 2014). In those studies, patient 
groups were stratified based on the tumour’s molecular profiles. The modified 
NPI+ tool could differentiate significant differences in survival outcomes 
(p<0.0001) within the following subgroups: oestrogen receptor+, HER2+, and 
triple-negative breast tumours (Rakha et al., 2014, Green et al., 2016).                 
 
1.8.5 Tumour Size and Lymph Node Invasion 
 
 The initial tumour size and lymph node invasion before and after 
neoadjuvant chemotherapy is a prognostic factor (Huber et al., 2009, Honkoop 
et al., 1998, Cianfrocca and Goldstein, 2004).  Data on 2310 Canadian women 
have shown that 15-year overall survival was improved when nodal status was 
negative at diagnosis (survival range 78.5%-91.8%) (Narod, 2012).  Also, larger 
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tumours were associated with a lower survival rate in comparison to smaller 
tumours and this was independent of nodal status (Table 1.10).   
 
 Survival after 15 years (%) 
Tumour Size Group (cm) Node + Node - 
0.1-1.0 80.4 91.8 
1.1-2.0 70.1 89.3 
2.1-5.0 47.1 78.5 
Table 1.10: [Adapted from (Narod, 2012)].  15-year survival data on Canadian 
women (n=2310).  Data demonstrates a negative correlation between survival, 
tumour size, and nodal status.   
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1.9 Case Study 
 
 The purpose of the following section describes the “breast cancer patient 
experience”. In so doing, the patient experience, provides an aid to 
conceptualize Section 1.1 to Section 1.8 where the diagnostic and treatment 
pathway for a typical breast cancer patient, (screening, diagnosis, tumour 
characteristics and treatment frameworks) are relevant to this thesis.  To this 
end, a case study is presented for a 45-year old woman who was diagnosed 
with locally advanced breast cancer, and received treatment at the host 
healthcare institution.    
 
1.9.1 Reason for Referral and Diagnosis 
 
  A 45-year-old, pre-menopausal, woman presented with a left sided mass 
in the upper outer quadrant of the breast, diagnosed as locally advanced breast 
cancer in July 2015.   
 
1.9.2 History of Present Illness and Work-Up 
 
 The patient first discovered a lump in her left breast, during a breast self-
examination in May 2015.  She sought medical attention from her family 
physician who referred her to the Rapid Diagnostic Unit (RDU) at the host 
healthcare institution (Toronto Canada) for further examination.  She underwent 
bilateral mammograms and bilateral breast ultrasound which revealed a benign 
sub-areolar cyst in her right breast, and a hypoechoic mass in her left breast.  
Further investigation included a bilateral ultrasound-guided biopsy, which 
confirmed a cystic lesion measuring 12 x 7 x 11 mm in her right breast.  Results 
of the biopsy indicated malignant cells in the left breast at 2:00 o’clock radian 
position, and histological analysis confirmed invasive ductal carcinoma, which 
was ER/PR positive, and HER2/Neu positive.  A fine needle aspiration biopsy of 
the left axillary lymph node was positive for metastatic lymphadenopathy.   A 
follow-up MRI confirmed malignancy in the left lateral breast; measuring 59 x 27 
x 62 mm and involved both the upper and lower quadrants.  Radiological 
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grading was BIRADS 63.  From the MRI, prominent and thickened left axillary 
lymph nodes, consistent with previous ultrasound findings for lymphadenopathy 
in the left axilla was noted. At the time of diagnosis, the patient did not present 
with any skin changes, erythema, or nipple discharge that would otherwise 
indicate inflammatory breast cancer.  
 Two months later, the patient underwent staging and metastatic work-up; 
CT of the chest, abdomen, and pelvis.  CT of the chest revealed several dense 
nodules measuring 1-3 mm, in the superior segment of the left lower lobe, and 
the right middle lobe.  The nodules were reported as post-pulmonary infection 
fibrosis, and findings did not indicate metastatic disease to the lungs.  CT of the 
abdomen and pelvis did not show any evidence of osseous metastatic disease, 
or otherwise distant metastasis in the soft tissue.  A bone scan was also 
performed, and revealed no abnormalities.  A multi-gated acquisition (MUGA) 
scan was also performed, which revealed a normal cardiac ejection fraction of 
65%.          
   
1.9.3 Past Medical History 
 
 The patient was previously diagnosed with Coeliac disease.  The patient 
reported taking no other medications.  There were no known drug allergies.      
 
1.9.4 Family History and Risk Factors 
 
 The patient’s maternal grandmother was diagnosed with breast cancer.  
There was otherwise no history of breast cancer or ovarian cancer in her family.  
Her gynaecological and obstetric history was gravida 4, parity 3, and abortus 0; 
with her first child at 34 years old.  She had reached menarche at 13 years old 
and was pre-menopausal at the time of consultation.  She was a non-smoker, 
and did not consume alcohol regularly.       
 
                                            
3 Scale 1-6: BIRADS 0 (Incomplete, need for additional imaging); BIRADS 3 
(Benign lesion); BIRADS 6 (Histologically proven malignancy) (Balleyguier et 
al., 2007). 
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1.9.5 Impression and Plan 
 
 The patient was scheduled to receive 6 courses of FEC-D neoadjuvant 
chemotherapy, and Herceptin due to her HER2/Neu status.  Following 
chemotherapy, the patient underwent a total mastectomy approximately 6 
weeks after chemotherapy completion.  Recovery of the chest wall persisted for 
another 6 weeks, in which the patient underwent radiotherapy of the chest wall, 
and supraclavicular nodes for 5 weeks (25 fractions, 50 Gy)4.     
 
1.9.6 Treatment Interval Assessments 
 
The patient presented with shortness of breath approximately after two 
cycles of chemotherapy.  A CT angiogram was ordered to rule out any 
pulmonary embolus, and was negative.  At mid-treatment, she presented with 
mucositis of the mouth, and was referred to a head and neck physician for 
management.  She was prescribed mouthwash (Lidocaine and Nystatin), and 
advised to take over-the-counter Tylenol, which helped resolve the symptoms.  
The patient has also complained of persistent back pain during treatment.  
Given her risk of neutropenia, the patient underwent several blood tests, and all 
blood work was within normal range (haemoglobin, white blood cell count, 
platelet count, and neutrophil count).  Additionally, due to her persistent 
difficulty in breathing, and complaints of chest pain, an echocardiogram was 
ordered and did not reveal any cardiac abnormalities.  After the first (FEC) 
treatment cycle, the patient experienced frequent episodes of diarrhoea, 
however this could have been a result of her Coeliac disease.  Her pain 
increased during treatment; specifically, symptoms of neuropathy and swelling 
were present and the patient was prescribed Tylenol 3 to alleviate pain.  The 
patient presented with low white blood cell count on routine blood work and was 
prescribed Neupogen (i.e. to recover white blood cells).  Due to higher risk of 
infection, the patient was monitored carefully to assess for any signs of 
respiratory distress, or otherwise signs of infection.     
                                            
4 Canadian practice guidelines use NCCN (USA), NINV-1 V.2.2016 (National 
Comprehensive Cancer Network,  2016).  In the UK, breast radiotherapy 
guidelines indicate 40 Gy/15 fractions (Haviland et al., 2013).          
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1.9.7 Post-Treatment Assessments 
 
The post-treatment MRI scan indicated that the patient was responsive to 
treatment and was classified by RECIST5 criteria as having at least a 30% 
decrease in the sum of diameters of the target lesion.  Under pathological 
examination, there was a significant reduction in tumour cellularity, with 
significant fibroadenomas, and fibrosis present within the tumour bed, and the 
patient was determined as a “responder” to chemotherapy treatment.  Figure 
1.10 demonstrates the pre- and post-MRI.   
 
 
Figure 1.10:  Left breast carcinoma prior to treatment (left image) and after 
neoadjuvant chemotherapy (right image).  A significant reduction in the mass 
was observed in the patient, with remaining fibrosis within the tumour bed.  The 
patient mastectomy samples revealed that she responded to treatment.   Red 
arrows indicate the tumour area.   
                                            
5 RECIST is the Response Evaluation Criteria In Solid Tumours and is a system 
used to evaluate tumour size changes from CT and/or MR images.  Response 
categories are based on the overall percent-changes in size:  Complete 
Response (Disappearance of lesion); Partial Response (At least 30% reduction 
in lesion size); Progressive Disease (At least 20% increase in lesion size); 
Stable Disease (Insufficient shrinkage or no overall change) (Eisenhauer et al. 
2009).  
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1.9.8 Case Report Summary 
 
The case report demonstrates that in this patient: 
1) Chemotherapy causes severe toxicity (i.e. side effects) and this can 
affect the patient’s quality of life and wellbeing in this patient only.   
2) The unknown pathological response during treatment is a real clinical 
problem because clinicians cannot modify or adapt treatment based on 
tumour response to therapy.  
In this patient, it was important for this particular patient to know if treatments 
were working or if she was a good candidate for the chemotherapy treatment.   
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1.10 Study Motivations and Aims 2 
 
Identifying the Clinical Problem 
 
The clinical challenges for managing LABC patients include: 
1) A significant proportion of patients (i.e. 80%) will respond only partially 
(i.e. tumours do not demonstrate a significant reduction in size according 
to the current methods, i.e. RECIST). This can make resecting the 
tumour during surgery more difficult. 
2) The proportion of partial responders will be at higher risk for recurrent 
disease, which will affect long-term survival. 
3) Ineffective and suboptimal chemotherapy exposes patients to many 
months of unnecessary chemotherapy toxicity.   
4) Pathologic evaluation of treatment response is completed at the end of 
chemotherapy when it is too late to modify treatments.   
To address these challenges, clinicians have traditionally used clinical palpation 
or conventional medical imaging to measure the changes in the tumour size 
during treatment.  However clinical palpation is unreliable because the 
estimated size may be confounded with fibrosis, collagen, fatty tissue and 
oedema of the breast.  Additionally, palpation only estimates the size at the 
surface of the breast and therefore the deep tumour margins cannot be 
appropriately evaluated.  Conventional medical imaging is also limited since the 
tumour size changes may take several weeks before detectable. Hence, the 
aim for this research was to identify imaging-based markers that could be used 
in the future as a predictor of outcome should the parameters under test 
correlate with the selected endpoint.  The final pathologic endpoints would be 
determined by a standard and systematic technique such as Miller-Payne 
pathological response criteria.   Thus, in the next section, a review of the status 
of existing imaging techniques was completed to identify the gaps, challenges 
and areas for which research could be focused for addressing the current 
clinical problem.      
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1.11 Systematic Review Question and Search Results 
 
1.11.1 Overview and Literature Review Question 
  
This systematic review of the literature is presented as three major 
sections.  In the first section, the literature review strategy and search results 
are presented, as indicated in the following literature search question:   
 
Which previous imaging biomarker analysis and modalities have been studied 
to measure tumour response in locally advanced breast cancer patients treated 
with neoadjuvant chemotherapy? Are there gaps and limitations of using such 
imaging techniques? 
 
The second section presents literature of studies on the following 
imaging modalities as a narrative literature review: 1) Magnetic Resonance 
Imaging (MRI), Positron Emission Tomography (PET), Computed Tomography 
(CT), X-Ray Mammography and 99-Technetium Scintigraphy Imaging (99-Tc).   
In the third section, a systematic review was completed which focussed 
on DOS and QUS imaging only.  This section provides a framework to support 
the research questions of the thesis, which are presented in the subsequent 
chapters (Chapter 3 Methods, and Chapter 4 Results).   
 
1.11.2 Systematic Review Strategy 
 
 A literature review was conducted to find previous studies between 1975-
2016 that used medical imaging to evaluate neoadjuvant chemotherapy 
response in locally advanced breast cancer.  The search dates were selected 
based on the dates that neoadjuvant chemotherapy for breast cancer was first 
introduced as a treatment.  The literature review had two components:  1) a 
narrative literature review of all previous imaging modalities such as MRI, PET, 
CT, X-Ray Mammography, and 99-Tc to evaluate NAC treatment response in 
locally advanced breast cancer; and 2) a systematic review that focused on 
imaging modalities studied in this thesis; specifically, diffused optical 
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spectroscopy (concept 1), ultrasound imaging (concept 2a) and quantitative 
ultrasound spectroscopy (concept 2b).   
 A summary of the search strategy such as databases used, and MESH 
words are outlined in Table 1.11.    For the systematic review, the PRISMA 
Statement (Preferred Reporting Items for Systematic reviews and Meta-
Analyses) was used as a reporting guideline (Moher et al., 2009).     The 
systematic review also evaluated the quality of DOS, US, and QUS studies 
using the following standardized tools: 1) Statement for Reporting Studies of 
Diagnostic Accuracy [STARD] (Bossuyt et al., 2003); and 2) Quality 
Assessment for Diagnostic Accuracy Studies tool (QUADAS-2) (Whiting et al., 
2011).  The literature review search results are indicated in Figure 1.11.    
The literature review did not include imaging studies specifically targeted 
at tumour-size changes as markers for treatment response since the focus of 
this thesis was to study functional imaging for treatment response evaluation.  A 
description of radiological tumour response endpoints and its limitations are 
outlined in Appendix 1 for reference.  To highlight the limitations of size-based 
measurements, previous studies that have used changes in the tumour’s size 
as an indicator for treatment response have reported the following limitations:  
1) objective measurements are not always attainable due to multiple imaging 
planes from MRI and CT (i.e. tumour localization can vary depending on the 
volumetric view); 2) reproducibility (i.e. inter-user variability); 3) and repeatability 
of obtaining the same image quality between imaging series during treatment;  
(Kang et al., 2012, Eisenhauer et al., 2009, Park et al., 2003). 
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CRITERIA DESCRIPTION REFERENCE 
Search 
Databases 
Medline 
PubMed 
EMBASE 
Cochrane library 
Science Direct (secondary 
database after initial search) 
Database search from 1974- 1 
April 2017 
Scally and Brealey, 2010 in 
Medical Imaging and 
Radiotherapy Research, 
(Ramlaul, 2010) 
 
Date entries based on the 
years that NAC have been 
used.   
 
MeSH 
Headings 
Locally advanced breast cancer 
imaging 
Imaging biomarkers 
Neoadjuvant chemotherapy 
Breast cancer response imaging 
markers, neoadjuvant 
chemotherapy 
 
Headings were combined with 
the following key words: 
Sensitivity and specificity 
 
“Related articles” were searched 
 
 
 
 
 
 
 
 
 
STARD guideline (Bossuyt et 
al., 2003) 
Inclusion/Exclusion Criteria 
Number of 
subjects 
Minimum number of 10 subjects 
Case studies also excluded 
Studies with less than 10 
participants could not make 
statistically significant 
conclusions.   
(Leff et al., 2008).   
 
Case studies were excluded 
from this analysis since it is the 
lowest level of evidence and 
are limited in its generalizability 
(Scally and Brealey, 2010 in 
Medical Imaging and 
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Radiotherapy Research, 
(Ramlaul, 2010). 
Types of 
studies  
Human studies included only 
Phantom and pre-clinical 
(animal) work excluded 
Animal and phantom systems 
were used for foundational and 
background information 
 
Anatomic site Breast only Imaging of other anatomic 
sites uses variations in imaging 
system settings, such as 
ultrasound frequency, and 
limitations in imaging depth 
from modalities such as DOS.  
  
Publication 
Dates 
Studies published between 
1974-2016 were included.  
These dates were chosen based 
on the approximate date in 
which NAC was introduced 
clinically.   
Only recent studies within the 
last 10 years were analysed to 
keep the review relevant to the 
improvements in computing 
and image processing 
systems.   
 
Quantitative 
and semi-
quantitative 
imaging studies 
only.   
Tumour size changes were not 
included in search strategy.    
Size and volume 
measurements do not fall 
under the definition of 
biomarkers.  These are 
classified as radiological 
response criteria.       
Table 1.11.  Systematic review search strategy.  A systematic review of 
breast cancer imaging studies was conducted to extract relevant studies that 
were related to neoadjuvant chemotherapy monitoring.   
 
1.11.3 Search Strategy Results 
 
 The literature search resulted in 194 articles related to imaging 
biomarkers after screening for subject relevance and applying the inclusion and 
exclusion criteria.  There were 158 duplicate studies in the search results and 
2804 studies were excluded because the reports were animal and phantom 
experiments, case reports or proceedings, studies on other tumour types, trials 
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that involved experimental or unconventional drugs and therapies, or trials that 
did not examine biologically-based imaging markers.  Of the eligible studies, 
magnetic resonance imaging studies yielded the largest number of studies 
(n=113) for measuring LABC response to NAC. The results demonstrated 
several imaging modalities used to measure chemotherapy response in breast 
cancer from imaging biomarkers such as positron emission tomography (PET; 
n=42), computed tomography (CT, n=1), X-ray mammography (n=1), 99m-
Technium (99-Tc, n=6), diffuse optical tomography (DOS, n=16), and 
ultrasound (US, n=15).  The systematic search strategy and results is presented 
in Figure 1.11.    Results of the literature search showed that medical imaging 
was used to measure biological features such, morphology, blood flow, 
metabolism, cell death, and tissue composition as markers for chemotherapy 
response in breast cancer.  Studies that used tumour volume or size changes to 
measure chemotherapy response did not meet inclusion/exclusion criteria.  
 
 
Figure 1.11:  Systematic search strategy and search results.  A systematic 
literature search was completed for imaging studies conducted between 1974-
2016.  The search strategy was based on identifying imaging systems that were 
used to measure chemotherapy response in breast cancer.  The results of the 
literature search yielded studies that involved MRI, PET, CT, XRAY and 99m-
Technitium, DOS and QUS imaging biomarkers.  The literature review was 
divided into a narrative literature review for MRI, PET, CT, XRAY and 99m-
Technitium.  A systematic review was conducted for DOS and US studies.   
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1.12 Narrative Review of Imaging in Breast Cancer 
 
 The results of the narrative review showed that more than 12,000 locally 
breast cancer patients have been included into imaging studies with the aim of 
measuring tumour response to chemotherapy.  The imaging modalities 
included: MRI, PET, CT, XRAY and 99m-Technitium.  In the proceeding 
sections, these imaging modalities are described and the corresponding studies 
and results are reviewed.   
 
1.12.1 Magnetic Resonance Imaging (MRI) 
 
 MRI-based imaging includes diffusion-weighted imaging (DWI-MRI), 
dynamic contrast enhancement imaging (DCE-MRI), blood-oxygen level 
depending imaging (BOLD-MRI) and MRI-spectroscopy (MRI-SPEC).    These 
techniques are capable of mapping tumour oxygenation, vascularization, 
metabolism and the extracellular matrix as response markers to neoadjuvant 
chemotherapy in breast cancer.  Diffusion-weighted MR measure the diffusion 
of water molecules (i.e. Brownian motion) in tissue (O'Flynn and DeSouza, 
2011, Belli et al., 2011).  Tissue contrast can be displayed in DW-MRI imaging 
based on areas of high and low water diffusion; where areas of low water 
motion (i.e. tumours) demonstrate an enhanced signal.  Previous studies have 
demonstrated that areas with low water motion are associated with malignant 
tissue due to densely arranged cells which limit the motion of water in the 
extracellular space (Belli et al., 2011).       
 Extrinsic contrast imaging techniques include dynamic contrast 
enhancement imaging (DCE-MRI) which detects the concentration of an 
injected contrast agent (gadolinium chelate) in the intravascular and 
extravascular space using primarily T1-weighted signals (O'Flynn and 
DeSouza, 2011).  DCE-MRI images provide information on tumour vascularity 
and blood flow and measures the gadolinium “wash-in” and “wash-out”.  
Tumours preferentially accumulate gadolinium from an increased vascular 
supply compared to normal tissue, and therefore demonstrate an enhanced 
signal in MRI (Craciunescu et al., 2009).  Blood-oxygen level dependent 
(BOLD-MRI) imaging is also used to measure the tumour vascularity, and 
tumour oxygenation.  This is accomplished by detecting deoxyhaemoglobin, 
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which is paramagnetic and therefore results in signal loss in T2-weighted 
images (Jiang et al., 2013).   
 Other techniques include MR spectroscopy imaging (MRI-SPECT) which 
detects the activity of atoms with unpaired protons such as Hydrogen (1H), 
Phosphorus (31P), Sodium (23Na) and Fluorine (19F) within a magnetic field 
(O'Flynn and DeSouza, 2011).  Biochemical compounds such as Choline and 
N-acetyl aspartate (NAA) demonstrate high 1H atomic energy shifts in magnetic 
fields and provide spectral signatures in cancer.   For example, MRI-SPECT 
has been used to distinguish between normal and malignant lesions as well as 
identifying areas of necrosis within tumours (Horska and Barker, 2010).  
Malignancies contain variations in spectral frequencies and peaks within the 
measured signal compared to normal tissue (O'Flynn and DeSouza, 2011).     
  MRI has been used to measure chemotherapy response in breast 
cancer.  The literature search results yielded studies that showed variations in 
the chemotherapy drugs and schedules administered to patients, imaging time-
points measured during chemotherapy, contrast-injection protocols, and data 
analyses used to obtain the sensitivity, specificity and accuracy of imaging tests 
against gold-standard endpoints.  There were variations in the chemotherapy 
drugs and schedules between institutions. Ah-See et al. (2008) did not study 
patient response to taxane-based drugs which are commonly used in breast 
cancer treatment (Ah-See et al., 2008); whereas Cao et al. (2012) used only 
four cycles of chemotherapy compared to conventional 6-8 cycles (Cao et al., 
2012a).  A report by Chang et al. (2002) studied 13 patients using DCE-MRI 
who received variable chemotherapy drugs within their study sample: three 
patients in this study received anthracycline drugs; three patients were given 
taxanes; six patients received weekly taxanes combined with antimetabolites 
and one patient underwent plant-alkaloid chemotherapy as primary treatment   
(Chang et al., 2004).  A Japanese study used 12 cycles of chemotherapy which 
is not traditionally implemented in North America and Europe (Michishita et al., 
2015).  Because of these variations in chemotherapy drug schedules, different 
research groups measured chemotherapy response at different times.  There 
were also variable measured time intervals between patients, within the same 
study, for example, Yu et al. (2010) imaged their patients at variable 
chemotherapy times, i.e. between their second and fourth cycle of 
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chemotherapy (Yu et al., 2010); yet, the results were pooled together.  This may 
have affected the results since chemotherapy response is time-dependent.      
 There were also variations in the MR imaging protocols used to obtain 
quantitative data across studies.  Gadolinium chelate contrast agents used for 
DWI-MRI, DCE-MRI, BOLD-MRI imaging employed a standard injection dose of 
0.1 mmol/kg however the MRI machines used to collect data varied in magnet 
field-strengths that were between 1.5 T-3.0 T.  Experiments by Abramson et al. 
(2013), Ahmed et al. (2013), Ko et al. (2013), and O’Flynn et al. (2011) used 3.0 
T imaging units which can provide greater image resolution, higher signal-to-
noise ratio and thus provide overall better image quality compared to 1.5 T 
systems (Ko et al., 2013, Ahmed et al., 2013, O'Flynn and DeSouza, 2011, 
Abramson et al., 2013, Tanenbaum, 2006).       
 Data processing and analysis techniques included variations in selecting 
the tumour regions of interest (ROIs).  ROIs were selected in either single-frame 
or multi-frame slices of the MRI images, and the distance and slice thickness 
varied between studies which can affect study outcomes.  Also, ROIs were 
selected manually by observers (Wu et al., 2016, O'Flynn and DeSouza, 2011, 
Yu et al., 2010, Pickles et al., 2005) or by using a semi-automated approach 
which used an intensity-map histogram after an initial contour by the observer 
(Teruel et al., 2014, Minarikova et al., 2016).  In select studies, radiologists were 
not involved in MRI analysis to define tumour ROIs which can affect the quality 
of the study and analysis (Atuegwu et al., 2013, Aghaei et al., 2016, Teruel et 
al., 2014, Mani et al., 2013, De Los Santos et al., 2013).  Other studies also 
didn’t report on using blinded-analysis which could potentially cause bias from 
knowing pathologic and radiologic response.   
 
1.12.2 Positron-Emission Tomography (PET) 
 
 PET imaging can be used to measure the metabolic activity by tracking 
the cellular uptake of a glucose analogue, [18F]-fluorodeoxyglucose (FDG).  
FDG is injected intravenously, and transported into cells like glucose and is 
labelled with a radioactive tracer that undergoes radioactive decay; permitting 
PET imaging to map metabolic activity in tissue.  Increase FDG-uptake is 
shown in tumours since tumour metabolism is greater compared to normal 
tissue. PET imaging can therefore serve to identify the extent of malignancies 
 55 
(Andrade et al., 2013).  PET imaging is achieved with the release of a pair of 
annihilation photons and is detected by a photon-detection device during 
radioactive decay; this is known as positron-electron annihilation (Figure 1.12).  
Another radiotracer used in PET includes the radionuclide 15O-H2O, which 
permits tumour blood flow measurements; where the distribution of water can 
be equated to blood activity in blood vessels (Lodge et al., 2000).  
 PET imaging has been studied to measure glycolytic metabolism and 
vascular alterations in breast tumours (Garcia Vicente et al., 2014, Lodge et al., 
2000).  However, there are significant limitations to using PET clinically and 
studies demonstrate data variations based on image processing techniques 
used between studies.  One major limitation includes not being able to use PET 
imaging for patients who are diabetic (Burcombe et al., 2002).  PET imaging 
depends on glycolytic activity and therefore patients with diabetes mellitus (DM) 
who exhibit altered sugar metabolism are excluded for this reason.  Other 
limitations include undetectable signals for smaller tumours.  A study by Park et 
al. (2011) studied 50 patients and reported that 50% of the tumours that were 
not detectable by PET were less than 1 cm in size (Park et al., 2011).  However, 
Kolesnikov-Gauthier et al. (2012) did not find a correlation between tumour size 
and the standard uptake value but all tumours in their study were greater than 2 
cm (Kolesnikov-Gauthier et al., 2012).   
 Imaging protocols were compared between studies and showed 
differences in approaches to acquire PET data.  In terms of preparing patients 
before imaging, patients are required to fast, however the fasting period ranged 
between 4-6 hours between studies (Duch et al., 2009, Martoni et al., 2010) 
(Hatt et al., 2013, Keam et al., 2011, Andrade et al., 2013, Burcombe et al., 
2002).   This can affect the glycaemic index and alter the uptake of the FDG into 
the tumour (Berriolo-Riedinger et al., 2007).   Also, the radiotracer-injection 
doses differed between studies; with some studies adjusting the dose according 
to the subject’s body mass (Ogino et al., 2014); while others gave standard 
doses to all patients (Buchbender et al., 2012). Imaging protocols across 
studies showed differences in the time to measure the SUV after FDG injection.  
Andrade et al. (2013) measured the tracer signal after 90 minutes from 
injecting; while another study by Berriolo-Reidlinger et al. (2007) quantified 
tracer-uptake after 60 minutes (Andrade et al., 2013, Berriolo-Riedinger et al., 
2007).  The elapsed time between tracer injection to its detection can affect the 
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measured signal intensity.  This is due to the tracer’s radioactive decay and its 
time-dependent uptake and clearance from the tumour.      
 
 
Figure 1.12:  PET Imaging.  Tumour cells exhibit high metabolism which 
require energy from glucose.  PET imaging uses radiolabelled FDG molecules 
which are glucose analogues and tracks its uptake in tissue.  FDG molecules 
release a positron and annihilate with an electron to create a pair of annihilation 
photons.  A photon detector collects the radioactive signal and constructs the 
image based on the signal intensity.  
 
1.12.3 Computed Tomography (CT) 
 
 CT imaging uses an X-ray source and detector to construct volumetric 
images based on differences in photon attenuation.  CT helical perfusion 
imaging, which exploits dynamic contrast-enhanced computed tomography 
captures physiological information such as regional tumour blood flow and 
blood volume (Li et al., 2012).  The image resolution is high and data is 
acquired from both the unenhanced anatomical CT-images and images 
obtained from iodinated contrast agents to produce vascular maps (Eastwood 
et al., 2003).  Imaging data is generated from an arterial time-attenuation curve 
that output blood-parameters: blood flow (ml/min/100ml), blood volume (ml/100 
ml), and the flow extraction product (ml/min/100 ml) (Li et al., 2012).   
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 Conventional applications for CT imaging measure the tumour’s size 
during treatment or as an anatomical reference to PET imaging.  However, one 
study by Li et al. (2012) has used quantitative perfusion CT to investigate 
vascular parameters in breast tumours treated with neoadjuvant chemotherapy 
(Li et al., 2012).  These parameters included the regional blood flow (BF), blood 
volume (BV), and the flow extraction product (FE).  The study examined 20 
patients and the results indicated that there was a significant difference in the 
BF, and FE between patients who achieved pathological complete response 
compared to non-responders (P=0.032) and this corresponded to an AUC of 
0.87 (Li et al., 2012).  Although these studies demonstrated promising results, 
the study population was small and no power calculation was included.  
Additionally, CT imaging employed a slice collimation of 5 mm and therefore 
limits this technology from detecting microscopic disease below this size.  
Additionally, the study used a single-observer to analyse the ROI which may 
cause additional bias to the study results.  CT imaging is not advantageous 
because it exposes patients to ionising radiation and therefore limits the number 
of repeated scans that can occur during the patient’s chemotherapy treatment.  
This study also involved variable treatments for patients; one patient received 
an anti-angiogenic drug which can affect the results since blood volume and 
perfusion are measured.  Also, two patients in this study did not undergo 
surgery but were classified as non-responders.  Therefore, not all patients 
underwent standard ground-truth classification and this can affect the results of 
the receiver operating characteristic (ROC) curve.    
 
1.12.4 X-Ray Mammography 
 
 X-Ray mammography for monitoring NAC response uses radiographic 
breast density (BD) to correlate to pathologic response (Elsamany et al., 2015).  
The mammographic BD is defined as the ratio between radio-dense areas to 
normal breast and represents the stromal, epithelial cells, collagen, 
fibroglandular and adipose tissue (McCormack and dos Santos Silva, 2006).  It 
is hypothesized that dense breasts carry an increased risk of aggressive breast 
cancer since dense breasts demonstrate rapidly dividing epithelial cells 
(McCormack and dos Santos Silva, 2006).  Radiographic breast density is 
classified by methods established by Wolfe et al. (1976) into a 4-point scale 
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based on the radiologist’s visual assessment (Wolfe, 1976, Saftlas et al., 1991) 
(Table 1.12). 
 X-Ray mammography has not been studied to monitor chemotherapy 
response in breast cancer; rather the BD from diagnostic x-ray mammograms 
have been previously used as a predictive marker (i.e. before treatment has 
started).  Elsamany et al. (2015) previously showed that patients with a low BD 
on mammographic assessment at diagnosis were more likely to achieve a 
pathological complete response to NAC compared to those patients who had 
dense breasts (p=0.056) (Elsamany et al., 2015).  However, the BD 
demonstrated a relatively poor area under the curve of only 0.59 which 
suggests that the BD is a poor parameter for predicting response in patients.    
There are significant limitations for using mammographic breast density to 
predict treatment response.  One limitation involves the potentially variable 
assessment from the radiologist’s visual assessment of breast density and thus 
can lead to inter-observer variability (Spayne et al., 2012).  This has also been 
observed in both digital and analogue breast images (Spayne et al., 2012).  
Table 1.12 presents the criteria used by radiologists to assess breast density 
based on visual inspection.   
 
BD Category Description 
N1 Non-dense breasts, composed of fat and few fibrous 
connective tissues.  
P1 Beaded linear patterns denoting prominent ducts.  Up to 
25% of the breast presented as nodular densities.   
P2 Prominent duct patterns in radiograph.  Over 25% of the 
breast demonstrates nodular and mammographic 
densities.   
DY Highly dense parenchyma pattern in radiograph.  
Homogenous dense areas which appear like sheet-like 
regions.    
 Table 1.12:  Breast Density (BD) grades for mammographic assessment.   
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1.12.5 Technetium 99m (99m-Tc) scintigraphy 
 
 Previous studies have shown that increased drug efflux in tumour cells is 
mediated by P-glycoproteins (PgP) that can lead to chemotherapy resistance 
(Mechetner and Roninson, 1992).  99m-Tc scintigraphy is a molecular imaging 
technique that measures PgP activity with a radiolabelled tracer, 99m-Tc-
Sestamibi (Ciarmiello et al., 1998).   An increase in 99m-Tc-Sestamibi efflux 
through PgP was previously correlated to increased PgP activity in taxane- and 
anthracycline-based chemoresistant breast tumours (Mittal et al., 2012, 
Ciarmiello et al., 1998).  More recent 99m-Tc scintigraphy techniques include 99m-
Tc-3PRGD2 SPECT to evaluate the vascular status of tumours undergoing 
treatment (Ji et al., 2015).   A radiotracer 99m-Tc-3PRGD2 is used to detect 
biomolecules responsible for vascular and tumour cell growth.  A study by Ji et 
al. (2015) recently reported that 99m-Tc-3PRGD2 SPECT can predict breast 
tumour response to NAC with a sensitivity and specificity of 86.7% and 85.7%, 
respectively (Ji et al., 2015).     
 The major limitation to 99m-Tc scintigraphy is the repeated radiation 
exposure to patients. 99m-Tc scintigraphy is also dependent on the uptake and 
metabolism of radiotracers which can vary between patients (Ji et al., 2015).  
Additionally, patients must be excluded from 99m-Tc scintigraphy on the basis of 
renal and liver dysfunction (Mittal et al., 2012).  Studies also showed variations 
in the tracer’s radioactivity (range: 500-925 MBq) which can potentially alter the 
measured signal intensity if not normalised (Ji et al., 2015, Ciarmiello et al., 
1998, Spanu et al., 2008, Wilczek et al., 2003, Zaman et al., 2009).  In one 
study by Spanu et al. (2008), the analysis included patients who received a 
range of treatment types that included chemotherapy or hormonal therapy only 
(Spanu et al., 2008, Travaini et al., 2007).  A study by Ciarmiello et al. (1998) 
showed that tumour region-of-interest (ROI) selection varied between 3-7% 
which can affect the measurements and outcomes (Ciarmiello et al., 1998).   
 
1.12.6 Summary of Imaging Studies 
 
 A summary of imaging studies (MRI, PET, CT, 99m-Tc Scintigraphy) is 
outlined in Table 1.13, Table 1.14, and Table 1.15.  DOS and QUS imaging 
descriptions are outlined in the subsequent section (i.e. systematic literature 
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review).   Table 1.13 describes the biological measurements associated with 
each imaging modality.  Table 1.14 presents the clinical study characteristics 
and Table 1.15 shows the measured performance outcomes (i.e. the best 
measurements) of each imaging test.   
 
Modality/Technique Biological Measurements Reference 
 
Magnetic Resonance Imaging 
DWI-MRI 
Extracellular water motion 
Tumour-cell density 
Tissue micro-structure 
Cell membrane integrity 
Cell membrane 
permeability 
(Belli et al., 2011) 
(O'Flynn and DeSouza, 2011) 
DCE-MRI 
Vascular permeability 
Dynamic blood flow 
(O'Flynn and DeSouza, 2011) 
(Martincich et al., 2011) 
BOLD 
Tumour oxygenation 
Tumour vascularity 
Angiogenesis 
Blood Volume 
Blood Flow 
(Fan et al., 2011) 
(Jiang et al., 2013) 
(Padhani, 2002) 
SPECT 
Reduction in mitotic count 
Tumour cellularity 
Cell membrane integrity 
Tumour metabolism 
Tissue composition (lipid) 
(Baek et al., 2009) 
(Tozaki et al., 2010) 
   
Positron-Emission Tomography 
 
18F-FDG Tumour metabolism 
(Mankoff et al., 2002) 
 
15O-H2O Tumour blood flow 
(Lodge et al., 2000) 
(Mankoff et al., 2002) 
Computed Tomography Imaging 
DCE-CT 
 
Tumour metabolism 
(Li et al., 2012) 
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Blood flow per unit volume 
in tissue (BF) 
Proportion of tissue with 
blood flow (BV) 
Rate of transfer of contrast 
agent from intra- to 
extravascular space (FE). 
 
X-Ray Mammography 
 
X-Ray 
Stromal cell density 
Epithelial cell density 
Collagen 
Fibroglandular tissue 
Fatty (adipose) tissue 
(McCormack and dos Santos 
Silva, 2006) 
 
99mTc Scintigraphy 
 
99mTc scintigraphy 
P-glycoprotein (P-gP): Cell 
pumps that export 
chemotherapy out of 
tumour cells (drug 
resistance mechanism). 
(Takamura et al., 2001) 
99m-Tc3PRGD2-
SPECT 
Integrin proteins in tumour 
vasculature; measuring 
tumour vasculature 
(Ji et al., 2015) 
 
Table 1.13 Biological measurements according to imaging modalities.  
Imaging studies included measurements of several biological features that 
included cellularity, tissue composition, cell structure and tumour cell activity.   
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Imaging 
Modality 
Patients 
(n) 
Drug Treatments 
Chemotherapy 
Cycles 
Response 
Measurements 
MRI 8446 
Anthracyclines 
Taxanes 
Trastuzumab 
 
3-12 cycles 
 
 
 
Mandard 
RECIST 1.1 
RCBI Score 
Miller-Payne 
No clinical 
convention followed 
(pathologist 
evaluation) 
PET 3138 
Anthracyclines 
Taxanes 
Alkylating Agents 
Antimetabolites 
Trastuzumab 
Bevacizumab 
3-6 cycles 
 
RCBI Score 
Miller-Payne 
Sataloff 
NCI-EORTC 
Collaborative (1977) 
PERCIST 
CT 20 
Anthracyclines 
Taxanes 
Alkylating Agents 
Antimetabolites 
Trastuzumab 
Bevacizumab 
 
6 cycles 
 
RECIST 1.1 
No clinical 
convention followed 
(pathologist 
evaluation) 
 
X-RAY 241 
Anthracyclines 
Taxanes 
Alkylating Agents 
Antimetabolites 
Trastuzumab 
4-8 cycles 
No clinical 
convention followed 
(pathologist 
evaluation) 
99m-Tc 255 
Anthracyclines 
Taxanes 
Alkylating Agents 
Antimetabolites 
Trastuzumab 
3-8 cycles 
RCBI Score 
No clinical 
convention followed 
(pathologist 
evaluation) 
Radiologically 
Assessed (no 
convention) 
WHO criteria 
(radiographic) 
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Abbreviations and Legend 
 
Response Measurements:   
RECIST 1.1 (Response Criteria in Solid Tumours 1.1)  
RCBI (Residual Cancer Burden)   
NCI-EORTC (National Cancer Institute-European Organization for Research on 
Treatment of Cancer) 
WHO (World Health Organization) 
PERCIST (PET Response Criteria in Solid Tumours)  
 
Table 1.14 Clinical Study Characteristics.  Clinical study characteristics 
included the number of patients included in all studies combined.  Studies were 
focused on breast cancer patients treated with anthracycline and taxane based 
chemotherapies.  The response criteria (endpoints) varied between studies.   
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Modality 
Chemo 
Cycle 
Measured 
Measurement 
Techniques 
Imaging 
Markers 
Maximum 
Outcome, (Time 
Interval) 
MRI 
B, M1, 
M2, M3, 
M4, P 
Diffusion-Weighted 
(DW) 
Dynamic-contrast 
Enhanced (DCE) 
Spectroscopy 
Blood-oxygen level 
dependent (BOLD) 
ADC 
MPTS 
Texture 
∆SI 
MD 
VC 
VO 
ECU 
Cho 
L-Trans 
Kep 
R2 
T2R 
RBV 
RBF 
Wash-in 
Wash-out 
EF 
AUC=0.96, (B) 
PET 
B, M1, 
M2, M3, 
M6, P 
18FDG 
15O-H2O 
SUV 
MTV 
TLG 
AUC=0.85, (M4) 
CT B 
Dynamic contrast-
enhanced (DCE) 
BF 
BV 
FE 
AUC=0.87 (B) 
X-RAY B Mammographic Density BD AUC=0.59 (B) 
99m-Tc 
B, M1, 
M2, M3, P 
99mTc Scintigraphy 
99mTc- SPECT 
99mTc-D 
SPECT 
Acc=89% (B) 
(AUC not reported) 
Abbreviations and Legend 
Imaging Timeline Measures:  
B (Baseline)  
M (Mid-treatment, chemotherapy cycle)  
P (Post-chemo) 
Maximum Outcome Measures:  
Acc (Accuracy %)  
AUC (Area Under Curve) 
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Biomarkers 
MRI: 
ADC (Apparent Diffusion Coefficient) 
MD (Mean Diffusivity)  
MPTS (Morpho-Physiological Tumour Score) 
VC (Vascular Count)  
VO (Vascular Oxygenation)   
∆SI (Change in Signal Intensity) 
ECU (Early Enhancement Ratio) 
EF (Enhancement Fraction) 
Cho (Normalized Choline Signal)  
k-Trans (Transfer Constant) 
Kep (Rate Constant) 
R2 (Transverse Relaxation Rate) 
T2R (T2-weighted Relaxivity) 
RBV (Relative Blood Volume)  
RBF (Relative Blood Flow) 
PET: 
SUV (Standardized Uptake Value) 
MTV (Metabolic Tumour Volume) 
TLG (Total Lesion Glycolysis) 
CT: 
BF (Regional Blood Flow) 
BV (Blood Volume) 
FE (Flow Extraction Product)  
X-Ray: 
BD (Breast Density)  
99m-Tc: 
99Tc-D (99mTc-sestamibi Decay [Half-life]) 
RI (Retention Index) 
SPECT (Single Photon Emission Computed Tomography Signal) 
Table 1.15 Measurement parameters.  Imaging modalities were used to 
measure chemotherapy response at various time intervals (indicated as chemo 
cycle measured in table).  Imaging biomarkers varied between imaging studies 
and modalities.  The best performance time intervals are indicated in the table.  
The results show that MRI imaging biomarkers were the best features to 
measure tumour response.    
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1.13 Systematic Review of DOS and US Imaging in 
Breast Cancer 
 
1.13.1 Systematic Review Outline 
 
In this section, a review of diffuse optical spectroscopy and ultrasound 
imaging are reviewed in terms of their technical framework, their use for 
characterizing tissue and the technical limitations associated with each imaging 
modality.  The descriptions are divided into two major concepts:  1) Concept 1: 
DOS Imaging and; 2) Concept 2: Ultrasound Imaging.  Since ultrasound 
imaging is a broad domain, the proceeding sections will describe ultrasound 
imaging as two subcategories:  1) General ultrasound imaging which include 
power Doppler ultrasound, elastography and contrast enhanced ultrasound 
(Concept 2a) and; Concept 2b, quantitative ultrasound spectroscopy (Figure 
1.13).    
 
 
Figure 1.13  The literature review was divided into two major concepts for the 
purpose of describing the various DOS and QUS imaging techniques. Diffuse 
Optical Spectroscopy: Concept 1 included studies that used both topographic 
and tomographic DOS.  Ultrasound Imaging: Concept 2a (general ultrasound 
imaging) included power Doppler ultrasound, elastography and contrast-
enhanced ultrasound imaging.  Concept 2b includes two QUS-based 
techniques. 
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1.13.2 Principles of Optical Imaging for Tissue Characterization 
 
 Light can be described using wave theory where it is characterised as an 
electromagnetic wave or using particle theory to describe photon migration in a 
medium (Welch and Gemert, 2010).  Both theories describe the nature of light 
propagation within two common parameters, in which light is dependent on: 1) 
frequency and; 2) wavelength (Welch and Gemert, 2010).  Both light theories 
(i.e. electromagnetic wave and particle theory) are used to describe attributes of 
light; for example, the wave’s frequency and wavelength are proportional to a 
photon’s energy.  The energy, frequency and wavelength of light is represented 
by an electromagnetic spectrum whereby the optical wavelength is inversely 
proportional to the photon’s energy (Figure 1.14). The light energy is an 
important parameter since it determines the dominant light interactions in tissue, 
such as absorption and scattering.  Optical absorption and scattering in tissue 
are the basis of understanding DOS-based measurements in tissue.     
 
 
Figure 1.14:  The electromagnetic spectrum.  The electromagnetic spectrum 
demonstrates the various bands of light such as ultraviolet light, visible light and 
near-infrared light.  The various bands are defined by a range of wavelengths 
that are inversely proportional to the energy of light.   This is represented by the 
following equation: 𝐸 = ℎ𝜐; where E is the energy (units; eV) and ℎ is Plank’s 
constant and 𝜐 is the frequency (units; Hz) (Welch and Gemert, 2010). 
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For near-infrared light interactions in tissue, scattering dominates over 
absorption; here, absorption is referred to as the decrease in the light intensity 
as a function of increasing path length in tissue (Jacques, 2013).  Also, light 
scattering in tissue is defined as a deflection (change in direction) from the 
incident light path after the photon interacts with a particle (Liu, 2011).  The 
near infrared (NIR) optical scattering in tissue is described predominantly by 
either Mie scattering theory or Raleigh scattering theory6, which is a function of 
the size of the scatterer (particle), relative to the optical wavelength (Figure 
1.15) (Xu and Povoski, 2007).    
 
 
Figure 1.15.  Scattering regimes based on wavelength and scatterer size.  
Adapted from (Petty, 2006).  The scattering is based on the relationship 
between the size of the scatterer and the wavelength of the photon.  
                                            
6 Mie scattering theory describes the phenomenon when the incident photon is 
scattered by particles approximately of the same size of the photon wavelength.  
This causes anisotropic and forward scattering.  Raleigh scattering (also 
referred to as elastic scattering) describes the phenomenon when the size of 
the particle is much smaller than the photon wavelength, thus causing no 
change in the incident wavelength, thus resulting in predominantly isotropic 
scattering.     
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Diffuse optical spectroscopy measures the near-infrared light interactions 
in tissue that result from optical absorption and scattering from intrinsic 
chromophores such as water, lipid, and haemoglobin (Cerussi et al., 2001). 
Light transmission from one medium to another medium (e.g. tissue) depends 
on the refractive index, 𝑛, and is expressed as the ratio of the speed of light in a 
vacuum (𝑐) to the phase velocity (?̅?) in tissue.  The refractive index is dependent 
on tissue density and early works by Barer et al. (1957) reported that tissue 
constituents such as cells, cell proteins and water were significantly involved in 
light refraction in tissue (Barer, 1957).  Using Snell’s law, the refractive index 
can provide information on the directional change of the propagating light wave 
between the incident light and the transmitted light travelling across two 
mediums.  The direction of the light in tissue is an important consideration since 
DOS mammography detects light transmission (or reflection) across the breast 
tissue (Figure 1.16).     
 
Figure 1.16:  Tissue-Light interaction.  A.  Light can be absorbed at the tissue 
interface. The light that is transmitted may also result in remission.  B.  Light 
that is transmitted may alternatively undergo elastic scattering whereby the 
incident light and the scattered light has the same wavelength.  Transmission of 
light is represented by Snell’s law: 𝑛) sin(𝜃)) = 𝑛0 sin(𝜃0).   
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Tissue measurements using diffuse optical spectroscopy are based on 
optical absorption and scattering principles in the near-infrared spectrum 
(wavelengths=600nm-1100 nm).   In breast tissue, light scattering is 
significantly greater (100-fold) than light absorption, and hence the term 
“diffuse” in DOS refers to a diffusion regime that is caused by multiple scattering 
events across the gradient (Cerussi et al., 2001, Dehghani et al., 2009, 
Tromberg et al., 2005).  Although chromophore measurements are based on 
the absorption co-efficient (haemoglobin, water, lipids, oxygen saturation), 
measuring the scattering in tissue can give important insight to tissue 
substructures such as the scattering that can occur from tumour cell nuclei or 
mitochondria.  Raleigh scatterers such as mitochondria, nuclei, and collagen 
fibres can be measured from DOS; thus, measuring the scattering coefficient 
can also indicate substructural constituents (and its state from cell death and 
cytotoxic stress) in the breast and tumours that arise in the breast (Cerussi et 
al., 2006, Liu, 2011). 
 
1.13.3 DOS for Breast Imaging (Concept 1)  
 
 Diffuse optical spectroscopy (DOS) imaging can measure tumour 
response to chemotherapy by detecting changes in haemoglobin content, tissue 
composition and light scattering features (Roblyer et al., 2011, Cerussi et al., 
2007, Jiang et al., 2014).  Maps of tumour physiological features, such as 
haemoglobin are computed from tissue-optical properties that are based on 
near-infrared optical scattering and absorption within the near-infrared spectrum 
(600-1100 nm) (Cerussi et al., 2006).  For breast tissue, significant optical 
absorbers include oxy-haemoglobin (HbO2), deoxy-haemoglobin (Hb), water 
(H2O) and lipids (Li) (Cerussi et al., 2006).   Chromophore concentrations can 
be estimated by measuring the absorption co-efficient [µa] and using Beer’s law 
equation (Cerussi et al., 2011).  Also, tissue optical parameters such as the 
reduced scattering co-efficient [µ¢s] can provide additional information on tissue 
microstructure (~0.2 µm); corresponding to optical scattering effects from 
mitochondria and the cell nucleus (Mourant et al., 2000, Cerussi et al., 2006) 
(methods for calculating chromophore concentration is further described in  
Chapter 2, Methods).    
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DOS systems can be built as topographic devices (usually handheld and 
obtain 2D images), or larger tomographic systems that are referred to as diffuse 
optical tomography (DOT) devices that construct three-dimensional images of 
the breast (Figure 1.17).   Both systems have their respective advantages, such 
as broad optical bandwidth and tissue penetrance.  For example, advantages 
for DOT include the capability of imaging deeper tumours, and major technical 
advancements have increased the performance of DOT systems to separate 
the specific contributions of light absorption and scattering in tissue for 
improved tissue contrast.   
 Three types of DOS techniques, such as frequency domain (FD), time 
domain (TD) or continuous wave (CW) have been used to measure photon 
migration in tissue.  Continuous wave systems emit light with constant 
amplitude and measure the attenuation (Xu and Povoski, 2007); whereas 
frequency domain DOS employ light emission that is sinusoidally modulated at 
high frequencies.  FD systems measure the attenuation and phase shift of the 
light to measure the optical absorption and scattering.  The major advantage to 
FD systems is a relatively higher signal-to-noise ratio, and it is generally 
portable, which makes it potentially desirable as a “bedside” tool.  In a TD 
system, used in the thesis study, short pulses of light are emitted and the times 
of flight are measured.  The major advantage is the tissue-depth penetrance 
and improved resolution, compared to other DOS systems.  However, TD 
systems are often large due to the requirement for several subcomponents 
used in signal detection and processing.  
 Continuous wave, frequency domain and time domain systems utilize the 
absorption co-efficient to calculate the biochemical composition of tissue.  Using 
the Beer-Lambert law, with the known molar extinction co-efficient, one can 
calculate the concentrations of haemoglobin, oxy-haemoglobin, water, and 
lipids.  It is important to note that breast tissue demonstrates significantly higher 
scattering than absorption, and this is due to the tissue’s composition, and 
cellular structure.  Other DOS parameters such as the scatter power and scatter 
amplitude, calculated by using the power-law function, are representative of the 
tissue’s substructure, which is related to cellularity, cell arrangement and light-
scatterer spatial distributions (Fantini and Sassaroli, 2012).  As a result, DOS 
can demonstrate a good sensitivity to the biochemical characteristics of tissue.  
A summary of DOS imaging is described in Table 1.16.   
 72 
DOS Imaging 
Technique Description Reference 
 
 
Frequency 
Domain (FD) 
 
 
Emits light that is sinusoidally 
modulated at high frequencies.   
FD detection systems measure the 
attenuation and phase shift of the 
light to report the absorption and 
scattering.   
Portable 
Relatively higher signal-to-noise ratio 
(Soliman et al., 
2010) 
(Durduran et al., 
2010) 
(Gibson et al., 
2005) 
 
 
Time Domain  
(TD) 
Uses short pulses of light and 
measure the times of flight of the 
transmitted light.    
The major advantage is the tissue-
depth penetrance and improved 
resolution, compared to other DOS 
systems. 
Large system due to many 
subcomponents in detection and 
computing system. 
(Soliman et al., 
2010) 
(Fantini and 
Sassaroli, 2012) 
(Gibson et al., 
2005) 
Continuous 
Wave (CW) 
Continuous wave systems emit light 
with constant amplitude and 
measure the attenuation. 
(Xu and Povoski, 
2007) 
Table 1.16. DOS imaging can be approached using several systems that 
employ frequency domain, time domain and continuous wave techniques 
 
1.13.4 Technical Considerations and Limitations for DOS 
 
In terms of technologies used, DOS clinical studies showed variations in 
the use of frequency domain, time domain or continuous wave systems. 
Imaging devices were built as laboratory (i.e. research devices) or commercially 
manufactured systems.  The systems were either topographic systems that 
acquired 2-dimensional images or tomographic systems that were capable of 
constructing 3-dimensional breast images (Figure 1.17).  Hand-held 
topographic devices were capable of only measuring fixed-sized areas of up to 
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20 cm, while bulkier tomographic devices were capable of probing the whole 
breast volume.  All the devices used near-infrared light (600-1100 nm) and this 
corresponded to the spectral window of known chromophores such as 
haemoglobin, lipids and water.  It is important to note the distinction between 
DOS topography and DOS tomography systems used in previous studies.  
Although both systems use similar light scattering and absorption 
measurements, DOS tomography enables volumetric image reconstruction 
compared to DOS topography, and can penetrate at greater depths. Hand-held 
topography DOS systems, such as those used by Cerussi et al. (2011) may be 
limited by its optical penetrance due to the geometry of the detectors and the 
probe’s construction.  Therefore, hand-held DOS devices are often restricted to 
tumours situated 10-20 mm below the skin surface (Cerussi et al., 2011).  Also, 
tumours with deep posterior margins beyond this distance are poorly measured 
by DOS topography, and are better measured using DOS-tomography.   
 
 
Figure 1.17.  Differences between hand-held reflectance-type topography 
probes (left) and DOS tomography systems (right).   A.  Hand-held devices are 
placed over the breast and 2-D chromophore maps are constructed.  B.  
Tomography devices (as used in this study) involve whole-breast imaging and 
are coupled with optical compensation medium (OCM).  3-D maps are 
constructed with multiple scan planes that report the concentration of the 
chromophore of interest, for example deoxy-haemoglobin (Hb).    
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1.13.5 Principles of Ultrasound Imaging for Tissue Characterization 
 
The ultrasonic signal represents the tissue composition and 
microstructure.  Tumour structures such as cells and the vasculature are 
susceptible mediums for ultrasound scattering.  Ultrasound is a propagating 
pressure wave that has frequencies greater than the audible range in humans, 
which is approximately 20 KHz (Shung and Thieme, 1993).  Medical 
applications exploit ultrasound waves that carry energy and demonstrate 
predominantly longitudinal wave properties; thus, causing particle 
displacements that are parallel to the direction of the propagating wave (Shung 
and Thieme, 1993).   
Ultrasound waves that travel from one medium to another medium 
undergo refraction or reflection which causes a change in the wave’s direction 
at the interface.  For refraction, the directional change can be calculated using 
Snell’s law, where the angle and velocity of the incident wave is proportional to 
the angle and velocity of the reflected or refracted wave.  In biological tissue 
(i.e. tumours), the transmitted wave encounters a highly inhomogeneous 
medium and the acoustic energy is lost as a function of distance; this is caused 
by acoustic absorption and scattering.  The absorbed energy produces heat 
while the scattered energy results in either forward- or backscattering.  Thus, 
acoustic scattering is defined as the redistribution in the acoustical energy in a 
non-uniform medium; where there is a change in the amplitude, frequency, 
phase velocity, or direction of the acoustical wave (Chivers, 1977) (Figure 
1.18).   
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Figure 1.18:  Wave propagation and transmission.  A.  Ultrasound waves that 
travel between interfaces demonstrate reflection and refraction.  For reflection, 
the incident angle (qi) is equal to the reflected angle (qr).  For refraction, the 
incident angle and the refraction (transmitted) angle (qt) is dependent on the 
speed of sound between interfaces (Snell’s law).  B.  Wave propagation in 
biological tissue encounter a highly inhomogeneous medium and therefore the 
refracted wave loses energy as a function of distance.  The loss in energy is a 
result of absorption (producing heat) and scattering.   
 
1.13.6 General US Imaging (Concept 2a) and QUS (Concept 2b) 
 
General Ultrasound Imaging (Concept 2a) 
 
 Conventional breast ultrasound uses acoustic frequencies between 9-15 
MHz to obtain good contrast and axial (depth) resolution in breast tissue 
(Athanasiou et al., 2009).  Breast sonography techniques include mechanical 
imaging such as elastography or functional imaging such as contrast-enhanced 
imaging, power-Doppler ultrasound and quantitative ultrasound spectroscopy.    
Ultrasound elastography measures the tissue’s stiffness and therefore 
characterizes the tissue’s biomechanical properties.  Tumours are “harder” than 
the surrounding normal parenchyma because it is comprised of densely 
populated and rapidly dividing cells, increased vasculature and fibroglandular 
components that alter its mechanical properties (Schrader et al., 2011, Wells 
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and Liang, 2011, Hayashi et al., 2012).  Tissue stiffness can be measured in 
terms of tissue stress and strain (units; pascals [Pa]) using shear-wave 
elastography or compression-based elastography.  These imaging techniques 
compute the alterations in sound wave propagation in soft and hard tissue 
(Wells and Liang, 2011). 
 Functional ultrasound imaging, such as contrast-enhanced imaging 
(CEUS) and power Doppler measures tumour blood flow; while quantitative 
ultrasound techniques have been used to measure morphologic features of the 
whole-cell and subcellular structures such as the nucleus  (Czarnota et al., 
2002, Cao et al., 2012b, Shia et al., 2015).  Contrast-enhanced ultrasound 
(CEUS) uses a contrast medium, such as microbubbles for improved 
visualization of the blood vessels.  Microbubbles are small lipid, protein or 
biopolymer microspheres that encapsulate a gas.  Under varying acoustic 
pressure, microbubbles oscillate due to their echogenicity which result in 
increased echoes that are detected by the ultrasound system (Blomley et al., 
2001).  For power Doppler imaging, the vasculature is assessed by detecting 
the frequency shift and amplitude (power) of the ultrasound backscatter signal 
caused by scatterers in the blood vessels (Martinoli et al., 1998).       
 
Quantitative Ultrasound Spectroscopy (QUS) (Concept 2b) 
     
Quantitative ultrasound spectroscopy for tissue characterization has 
many medical applications such as detecting cardiac ischemia, characterising 
liver histology and renal imaging (Lizzi et al., 1997b).  In oncology, QUS aims to 
provide acoustic data about tumour microstructure (cells and cell nuclei) that 
can be used for diagnosis and treatment-response evaluation (Sannachi et al., 
2015).  The major advantage of analysing the radiofrequency data in 
comparison to conventional B-Mode “grey-scale” ultrasound is the added 
information about tissue properties such as attenuation, integrated backscatter, 
scatterer size and concentration (Kolios et al., 2002).  Additionally, a significant 
advantage to using QUS data to characterize tumours is to mitigate operator 
dependent variations associated with conventional grey-scale imaging such as 
time-gain compensations and image contrast adjustments.    
 Quantitative ultrasound spectroscopy (QUS) uses the spectral 
information of radiofrequency (RF) backscatter signals that are typically 
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discarded in conventional grey-scale sonography; thus, it is unique from other 
types of sonography since the information collected is based on the frequency-
dependent power spectrum.  QUS can employ either low or high (>20MHz) 
frequency ultrasound for tissue characterization based on the desired acoustic 
resolution, and required depth for imaging (Feleppa et al., 2011).  QUS 
parameters using spectral analysis, such as the mid-band fit (MBF), 0-MHz 
intercept (SI) and spectral slope (SS) are determined by applying a linear 
regression function within a discrete frequency bandwidth of the computed 
power spectrum (Czarnota et al., 1999, Kolios et al., 2002, Lizzi et al., 1997b, 
Feleppa et al., 2011) (methods for calculating QUS parameters are described in 
Chapter 2, Methods).  In early studies by Lizzi et al. (1997), QUS parameters 
were studied for therapy response monitoring in hyperthermia-treated ocular 
tumours (Lizzi et al., 1997b).  The results of their study showed an increase in 
the SI in responsive lesions, in comparison to the surrounding normal tissue 
(p=0.003).  This increase in the backscatter intensity was explained as 
corresponding to changes in tissue microstructure caused by focal areas of 
increased cell death (Lizzi et al., 1997b).  It was hypothesized that changes in 
the scattering surfaces at subcellular levels from cell death, such as fragmented 
nuclear structures, may modulate acoustic scattering in tissue.   Later reports by 
Czarnota and colleagues applied Lizzi et al.’s theoretical framework to study the 
effects of apoptotic cell death and QUS in acute myeloid leukaemia (AML) cells 
treated with chemotherapy in vitro (Czarnota et al., 1999).  That work used QUS 
methods as markers for apoptotic cell death.  Chemotherapy-treated AML cells 
demonstrated a 2.92-fold to 5.83-fold increase in backscatter intensity 
compared to non-treated cells, and histological data revealed morphological 
changes resulting from cellular pyknosis, karyorrhexis and apoptotic cell death 
(Czarnota et al., 1999).  In another study, Kolios et al. demonstrated an 
increase in the MBF (+13 dB) after treating AML cells to chemotherapy in vitro, 
and linked these findings to morphological changes from chromatin 
condensation (Kolios et al., 2002).  These studies demonstrated the link 
between changes in tissue features, nuclear morphology and the resulting 
acoustic scattering in tissue (Sannachi et al., 2015) (Figure 1.19). Theoretical 
frameworks in these early QUS studies for cancer imaging have driven efforts to 
study chemotherapy response in breast cancer in vivo (Sadeghi-Naini et al., 
2013b, Tadayyon et al., 2014).  To date, QUS has been used to monitor 
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treatment response in photodynamic therapy, chemotherapy, and radiation 
therapy; both in animal and human studies (Lee et al., 2012, Czarnota et al., 
1999, Banihashemi et al., 2008, Sadeghi-Naini et al., 2013a, Sadeghi-Naini et 
al., 2013b, Tadayyon et al., 2014).   
The sensitivity of QUS to measure the biomechanical features of tumours 
is dependent on two main factors:  1) Tissue-dependent features (i.e. scatterer 
size, distribution, organization) and; 2) the ultrasound (wave) properties (Lizzi et 
al., 1997a, Lizzi et al., 1997b, Insana and Hall, 1990).  In this section, important 
principles of ultrasound imaging are discussed since the experimental QUS 
parameters used in this study should be interpreted in terms of its relationship 
to the tumour response and biology.  The important factors discussed here 
include image resolution, image reconstruction and system corrections that 
have a critical role in the QUS data that represents the tumour’s biological 
characteristics.   
 
 
Figure 1.19:  Quantitative ultrasound using spectral analysis can be used to 
estimate morphological changes in cells.  Increased nuclear fragmentation 
caused by treatments can affect the intensity of the spectral form.  The 
backscatter is measured in terms of the normalized intensity (power) in decibels 
(dBr).   
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1.13.7 Technical Considerations and Limitations for US Imaging 
 
 Ultrasound image quality is affected by the characteristics of the 
ultrasound system itself, such as the quality of the display monitor and its 
display settings (Sehgal et al., 2006).  The system’s hardware include 
transducer types that use variable frequencies, bandwidths, focal distances and 
aperture that can change the output display of the ultrasound image (Sehgal et 
al., 2006).    
 
Ultrasonic Parameters for Optimal QUS Imaging  
 
QUS data is based on the digitized radiofrequency signal from tissue 
backscatter.  The practical challenges of optimal QUS imaging arises in terms 
of achieving a desirable resolution in both the lateral and axial direction of the 
ultrasound image and this is dependent on the ultrasound parameters used for 
imaging.  In order to attain useful QUS data and information, QUS imaging 
parameters must be capable of resolving cellular and subcellular structures.  
For this, the optimal lateral and axial resolution are dependent on the following 
parameters: wavelength (𝜆), f number (ƒ234567), acoustic frequency bandwidth 
(B), and the speed of sound (𝑐).  These parameters are described below in 
terms of its relationship to achieving the desired lateral and axial resolution in 
an ultrasound image for useful QUS analysis.   
 The lateral resolution is spatially perpendicular to the beam axis (O'Brien, 
2007) and permits imaging objects that are positioned side-by-side.  The lateral 
resolution is defined as the minimum resolvable distance to differentiate or 
contrast two adjacent reflectors or structures (O'Brien, 2007).  The lateral 
resolution is high when the beam width is at its narrowest due to a small 
distance between acoustic scan lines.  The lateral resolution is dependent on 
the frequency (and thus wavelength, l) and the geometric characteristic of the 
acoustic focus, such as the diameter of the transducer (D) and the focal depth 
(F).  The optimal parameters for optimal imaging include the following 
parameters: 
i.Shorter wavelength (l); 
ii.High frequency (f) 
iii.Large diameter (D) 
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At distances beyond the focal zone (i.e. the far zone), the lateral resolution 
deteriorates as the beam width diverges (i.e. wider) beyond this point.  Thus, 
optimal lateral-resolution is achieved within the near zone and up to the focal 
zone (Figure 1.20).   
 
 
Figure 1.20:  Lateral resolution is best when the beam width is narrow; allowing 
for distinguishing side-by-side structures.  The lateral resolution is highest within 
the focal zone at the focal point (;2); where the beam converges, and is 
narrowest.   
 
The lateral and axial resolution are important in imaging locally advanced breast 
cancer tumours due to the size of the tumour which can span several cm across 
the breast (>5 cm).   The axial resolution is defined as the distance of one 
wavelength (l) along the axis of the ultrasound beam.  Thus, an object can be 
resolved that is equal to the distance occupied from one cycle or pulse of 
ultrasound (O'Brien, 2007).   In practical US imaging, single wavelengths are 
not used rather, pulses of ultrasound are employed that contain N wavelengths 
per pulse; this is termed the spatial pulse length (SPL).  The SPL can be used 
to calculate the axial resolution based on the frequency bandwidth (Figure 
1.21).    
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Figure 1.21: Axial resolution for ultrasound imaging.  The axial resolution is 
determined by the wavelength of an ultrasound pulse (A).  However, in practical 
ultrasound imaging, a pulse of ultrasound will contain several wavelengths as it 
propagates through the imaging medium (e.g. tissue).    The spatial pulse 
length (SPL) is defined as the number of wavelengths in a repeated pulse 
waveform.  For practical ultrasound imaging, the SPL is used to determine the 
optimal (best) axial resolution.  In this example in (B), the SPL is equal to 2l.   
 
For QUS quantification of biological tissue which can contain several 
scatterers, a Born approximation is assumed; that is, the backscattered field is 
the sum of the individual scatterers within that acoustic field (Chivers, 1977).  
Thus, QUS measurements in breast tumours represent the net change in 
scatterers (i.e. dying cells).  It is also important to mention that in QUS 
modelling, the backscatter intensity calculations assume that the tumour is a 
low-density medium and that scatterers within the tumour microenvironment are 
randomly distributed (Oelze et al., 2002). Previous experiments have developed 
a framework to show the relationship between QUS parameters and scatterer 
properties (outlined below in Table 1.17) (Lizzi et al., 1997b, Insana and Hall, 
1990, Kolios et al., 2002, Feleppa et al., 1986).   
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Scatterer 
Property 
QUS 
Parameters 
Findings Reference 
Size  Spectral 
Intercept 
A two-fold increase in the 
scatterer diameter showed 
an 18 dB increase in the 
Spectral Intercept.   
(Feleppa et al., 
1986) 
Size  Spectral 
slope 
The size of the scatterer of 
less than ~20 µm has 
insignificant effects on the 
spectral slope (i.e. slope 
remains constant).   
(Feleppa et al., 
1986) 
Size Mid-band Fit The mid-band fit increases 
from an increase in the 
scatterer diameter for 
effective diameters of up to 
~60 µm 
(Feleppa et al., 
1986).   
 
(Lizzi et al., 1997b) 
Number of 
scatterers 
Spectral 
Intercept 
An increase in the number 
of scatterers increases the 
spectral intercept due to an 
increase in the number of 
scattering surfaces 
(Lizzi et al., 1997b) 
Concentration 
of scatterers 
Spectral 
Slope 
An increase in the 
concentration of the 
scatterers decreases the 
spectral slope  
(Lizzi et al., 1997b) 
Table 1.17:  QUS dependence on scatterer properties.  Scatterer properties 
such as the size, number and distribution have been shown previously to 
change the acoustic scattering in tissue 
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In general, the quality of US imaging is reliant on angle dependence, 
aliasing (indeterminate ultrasound signals) and a poor signal-to-noise ratio that 
can result from user error (Hamper et al., 1997).  Other technical considerations 
for US include breast density and breast-tissue composition (connective tissue, 
lactiferous ducts) that can affect image quality since it can alter the speed-of-
sound in tissue, cause speckle, and scattering; these factors may result in 
image artefacts (Sehgal et al., 2006).  For elastography, tissue composition can 
affect the elasticity reading between patients that demonstrate higher fatty-
tissue content and fibrosis, as these features can change the biomechanical 
properties of the breast and alter the strain measurements (Butcher et al., 2009, 
Wells and Liang, 2011).   US imaging can also be limited by penetrance, also 
known as the acoustic impedance.   This is because US imaging is dependent 
on the wavelength and frequency of the acoustic wave.  Variations in the 
ultrasound frequency may limit the quality of images if tumours are situated 
deeper into the breast tissue (Athanasiou et al., 2009).  Conventional breast 
sonography uses frequencies between 9-12 MHz, and this allows imaging axial 
distances of up to 5 cm (Athanasiou et al., 2009).  As a rule, higher frequency 
(>20 MHz) ultrasound can improve resolution but due to high scattering in 
tissue, these frequencies are better suited for superficial lesions.  Conversely, 
lower frequency ultrasound (2-5 MHz) can penetrate greater tissue depths, but 
resolution is compromised (Athanasiou et al., 2009).  Previous US clinical 
studies have employed transducers that operated at between 5-13 MHz 
(Gangeh et al., 2016, Sadeghi-Naini et al., 2013b, Sannachi et al., 2015, 
Tadayyon et al., 2016, Tadayyon et al., 2017, Amioka et al., 2016, Shia et al., 
2015).  These frequencies are consistent with clinical breast sonography but the 
variations in acoustic parameters (i.e. frequency, time-gain compensation, pulse 
repetition frequency and focal depth) limit the comparisons that can be made 
between studies since the experimental conditions (i.e. technology, biological 
measurements, image processing techniques) were different.     
 Functional imaging techniques such as contrast-based ultrasound 
(CEUS) also have limitations.  For CEUS, invasive injections are required and 
there are potential adverse reactions from using contrast agents (Stewart and 
Sidhu, 2006).  Also, the contrast agents’ lifetime in blood vessels are short and 
therefore multiple injections are needed for optimal image acquisition (Heijblom 
et al., 2011). 
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1.13.8 DOS and QUS Measurements Represent the Tumour’s Spatial and 
Biological Properties 
 
The Tumour’s Biological Architecture  
 
One mechanism by which chemotherapy agents exert their therapeutic 
effect is by committing tumour cells to apoptosis (Figure 1.22) (Bold et al., 
1997, Mizutani et al., 2005).  In comparison to other forms of cell death such as 
necrosis, apoptotic cell death is energy dependent, genetically controlled and 
morphologically distinct, i.e., developing apoptotic bodies, cell shrinking and 
nuclear condensation (Majno and Joris, 1995).  Under microscopy apoptosis is 
identified as cell shrinking, membrane blebbing, forming apoptotic bodies and 
having nuclear restructuring.   Nuclear reorganization undergoes karyolysis 
(nuclear breakdown), pyknosis (nuclear condensation), and finally karyorrhexis 
(nuclear fragmentation) (Majno and Joris, 1995).  Fragmented cellular and 
nuclear debris are engulfed by phagocytes.  Apoptosis has been identified in 
primary breast tumours treated with neoadjuvant chemotherapy in situ.  Studies 
by Chang et al. (2000) and Ellis et al. (1997) demonstrated that there was an 
increase in apoptosis in responsive tumours and detected as early as 24 hours 
after the administration of chemotherapy using immunohistochemistry analysis 
(Chang et al., 2000, Ellis et al., 1997).  Chang et al. (2000) showed that 
increased apoptosis, as assessed by serial biopsies, was linked to pathological 
complete response where there was no residual or palpable disease after 
therapy (Chang et al., 2000).  Buchholz et al. (2003) also measured the 
apoptotic activity in breast tumours after 48 hours of chemotherapy using breast 
tumour biospecimen analyses.  Patients who had a 25% increase in the 
apoptotic actively, as assessed by immunohistochemistry, had gone on to 
achieve pCR.  The apoptotic activity was significantly different to patients who 
did not achieve pCR (p<0.015)  (Buchholz et al., 2003).   These previous clinical 
experimental results suggest that apoptosis is a major biological response 
mechanism to chemotherapy response in tumours (Simstein et al., 2003, Bold 
et al., 1997, Okada and Mak, 2004).  In contrast, chemoresistant tumours show 
defects in the apoptotic pathway and have evolved to evade programmed cell 
death (Simstein et al., 2003).  A summary of previous studies that have 
evaluated apoptosis using serial biopsies is presented in Table 1.18.    
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Figure 1.22:  Apoptosis in cancer cells.  Apoptosis is characterised as an 
energy dependent mechanism where cells undergo programmed morphological 
changes.  Chemotherapies drive apoptosis in tumour cells and this results in 
cell shrinking and nuclear restructuring such as karyolysis, pyknosis and 
karyorrhexis.  These morphological changes are the basis of detection methods 
in quantitative ultrasound.     
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 Reference n Cx Time Findings/Notes/Limitations 
1 (Arpino et 
al., 2005) 
33 • A • D0  
• 24h 
• D7 
• Ds 
• Results did not demonstrate a 
significant difference between 
responders and non-responders at all 
time points.  However, the trends for 
responders and non-responders 
demonstrated a higher apoptotic index 
in responders compared to non-
responders (p=0.1).   
• Limitations:  Small sample size and 
data from study did not demonstrate 
statistical significance which contrasted 
other studies.      
2 (Buchholz 
et al., 
2003) 
25 • A 
• T 
• D0  
• 24h 
• D2 
• There was a 25% difference in the 
apoptotic index between responders 
and non-responders at 48 hours 
(p=0.015).  
• Limitations: Data based on 16 breast 
tumours only (small sample size).   
3 (Chang et 
al., 2000) 
28 • M • D0  
• 24h 
• D7 
• D21 
• Median change of 3.4% in responders 
versus -0.1% in non-responders 
(p=0.03) after 24 hours.   
• Limitations: Variable tumour types 
were included in the study sample.   
• Limitations: Mixed areas of necrosis 
and apoptosis identified in all tumours 
(risk of overestimated findings). 
4 (Symmans 
et al., 
2000) 
11 • T • D0  
• 24h 
• D3 
• D4 
• All patients were pooled for analysis.  
There was a 3.0-6.0-fold increase in the 
apoptotic activity at 4 days after one 
treatment.   
• Limitations:  No statistical tests were 
performed to compare between 
responders and non-responders and 
this was due to the small sample size.   
5 (Ellis et al., 
1997) 
27 • A 
• AL  
• M 
• D0  
• 24h 
• Responders showed >50% increase in 
the apoptotic index.  
• Non-responders showed no significant 
changes in apoptosis after 24 hours 
(p=0.22).   
• Limitations: small sample size and 
unequal responder/non-responder ratio.   
Cx (Chemotherapy): A=Anthracycline; T=Taxane; M=Antimetabolite; 
AL=Alkylating Agent.    Time (Measured relative to chemo-cycle 1): 
D0=Baseline (prior to chemotherapy starting), 24h (hours), D2=2 days (48 
hours); D3=Day 3; D4=Day 4; D7=Day 7, D21=Day 21; Ds=Surgical Specimen.   
Table 1.18: Clinical studies that used serial biopsies to measure apoptosis in 
breast tumours.  The results indicate that apoptotic tumour response may be 
initiated as early as 24 hours after giving chemotherapy.  
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Additionally, tumour cells exhibit genetic modifications that enable 
proliferation, despite unstable environments caused by hypoxia, overpopulation 
and inefficient vascularization (Jain, 2005).  Tumours have abnormal vascular 
architecture which contributes to a spatially heterogeneous environment (Jain, 
2005).  The vascular morphology and organization have been well studied; 
blood vessels are disorganized, distributed unevenly, immature and leaky, 
which also affects the tumour’s response to treatment (Dvorak et al., 1988).  
The tortuous vessel formations have been shown previously to inhibit drug 
efficacy by secreting factors that block chemotherapy effects (Gilbert and 
Hemann, 2010, Junttila and de Sauvage, 2013) .  Additionally, abnormal 
morphologies such as variable vessel diameters and weak junctions in the 
vessel walls have been shown to inhibit efficacious drug delivery since leaky 
vessels reduce drug concentrations in tumours (Hashizume et al., 2000, Damia 
and Garattini, 2014).  Additionally, the uneven vascular scaffold creates areas 
with variable and high interstitial fluid pressure, which resists the transport of 
cytotoxic agents into the stroma (Rofstad et al., 2014, Junttila and de Sauvage, 
2013, Minchinton and Tannock, 2006).  Solid tumours that respond to 
chemotherapy exhibit characteristic patterns in their vessel reorganization  
(Jain, 2005).  Jain et al. (2005) described these patterns as vascular 
“normalization” by which the vascular architecture is reconfigured to eliminate 
inefficient, saccular, leaky and immature vessel formations  (Jain, 2005).  This 
results in improved oxygen delivery and cytotoxic efficacy.   In highly responsive 
tumours, the vasculature eventually regresses and limits the nutrient supply to 
tumour cells (Jain, 2013).  Taken together, the important hallmarks in tumour 
response to chemotherapy include vascular normalization and regression, cell 
death and changes in the tissue composition and are observed explicitly under 
microscopy (Figure 1.23).  These biological changes result in spatial and 
structural reorganization in tumours which can be detected by ultrasound and 
optical imaging techniques. 
 
 88 
 
Figure 1.23:   A comparison of the vascular organization. A.  Normal tissue 
exhibits normal sized and well-organized vasculature, which permit exchange of 
biomolecules and gas (arrows).  B.  Untreated tumours show high density 
vasculature and do not permit free exchange of biomolecules and gasses.  C.  
Normalized tumours demonstrate greater organization closer to that of normal 
tissue.  D.  In regressed tumours, the vasculature may be absent, or minimal.    
 
Detecting the Tumour’s Biology and Characterizing its Structure using DOS and 
QUS 
 
Ultrasonic and optical wave interactions in tissue are a function of the 
tumour’s biologic properties.  The tumour’s biological components, i.e. tumour 
cells, normal cells, fragmented apoptotic bodies, stromal features, vasculature 
and substructures such as mitochondria and cell nuclei can scatter light and 
sound.  Thus, these components are often termed “scatterers” in the context of 
optical and acoustic imaging.   As tumours respond to chemotherapy, 
alterations occur with respect to scatterer spacing, organization, density and 
concentration, which can affect the DOS and QUS signals that are measured.   
The current understanding of a solid tumour’s biological matrix illustrates 
a microenvironment that is made from densely arranged cells, tortuous 
vasculature, and high interstitial fluid at its onset and progression  (Nishida et 
al., 2006).  Tumours that respond to chemotherapy show opposite 
characteristics such as sparse tumour cells, low vascularity and low interstitial 
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fluid and this is the basis of optical and acoustic parameters to measure tumour 
response to chemotherapy.  
Here it is important to illustrate the biological “landscape” in solid tumours 
at initial diagnosis.   Before treatments are administered to kill the tumour, it has 
been shown that there is a high interdependency between cellularity and 
vascularity; i.e., tumour cells trigger the growth of blood vessels, and blood 
vessels support tumour cell growth by supplying vital nutrients.  Previous work 
by Muthukkarruppan et al. (1982) showed that tumours that grow beyond 2 mm3 
initiate an “angiogenic switch” to drive neovascularization (Bergers and 
Benjamin, 2003, Muthukkaruppan et al., 1982). Growing blood vessels infiltrate 
the tumour into a woven matrix that enables oxygen exchange and trafficking of 
proteins for cell signalling.  The irregular vascular distribution and variable 
tumour cell phenotypes also contribute to intratumoural heterogeneity (Polyak, 
2011).  Cancer cells may transform into more aggressive tumour cells with each 
replication cycle and this can result in morphological heterogeneity such as 
condensed and irregular nuclear bodies and enlarged or shrunken cell sizes 
(Swanton, 2012). Thus, even within short distances within the tumour’s 
subregions, tumour cells may demonstrate variable rates of cell proliferation 
and cell cycling.  Other physiological conditions that lead to spatial variances 
within the tumour stroma include fluctuating interstitial fluid, variable vascular 
perfusion and circulating biomolecules (O'Connor et al., 2015).  To compound 
the spatial complexity, the tumour stroma is also constructed from a variety of 
cell-types such as fibroblasts, immune cells, adipocytes and normal breast 
epithelial cells (Figure 1.24) (Polyak, 2011, Pietras and Ostman, 2010).  Taken 
together, tumours are composed of disorganized and aberrant cells, and 
circulating biomolecules that are “woven” into a turbulent vascular scaffold and 
environment.   These aberrations are the cause of inter- and intra-tumour 
heterogeneity and result in significant treatment challenges in breast cancer 
(Rofstad et al., 2014).  
 
Tissue-dependent Factors in Ultrasonic Backscattering 
 
QUS is a measure of the ultrasonic backscatter intensity in tissue.  
Scatterers in tissue include fibroblasts, collagen, tumour cells, blood-related 
cells, collagen, normal cells and their subcellular structures such as the nucleus 
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and proteins.  Spatial heterogeneities of those structures cause changes in 
ultrasonic scattering in tissue.  The backscatter is measured in terms of intensity 
(power) in decibels (dB) (Chivers, 1977).  The average speed of sound (c) in 
soft tissue is 1540 m/s and this is dependent on the tissue’s elastic properties 
(compressibility, k) and density (𝜌). 
 
Figure 1.24: Tumour composition.  The tumour is a complex system which is 
composed of several cell types and subcomponents which contribute to its 
spatial heterogeneity.   
 
Thus, variations in ultrasonic scattering is dependent on tissue 
biophysical properties such as its density and compressibility that are regulated 
by cells, vasculature, fluid and biomolecules.  In this study, it is hypothesized 
that changes in the tumour’s biophysical properties are a result of the spatial 
heterogeneities that can be detected by ultrasound and subsequently used to 
measure tumour response during chemotherapy.  This hypothesis is based on 
previous studies by Czarnota et al. (1999) and Kolios et al. (2002), in which the 
results showed that there was a relationship between cell structural changes 
from apoptosis that were detected from ultrasonic backscatter signals (Czarnota 
et al., 1999, Kolios et al., 2002).  In those studies, a time-course analysis (0h-
48h) under microscopy showed changes in size, number and concentration of 
the scatterers (cells and cell nuclei). The conclusions of these previous studies 
indicated that the backscattered signal was correlated to condensed nuclei 
(pyknosis), fragmented DNA (karyorrhexis) and membrane blebbing from 
apoptotic cell death (Czarnota et al., 1999).  A summary of the biological 
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correlates associated with DOS and US imaging biomarkers, as indicated from 
previous studies, is outlined in Table 1.19.   
 
 
Technique Biological Measurements Reference 
 
Diffuse Optical Spectroscopy 
DOS 
Metabolism 
Cell activity 
Vascular Density 
Oedema 
Breast tissue composition 
Cellularity 
Cell distribution 
Cell death 
Tissue contrast 
Hypoxia 
Nuclear fragmentation 
 
(Cerussi et al., 2006) 
(Cerussi et al., 2001) 
(Cerussi et al., 2011) 
(Intes, 2005) 
(Fantini and Sassaroli, 2012) 
(Cerussi et al., 2006) 
(Fantini and Sassaroli, 2012) 
(Fantini and Sassaroli, 2012) 
General Ultrasound Imaging and Quantitative Ultrasound Spectroscopy 
Elastography 
Tumour progression 
Extracellular matrix 
Collagen crosslinking 
Tissue composition (fibrosis) 
(Hayashi et al., 2012) 
(Schrader et al., 2011) 
(Evans et al., 2013) 
CEUS Vascular blood flow (Cao et al., 2012b) 
Power Doppler 
Vascular blood flow 
Blood perfusion 
Vascularity 
(Shia et al., 2015) 
QUS 
Cell Death (Apoptosis) 
Scatterer size 
Scatterer distribution 
Scatterer concentration 
(Lizzi et al., 1997a) 
(Lizzi et al., 1997a) 
(Hunt et al., 2002) 
Table 1.19.   Physiological measurements by DOS and US.  Scatterers for 
QUS include tumour cells and subcellular organelles and other cell and tissue 
types.     
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1.14 Results of DOS and US Systematic Review 
 
1.14.1 Patients 
 
Between 1975-2017, DOS (n=394 patients), US (n=294 patients) and 
QUS (n=244 patients) have been studied in 932 patients with locally advanced 
breast cancer to measure neoadjuvant chemotherapy response (Table 1.20).  
Patients from these studies exhibited breast tumours that were histologically 
and molecularly heterogeneous (ER +/-, PR+/-, HER2+/-), and were treated 
with taxane- and anthracycline-based chemotherapies (Table 1.20).  However, 
two DOS studies included a subset of patients (n=23) who were treated with 
bevacizumab, which is an anti-angiogenic agent (Cerussi et al., 2011, Roblyer 
et al., 2011).  Since DOS, CEUS, and power Doppler ultrasound measures 
blood perfusion and vascular density; it is unclear if this affected the 
comparative haematological measurements between patients treated +/- 
bevacizumab.   
 
Imaging 
Modality 
Patients 
(n) 
Drug Treatments 
Chemotherapy 
Cycles 
Response 
Measurements 
DOS 394 
Anthracyclines 
Taxanes 
Alkylating Agents 
Trastuzumab 
Bevacizumab 
3-12 cycles 
No clinical 
convention followed 
(pathologist 
evaluation) 
Radiologically 
Assessed (no 
convention) 
RECIST 1.1 
Miller-Payne 
General 
US and 
QUS 
538 
Anthracyclines 
Taxanes 
Alkylating Agents 
Antimetabolites 
Trastuzumab 
3-8 cycles 
No clinical 
convention followed 
(pathologist 
evaluation) 
Radiologically 
Assessed (no 
convention) 
RECIST 1.1 
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Miller-Payne 
RCBI Score 
Abbreviations and Legend 
 
Response Measurements:   
RECIST 1.1 (Response Criteria in Solid Tumours 1.1)  
RCBI (Residual Cancer Burden)   
NCI-EORTC (National Cancer Institute-European Organization for Research on 
Treatment of Cancer) 
WHO (World Health Organization) 
PERCIST (PET Response Criteria in Solid Tumours)  
 
 Table 1.20:  Patients, treatment and endpoints in DOS and QUS imaging 
studies.  
 
A summary of each study identified from the systematic literature search 
is presented in Table 1.21, which outlines the number of study participants, the 
chemotherapies used within each study and study results.   
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Reference 
 
N Cx 
Tumour 
Histology 
Time 
points 
(weeks)§ 
Imaging 
 
Markers 
Study 
Results 
 
Concept 1: Diffuse Optical Spectroscopy Imaging 
 
1. (Cerussi et 
al., 2007) 
11 A, T, 
+ 
1, 2, 3 B, W3, 
W6, W9, F 
DOS, FD Hb, HbO2, 
H2O, Li, 
SP 
1 
         
2. (Zhu et al., 
2008) 
11 A, T, 
+ 
1, 2, 3, 4 B, W3, 
W6, W15, 
F 
DOST HbT 
 
1,2 
         
3. (Jiang et 
al., 2009) 
7 A, T, 
+ 
1, 3, 4 B, W1, 
W3, W4, F 
DOST, FD Hb, HbO2, 
H2O, SP, 
SA, St, 
StO2 
1,2 
         
4. (Soliman et 
al., 2010) 
10 A, T, 
+ 
1, 2, 3, 4 B, W1, 
W4, W8, F 
DOST, TD Hb, HbO2, 
H20, Li, 
TOI 
1,2 
         
5. (Cerussi et 
al., 2011) 
34 
(36)a 
A, T, 
+ 
B 
N/A  B, W8, 
W9, F 
DOS, FD Hb, HbO2, 
H2O, Li, 
TOI 
1,2 
         
6. (Pakalniskis 
et al., 2011) 
11 A, T, 
+ 
B 
1, 2, 3, 4 B, W 
(N/A)b, F 
DOST, FD HbT 
 
1,2 
         
7. (Roblyer et 
al., 2011) 
23 
(24)a 
A, T, 
+ 
1, 2, 3, 4 B, D1-7 DOS, FD Hb, HbO2, 
H2O, Li 
2 
         
8. (Falou et 
al., 2012) 
15 A, T, 
+ 
1, 2, 3, 4 B, W1, 
W4, W8, F 
DOST, TD Hb, HbO2, 
HbT, St, 
StO2, SP, 
SA, H2O, 
Li, TOI 
1,2 
         
9. (Ueda et 
al., 2012) 
41 A, T, 
+ 
1, 2, 3, 4 B DOS, FD Hb, HbO2, 
HbT, 
StO2, TOI 
3 
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10. (Zhu et al., 
2013) 
32 A, T, 
+ 
B 
1, 2, 3, 4 B, W3, 
W6, W9, 
W12, 
W15, F 
DOST Hb, HbO2, 
HbT 
2,3 
         
11. (O'Sullivan 
et al., 2013) 
28 A, T, 
+ 
N/A B, W4, F DOS, FD Hb, HbO2, 
HbT, 
StO2, 
H2O, Li, 
TOI 
1 
         
12. (Jiang et 
al., 2014) 
19 A, T, 
+ 
1, 2 B, W1, 
W2, W3, 
W8 
DOST, FD HbT, 
StO2, H2O 
1,2,3 
         
13. (Schaafsma 
et al., 2015) 
22 A, T, 
+ 
1, 2, 3 B, W3, 
W6, W9 
DOST, TD Hb, HbO2 
 
2 
         
14. (Sadeghi-
Naini et al., 
2015) 
12 A, T, 
+ 
1,2,3 B, W1, 
W4, W8, F 
DOST, TD Hb, HbO2, 
HbT, H2O, 
TOI + 
Texture 
1,2 
         
15. (Tromberg 
et al., 2016) 
(ACRIN 
6691 Trial) 
34 N/A 
B 
1,2,3 B, W1, W 
(N/A)b, F 
DOS, FD Hb, HbO2, 
HbT, 
StO2, TOI 
1,2,3 
         
16. (Ueda et 
al., 2016) 
84 A, T, 
+ 
B 
1,2,3 B, W3, W6 DOS, FD Hb, HbO2, 
HbT, StO2 
1,2 
         
Concept 2a: General Ultrasound Imaging 
         
1. (Singh et 
al., 2005) 
25 A, + 1 B, F CFUS, 
CD 
Vmax, PI, 
RI 
1 
         
2. (Huber et 
al., 2009) 
17 + 1,2,5 B, F CFUS, 
CD 
CPD 1 
         
3. (Hayashi et 
al., 2012) 
55 A, T, 
+ 
1, 3, 4, 5 B CFUS, EL EG 3 
         
4. (Cao et al., 
2012b) 
31 A, T 1 B, F CFUS, 
CEUS 
MTT, 
PI(C), RT, 
TTP, WIS 
1 
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5. (Evans et 
al., 2013) 
40 A, T, 
+ 
1 B CFUS, EL ME 3 
         
6. (Falou et 
al., 2013) 
15 A, T, 
+ 
1, 2, 3, 4 B, W1, 
W4, W8, F 
CFUS, EL SD, SR 
 
1,2 
         
7. (Shia et al., 
2015) 
29 A, T, 
+ 
1, 3, 4, 5 B, W3, W6 CFUS, PD VI, FI, VFI 2,3 
         
8. (Amioka et 
al., 2016) 
63 A, T, 
+ 
B 
1, 3, 4 F CFUS, 
CEUS 
PI(C), 
TTP, AS 
1 
         
9. (Saracco et 
al., 2017) 
19 A, T, 
B 
1,2,5 B, W2, W5 CFUS, 
CEUS 
MTT, 
PI(C), 
Cmax, 
TTP, WIS 
2 
             
Concept 2b: Quantitative Ultrasound Spectroscopy 
         
10. (Sadeghi-
Naini et al., 
2013b) 
24 A, T, 
+ 
1, 2, 3, 4 B, W1, 
W4, W8, F 
CFUS, 
QUS 
MBF, SI, 
SS 
 
1,2 
         
11. (Sadeghi-
Naini et al., 
2014) 
20 A, T, 
+ 
1, 2, 3, 4 B, W1, 
W4, W8, F 
CFUS, 
QUS 
MBF, SI, 
SS, 
Texture 
 
1,2 
         
12. (Sannachi 
et al., 2015) 
30 A, T, 
+ 
1, 2, 3, 4 B, W1, 
W4, W8, F 
CFUS, 
QUS 
IBC, ASD, 
AAC 
 
1,2,3 
         
13. (Gangeh et 
al., 2016) 
56 A, T, 
+ 
1, 2, 3, 4 B, W1, 
W4, W8, F 
CFUS, 
QUS 
MBF, SI, 
SS 
 
1,2 
         
14. (Tadayyon 
et al., 2016) 
58 A, T, 
+ 
1, 2, 3, 4 B, W1, 
W4, W8, F 
CFUS, 
QUS 
MBF, SS, 
SI,  
SAS, 
ACE, 
ASD, AAC 
1,2 
         
15. (Tadayyon 
et al., 2017) 
56 A, T, 
+ 
1, 2, 3, 4 B CFUS, 
QUS 
MBF, SI, 
SS, 
3 
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ACE, 
ASD, 
AAC, 
Texture 
         
 Patients Enrolled: aNumber of tumours studied (patients with bilateral 
disease, or multifocal disease) 
Chemotherapy Strategy (Cx):  A=Anthracycline-based chemotherapies; 
T=Taxane-based Chemotherapies; +=Other chemotherapies; 
B=Bevacizumab (Avastin).  
 
Tumour Histology: 1=Invasive Ductal Carcinoma, 2=Invasive Lobular 
Carcinoma, 3=Oestrogen/Progesterone Receptor Positive, 4=Growth 
Hormone Amplification (HER2), 5=Other Types 
 
Measured Timelines: B=Baseline (Pre-Chemotherapy); D=Number of 
Days; W=Number of Weeks; F=Finish of Chemotherapy; bAuthors indicate 
“during treatment” but no times specified. Study authors report the cycle, 
and this has been converted to weeks relative to start of chemotherapy.   
 
Imaging: DOS=Diffuse Optical Spectroscopy Imaging (Topographic 2D); 
DOST=Diffuse Optical Tomography.  FD= Frequency Domain.  TD= Time 
Domain.  All optical imaging uses NIR light (600 nm-1000 nm).  
CFUS=Conventional Frequency Ultrasound. QUS=Quantitative Ultrasound 
Spectroscopy.  EL=Elastography.  CEUS= Contrast Enhanced Ultrasound.  
PD= Power Doppler Ultrasound.  CD=Colour Doppler Imaging (Velocity 
Doppler).   
 
Parameters Measured Per Study: Hb=Deoxy-haemoglobin; 
HbO2=Oxyhaemoglobin; HbT=Total Haemoglobin; St=Oxygen 
Desaturation; StO2=Oxygen Desaturation; SP=Scatter Power; SA=Scatter 
Amplitude; H2O=%Water; Li=%Lipid; TOI=Tissue Optical Index; MBF=Mid-
band Fit, SI= Spectral Intercept (0-MHz Intercept); SS=Spectral Slope; 
SAS=Spacing Among Scatterers; ESD=Effective Scatterer Diameter; 
EAC=Effective Acoustic Concentration; IBC=Integrated Backscatter 
Coefficient; ASD=Average Scatterer Diameter; AAC=Average Acoustic 
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Concentration, ACE=Attenuation Coefficient Estimate.  Vmax=Maximum 
Flow Velocity.  PI=Pulsatility Index.  RI=Resistivity Index.  
CPD=Percentage of Colour Pixels (Colour Doppler).  SR=Strain Ratio.  
SD=Strain Difference.  EG=Tsukuba Elasticity Score.  MTT=Mean Transit 
Time.  PI(C)=Peak Intensity.  RT=Rising Time.  TTP=Time To Peak.  
WIS=Wash-in Slope.  AS=Ascending Slope.  ME=Mean Elasticity.  
VI=Vascularization Index. FI=Flow Index.  VFI=Vascularization-flow Index.  
Cmax=Curve Maximum 
 
Study Results: 1=Significant parameter changes for Responders but not 
Non-Responders after NAC (95% CI, α=0.05); 2=Significant parameter 
changes for Responders but not Non-Responders during NAC (intra-
treatment monitoring) (95% CI, α=0.05); 3=Significant difference in 
parameters between Responders and Non-Responders at baseline (prior 
to NAC) (95% CI, α=0.05) 
Table 1.21:  Summary of research for DOS and US in breast cancer 
chemotherapy response. 
 
1.14.2 Quality Assessment Using QUADAS-2 and STARD 
 
For this review, 31 observational trials were identified.  Due to the recent 
use of DOS and QUS for chemotherapy response monitoring for breast cancer 
compared to other modalities, no trials were identified as randomized controlled 
trials (RCTs) and there were no RCTs for other US-based imaging.  Thus, it 
should be noted that these limitations affect the generalizability of this literature 
review.  Further, it should be noted that a single evaluator performed the quality 
assessments only (William Tran), thus limiting the objectivity of the results of 
this review.  Nevertheless, the results of the review identified areas of high risk 
for bias.  
 
1.14.3 QUADAS-2 Results 
  
A risk for bias for patient selection was identified in 26% of all studies 
and this was higher in DOS studies (5/16, 31%) compared to US and QUS 
studies (3/15, 20%).  The major weaknesses were found in signalling questions 
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surrounding case-control designs and related to the index test (48% of all 
studies), where there was a higher risk in DOS studies (11/16, 69%) compared 
to US studies (4/15, 27%).  A higher risk of bias could be due to analysis 
performed with prior knowledge of pathological response to NAC, and when 
studies were performed retrospectively.  One study demonstrated an unclear 
risk with respect to the reference standard because pathologic outcomes were 
not described clearly with current clinical standards (Huber et al., 2000).  In all 
applicability concern categories, the reference standard was reported as high 
risk for US studies (6/9, 67%).  This is due to the variabilities in which the tests 
and measurements were completed during chemotherapy (i.e. various 
measurement timelines) and technical concerns about the parameters used to 
acquire and measure the ultrasound signals.  For example, ultrasound studies 
did not indicate the ultrasound frequency (MHz) used to acquire images and 
image optimization methods were missing from the materials and methods 
section.  Additionally, DOS and US studies that measured chemotherapy 
response demonstrated variable chemotherapy regimens which could have 
affected the results of the studies as the heterogeneity of tumours (i.e. intrinsic 
molecular features) could be responsive to one treatment over another.  In 
some studies, an antivascular drug (Bevacizumab; tradename, Avastin®) was 
transiently used in some patient populations and studies and this could have 
affected the results for tests that measured haemoglobin, blood flow and 
vascularity  (Ueda et al., 2012, Zhu et al., 2013, Tromberg et al., 2016, 
Pakalniskis et al., 2011, Cerussi et al., 2011, Amioka et al., 2016, Saracco et 
al., 2017).   A summary of the QUADAS-2 results is presented in Table 1.22 
and Figure 1.25. 
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QUADAS-2 
References (Study) 
RISK OF BIAS 
APPLICABILITY 
CONCERNS 
Patient 
Selection 
Index 
Test 
Reference 
Standard 
Timing & 
Flow 
Patient 
Selection 
Index 
Test 
Reference 
Standard 
 
Concept 1: Diffuse Optical Spectroscopy Imaging 
1 (Cerussi et al., 2007) L L J L L L J 
2 (Zhu et al., 2008) J L J J J J J 
3 (Jiang et al., 2009) L L J J L J J 
4 (Soliman et al., 2010) J L J J J J J 
5 (Cerussi et al., 2011) L L J J J J J 
6 (Pakalniskis et al., 2011) L J J L L J J 
7 (Roblyer et al., 2011) J L J J J J J 
8 (Falou et al., 2012) J J J J J J J 
9 (Ueda et al., 2012) J L J J J J J 
10 (Zhu et al., 2013) J L J J J J J 
11 (O'Sullivan et al., 2013) L L L J L J L 
12 (Jiang et al., 2014) J L J J J J J 
13 (Schaafsma et al., 2015) J L J J J J J 
14 (Sadeghi-Naini et al., 2015) J J J J J J J 
15 (Tromberg et al., 2016) J J J J J J J 
16 (Ueda et al., 2016) J J J J J J J 
 
Concept 2a: General Ultrasound Imaging 
1 (Singh et al., 2005) J J J J J J J 
2 (Huber et al., 2009) L L ? J ? ? L 
3 (Hayashi et al., 2012) J L L J J L L 
4 (Cao et al., 2012b) J J L J J J L 
5 (Evans et al., 2013) L L J J L L J 
6 (Falou et al., 2013) J J J J J J J 
7 (Shia et al., 2015) L J L J L J L 
8 (Amioka et al., 2016) J J L J J J L 
9 (Saracco et al., 2017) J L L J J L L 
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Concept 2b: Quantitative Ultrasound Spectroscopy 
10 (Sadeghi-Naini et al., 2013b) J J J J J J J 
11 (Sadeghi-Naini et al., 2014) J J J J J J J 
12 (Sannachi et al., 2015) J J J J J J J 
13 (Gangeh et al., 2016) J J J J J J J 
14 (Tadayyon et al., 2016) J J J J J J J 
15 (Tadayyon et al., 2017) J J J J J J J 
 Risk of Bias and Applicability Concerns scale: 
 
    
 
 
Table 1.22. QUADAS-2 was used to study the diagnostic accuracy of previous 
studies. The QUADAS-2 evaluation tool was adapted from (Whiting et al., 
2011).     
 
 
 
 
 
 
 
 
 
 
 
 
 
J Low 
Risk 
L High Risk ? Unclear Risk 
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Figure 1.25. A. QUADAS-2 Domain (Bias); B. QUADAS-2 Domain 
(Applicability).  Proportion of studies with low, high, or unclear concerns 
regarding bias and applicability, % for DOS, US, and QUS studies.  
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1.14.4 STARD Assessment Results 
 
 For STARD results, 4/25 items scored less than 50% across all studies.  
These scores corresponded with items no. 10, 11, 20 and 24 of the STARD 
assessment.  Of the studies yielded in this literature review, test methods 
demonstrated lower reporting on the number, training and expertise of readers 
who did the imaging analysis (STARD, no. 10). (Bossuyt et al., 2003).  This was 
particularly high in QUS studies.  There was a risk of data variance which could 
have resulted from differences in tumour volume analysis, 2D versus 3D image 
acquisition and determining tumour ROIs for analysis.  Schaafsma et al. (2015) 
reported that a 5-mm displacement of DOS ROIs could affect the results of up 
to 8% depending on the size of the tumour (Schaafsma et al., 2015).   
Additionally, 45% of the studies did not report blinding readers from the 
reference standard (STARD, no.11) and these limitations are consistent with the 
QUADAS-2 assessment results.  For adverse events reporting (STARD, no.20), 
it would be expected to observe a low reporting rate for this category because 
QUS and optical imaging does not involve any contrast agents, and the risk for 
adverse effects to contrast-based ultrasound is relatively low (Stewart and 
Sidhu, 2006).  Finally, another area of concern involves the reproducibility of 
results which include inter- and intra-user variance (STARD, no. 24).  Only 42% 
of all studies reported a kappa-statistic or inter-user validation and analysis.  
This was particularly low in QUS studies that reported no such methods.  
Results of the STARD assessment are presented in Table 1.23. 
 
 
 
 
 
 
 
 
 
 
 
 
 104 
STARD CHECKLIST RESULTS 
SECTION AND TOPIC 
Imaging Technique 
DOS US QUS ALL 
n n n n 
(%) (%) (%) (%) 
TITLE/ABSTRACT/KEYWORDS 
 1. Identify the article as a study of 
diagnostic accuracy (recommended 
MeSH heading ‘sensitivity and 
specificity’). 
15 9 6 30 
94 100 100 97 
INTRODUCTION 
 2. State the research questions or study 
aims, such as estimating diagnostic 
accuracy or comparing accuracy between 
tests or across participant groups. 
16 9 6 31 
100 100 100 100 
METHODS 
Participants 3. Describe the study population: The 
inclusion and exclusion criteria, setting 
and locations where the data were 
collected. 
15 9 6 30 
94 100 100 97 
 4. Describe participant recruitment: Was 
recruitment based on presenting 
symptoms, results from previous tests, or 
the fact that the participants had received 
the index tests or the reference standard? 
15 9 6 30 
94 100 100 97 
 5. Describe participant sampling: Was the 
study population a consecutive series of 
participants defined by the selection 
criteria in items 3 and 4?  If not, specify 
how participants were further selected. 
16 9 6 31 
100 100 100 100 
 6. Describe data collection: Was data 
collection planned before the index test 
and reference standard were performed 
(prospective study) or after (retrospective 
study)? 
13 9 6 28 
81 100 100 90 
Test 
methods 
7. Describe the reference standard and 
its rationale. 
15 8 6 29 
94 89 100 94 
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 8. Describe technical specifications of 
material and methods involved including 
how and when measurements were 
taken, and/or cite references for index 
tests and reference standard. 
16 9 6 31 
100 100 100 100 
 9. Describe definition of and rationale for 
the units, cut-offs and/or categories of the 
results of the index tests and the 
reference standard. 
15 8 6 29 
94 89 100 94 
 10. Describe the number, training and 
expertise of the persons executing and 
reading the index tests and the reference 
standard. 
9 6 0 15 
56 67 0 48 
 11. Describe whether or not the readers 
of the index tests and reference standard 
were blind (masked) to the results of the 
other test and describe any other clinical 
information available to the readers. 
4 5 5 14 
25 56 83 45 
Statistical 
methods 
12. Describe methods for calculating or 
comparing measures of diagnostic 
accuracy, and the statistical methods 
used to quantify uncertainty (e.g. 95% 
confidence intervals). 
16 9 6 31 
100 100 100 100 
 13. Describe methods for calculating test 
reproducibility, if done. 
16 9 6 31 
100 100 100 100 
RESULTS 
Participants 14. Report when study was done, 
including beginning and ending dates of 
recruitment. 
9 8 1 18 
56 89 17 58 
 15. Report clinical and demographic 
characteristics of the study population 
(e.g. age, sex, spectrum of presenting 
symptoms, comorbidity, current 
treatments, recruitment centres. 
16 9 6 31 
100 100 100 100 
 16. Report the number of participants 
satisfying the criteria for inclusion that did 
15 9 6 30 
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or did not undergo the index tests and/or 
the reference standard; describe why 
participants failed to receive either test (a 
flow diagram is strongly recommended). 
94 100 100 97 
Test results 17. Report time interval from the index 
tests to the reference standard, and any 
treatment administered between. 
15 9 6 30 
94 100 100 97 
 18. Report distribution of severity of 
disease (define criteria) in those with the 
target condition; other diagnoses in 
participants without the target condition. 
15 8 6 29 
94 89 100 94 
 19. Report a cross tabulation of the 
results of the index tests (including 
indeterminate and missing results) by the 
results of the reference standard; for 
continuous results, the distribution of the 
test results by the results of the reference 
standard. 
16 8 6 30 
100 89 100 97 
 20. Report any adverse events from 
performing the index tests or the 
reference standard. 
0 0 0 0 
0 0 0 0 
Estimates 21. Report estimates of diagnostic 
accuracy and measures of statistical 
uncertainty (e.g. 95% confidence 
intervals). 
16 9 6 31 
100 100 100 100 
 22. Report how indeterminate results, 
missing responses and outliers of the 
index tests were handled. 
 
 
14 9 6 29 
88 100 100 94 
 23. Report estimates of variability of 
diagnostic accuracy between subgroups 
of participants, readers or centres, if 
done. 
 
16 9 6 31 
100 100 100 100 
 24. Report estimates of test 
reproducibility, if done. 
9 4 0 13 
56 44 0 42 
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DISCUSSION 
 25. Discuss the clinical applicability of the 
study findings. 
16 9 6 31 
100 100 100 100 
STARD checklist for quality assessment of studies.  Studies were stratified into 
their respective imaging domains and overall score (all studies combined).  
Stratified data: DOS; n=16, Ultrasound Imaging; n=9, QUS; n=6.    
All pooled studies; n=31. 
Areas with scores of less than 50% are highlighted in orange.   
 
Table 1.23:  STARD assessment results.  The STARD assessment tool was 
adapted from (Bossuyt et al., 2003).   
 
1.14.5 Summary Findings from Literature Review 
 
 The results of the literature review showed that MRI studies were most 
frequently reported for measuring chemotherapy response in locally advanced 
breast cancer.  MRI technique included: DCE-MRI, DWI-MRI, BOLD-MRI and 
SPECT-MRI.  MRI imaging biomarkers were used to measure tumour vascular 
perfusion, tumour cellularity and tumour cell features (i.e. cell membrane 
integrity associated with cell death).  The major limitations for using MRI 
included needing contrast agents (i.e. variable contrast injection techniques 
caused variability in data) and variable image quality (i.e. using 1.5T and 3.0T 
MRI systems produced images with variable signal-to-noise ratios).  Other 
imaging studies for PET, CT, X-Ray and 99m-Tc Scintigraphy showed 
promising results that reached a classification accuracy of up to 89%; however, 
the major limitations included small sample sizes that may have caused 
overestimated results, variable definitions of tumour response endpoints (i.e. 
radiological versus pathological endpoints) and imaging results were dependent 
on the adequate uptake of contrast agents in tumours.        
For DOS and QUS, QUADAS-2 and STARD tools were used to 
systematically identify the quality of previous imaging studies. QUADAS-2 and 
STARD assessment results demonstrated that more work is required to 
optimize the index test and reference standards of future studies in DOS and 
QUS.  Based on analysis of previous studies, the experimental design of future 
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DOS and QUS studies should involve the following to optimize the quality of 
studies due to the limitations identified from previous work:   
a. Blinded analysis.  There should be no prior knowledge of the 
disease outcome or reference standard for tumour analysis.  
b. Reference standards.  Ground-truth labels (i.e. tumour response 
endpoints) should follow standard pathologic classification from 
established and accepted clinical guidelines. 
c. Expertise and Experience of Analysts.  Clinical breast images 
using DOS and QUS should be verified with expert radiologists to 
confirm correct analysis of the tumour volume; 
d. Reproducibility.   Reproducibility should be verified by using the 
same technical frameworks with DOS and QUS systems that are 
comparable.  There should also be a comparative analysis of 
tumour ROI analysis (i.e. kappa statistic) should be completed.   
e. Index Tests.  Patients should demonstrate the most 
homogenous chemotherapy treatments.   
 
1.14.6 Limitations of Literature Review 
 
 Limitations to this systematic review include the small number of studies 
available for analysis.  Additionally, this review was conducted by one observer 
with experience in QUS analysis which could result in a bias in assessing QUS 
experiments.   Taken together, since the research question was to test if DOS 
and QUS markers could be used to measure NAC response in breast cancer, it 
is acknowledged that this focused research area may limit the search results 
from the literature.  
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Chapter 2 
Methods 
 
2.0 Chapter Overview 
 
 The first section of this chapter will highlight the background and clinical 
problem, as described previously from Chapter 1.   In section two, the research 
questions to the study are presented, which will also introduce the primary and 
secondary aims of the study.  Section three outlines the ethical and regulatory 
approval, which will lead to describing the inclusion and exclusion criteria of 
patients that were enrolled in the study.  In section four, the chemotherapy 
treatment protocol and imaging schedule pertaining to the aims of the study are 
presented.  In section five, the DOS and QUS imaging methods, in terms of 
experimental analysis to the research study are outlined.   These sections cover 
DOS and QUS imaging instrumentation, data handling and the computations 
involved in DOS and QUS biomarker extraction.  In section six, the quality 
assurance methods are presented, and the chapter ends with section seven, 
which describes the statistical frameworks used to model DOS and QUS 
parameters as indicators (markers) for chemotherapy response in locally 
advance breast cancer.   
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2.1 Background 
 
 Treatment for locally advanced breast cancer (LABC) involves 
neoadjuvant chemotherapy (NAC) to reduce tumour size before surgery.  
However, tumour response to NAC is variable and only 45% of patients achieve 
sufficient down-staging prior to surgery (Cance et al., 2002) .  Measuring tumour 
response during NAC may help guide treatments and help both patients and 
physicians make the best treatment choices for improved outcomes.    
Currently, tumour response during NAC is measured by routine physical 
examination, or sometimes conventional imaging to measure the tumour size 
(Therasse et al., 2000). However, conventional imaging using MRI, CT or FDG-
PET are associated with high equipment costs and these procedures require 
contrast agents for image optimization (Eisenhauer et al., 2009).   Due to these 
limitations, major efforts have been made to explore alternative imaging 
techniques to evaluate both pre-treatment and intratreatment indicators for 
tumour response to therapy.  However clinical adoption of past and newly 
developed quantitative imaging techniques to guide chemotherapy have not 
surpassed the experimental setting (Eccles et al., 2013).     
 Recent priorities for breast cancer treatment and research were outlined 
by a UK-based working group (Eccles et al., 2013).  The group made 
recommendations for advancing biomarker discovery and integrating imaging 
biomarkers into the clinical workflow to guide therapies.  The endpoints were 
precision medicine and individualization (personalization) of treatments.   The 
recommendations were made to address the current treatment practices which 
delivers a “one-size-fits-all” chemotherapy approach.  This is problematic as this 
approach often leads to variable tumour response to treatment and have been 
shown to demonstrate higher mortality (von Minckwitz et al., 2013).   
Taken together, the potential benefits of exploring imaging biomarkers to 
help guide treatments is enticing and can potentially improve patient care.  The 
overall benefit will be to advance treatment outcomes (i.e. improve patient 
survival) and optimize healthcare economics by saving money on unnecessary 
and ineffective treatments (Eccles et al., 2013).   
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2.2 Research Design Summary 
 
2.2.1 Study Design 
 
This project was an exploratory, observational (cross sectional) study in 
human subjects.  The study was approved by the institutional ethics review 
board (IRB)7.   The research was performed to study quantitative ultrasound 
and diffuse optical spectroscopy imaging in breast tumours treated with 
neoadjuvant chemotherapy.  The results were used to examine the utility of 
DOS and QUS imaging parameters (biomarkers) as potential surrogate markers 
for pathological tumour response to chemotherapy, as assessed by Miller-
Payne pathologic response criteria.  The project was divided into two 
subprojects (described below).  
 
2.2.2 Aims of the Study 
 
Subproject one Aims 
 
v To measure the biological changes in breast tumours during 
chemotherapy using quantitative ultrasound spectroscopy (QUS) and 
diffuse optical spectroscopy (DOS).  The intratreatment measurements 
were aimed at the following times, which corresponded to the 
chemotherapy schedule:  pre-treatment, week one, week four, week 
eight, and preoperatively.   
 
v To test the relationship between multivariate QUS+DOS statistical 
models with the final pathologic tumour response as assessed by Miller-
Payne pathologic response scale (defined in Table 2.1).   
 
                                            
7 The IRB approval forms are found in Appendix 2: Supplemental Information 
to Chapter 2 (Methods).   
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v To evaluate the earliest time points when DOS and QUS measurements 
demonstrate significant differences between Miller-Payne pathologic 
response classes (i.e. responders versus non-responders).   
 
Subproject Two Aim 
 
v To identify pre-treatment DOS imaging biomarkers for significant 
differences between response classes (responders versus non-
responders), as measured by Miller-Payne pathological response criteria.  
  
v To test the utility of DOS-texture analysis for predicting chemotherapy 
responders from non-responders before treatment starts.   
 
v To investigate the accuracy of pre-treatment DOS-texture features in 
multivariate models for predicting chemotherapy response.  
 
v To evaluate the relationship between DOS imaging biomarkers and the 
tumour’s biological characteristics and treatment types.   
 
2.2.3 Research Questions (Subproject 1 and Subproject 2) 
 
v Do DOS and QUS imaging biomarkers demonstrate statistically 
significant changes over the course of chemotherapy? 
 
v Can DOS and QUS imaging biomarkers be modelled using univariate 
and multivariate parameters to measure treatment response at early time 
intervals (i.e. after one or two cycles of chemotherapy)?   
 
v Do breast tumours demonstrate significant differences in DOS-texture 
parameters between responders and non-responders, as measured 
before chemotherapy?  
 
v Can DOS markers predict chemotherapy response prior to starting 
chemotherapy? 
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v Are there differences in DOS-texture prediction models for breast cancer 
subtypes (i.e., ER+ and triple negative) and chemotherapy treatments 
(i.e. FEC-D and AC-T)? 
 
2.2.4 Endpoints 
 
Primary Endpoints 
 
v The primary endpoint of subproject one was accuracy in measuring 
chemotherapy response, in terms of its association to Miller-Payne 
pathologic response criteria, using intratreatment DOS and QUS imaging 
biomarkers.   
 
v The primary endpoint of subproject two was accuracy of predicting 
chemotherapy response, in terms of its association to Miller-Payne 
pathologic response criteria, using the pre-treatment DOS-texture 
parameters.   
 
Accuracy of Measuring Chemotherapy Response 
 
Within the patient’s standard of care, all mastectomy specimens were 
evaluated with high-magnification light microscopy by board-certified breast 
pathologists at the host institution. Mastectomy specimens were prepared in 
paraffin blocks and 5-micron-thick microtome specimens and whole-mounted 
for histological staining.  The samples were stained using standard 
haematoxylin and eosin (H&E) techniques (Figure 2.1).  Pathologic outcome 
measures were assessed using Miller-Payne response criteria by a breast 
pathologist.  The tumour response to treatment was reported in the patient’s 
electronic treatment record based on Miller-Payne assessment criteria, 
described further below. 
 
Standardized Tumour Response Endpoints (Pathologic Response Definition) 
 
  For this study, Miller-Payne Pathologic Response Criteria (MP) was 
used to define “pathologic response” outcomes in the sample population 
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(Ogston et al., 2003).  As there is no current consensus on defining “pathologic 
response” in breast cancer chemotherapy, the MP scale was chosen among 
other clinically-accepted standards, since it systematically defines the changes 
in cellularity within the primary lesion only.  This is important since defining the 
change in the primary lesion corresponds to the imaging measurements of the 
tumour only in this study.   In comparison to other pathologic response scales, 
such as the residual cancer burden index (RCBI), those scales use multiple 
variables such as lymph node status and tumour size reduction as part of the 
criteria for pathologic response (von Minckwitz et al., 2012, Symmans et al., 
2007).  
Thus, in this study, “pathologic response” were defined systematically 
using Miller-Payne (MP) pathologic response criteria (Ogston et al., 2003). A 
cut-off score was chosen within the MP scale for binary classification, based on 
the recommendation of a breast pathologist.  Tumours that were graded as 
MP1 or MP2 were classified as non-responders [NR].  Tumours graded as MP 
grade 3, 4, or 5 were classified as responders [R].  The classification decision-
tree is outlined in Table 2.1.   
 
 
Figure 2.1:  H&E-stained whole breast mounts for a representative 
responder and non-responder.  The pathologists used H&E to measure 
tumour response after neoadjuvant chemotherapy.  The cellularity of the tumour 
bed was quantified and reported using a graded score (Miller-Payne criteria).  
On the left slide (yellow contour), a responder demonstrated a significant 
reduction in the size and cellularity under microscopy.  In contrast on the right 
specimen, a patient who did not respond to chemotherapy demonstrated a 
large, bulky residual tumour (yellow contour) with high cellularity.   
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Grade Pathologic Description Binary Classification 
Grade 1 No change to overall tumour cellularity 
Non-Responders [NR] 
Grade 2 Minor loss; up to 30% loss 
Grade 3 Between 30%-90% loss in tumour cells 
Responders [R] Grade 4 Greater than 90% loss of tumour cells 
Grade 5 No remaining tumour cells. 
Table 2.1: The MP classification method is based on a comparison of the 
cellularity before and after treatment.  A binary classification was used to 
classify patients into responders (R) or non-responders (NR) based on a 
chosen cut-off point that was recommended by the breast pathologist.   
 
In addition, other histological assays were completed outside of the 
patient’s usual standard of care for this study and were approved by the 
institution’s IRB.   This included cluster of differentiation staining (CD-31), which 
was used to quantify the number of blood vessels within the tumour bed after 
chemotherapy (JC07 clone, Leica Biosystems, Concord, Ontario Canada). 
Quantification for CD-31 stained vessels were performed on the whole-mount 
specimens after staining (TissueScope, Huron Digital Pathology, Waterloo, 
Canada).  Stained vessels were counted for each specimen (counts/field) and 
the vessel counts were averaged across all respective normal or tumour 
regions.  
 
Radiologic Endpoints 
 
Radiologic endpoints were collected from the patient’s medical record to 
compare the treatment size before, and after chemotherapy only as to report 
the patient’s clinical characteristics.       
As part of the patient’s standard of care at the host institution, all patients 
who completed chemotherapy with operable tumours underwent a surgical 
planning MRI.  The surgical-planning MRI was used to compare the tumour size 
changes from before and after chemotherapy.  Radiologic endpoints were 
evaluated using standard RECIST 1.1 criteria (Eisenhauer et al., 2009).  Pre-
and post-chemotherapy tumour size measurements were recorded as part of 
the patient’s clinical data.    
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2.2.5 Overview, Research Design Summary 
 
 The research design summary is outlined in Table 2.2 and also 
presented schematically in Figure 2.2.   
 
Title Thesis Title:   
 
Measuring Chemotherapy Response in Breast Cancer 
Using Optical and Ultrasound Spectroscopy.  
 
 
 
Subproject one:  
 
Multiparametric Monitoring of Chemotherapy Treatment 
Response in Locally Advanced Breast Cancer using 
Quantitative Ultrasound and Diffuse Optical 
Spectroscopy 
 
Subproject two: 
 
Predicting Breast Cancer Response to Neoadjuvant 
Chemotherapy Using Pre-treatment Diffuse Optical 
Spectroscopic-Texture Analysis  
Aim Subproject one Aims:  
 
The purpose of this observational study was to measure breast 
tumour response to chemotherapy using DOS and QUS 
imaging.  The aims were:  
 
1. To measure the biological changes in breast tumours 
during chemotherapy using imaging biomarkers from 
quantitative ultrasound spectroscopy (QUS) and diffuse 
optical spectroscopy (DOS).  The intratreatment 
measurements were aimed at the following times, which 
corresponded to the chemotherapy schedule:  pre-
treatment, week one, week four, week eight, and 
preoperatively.   
 
2. To test the relationship between multivariate QUS+DOS 
statistical models with the final pathologic tumour 
response.   
 117 
 
3. To evaluate the earliest time points when DOS and QUS 
measurements demonstrate significant differences 
between response classes (i.e. responders versus non-
responders).  
 
Subproject two Aims: 
 
The purpose of this study was to evaluate texture features of 
pre-treatment DOS functional maps for predicting LABC 
response to NAC.  The aims were:  
 
1. To identify pre-treatment DOS imaging biomarkers for 
significant differences between response classes 
(responders versus non-responders).  
 
2. To test the utility of DOS-texture analysis for predicting 
chemotherapy responders from non-responders before 
treatment starts.   
 
3. To investigate the accuracy of pre-treatment DOS-
texture features into multivariate models for predicting 
chemotherapy response.  
 
4. To evaluate the relationship between DOS imaging 
biomarkers and the tumour’s biological characteristics 
and chemotherapy type.  
Eligibility 
Criteria 
All the following criteria were met for entry to the study.  
 
• Both men and women were eligible.   
• Histologically confirmed locally advanced breast 
carcinoma.  
• All tumour molecular subtypes were eligible. 
• Patients who had not been treated with any other first-
line therapy.   
• Treatment with anthracycline or taxane based 
neoadjuvant chemotherapy.  
• The patients must have had measurable disease > 10 
mm in the breast.  This minimal size was needed to 
visualize the tumour upon DOS and QUS imaging.   
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• Scheduled for mastectomy or lumpectomy after 
neoadjuvant chemotherapy with pathologic assessment.   
• Life expectancy of at least 6 months. 
• Patients had the ability to understand and the willingness 
to sign a written consent form document in English.  
 
 
Exclusion Criteria 
 
• History of allergic reactions attributed to compounds of 
similar chemical or biologic composition to ultrasound 
gel or optical compensation medium. 
• Any condition that is unstable or could jeopardize the 
safety of the patient and their compliance in the study 
during imaging.  
• Inability to position arm above the head for ultrasound 
scanning or lay supine for QUS imaging. 
• Inability to position in the prone position for optical 
scanning. 
• Tumours deeper than 4 cm in the posterior direction of 
the breast, or tumours that were larger than 6 cm across 
the lateral distance.         
• A maximum cranio-caudal breast separation (thickness) 
of 80 mm. 
 
Study 
Design 
This study is an observational (cross sectional) study in human 
subjects. 
 
Endpoints Primary Endpoints for Observational Study 
 
• The primary endpoint of subproject one was accuracy in 
measuring chemotherapy response, in terms of its 
association to Miller-Payne pathologic response criteria, 
using intratreatment DOS and QUS imaging biomarkers 
 
• The primary endpoints of subproject two was accuracy 
of predicting chemotherapy response, in terms of its 
association to Miller-Payne pathologic response criteria, 
using the pre-treatment DOS-texture parameters.   
 
 
Primary Efficacy Endpoint 
 
• Accuracy in discriminating pathologic response classes 
is calculated using statistical measures within the 95% 
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confidence interval.  It is expected that DOS and QUS 
imaging biomarkers can be used as surrogate endpoints 
towards standardized pathologic response criteria.   
Sample 
Size 
Calculation 
A sample size calculation was completed based on the 
following: 
 
DOS 
 
Z=1.96 (Confidence interval of 95%) 
Margin of Error (ME): 20% (based on literature) 
Standard Deviation (SD): 43% (based on literature) 
 
QUS 
 
Z=1.96 (Confidence interval of 95%) 
Margin of Error (ME): 30% (based on literature) 
Standard Deviation (SD): 65% (based on literature) 
 
Thus, the calculation for the sample size in this study, given an 
expected attrition of 20% is: 
 
Sample size required: 22 patients 
 
 
Outcomes Outcome 1 (Subproject one) 
 
• Significant differences in the mean DOS and QUS 
parameters between responders and non-responders 
during chemotherapy, as measured at week one, 4, 8 
and pre-operatively.   
• Correlation to pathologic response, as defined by Miller-
Payne response criteria.  
 
Outcome 2 (Subproject two) 
 
• Pre-treatment DOS-texture parameters demonstrate 
significant differences between response classes before 
treatment begins.   
• Discrimination of responders and non-responders are 
determined prior to treatment.   
• Correlation to pathologic response, as defined by Miller-
Payne response criteria.  
Table 2.2:  Trial summaries for the study.  
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Figure 2.2:  Work-flow and methods summary.  The study entailed two 
subprojects.  The objective of subproject one was to demonstrate the utility of 
intratreatment DOS and QUS imaging biomarkers to discriminate pathologic 
response, as defined by Miller-Payne pathologic grading; while subproject two 
used pre-treatment DOS imaging biomarkers to classify pathologic response 
(Miller-Payne) before the start of chemotherapy.  Novel classification 
approaches included multiparametric DOS-QUS modelling, machine learning 
algorithms and textural analysis of DOS parameters.   
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2.3 Ethics and Regulatory Approval 
 
2.3.1 Ethics Approval 
 
All research was conducted at the host institution (Toronto, Canada). 
DOS and QUS imaging studies were approved by the institutional ethics review 
board (IRB) prior to data collection and analysis (IRB # 186-2006 and IRB# 
185-2006, documentation presented in Appendix 2).  All patients enrolled in 
this study signed a written consent form to participate in DOS and QUS studies 
prior to any data collection.  No patients were within the investigator’s circle of 
care at the time of recruitment.  
 
2.3.2   Eligibility (Inclusion/Exclusion Criteria) 
 
 Patients were approached to participate in the study based on a biopsy-
proven diagnosis of locally advanced breast cancer during their initial visit to the 
medical oncologist.  Patients were referred for participation in the clinical study 
by the medical oncologists involved in the patients’ care.  Patients were 
identified using the hospital’s electronic medical appointment system.  Both men 
and women between 18-65 years of age were eligible for this study; however, 
since men accounted for <1% of the institution’s patient population for breast 
cancer, no men were eligible during the study recruitment phase and therefore 
no male enrolments were made.  A detailed summary of the inclusion and 
exclusion criteria are outlined below: 
 
Inclusion Criteria: 
 
• Both men and women were eligible to participate in the study 
• Participants of all races were eligible to the trial.   
• Histologically confirmed locally advanced breast carcinoma (Stage IIB/III 
disease, invasive breast cancer with all histological types eligible).    
• All molecular subtypes were included: ER +/-, PR +/-, HER2-Neu +/-. 
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• Patients who had not been treated with any other first-line therapy 
(hormone therapy, other chemotherapy, surgery, radiation, or 
experimental anticancer drugs). 
• Treatment with neoadjuvant chemotherapy: fluorouracil, epirubicin, 
cyclophosphamide, docetaxel (FEC-D); or Adriamycin (doxorubicin), 
cyclophosphamide, paclitaxel (AC-T).  Patients with HER2-Neu amplified 
tumours who were scheduled for Trastuzumab were eligible to 
participate.     
• The patients must have had measurable disease > 10 mm in the breast 
and for imaging using DOS and QUS (this size is needed in order to 
visualize the tumours for analysis).  Patients’ tumours were thus 
radiologically defined by MRI or CT, or mammogram or ultrasound, prior 
to neoadjuvant chemotherapy and participation in the trial.   
• Scheduled for mastectomy or lumpectomy after neoadjuvant 
chemotherapy with pathologic assessment for response to treatment or 
eligible for surgical consultation.   
• Eastern Co-operative Oncology Group (ECOG) Performance Status of 0 
or 1. 
• Life expectancy of at least 6 months 
• Patients had the ability to understand and the willingness to sign a 
written consent form document, or in the cases where English was not 
the primary language, the patient were accompanied by a translator or a 
substitute decision maker at the time of consent. Signed informed 
consent was obtained prior to any study specific procedures.   
 
Exclusion Criteria 
 
Patients were not eligible for inclusion in the study in the event of the following 
criteria:  
 
• Past or recent history of allergic reactions attributed to compounds of 
similar chemical or biologic composition to ultrasound gel. 
• Uncontrolled or unmanaged other illnesses or medical conditions 
including, but not limited to ongoing or active infection, symptomatic 
congestive heart failure, unstable angina pectoris, and cardiac 
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arrhythmia or psychiatric disorders that could jeopardize the safety of the 
patient during the study.   
• An inability to position the arm above the head for ultrasound scanning or 
unable to lay in supine position.   
• An inability to position in the prone position for optical scanning.    
• Due to the optical absorption caused by melanin in the skin, patients with 
dark skin or freckled skin were excluded from this study.      
 
2.3.3 Sample Size Justification 
 
A sample size was calculated for each imaging modality.  The justification for 
the sample size proposed is presented below.  Separate calculations were 
performed for DOS and QUS imaging, since each imaging modality had 
separate reference data that was needed within the following statistical 
frameworks:   
1. A desired 95% confidence interval (with corresponding Z score) 
2. Margin of error (ME) permitted (based on previous works) 
3. Standard deviation of the outcome of interest. 
 
Sample size calculation (DOS imaging) 
 
The sample size for DOS imaging was determined from the following 
calculation: 
 
One sample, continuous outcome (based on oxy-haemoglobin, Cerussi et al. 
2011). 
The concentration of oxy-haemoglobin was previously reported in the literature 
as 15.3 µM ± 1.1 (STE) (Cerussi et al., 2011)8.  
 
 
                                            
8 The concentration of oxy-haemoglobin represents the value obtained in breast 
tumours, as measured at the end of chemotherapy.  The time interval 
corresponded with the desired time interval measured in the thesis study.   
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The standard deviation was calculated based on the reported population size in 
that study of n=24; therefore:  𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑	𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛	(𝑆𝐷) = 𝑆𝑇𝐸	 × 	√𝑛 𝑆𝐷 = 1.1	 ×	√36 𝑆𝐷 = 𝟔. 𝟔 
 
To calculate the margin of error (ME), a value of 20% was used based on 
observations of the literature; therefore: 
 𝑀𝑎𝑟𝑔𝑖𝑛	𝑜𝑓	𝐸𝑟𝑟𝑜𝑟	(𝑀𝐸) = 20%		(15.3	µM	) = 𝟑. 𝟎𝟔 
 
Therefore, the sample size calculation would be (Eq. 2.1): 
 𝑛 = [𝑍 ∙ (𝑆𝐷)𝑀𝐸 ^_ 𝑛 = [1.96 ∙ (6.6)3.06 ^_ 𝑛 = 17.87 ≅ 18	𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠 
 
Based on the sample calculation, a total of 18 patients were required as the 
minimum sample size for DOS imaging.  However, an attrition rate of 20% was 
estimated; therefore the study was aimed to recruit 22 patients for DOS 
imaging. 
 
Sample size calculation (QUS imaging) 
 
The sample size was determined for QUS imaging using the following 
calculation: 
One sample, continuous outcome (based on MBF, Sadeghi-Naini et al. 2013). 
The MBF was reported as 9.1 dBr ± 1.2 (STE) (Sadeghi-Naini et al., 2013b).  
The standard deviation was calculated based on the reported population size in 
that study of n=24; therefore:  𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑	𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛	(𝑆𝐷) = 𝑆𝑇𝐸	 × 	√𝑛 𝑆𝐷 = 1.2	 ×	√24 
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𝑆𝐷 = 𝟓. 𝟖 
To calculate the margin of error, we use a value of 30% based on observations 
of the literature; therefore: 
 𝑀𝑎𝑟𝑔𝑖𝑛	𝑜𝑓	𝐸𝑟𝑟𝑜𝑟	(𝑀𝐸) = 30%		(9.1	) = 2.7 
 
Therefore, the sample size calculation would be (Eq. 2.2): 
 𝑛 = [𝑍 ∙ (𝑆𝐷)𝑀𝐸 ^_ 𝑛 = [1.96 ∙ (5.8)2.73 ^_ 𝑛 = 17.33 ≅ 18	𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠 
 
Based on the sample size calculation, a minimum of 18 patients were calculated 
for imaging with QUS.  However, an attrition rate of 20% was estimated; 
therefore the study was aimed to recruit 22 patients for DOS imaging.   All 
patients were presented with the option to participate in either QUS and/or DOS 
imaging for the study.   
  
Taken together, the sample calculation indicated a minimum of 22 
patients required to obtain a significant result within the 95% confidence interval 
for either QUS or DOS imaging.  Subproject one involved DOS and QUS 
imaging; therefore, 22 subject data-points (i.e. samples) were targeted. 
Subproject two involved DOS imaging only, and therefore, the objective was to 
recruit 22 subjects.  The recruitment results of this study were:  
 
1) Subproject one; 22 patients were recruited and imaged using DOS 
and QUS.  
2) Subproject two; 15 patients were recruited for pre-treatment DOS 
imaging.  The baseline DOS images from subproject one (n=22 
patients) were included into a pooled analysis of the pre-treatment 
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DOS images.  Therefore, 37 samples were included for analysis in 
this subproject9. 
 
As previously mentioned, patients were recruited into the study by way of 
referral from the medical oncologists involved in the patients’ care. A summary 
of the recruitment scheme is outlined in Figure 2.3.   
 
 
Figure 2.3:  Schematic representation of Subproject one and Subproject 
two.  The aim of the study was to recruit 22 subjects, which was based on the 
sample size calculation.  However, this study (subprojects one and  two) 
recruited a total of 37 patients.  Subproject one included 22 samples in the 
dataset; while subproject two had 37 samples within the dataset, that was 
pooled from the baseline DOS data from subproject one.        
 
2.3.4 Access to Patient Electronic Medical Record 
 
 Patient demographics and medical information was recorded from the 
electronic medical record and included the following descriptors: age, sex, 
tumour/breast laterality, clinically and radiologically measured tumour size 
before and after treatment, tumour histological features, chemotherapies, 
                                            
9  The institution’s IRB approved a sample size of 100 patients; thus, permitting 
the inclusion of 37 patients in subproject two.   
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pathologic response criteria (MP), radiologic endpoints (RECIST 1.1 data) and 
physician notes were recorded to monitor the patient’s eligibility during the study 
and for subsequent statistical analysis (described further below).  
 
2.3.5 Research Location 
 
Data reading and analysis was carried out on specifically designed 
image-processing workstations (Dell Dimension 2400 work stations) in a locked 
examination/analysis room for data security.  The electronic DOS and QUS data 
was copied for the purposes of handling and stored electronically in a password 
protected server and a secondary copy was made for security purposes 
separately in a secured facility at the host institution.  All patient case-report 
forms (CRFs) were stored in paper-form and locked in a cabinet, inside a locked 
storage area as per institutional regulations.  All electronic imaging data for 
analysis were anonymized (de-identified) for patient confidentiality.  The data 
key was encoded only to the investigator and the investigator’s supervisor to 
ensure patient confidentiality. 
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2.4 Patients and Acquiring Imaging Data 
 
2.4.1 Chemotherapy Treatment Schedule 
 
Patients enrolled into the study received the institution’s chemotherapy 
treatment protocol which was in accordance with NCCN guidelines (National 
Comprehensive Cancer Network, 2016).  There were two chemotherapy 
treatment protocols at the host institution and the treatment course was 
determined by the medical oncologist responsible for the patient’s care.  Each 
protocol contained an anthracycline-drug for the first phase of treatment (phase 
1), followed by a taxane-drug in the second phase (phase 2).  Other 
concomitant drugs were given according to the treatment protocol and are listed 
in Table 2.3.  The chemotherapy dose and schedule are outlined in Table 2.3A, 
B.   
 
2.4.2 Imaging Schedule Based on Chemotherapy Treatment Schedule 
 
DOS and QUS imaging was completed according to the specific aims of 
each subproject.  Subproject one involved imaging patients with DOS and QUS 
(n=22) during chemotherapy (1 pre-treatment scan and 5 intratreatment scan 
points) (Figure 2.4).  The imaging timelines were: (Scan 1) baseline (prior to 
treatment), (Scan 2) week one, (Scan 3) week four, (Scan 4) week eight, (Scan 
5) preoperatively and these corresponded with the patients’ chemotherapy 
schedule (Figure 2.4, Table 2.3).  For subproject two, an additional 15 patients 
were recruited and those patients underwent only 1 scan time, which was the 
pre-treatment DOS imaging only.  A schematic summary of the imaging times in 
correspondence to the chemotherapy protocols is outlined in Figure 2.4.  
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A. Chemotherapy Treatment Protocol 1 (AC-T) 
Phase  Drug Name [Abbreviation] Drug Class Schedule 
1 
Adriamycin [A] Anthracycline • 4 cycles  
• Every 2 weeks Cyclophosphamide [C] Alkylating Agent 
2 
Paclitaxel [T] Taxane • 4 cycles  
• Every 2 weeks 
Trastuzumab [H]10 Monoclonal 
Antibody 
• Every 3 weeks 
 
B. Chemotherapy Treatment Protocol 2 (FEC-D) 
Phase  Drug Name [Abbreviation] Drug Class Schedule 
1 
Fluorouracil [F] Antimetabolite • 3 cycles 
• Every 3 weeks Epirubicin [E] Anthracycline 
Cyclophosphamide [C] Alkylating Agent 
2 
Docetaxel [D] Taxane • 3 cycles 
• Every 3 weeks 
Trastuzumab [H]2 Monoclonal 
Antibody 
• Every 3 weeks 
Table 2.3:  Chemotherapy treatment protocols. A.  Protocol 1 included AC-T 
chemotherapy.  B.  Protocol 2 included FEC-D chemotherapy.  Chemotherapy 
treatments were given in two phases.  Trastuzumab was given to patients who 
were HER2 positive in phase 2 (this was due to potential cardiac toxicity if given 
with anthracycline drugs during phase 1).     
 
2.4.3 Sequencing DOS and QUS Imaging Per Patient 
 
Subproject one (DOS + QUS serial imaging) 
 
DOS and QUS scans were completed sequentially within the same 
appointment session.  Patients were imaged with QUS first, then immediately 
following the imaging procedure, the patient was transferred onto a DOS 
imaging device for scanning. 
                                            
10 Trastuzumab was given to patients who were HER2 positive only. 
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Subproject two (baseline DOS imaging (i.e. pre-treatment) only) 
 
Patients recruited into subproject two participated in one DOS scan 
which included the baseline (pre-treatment) scan only.  No QUS acquisition was 
acquired for this patient group (patients declined participation into parallel DOS 
and QUS studies).          
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Figure 2.4:  LABC patients received either FEC-D (red dots) chemotherapy or 
AC-T chemotherapy (green dots), which required two dosing schedules.  The 
types of chemotherapy drugs given are indicated as blocks in the figure.  For 
subproject one, the intratreatment imaging scans (QUS+DOS, yellow dots) 
were scheduled based on an early assessment aim of after 1 cycle of 
chemotherapy and 2 cycles of chemotherapy for both chemotherapy regimens.  
For subproject two, patients only attended for the pre-treatment DOS scan.   
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2.4.4 Quantitative Ultrasound Data Acquisition 
 
For this imaging modality, patients were positioned supine with the 
ipsilateral arm positioned over the head (Figure 2.5).  The total duration of the 
ultrasound scans were approximately 20 minutes.   
 Data was collected in both normal breast tissue and within the whole 
tumour volume by employing a continuous panoramic scan across the breast 
(Figure 2.5).  To acquire the data, a Sonix RP system (Ultrasonix, Vancouver, 
Canada) operating with a 128-element, 60 mm- linear array transducer was 
used (L14-5/60, Ultrasonix, Vancouver Canada). The ultrasound transducer 
frequency was 10 MHz, corresponding to conventional breast imaging. The 
centre frequency was ~7 MHz, 40 MHz 8-bit dynamic range radiofrequency 
digitization frequency and data collected included 512 axial radiofrequency 
scanlines.  The lateral scan distance was 6 cm and the axial depth was 4 cm.   
Also, the focal depth was placed to correspond to tumour position.  The focal 
depth remained constant throughout the ultrasound imaging series for each 
patient.  The axial resolution was 0.154 mm and the lateral resolution at the 
focus was 0.21 mm11 based on the central frequency (i.e. ~7 MHz) used during 
scans.  
The ultrasound data collected included conventional b-mode (greyscale) 
images and the radiofrequency (RF) data.  The data was stored within the 
system and subsequently downloaded for image processing on a separate 
computer workstation.    
 
 
 
 
 
                                            
11 Calculations for the axial and lateral resolution can be found in Appendix 2.   
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Figure 2.5:  QUS breast imaging.  Radiofrequency (RF) data and grey-scale 
images were acquired over the entire volume of the tumour and included normal 
breast tissue (point A-B).   
 
2.4.5 Diffuse Optical Spectroscopy Tomography Data Acquisition 
 
Patients were scanned with a commercially available diffuse optical 
tomography system to acquire DOS images (SoftScan, Advanced Research 
Technologies, Montreal, Canada).  The pre-treatment DOS data was collected 
in 37 patients (22 patients from subproject one, and 15 during subproject two).     
The patient was positioned prone and the breast was placed into an 
enclosed imaging aperture (aquarium) and stabilized by opposing plexiglass 
plates with soft compression in the cranio-caudal direction (Figure 2.6).  The 
distance (thickness) between plates was recorded at baseline (average 
thickness = 73.3 ± 10.3 mm [STD]) and this distance was maintained during the 
imaging series for each individual patient.  The optical compensation medium 
(OCM) was warmed to 23°C and then added to the imaging aperture 
(aquarium) and filled to cover the entire breast surface (Figure 2.6).  The OCM 
was used to improve light transmission between surfaces and was formulated 
as an emulsion of lipids, water, and dye to mimic optical properties of breast 
tissue.  The optical absorbance (µa) and scattering (µs) of the OCM was 
characterized prior to experimentation (µa=0.05 cm-1 and µs =11 cm1, (λ)=780 
nm) (Schaafsma et al., 2015, Intes, 2005).   
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Optical mammography employed a time-resolved system using four 
individual semiconductor diode lasers (LDH-P, PicoQuant, Berlin, Germany) 
that operated at 687, 734, 782, 834 nm.  The optical wavelengths were chosen 
to correspond to the optimal absorbance spectra of breast tissue chromophores 
such as haemoglobin, water, and lipids (Intes, 2005, Cerussi et al., 2001).  The 
pulse duration at the full width half maximum was less than 150 ps, driven at 20 
MHz.  For the optical detection system, the light was collected using a 
photomultiplier (H7422P-50, Hamamatsu Photonics, Shizuoka, Japan), which 
was opposite to the light source (Figure 2.6).  The optical detection array was a 
mobile platform that was constructed with five lens multi-mode fibres and 
arranged in an X-constellation (Intes, 2005, Falou et al., 2012). Temporal point 
spread functions (TPSF) were collected with a resolution of 10 ps within a 4s-
delay window (Intes, 2005).  The TPSF was used to calculate the optical 
absorption and scattering. The absorbance and scattering calculations are 
found in subsequent section (Section 2.5).        
DOS images were reconstructed into tomographic and parametric maps 
of the optical parameters (deoxyhaemoglobin, oxy-haemoglobin, total 
haemoglobin, %water, %lipids, scattering amplitude, scattering power, tissue 
optical index).  The calculation of these parameters is described later in Section 
2.5.   Each voxel size of the parametric image was 3 mm x 3 mm x 7 mm3.    The 
DOS image planes used for analysis were dependent the size of the breast 
which determined the volume reconstruction.  The total duration of the optical 
mammography scan was approximately 30-40 minutes.  DOS imaging data was 
stored into the system’s permanent memory drive and extracted for imaging 
analysis.   
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Figure 2.6:  DOS tomography imaging involved whole-breast (volumetric) data 
acquisition.  For DOS imaging, the whole breast is immersed into an aqua-tank 
which is filled with optical compensation medium (OCM).  The OCM is used to 
enhance the light transmission between surfaces.  The breast is compressed to 
allow for better light transmission.  The light is transmitted through the breast 
and detected on the opposite side by a mobile detector.  The detector fibre 
transmits the DOS data to a computing system for data storage.  The data is 
later extracted, processed and analysed on a separate workstation.     
 
 
 
 
 
 
 
 
 
 136 
2.5 DOS and QUS Image Processing 
 
2.5.1 Region of Interest (ROI) Selection 
 
  The ROIs were selected under the guidance of a breast radiologist with 
more than 15 years of breast imaging experience.  For QUS, conventional B-
Mode images (grey-scale) were used to guide analysis and ROI selection.  For 
DOS, the patients’ diagnostic MRI images were used to determine the location 
and extent of tumours in the breast.  The ROI contours were chosen in-plane for 
each of the volumetric DOS and QUS image datasets before knowing the 
ground-truth labels12.   
 
QUS ROI selection 
 
QUS imaging was completed in subproject one only.  The ROIs were 
selected on 10-14 equally spaced scan planes for QUS.  For QUS, 22 patients 
were analysed over five scheduled time intervals (baseline, week one, week 
four, week eight, pre-operatively).  The total number of ROIs contoured for QUS 
was 1210.   
 
DOS ROI selection 
For subproject one, 22 patients had DOS imaging over the entire course 
of chemotherapy.  There were 5-8 equally spaced scan planes for each patient; 
thus, 862 ROIs were selected. 
In subproject two, the 22 patients from subproject one were included in a 
pooled analysis.  The additional 15 patients who were recruited for subproject 
two underwent pre-treatment DOS imaging, which included an additional 120 
ROI contours that were completed for this component of the study.  
 
 
                                            
12 Ground truth labels are a statistical term for the pathological classification 
groups used in the study.  In this study, it refers to responders versus non-
responders, as assessed by Miller-Payne pathologic response criteria.   
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2.5.2 QUS: Ultrasound Radiofrequency Spectrum 
 
For the calculation of QUS parameters, spectral analysis of the acoustic 
backscatter signal was done using the radiofrequency signal within a fixed-size 
analysis window.  The ROIs were kept constant for the duration of the imaging 
series and determined from the baseline scan.  Radiofrequency data was 
analysed across 10-14 equally spaced ultrasound scan planes.  Spectral 
analysis of the ultrasound radiofrequency spectrum was previously described by 
Lizzi et al. (Lizzi et al., 1997a), and adapted for this study.  These studies 
demonstrated that the acoustic backscatter signal was correlated to tissue 
microstructure.  All spectrum analyses were performed using a MATLAB-based 
software (Matlab, MathWorks, Natick MA, USA) developed by Oelze et al. from 
the University of Illinois and based on previous work by Insana et al. (Insana 
and Hall, 1990). 
Calculation of the parameters of power spectrum is undertaken by 
applying a fast Fourier transform (FFT) of a gated radiofrequency data line 
segment to obtain the amplitude line spectrum (complete calculations can be 
found in Appendix 2).  To reduce spectral-noise artefacts, a sliding window 
algorithm was used with the settings of a Hamming window function for gating, 
where there was an 80% overlap between adjacent windows in the axial 
direction.  A reference phantom technique was used to remove system transfer 
effects from the data using a tissue-mimicking agar-embedded glass-bead 
phantom with known acoustic properties (Tadayyon et al., 2014). To normalize 
the tissue sample signal to the reference phantom, the amplitude line spectrum 
was calculated in the same manner; where the fast Fourier transform (FFT) of 
the gated radiofrequency signal was processed from the ROIs of the reference 
phantom.  The log power spectrum is computed by the average of the squared 
magnitudes of the amplitude line spectra by lateral windowing.  The depth-
dependent acoustic attenuation was employed for calculating the power 
spectrum (the normalized power spectrum calculation can be found in 
Appendix 2) (Insana and Hall, 1990).  
A linear regression line using the least squares of the normalized power 
spectrum was applied across the frequency spectrum.   Previous work from 
Lizzi et al (1983) demonstrated that the frequency bandwidth over the -6 dB 
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range from the peak amplitude were capable of characterizing tissue 
microstructure.  From the regression line of the spectral form, the mid-band fit 
(MBF), 0-MHz intercept (SI) and the spectral slope (SS) QUS parameters were 
calculated (Lizzi et al., 1983).  The MBF denotes the spectral intensity of the 
mid-point of the best-fit line; the SS is the slope of the line; and the SI is the 
interpolated line to the Y-axis (Figure 2.7).   
 
 
Figure 2.7:  Representative power spectrum.  QUS parameters were obtained 
by applying a regression line to the spectral form, within the -6 dB13 window.  
The red circles indicate the parameters obtained by analysing the regression 
line: 1) The 0-MHz intercept (spectral intercept, SI) is the interpolated line to the 
Y-axis; 2) the midband fit is the midpoint of the regression line; 3) the last 
parameter is the slope of the regression line (spectral slope, SS).    
 
2.5.3 DOS Data Calculations 
 
The optical tomography device used a time-resolved system to 
determine the absorbance and scattering properties of the sample.  These 
measurements were used to calculate the concentration of tissue 
                                            
13 dB refers to decibels.   The dB is a logarithmic unit of measurement for sound 
intensity.    
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chromophores.  The system employed short pulses of light and measured the 
photons’ arrival time and was plotted as the time-point spread function (TPSF) 
(Enfield et al., 2009) (Figure 2.8A, B).   
 
Figure 2.8.A:  Calculating the TPSF in tissue. Pulses of light are emitted 
within a discrete time (t) and frequency (f) (A).  The light pulses are attenuated 
through tissue and causes a delay and broadening of the light pulse profile (B).  
A photocathode is used to measure the delay of the transmitted light pulse (C) 
and used to plot a complete (integrated) TPSF (D).  Adapted from Handbook of 
Biomedical Optics (Boas et al., 2011).     
 
 
Figure 2.8.B: (A) The tissue properties (i.e. composition and biologic layout) 
can affect the TPSF and dictated by scattering and absorption. (B) A highly 
scattering medium will cause the TPSF to broaden since the path length is 
longer. (C) In highly absorbing mediums, the TPSF will narrow since many 
photons will be attenuated within the medium. Adapted from (Enfield et al., 
2009) 
The experimental TPSF from the tissue sample was fitted against a 
model of light propagation by curve fitting and this was previously reported by 
Patterson et al. (Sato et al., 2013, Patterson et al., 1989) .  For the DOS 
system, the attenuation coefficient (µa) was calculated from a time domain 
diffusion equation that used a Rytov approximation to characterize light 
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propagation in a medium (Intes, 2005, Intes et al., 2002). The concentration of 
dominant DOS chromophores in breast was estimated and included oxy-
haemoglobin [HbO2], and deoxy-haemoglobin [Hb] (Cerussi et al., 2006).  Their 
concentrations [C] were calculated using the Beer-Lambert law, with the known 
molar extinction coefficients [e] (Eq. 2.3): 
 
 µa = e × C (Eq. 2.3) 
 
Other DOS parameters, such as [%Water], [%Lipid], scattering power [b], and 
scattering amplitude [A] were measured using the power-law fit of the scattering 
spectra within a given wavelength bandwidth (l) (Eq. 2.4).  This relationship 
was based on a Mie scattering approximation (Tromberg et al., 2005):   
 
µs(l) = A ×	l-b (Eq. 2.4) 
 
Additionally, other optical parameters such as oxygen saturation [StO2], oxygen 
desaturation [St], total haemoglobin [HbT] and the tissue optical index [TOI] 
were calculated from the [Hb], [HbO2], [%Water], and [%Lipid], and these 
calculations are described as (Cerussi et al., 2011, Intes, 2005):   
 
Total Haemoglobin;  
HbT = Hb + HbO2 (Eq.2.5) 
 
Oxygen Saturation; 
StO2 (%) = 
HbO2
HbT
	× 	100 (Eq. 2.6) 
 
Oxygen Desaturation; 
St (%) = 
Hb
HbT
	× 	100 (Eq. 2.7) 
Tissue Optical Index;  
TOI = 
Hb x %Water
%Lipids
	 (Eq. 2.8) 
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Figure 2.9:  Absorbance spectra.   Significant optical chromophores in breast 
tissue include water, lipid and oxy- and deoxy-haemoglobin.  The absorption of 
light in physiological chromophores is dependent on the optical wavelength.  
Optical imaging systems operate within a fixed optical bandwidth, denoted as 
the spectral window (dotted box in figure).  The spectral window permits the 
investigation of multiple chromophores within the medium.  The µa (cm-1) 
indicates the optical absorbance in a medium.    
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Figure 2.10:  Scattering spectra.  A power-law fit14 is applied to the scattering 
spectra to obtain other DOS parameters such as the scattering power (b) and 
scattering amplitude (A).      
 
2.5.4 DOS-GLCM (Grey-Level Co-occurrence Matrix) Texture Analysis 
 
Texture feature-extraction methods using a grey-level co-occurrence 
matrix (GLCM) can be applied to compute the probabilities of relative pixel 
intensities of images from the spatial distribution of their voxels (Haralick et al., 
1973).  This work has previously been demonstrated to provide deeper 
information about the image’s spatial and textural features in breast cancer 
using other modalities such as MRI (Chen et al., 2007).  The texture features of 
an image can quantify the heterogeneity of the tumour image and provide 
meaningful statistical frameworks that are correlated to tumour and 
histopathological characteristics (Yang et al., 2012, Davnall et al., 2012).   In 
other studies, GLCM analysis has been able to classify benign and malignant 
lesions using planar (2D) and volumetric (3D) MRI images (Chen et al., 2007, 
Gibbs and Turnbull, 2003).  For X-ray mammography, GLCM analysis has been 
                                            
14 The power-law is a mathematical expression of a power function.   
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used to segment lesion borders of stellate (malignant) breast masses (Gupta 
and Undrill, 1995).  It was also recently reported that texture-based features 
from quantitative ultrasound (QUS) imaging can be used to classify responders 
and non-responders early during NAC treatment (Sadeghi-Naini et al., 2014).  
These previous findings suggested that textural features may detect the acute, 
heterogeneous microstructural features carried in the parametric layout 
(Sadeghi-Naini et al., 2014).          
In this study, a GLCM-texture analyses were applied to whole-breast 
tomographic DOS parametric maps (Figure 2.11).  DOS images were 
constructed with an in-plane resolution of 3 × 3 mm2 and slice thickness of 7.5 
mm.   The GLCM-texture analysis was applied to the entire tumour volume and 
averaged over multiple frames of the DOS parametric maps.  The image’s 
properties are first defined by shades of grey levels (Ng) within a finite scale and 
the texture of the image describes the intensity of one pixel within a 
neighbourhood of image pixels.   A bilinear interpolation was applied to 
compensate for differences in the spatial resolutions, thus obtaining volumetric 
images with isotropic voxels (3 × 3 × 3 mm3) (Sadeghi-Naini et al., 2015).  For 
the GLCM, grey-tone intensities (Ng) were quantized into 16 grey-levels from 
the DOS parametric maps.  A symmetric GLCM was constructed based on the 
spatial relationship of each voxel’s neighbours using a displacement vector; the 
magnitude of the displacement vector was one to four voxel distances.   
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Figure 2.11:  GLCM computation.  This matrix is a representation of an ROI 
region with pixels.  Each box represents one pixel that is spatially arranged next 
to the other.   The right matrix is a representation of an image with quantized 
grey-scale values.  There are eight grey-scale levels and this is represented by, 
Ng=8 (i.e. eight grey-levels, 3-bit data).  The left is the GLCM matrix 
corresponding to the pixel relationships of the grey-scale image or within a 
region of interest.  Here, the displacement vector is used to compute the matrix, 
where its magnitude is equal to one voxel distance at an angle of 0° (highlighted 
yellow with the adjacent pixels).     
 
 A cumulative GLCM was calculated in 13 directions (45° rotations in 
each adjacent direction) relative to the central voxel (Chen et al., 2007).  The 
resulting co-occurrence features included: Energy, Homogeneity, Contrast, and 
Correlation.  These were previously defined as  (Haralick et al., 1973, Haralick, 
1979): 
 
Energy; 
 (Ene)= n	op)qr n 	𝑝(𝑖, 𝑗)_
op
uqr     (Eq. 2.9) 
 
where the energy (angular second moment) describes the textural uniformity of 
the image, 0 ≤ Ene ≤ 1.   The function p(i,j) is the probability of having two 
neighbour voxels with a grey-tone intensity (i and j) in the matrix;  
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Homogeneity; 
	(Hom)=n  n 𝑝(𝑖, 𝑗)1 + |𝑖 − 𝑗| Ng
j=1
Ng 
i=1
     (Eq. 2.10) 
 
where the homogeneity (inverse difference moment) measures the diagonal 
elements within the displacement vector of the GLCM and relates the 
similarities in grey-tones between voxels;  
 
Contrast; 
 
(Con)=	 n |𝑖 − 𝑗|_Ng-1 
|i-j|=0
× zn  n𝑝(𝑖, 𝑗)Ng 
j=1
Ng 
i=1
 {    (Eq. 2.11) 
 
where the contrast measures the differences between the lowest and highest 
voxels’ grey-tones and lastly; 
 
Correlation; 
 
	(Cor) = ∑ 	∑ (𝑖)(𝑗)𝑝(𝑖, 𝑗) −  𝜇)𝜇u	opuqrop	)qr 𝜎)𝜎u 				(Eq. 2.12) 
 
where the correlation measures the linear dependency on neighbouring grey-
tone intensities; and si, sj are the standard deviations, and µi, µj are the means 
of the probability matrix.  Therefore, a total of 40 DOS-texture features was 
included for analysis; there were 10 DOS parameters comprised of 4 GLCM 
features for each parameter (Figure 2.12).  DOS-texture features were 
calculated using MatLab R2011b (The MathWorks Inc., Natick, MA, USA).  The 
GLCM-texture functions used in MatLab were obtained from an online tool by 
The Mathworks Inc (Uppuluri, 2008).  The function codes were adapted for DOS 
image analysis at the University of Toronto by Sadeghi et al. (2015).   
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Figure 2.12 DOS-Texture Features.  Parametric maps were generated for 
each of the pre-treatment DOS features.  In order to obtain the texture features, 
a GLCM function was used on the parametric maps to obtain the following 
texture features: Energy (ene), Homogeneity (hom), Contrast (con), and 
Correlation (cor).  A total of 40 features were extracted from texture analysis of 
the DOS parametric maps (i.e. 10 DOS features x 4 texture features = 40 total 
features).  
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2.6 Image Quality Verification 
 
 Quality verification was completed on imaging devices to ensure data 
consistency and quality throughout the imaging scans.  A description of the 
various quality procedures is described in the subsequent sections.   
 
2.6.1 Ultrasound Transducer Properties and Beam Characterization 
 
 The ultrasound beam was characterised from the Ultrasonix L5-14/60 
transducer used in this study.  Beam characterisation was completed using an 
open-access MATLAB-based software platform (Field II, Biomedical 
Engineering Group, Lyngby Denmark, (Jensen, 2017)).  The point-spread 
function was computed based on measurements obtained from several 
locations of an acoustic phantom.  The phantom had an echogenic surface and 
was constructed of plexiglass with known acoustic properties.  Beam 
characteristics obtained included the axial depth, the focal depth, centre 
frequency, frequency bandwidth, and FFT-frequency response along the axial 
waveform.  The frequency-response curve was obtained and corresponded with 
the 0-mm lateral distance.  The data presented in Table 2.4 were taken within 
the -6dB window, referenced at 0 mm lateral distance. The characterization 
features are listed below with the beam profiles (Figure 2.13, Table 2.4).      
Transducer Properties Measurements 
Number of elements (n) 128 
Kerf (distance between elements) [µm] 25 
Element width [mm]   0.48 
Element length (elevation) [mm] 4 
Elevation focus [mm] 14 
  
Beam Characteristics Measurements 
Focus position [mm] 13.8 
Centre frequency [MHz] ~7  
Frequency bandwidth range [MHz] 3-8 
Depth of focus [mm] 6.9 
Elevation beam resolution [mm] 0.77 
Lateral beam width at focus [mm] 0.21 
Table 2.4:  Transducer and Beam Characteristics.  The above characteristics 
were measured and compared to references (outlined by the manufacturer) for 
quality assurance.  
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Figure 2.13:  Transducer Beam Characteristics.  The ultrasound beam 
characteristics evaluated using a MATLAB-based software platform.  Feature 
profiles are outlined in Table 2.4. The colour maps represent the relative signal 
intensity (red; high intensity and blue; low intensity)    
 
2.6.2 Optical Imaging Characterization 
 
The diffuse optical spectroscopy tomography device was tested for data 
stability using an end-user phantom from the manufacturer (Advanced 
Research Technologies, Montreal, Canada).  The phantom was constructed of 
a polyurethane phantom suspended from a monofilament within a metal frame 
(Figure 2.14).  The phantom mimicked tissue optical properties within the near-
infrared spectrum.  
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Figure 2.14:  Optical Phantom Construction.  The phantom was constructed 
from a frame with a polyurethane cylinder material that was optically 
compatible.  The phantom permitted verification of the imaging geometry, and 
tested the quality of the light transmission of the device.  The colour maps 
represent the relative signal intensity (red; high intensity and blue; low intensity)    
 
To verify the imaging and data, the phantom was inserted into the DOS device 
for imaging.   A predefined ROI was selected with the following geometry for 
imaging to obtain the quality-check parameters (Table 2.5): 
 
Adjustment Scan Area  
 
Setting 
 
Measurement (mm) 
Phantom Width 54.0  
Phantom Offset 58.0 
Phantom Height 54.0 
Top Offset 25.0 
 Table 2.5:  Optical ROI Geometry for Quality Check. 
 
Optical scanning was completed using the same scanning protocol indicated for 
patients.  The data output was analysed on a separate workstation (ART 
Review Workstation, V. 1.07.01, Montreal Canada) (Figure 2.15, Table 2.6).  
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Figure 2.15:  DOS Data Verification.  Data verification included testing each 
transmission wavelength.  The test performance was based on verifying the 
image’s geometry and to test the transmission patterns.  The transmission 
patterns are compared to a reference image for verification.    
 
 
Analysis of the DOS data are outlined below in Table 2.6.   
 
DOS Imaging Characteristics Measurements 
Complete Scanning Area (mm) (W x H) 170 x 185 
Optical Wavelength Verification (nm) 687, 734, 782, 834 
Pixel dimension (in-plane) [mm] 3 x 3 
Contrast scale range [a.u.] 3-20 
Table 2.6:  Optical characteristics.  The DOS imaging characteristics are 
outlined with the corresponding measurements from the quality management 
process.   
 
2.6.3 Inter-Reader Variability Testing 
 
 Inter-user variability was tested on 25 DOS and 25 QUS datasets.  The 
ROI contour and volume were tested for pairwise agreement between two 
users.  Thus, each dataset had two readers analyse an ROI contour on the 
same DOS image and a QUS image (Figure 2.16).  A Cohen’s k  used to 
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compare ROI placement and this was based on the reader’s interpretation of 
whether the ROIs delineated between the “inside” and “outside” region of the 
tumour. These methods were previously used in a simulation-based study for 
PET imaging (Rucker et al., 2012).  To analyse if readers selected similar ROI 
volumes, an independent t-test was used.  A significance level of 0.05 was used 
to determine significant results.   
     
 
Figure 2.16. Inter-user agreement analysis.   For inter-user variability testing, 
the placement of the ROI was analysed by two readers for agreement statistics 
(k).   
 
Cohen’s k is expressed as: 𝜅 = ()(6)r	(6)     (Eq. 2.13) 
 
where; Pr(𝑎) denotes the observed agreement and Pr	(𝑒) represents the 
chance agreement (Rucker et al., 2012) and 0£k£1.  
The value and range of k represent the level of agreement; where 0-0.2 
demonstrate only a small probability of agreement; 0.21-0.40 is considered fair; 
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0.41-0.60 is moderate; 0.61-0.80 denotes a substantial agreement; and 0.81-
1.00 is an ideal agreement range between readers (McHugh, 2012).   A 
summary of tests and statistical measures are outlined in Table 2.7.    
 
Test Value 
n=25 DOS QUS 
(ROI Placement) [Cohen’s k] 0.779, p<0.001 0.740, p<0.001 
Volume Comparison (t-test) [p-value] NS (p=0.993) NS (p=0.839) 
Table 2.7:  Tests of comparisons (Inter-reader variability).  A Cohen’s k was 
calculated ROI placement.  Tumour ROI volumes were also compared for 
significant differences in chosen volumes between users.   
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2.7 Statistical Analysis and Machine Learning 
 
All statistical tests were performed using SPSS 20 (IBM Inc., Armonk 
New York, USA) and MatLab R2011b (The Mathworks Inc., Natick, MA, USA).  
A summary of the study workflow is outlined below.   
 
2.7.1 DOS and QUS Data 
 
Descriptive statistics were used on both DOS and QUS parameters. 
Mean value with standard deviation was calculated for each imaging dataset 
taken at each time interval when data was collected.  For QUS the change [∆] in 
QUS parameters was calculated by subtracting the measurements at each time 
interval from the value measured at baseline.  DOS measurements were 
expressed in percent changes from the baseline [% Change].    
 
2.7.2 Tests of significance between response groups (R versus NR) 
 
A comparison of each parameter mean values, using the DOS and QUS 
data were tested for significant differences between responders and non-
responders at each time interval.  First, a normality violation was tested for each 
parameter using a Shapiro-Wilk test (W).  For normally distributed parameter 
changes, an independent t-test was used (unpaired, two-sided, 95% confidence 
interval). Otherwise, an unpaired, Mann-Whitney U-test within the 95% 
confidence level was utilized (SPSS Inc., Chicago IL, USA) for parametric 
changes that were not normally distributed. The Mann-Whitney U-test is based 
on a calculation of the U-statistic for each group (Mann and Whitney, 1947).  
The U-statistic is then compared against a known distribution for which the null 
hypothesis is either accepted or rejected (Nachar, 2008).  
 
2.7.3 Tests of significance Between Time Intervals 
 
Significant changes over time were tested for each DOS and QUS 
parameter to compare its difference to baseline values using a one-way with 
repeated-measures ANOVA (analysis of variance).  For this, a Dunnett’s test 
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was used.  The statistical measures were considered significant at an alpha 
level of 0.05 or less.    
 
2.7.4 Selection of Feature Sets for Analysis 
 
Both univariate and multivariate analyses tested the performance of 
individual and combined DOS and QUS parameters against final pathologic 
endpoints, as measured by Miller-Payne response criteria.  All imaging 
parameters calculated from DOS and QUS were considered for univariate 
analysis.  For multivariate features and models, a maximum of two combined 
(binary) parameters were used and all binary forward combinations were 
considered for analysis.  The maximum feature set (multivariate model) were 
constrained by the number of data samples in this study. Using a binary feature 
model would mitigate the “curse of dimensionality” based on a maximum of 1/10 
of the data sample (Jain et al., 2000).  In subproject one, a total of 22 patients 
were analysed (maximum 2 feature sets in the multivariate model).  In 
subproject two, a maximum of 2 features was permitted within a multivariate 
model given the mathematical constraints of the prediction models used in the 
machine learning algorithm.      
 
2.7.5 Receiver Operating Characteristic Curve Analysis 
 
A receiver-operating characteristic curve (ROC) analysis was completed.   
The ROC provides the diagnostic accuracy of DOS and QUS parameters to 
discriminate between pathologic responders and pathologic non-responders 
(Metz, 2006).  The ROC is based on a distribution of the true positive fraction 
(TPF) and the false positive fraction (FPF) (Figure 2.17, Table 2.8).   
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 Disease   
Test Present n Absent n Total 
Positive 
True Positive 
Fraction (TPF) 
a 
False Positive Fraction 
(FPF) 
c a+c 
Negative 
False Negative 
Fraction  
(FNF) 
b 
True Negative Fraction 
(TNF) 
d b+d 
Total  a+b  c+d  
Table 2.8:  Measures of Diagnostic Test Accuracy. Table corresponds to 
Figure 2.17.  The TPF, FNF, FPF and TNF are used to calculate the test 
accuracy.   
 
 
Figure 2.17:  Test Distribution.    The sensitivity, specificity and accuracy of a 
diagnostic test can be calculated based on the true negative distribution and the 
true positive distribution.  The sensitivity and specificity points are employed to 
compute the ROC curve.   
 
Using the true positive distribution and the true negative distribution, predictive 
values can be expressed (using the notations in Table 2.8) as; 
 
Sensitivity; %𝑆𝑛 =	 𝑎(𝑎 + 𝑏)	× 	100			(Eq. 2.14) 
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where the %Sn represents the probability that the test result is positive when 
there is disease present;  
 
Specificity; %𝑆𝑝 = 	 𝑑(𝑐 + 𝑑)	× 	100			(Eq. 2.15) 
  
where the %Sp represents the probability that the test result is negative when 
the disease is not present;   
 
Accuracy; %𝐴𝑐𝑐 = 	 (𝑎 + 𝑑)(𝑎 + 𝑏 + 𝑐 + 𝑑) 	× 	100			(Eq. 2.16) 
 
where the %Acc represents the number of true assessments.   
To plot the ROC curve, the sensitivity and specificity was used as 
coordinates within the curve axes (Figure 2.18).  To determine the best cut-off 
point, Youden’s index (Q-point) was used.  The area under the curve (AUC) 
was determined by calculating the integral of the ROC.  
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Figure 2.18:  Receiver-Operating Characteristic Curve.  The ROC is plotted 
based on the sensitivity and the specificity of the test.  A random classification is 
determined at 0.5; while an ideal diagnostic test is depicted where the 
sensitivity and specificity is equal to 1 (top left corner of ROC).  Youden’s index 
at the Q-point (Q-Index) denotes where the sensitivity and specificity are equal 
(optimal test).    
 
In this study, multiple statistical models were used to calculate the 
sensitivity, specificity, accuracy and AUC of DOS and QUS imaging biomarkers.  
The following sections will describe classifier models used to discriminate DOS 
and QUS imaging parameters between pathologic response groups to obtain 
the sensitivity, specificity, area under the curve and accuracy.   
 
2.7.6 Linear Discriminant Analysis (LDA) 
 
 For subproject one, a LDA was used to classify responders and non-
responders based on their univariate DOS and QUS parameters.  The linear 
function was used as the cut-off point to determine the sensitivity, specificity 
and accuracy of the individual DOS and QUS variables.       
Linear discriminant analysis is based on Fisher’s linear discriminant 
model where a linear function is used to separate binary classes; given a set of 
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variables, [x1, x2,…. xn].  The linear classifier thus separates two “species” 
based on its feature space; whereby the goal is to determine the optimal ratio of 
the means and standard deviations that would discriminate the classes within 
the feature space (dimension) (Fisher, 1936).   The discriminant linear function 
is also referred to as the “decision boundary” (Figure 2.19). 
 
 
Figure 2.19:  Linear Discriminant Analysis.  The LDA is used to calculate the 
linear function which is used to discriminate between two species (Class 1 and 
Class 2, for example responders versus non-responders).   
    
2.7.7 Logistic Regression Analysis (LRA) 
 
Following methods by Xu et al. (2015), a logistic regression analysis 
(LRA) was used to compute the probability of multivariate combinations for DOS 
and QUS imaging markers to a dichotomous response variable (Y, 
Y1=Responder; Y2=Non-Responder) (Xu et al., 2015).  The predictive 
performance of the models was evaluated by using the LRA model within the 
training set and then a test set to measure the classification error.   
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2.7.8 k-Nearest Neighbour (k-NN) Classifier Statistics 
 
The k-NN classification is a non-parametric algorithm used for 
classification.  It was chosen since it is one of the least computationally-
demanding algorithms for supervised machine-learning (as this present study is 
exploratory).   The k-NN algorithm makes no assumptions about the form of the 
data (e.g. Gaussian distribution) and therefore it is ideal for exploratory studies 
where there is no prior knowledge about the attributes and distribution of the 
data. (Dudani, 1976).  The k-NN classification uses a weighting function that 
varies in value based on the distance between a sample and its neighbour; 
seeking out patterns in the distribution of the data within a sample set (Dudani, 
1976).  The data samples (known as “instances”) are treated in groups or 
“bags” with a defined label (Wang and Summers, 2012).  The bags are 
analysed in terms of their attributes or features.  In this study, the bags were 
labelled as either pathologic responders or non-responders and the attributes 
were all baseline DOS features (Figure 2.20). 
 The k-NN algorithm first organizes the bags into a feature space based 
on the values of the attributes and this is used for the training set.  The test set 
is assigned a label according to a majority vote that is dependent on the nearest 
neighbour as determined by the Euclidean distance calculation (Eq. 2.17, 
Figure 2.20).  For baseline DOS features, the training and test set used a k 
value of k=3 (three nearest neighbours).   
 
A Euclidean distance is defined as; 
 
Euclidean distance 
 𝑎r(r) − 𝑎r(_)_ +	𝑎_(r) − 𝑎_(_)_ +⋯ . 𝑎(r) − 𝑎(_)_	 (Eq.2.17) 
 
where; (𝑎(2)) represents the number of attributes for each instance.  Since 
different attributes may have varying scales or units of measure; they are all 
normalized between 0 and 1 for analysis within the k-NN feature space.  
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Figure 2.20:  k-NN Classifiers.  The kth nearest neighbour is three in this 
representation.  The bags are labelled as responders (green) or non-
responders (red) in the training set (A).  A test sample is used to compute the 
three nearest neighbours using a Euclidean distance calculation.  Depending on 
the labels of the nearest neighbours, a vote is tabulated and the majority vote 
determines how the test sample is labelled (B).    
 
2.7.9 Naïve Bayes (Bayesian) Classifier Statistics 
 
 Naïve Bayes classification can be used to predict the probability of a 
binary class membership (i.e. chemotherapy responder versus chemotherapy 
non-responder).  The algorithm uses the probabilities of the class label and its 
attributes to compute a probability prediction of a sample.  An important 
assumption for naïve Bayes classification algorithms is that the individual 
attributes (𝑎r, 𝑎_,… 𝑎2) of a class are independent to each other (conditional 
independence) (Han and Kamber, 2006).  The naïve Bayes classifier function is 
expressed as (Eq. 2.18): 
 
Naïve Bayes Classifier 
 𝑃(𝑋|𝐶)) = ∏ 𝑃(𝓍|𝐶))2qr 				(Eq. 2.18) 
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where; 𝑃(𝑋|𝐶)) is the probability of sample (X) labelled into a class (𝐶)); and  𝓍 
represents the value of 𝐴 attributes for sample X (Han and Kamber, 2006).  
For this study, (𝐶)) is the response class (responder versus non-responder; 𝑖	= 
1, 2) and 𝐴 corresponds to all the baseline DOS-texture features. 
 
2.7.10 Training, Test and Validation Sets 
 
Prior to training and test validation, the data set was randomly 
subsampled into 20 subsets with replacement.  Each subset had equal 
numbers of responders and non-responders; this method was used to account 
for the data imbalance between the two response groups.  Since each patient 
was represented using 40 DOS-GLCM features, and due to a limited sample 
size, in order to prevent the “curse of dimensionality” (Jain et al., 2000), a 
feature selection based on sequential forward selection (SFS) algorithm in a 
wrapper framework (Duda et al., 2001) was performed to find the best (in the 
univariate case), or at most two (in the multivariate case) features.  In order to 
prevent the peaking phenomenon due to the curse of dimensionality (Jain et al., 
2000), the number of features should be at most 1/10th of the number of data 
samples, and since in the balanced data, there were only 20 data samples, a 
maximum of two features were selected for multivariate analysis using the SFS 
algorithm.  The classifiers were evaluated using a leave-one-out cross 
validation at subject level. At each fold, the test set (one patient) remained 
unseen during the feature selection, tuning, and training of a classifier. 
Furthermore, at each fold, a leave-one-out cross validation was performed on 
the training set for the purpose of feature selection and tuning a classifier 
parameter (such as k in k-NN). Thus, at each fold, the training set was further 
divided into train and validation sets. The most discriminative feature(s) and the 
optimal classifier parameter were selected on the training set at each fold 
without involving the left-out test sample. Subsequently at each fold, the 
classifier was trained on the whole training set using the optimal classifier 
parameter and selected features, and tested on the test sample. This process 
was repeated on all samples (in the leave-one-out process) to evaluate the 
performance of the classifier. 
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2.7.11 Subgroup analysis 
 
To test if there was a correlation between DOS-GLCM features and 
tumour biology and clinical features, a multiple linear regression analysis was 
completed using methods previously reported for imaging biomarker analysis 
(Evans et al., 2013).  The following clinical variables were considered in the 
model:  Patient’s age, ER/PR status, HER2 status, tumour size, and pathologic 
response.  The regression coefficient (r) was calculated between the clinical 
variables and DOS-GLCM features.  A statistical test of significance was also 
performed using an ANOVA test with an alpha of 0.05. 
 
2.7.12 Power Analysis 
 
The statistical test of significance was performed with a relatively small 
sample size in each responding group and handling small datasets have been 
previously described (Siegel and Castellan, 1988, de Winter, 2013). In order to 
evaluate the reliability of the performed tests, the statistical power was 
calculated using PASS14 where the label with the highest sample size was fixed 
for analysis.  A power threshold of 0.70-0.80 was used (NCSS, LLC. Kaysville, 
Utah, USA). 
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Chapter 3 
Results 
 
 
3.0 Chapter Overview 
 
 In this chapter, the results of subproject one and subproject two of this 
study are presented.  The structure of this chapter is presented in three 
sections: 1) patients’ clinical and demographic characteristics; 2) measurements 
of DOS and QUS in breast tumours during chemotherapy (i.e. subproject one) 
and; 3) measurements of pre-treatment DOS in breast tumours before 
chemotherapy (i.e., subproject two).  Section one presents data on patient 
demographics (i.e. age) and the clinical presentations before chemotherapy (i.e. 
tumour size, tumour subtype, chemotherapy regimens) and after chemotherapy 
(i.e. Miller-Payne graded pathology response outcome and tumour size 
reduction).  The demographic and clinical characteristics were analysed in 
terms of its representation of cross-sectional breast cancer data (i.e. prevalence 
to cancer subtypes, age, tumour size at diagnosis).   
In section two of this chapter, the results from subproject one are 
presented within the framework of the following research questions:  
 
(Subproject one)  
 
1. Research Question 1: Do DOS and QUS imaging biomarkers 
demonstrate statistically significant changes over the course of 
chemotherapy? 
 
2. Research Question 2: Can DOS and QUS imaging biomarkers be 
modelled together to measure treatment response at early time intervals 
(i.e. after one or two cycles of chemotherapy)?   
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Here, parallel imaging time intervals using DOS and QUS are presented and 
statistical analyses are given in terms of their correlation to final pathologic 
endpoints (i.e. Miller-Payne score).  
 
In section three, the results from subproject two are presented in terms of 
addressing the following research questions:    
 
(Subproject two) 
 
1. Research Question 1: Do breast tumours demonstrate significant 
differences in DOS-texture parameters between responders and non-
responders, as measured before chemotherapy?  
 
2. Research Question 2: Can DOS markers predict chemotherapy 
response prior to starting chemotherapy? 
 
3. Research Question 3: Are there differences in DOS-texture prediction 
models for breast cancer subtypes (i.e., ER+ and triple negative) and 
chemotherapy treatments (i.e. FEC-D and AC-T)? 
 
In this section pre-treatment DOS texture results are presented and analysed 
for statistical differences between responders and non-responders using a total 
sample set of 37 patients.  To address the second and third research questions 
from subproject two, machine learning statistics and discrimination analyses 
results are presented from the 37 patients, and then subgroup analysis with 
ER+ tumours (subgroup of 27 patients), triple negative tumours (subgroup of 7 
patients), FEC-D chemotherapy-treated patients (subgroup of 16 patients) and 
finally AC-T chemotherapy-treated patients only (subgroup of 21 patients).        
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3.1 Patient Characteristics 
 
There were 37 patients recruited into the overall study.  For subproject 
one, there were 22 patients who enrolled and completed all DOS and QUS 
imaging scan times (i.e. baseline, week one, week four, week eight, pre-
operative).  For subproject two, an additional 15 patients were recruited who 
completed one DOS imaging session before starting their chemotherapy (i.e. 
pre-treatment).  All patients who signed the consent form completed their 
baseline scan for subproject two.  In the entire study, there were no study 
deviations and no attrition.  Patients were recruited consecutively.  Participants 
did not report any side-effects related to the study procedure.  A medical chart-
review showed that all participants completed their chemotherapy as scheduled.  
A summary of patient characteristics is outlined in Table 3.1 and described 
below.  
   
3.1.1 Pre-Chemotherapy and Treatment Characteristics 
 
The mean age was 50 years.  Tumour characteristics were recorded at 
the time of diagnosis.  In terms of histological type, lobular carcinoma 
accounted for 3% of patients (1 case) and the majority (97%, n=36) of cases 
were invasive ductal carcinoma in this study.  Previous studies have indicated 
that invasive lobular carcinomas account for 7.6-10% of breast cancer cases; 
while invasive ductal carcinomas were the most prominent histological type; 
accounting or 72.8% of histological types (Dossus and Benusiglio, 2015, Li et 
al., 2003).   
The search results from the patients’ electronic medical record indicated 
that 27 patients had oestrogen receptor (ER) positive tumours; while seven 
were “triple-negative” breast tumours and 12 patients had tumours that were 
HER2-positive.  Participants’ clinical characteristics in this study were 
comparable to cross-sectional breast cancer data by the National Cancer 
Institute (NCI).  The NCI database includes information on the prevalence of 
breast cancer subtypes such as, ER-expression and triple negative tumours; 
their data indicated that among 50,571 women, 72.7% of breast cancers were 
ER+, 12.2% were triple negative and 4.6-10.3% were HER2+. (Howlader et al., 
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2014).  In this study, 73% of patients were ER+, 19% were triple negative and 
32% had HER2+ breast tumours. With the exception of the proportion of HER2+ 
cancers there was an otherwise good correspondence to NCI cross-sectional 
data.  
 In this study, 21 patients were given AC-T based chemotherapy and 16 
patients were given FEC-D chemotherapy.  The chemotherapy regimen was 
consistent with treatment guidelines for advanced breast cancer, as 
recommended by the National Comprehensive Cancer Network (USA) and the 
National Institute for Health and Care Excellence (UK) (National 
Comprehensive Cancer Network, 2016, National Institute for Health and Care 
Excellence, 2017).    All patients completed their chemotherapy treatments.  A 
chart-review was performed and no additional or other chemotherapy drugs 
were administered to patients.  However, in 12 patients who were HER2+, 
Trastuzumab15 was given during their taxane phase chemotherapy, as this was 
also consistent with guidelines from the NCCN and NICE (National 
Comprehensive Cancer Network, 2016, National Institute for Health and Care 
Excellence, 2017).  
 
3.1.2 Post-Chemotherapy Characteristics 
 
A review of the patients’ medical records indicated that there were 27 
patients that were classified as responders, which corresponded to Miller-Payne 
scores 3-5 (MP3= 15 patients; MP4=7 patients; MP5=5); thus, there were 5 
pathological complete responders, i.e. categorized as Miller-Payne score 516.  
There were 10 patients that were non-responders as these patients had a 
Miller-Payne score of 1 or 2 (MP1=4 patients, MP2=6 patients).  For 
responders, the mean tumour size reduction from pre- to post-chemotherapy, 
as measured by MRI was 4.8 cm; 95% CI [3.8, 5.8], p<0.0001, paired t-test); 
while for non-responders, tumours shrunk by a mean value of 0.9 cm; 95% CI 
[0.4, 1.4], p=0.0029, paired t-test).  Thus, both responders and non-responders 
                                            
15 Trastuzumab is a monoclonal antibody (targeted therapy) used for breast 
tumours that are HER2-positive.    
16 Representative pathological specimens of a responder and non-responder 
are presented in Appendix 3.   
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had a statistically significant reduction in the tumour size between the pre- and 
post-treatment times as measured by MRI.       
 
Summary of Patient and Tumour Characteristics 
 
Patient Demographic Information 
 
Number of patients =37  
(All Subjects) 
   
Patients’ Age   
  Years (Range) 
 Mean Age  50 (29-79) 
   
Pre-Treatment Clinical Characteristics 
  
Breast Tumour Size  
 cm (Range) 
Mean Tumour Size at Diagnosis (MRI) 
 
5.9 (2.1-12.8)  
  
Molecular and Histological Features 
Number of patients n, (%) 
Oestrogen Receptor (ER)+ 27, (73) 
Triple Negative/Basal-Like 7 (19) 
HER2+ 12 (32) 
Invasive Ductal Carcinoma 36 (97)  
Invasive Lobular Carcinoma 1 (3) 
  
Chemotherapy and Targeted Therapies  
 Number of patients n, (%) 
 AC-T 21 (57) 
 FEC-D 16 (43) 
 Trastuzumab1 12 (32) 
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Post-Treatment Clinical Characteristics 
 
Post-Treatment Response Classification  
(Miller-Payne Pathologic Endpoints)2 
 Number of patients n, (%) 
Responders (MP 3-5) 27 (73) 
Non-Responders (MP 1-2) 10 (27) 
  
 
Mean Tumour Size Change from Pre- to Post-Chemotherapy  
(Largest Dimension of Tumour as Measured by MRI)3 
Change cm, (%) 
Responders (MP 3-5) -4.8, (-88) 
Non-Responders (MP 1-2) -0.9, (-13) 
Table 3.1. Summary of Patient Characteristics.  Pre- and Post-chemotherapy 
characteristics were recorded.   1 Trastuzumab was given to HER2+ patients in 
the second phase of treatment (i.e. during the patient’s docetaxel (D) or 
paclitaxel (T) treatment).  2 Miller-Payne (MP) Pathologic Response Criteria was 
defined as: MP1-No reduction in overall cellularity, MP2-Up to 30% loss in 
tumour cells, MP3-30-90% loss in tumour cells, MP4-more than 90% loss, MP5-
Complete disappearance of tumour cells. 3MRI measurements were obtained 
from the patients’ electronic medical record.     
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3.2 Results of Subproject One  
 
3.2.1 Overview of Results: Subproject One, Research Question 1 
 
In this section, the results to the following research question are 
presented: Do DOS and QUS imaging biomarkers demonstrate statistically 
significant changes during chemotherapy in responders and non-responders?  
This research question was approached using two statistical methods, as 
described below.       
The first statistical approach was an independent sample t-test to 
compare the mean differences between responders and non-responders during 
early and late time intervals.  Early time intervals were defined as corresponding 
to one to two cycles of chemotherapy, i.e. week one and week four of the 
imaging timelines of this study.  Late time intervals were defined as 
corresponding to the third cycle of chemotherapy and up to the end 
chemotherapy, i.e. week eight and the pre-operative time interval.  In the 
second statistical approach, a repeated measures ANOVA (i.e. within-subjects 
ANOVA) was calculated for responders, and for non-responders.  The repeated 
measures ANOVA was used to test if the changes in DOS and QUS parameters 
were significant over the entire treatment course for each response group 
(responders and non-responders).  All statistical tests were considered 
significant at a significance level of less than 0.05.   
The following section presents the results of the independent sample t-
test and repeated measures ANOVA in the following format:  1) DOS data and; 
2) QUS data.  Lastly, representative case studies of responders and non-
responders are presented to compare the coincident changes in DOS and QUS 
parameters at early and late time intervals.  DOS data is shown as a relative 
change from baseline, which was calculated for each time interval and defined 
as the percent comparison between the mean DOS parameter at each time 
interval to the mean DOS parameter measured at baseline.   QUS data is 
presented as the change in magnitude (increase/decrease) for each of the QUS 
parameters (i.e., ∆MBF, ∆SI, ∆SS).           
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3.2.2 Results of DOS Measurements- Haematological Parameters 
 
Early Time Intervals (week one and week four) 
 
Haematological parameters included the deoxy-haemoglobin (Hb), oxy-
haemoglobin (HbO2) and the total haemoglobin (HbT).  After one week of 
treatment, there were significant differences in the HbO2 and HbT between 
responders and non-responders (p<0.01).  The HbO2 concentration increased 
to 110.7% ± 5.4% (SD17) for non-responders, compared to responders whose 
tumours had a reduction in the HbO2 concentration to 73.7% ± 2.0%.  Similarly, 
the HbT concentration increased 103.2% ± 5.5% for non-responders; while 
responders showed a reduction in the HbT concentration to 78.2% ± 3.2%.  
During the fourth week of treatment, all haematological parameters (Hb, HbO2, 
HbT) were very statistically different between responders and non-responders 
(p<0.01) (Table 3.2).  The Hb parameter showed a greater reduction in 
responders; the change in Hb concentration was reduced to 29.9% ± 6.32% 
and non-responders had a smaller reduction to 68.7% ± 7.9%.  These trends in 
which there was a greater haematological reduction in responders compared to 
non-responders, was observed in the HbO2 and HbT parameters (Figure 3.1) at 
the same time interval.  A summary of the statistical differences for each 
parameter are presented in Table 3.2.   
 
Late Time Intervals (week eight and pre-operative time interval)   
 
 All haematological parameters (Hb, HbO2, HbT) were very statistically 
different between responders and non-responders at late time intervals, as 
measured at week eight and pre-operatively (p<0.001).  After eight weeks of 
treatment, the Hb parameter showed a decrease in concentration to 21.0% ± 
2.9% for responders and non-responders had tumours with higher Hb 
concentration (81.9% ±  9.4%, relative to baseline).  The reduction in the HbO2 
and HbT parameters were greater for responders compared to non-responders; 
the HbO2 and HbT corresponded to a reduction to 10.2% ± 2.3% and 12.7% ± 
                                            
17 SD; standard deviation 
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2.2%, respectively for responders.  The pre-operative measurements showed a 
further reduction in haematological parameters for responders; the Hb 
concentration reduced to 25.4% ± 4.5%, the HbO2 reduced to 10.5% ± 2.8% 
and the HbT concentration reduced to 12.7% ± 2.1% from the baseline value.  
Non-responders at this time interval showed a lesser change in tumour 
haemoglobin; the Hb reduced to 82.9% ± 7.9%, the HbO2 reduced to 84.9% ± 
7.6% and the HbT reduced to 84.4% ± 6.8% from the baseline value.  A 
summary of changes is presented in Figure 3.1.          
 
Tests of Significance Over the Treatment Time Course 
 
The ANOVA tested if there were significant changes in haemoglobin 
parameters over the entire treatment course (i.e. from the pre-treatment time 
interval to the pre-operative scan) for responders and for non-responders.  The 
results indicated that responders and non-responders had a significant change 
in all haemoglobin parameters (Table 3.2).  Thus, both responders and non-
responders demonstrated haematological changes from chemotherapy.     
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 Comparison between responders (R) 
and non-responders (NR) 
(Independent samples t-test)1 
Within-subjects 
comparison 
(ANOVA)2 
 Early Time  
Intervals 
Late Time  
Intervals 
All Time  
Intervals 
 Week 1 Week 4 Week 8 Pre-Op R NR 
Haematological Parameters     
 p-value p-value p-value p-value p-value p-value 
Hb 0.375 0.002 0.000 0.000 0.000 0.005 
HbO2 0.000 0.001 0.000 0.000 0.000 0.015 
HbT 0.004 0.000 0.000 0.000 0.000 0.003 
       
Table 3.2:  Summary of measured p values for DOS-haemoglobin 
parameters.   1DOS parameters were also tested for significant differences 
between responders and non-responders using an independent t-test within the 
95% confidence level following a test for normality.  Otherwise, a Mann-Whitney 
test was performed. 2A repeated-measures ANOVA was used to test for 
significant changes over time (i.e. repeated measures between time intervals) 
for DOS parameters. Bold and blue fonts indicate statistically significant 
results; p<0.05= statistically significant; p<0.01 very statistically 
significant.       
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Figure 3.1:  DOS haemoglobin parameters. Changes in haemoglobin 
parameters, measured as relative percent changes from baseline values. Error 
bars = Standard deviation, n = 14 responders and n = 8 non-responders.  
Significant differences between responders and non-responders were tested at 
each time interval and parametric changes over time were tested for responders 
and non-responders (Table 3.2). 
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3.2.3 Results of DOS Measurements- Tissue Parameters 
 
Early Time Intervals (week one and week four) 
 
 Tissue parameters included the %Water, %Lipids and the tissue optical 
index (TOI).  There were no significant differences between responders and 
non-responders after one week of treatment (p>0.05).  However, after four 
weeks of treatment, the %Water, %Lipids and TOI parameters were very 
statistically different between response groups (p<0.001).  The %Water reduced 
to 53.9% ± 3.3%, %Lipids increased to 166.4% ± 1.7%, and TOI reduced to 
8.1% ± 2.9% for responders; whereas non-responder tumours had a smaller 
reduction to 86.9% ± 10.9% for the %Water, 121.1% ± 5.6% for %Lipids and 
36.6% ± 6.5% for the TOI.  A summary of results is presented in Table 3.3 and 
Figure 3.2.   
 
Late Time Intervals (week eight and pre-operative time interval) 
 
 After eight weeks of treatment, the %Lipids and the TOI demonstrated 
significant differences between response groups (p<0.001), but not the %Water 
parameter (p=0.062).  However, all tissue parameters demonstrated a 
significant difference between response groups at the pre-operative time 
interval (p<0.001).  At this late time interval (pre-op), responders’ tumours 
showed that the %Water reduced to 57.1% ± 6.5%, the %Lipids parameter 
increased to 168.77% ± 0.8% and the TOI reduced to 6.6% ± 1.11%.  In 
contrast, non-responders showed the following changes to 
the %Water, %Lipids and TOI (relative to baseline):   %Water=86.9% ± 
10.9%, %Lipids=121.1% ± 5.6% and TOI=36.6% ± 9.1%. The late changes are 
presented in Figure 3.2 and tests of significance are outlined in Table 3.3.        
          
Tests of Significance Over the Treatment Time Course 
 
 The results of the repeated measures ANOVA revealed that all tissue 
parameters demonstrated a significant change over all treatment time intervals 
for responders, but not for responders.  A summary of results is presented in 
Table 3.3.   
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 Comparison between responders (R) 
and non-responders (NR) 
(Independent samples t-test)1 
Within-subjects 
comparison 
(ANOVA)2 
 Early Time  
Intervals 
Late Time  
Intervals 
All Time  
Intervals 
 Week 1 Week 4 Week 8 Pre-Op R NR 
Tissue Parameters     
 p-value p-value p-value p-value p-value p-value 
%Water 0.495 0.008 0.062 0.001 0.000 0.241 
%Lipids 0.838 0.000 0.000 0.000 0.000 0.595 
TOI 0.339 0.000 0.000 0.000 0.000 0.058 
       
Table 3.3:  Summary of measured p values for tissue parameters.   1DOS 
parameters were tested for significant differences between responders and 
non-responders using an independent t-test within the 95% confidence level 
following a test for normality.  2A repeated-measures ANOVA was used to test 
for significant changes over time (i.e. repeated measures between time 
intervals) for DOS and QUS parameters. Bold and blue fonts indicate 
statistically significant results; p<0.05= statistically significant; p<0.01 
very statistically significant.       
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Figure 3.2:  DOS tissue parameters measured. Changes in tissue 
parameters, measured as relative percent changes from baseline values. Error 
bars = Standard deviation, n = 14 responders and n = 8 non-responders.  
Significant differences between responders and non-responders were tested at 
each time interval and parametric changes over time were tested for responders 
and non-responders (Table 3.3). 
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3.2.4. Results of DOS Measurements- Scattering Parameters 
 
Early Time Intervals (week one and week four) 
 
Scattering parameters included the scattering power (SP) and the 
scattering amplitude (SA).  Early time interval measurements showed significant 
differences between responders and non-responders in scattering parameters 
after four weeks of treatment (p<0.01) only (i.e. not at week one).  After four 
weeks of treatment, the SP reduced to 42.3% ± 1.4% and the SA increased to 
111.5% ± 0.3% for responders; whereas non-responders had a change in the 
SP to 79.9% ± 5.4% (relative to baseline) and the SA decreased to 97.7% ± 
1.8% (relative to baseline).  The early changes are presented in Figure 3.3 and 
tests of significance are outlined in Table 3.4.             
 
Late Time Intervals (week eight and pre-operative time intervals) 
 
Late time intervals showed statistically significant differences in 
scattering parameters between responders and non-responders after eight 
weeks of treatment and up to the pre-operative time interval. (p<0.01).  The SP 
reduced to 43.0% ± 0.7% and the SA increased to 112.2% ± 0.7% for 
responders after eight weeks.  For non-responders, the SP was 91.9% ± 7.9% 
and the SA was 91.9% ± 4.4%.  The SP and SA did not make a significant 
change between eight weeks and the pre-operative scan; responders had an 
SP change to 43.3% ± 0.9% and an SA change to 112.3% ± 0.7%.  For non-
responders, the SP reduced to 96.3% ± 9.5%; while the SA reduced 
insignificantly to 99.8% ± 1.8%.  The late changes are presented in Figure 3.3 
and tests of significance are outlined in Table 3.4.        
 
Tests of Significance Over the Treatment Time Course 
 
A repeated measures ANOVA of the scattering parameters showed that 
responders had a significant change between the pre-treatment interval and the 
pre-operative treatment time (p<0.001).  Non-responders did not have 
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significant change over treatment (p>0.05).  A summary of the repeated 
measures ANOVA test for significance is presented in Table 3.4.    
 
 Comparison between responders (R) 
and non-responders (NR) 
(Independent samples t-test) 
Within-subjects 
comparison 
(ANOVA) 
 Early Time  
Intervals 
Late Time  
Intervals 
All Time  
Intervals 
 Week 1 Week 4 Week 8 Pre-Op R NR 
Scattering Parameters     
 p-value p-value p-value p-value p-value p-value 
SP 0.838 0.000 0.000 0.000 0.000 0.595 
SA 0.410 0.002 0.002 0.001 0.000 0.170 
       
Table 3.4:  Summary of measured p values for scattering parameters.   
DOS parameters were tested for significant differences between responders 
and non-responders and within-groups over the course of chemotherapy.  The 
corresponding data is presented below in Figure 3.3.  Significant p-values are 
bolded.  SP (Scattering power) and SA (Scattering amplitude).   
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Figure 3.3:  DOS scattering parameters (SP and SA) measured during 
treatment.  Changes in scattering parameters, measured as relative percent 
changes from baseline values. Error bars = Standard deviation, n = 14 
responders and n = 8 non-responders.  Significant differences are presented in 
(Table 3.4). 
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3.2.5 Results of QUS Measurements   
 
Early Time Intervals (week one and week four) 
 
After one week of chemotherapy, the difference in the spectral intercept 
parameter between response groups was statistically significant (p=0.009).  
Responders showed an increase in the mean spectral intercept (∆SI) of +3.93 ± 
1.86 [SD] dBr18; whereas, non-responders showed a smaller change of +1.83 ± 
1.83 dBr (Figure 3.4).  In comparison, there were no significant differences 
between responders and non-responders for the mid-band fit (p=0.413) and the 
spectral slope (p=0.222) after one week of treatment.  The change in the mean 
mid-band fit (∆MBF) was +3.27 ± 1.40 dBr for responders; while non-
responders yielded a change of +2.29 ± 1.53 dBr.  For the spectral slope, the 
change in the mean spectral slope (∆SS) was -0.12 ± 0.17 dBr/MHz for 
responders and +0.03 ± 0.11 dBr/MHz for non-responders (Figure 3.4).  
After four weeks of treatment, there were significant differences between 
responders and non-responders with respect to the ∆MBF and ∆SI parameters 
(p<0.001), but not the ∆SS (p=0.275).  Responders had a ∆MBF increase of 
+7.91 ± 1.39 dBr; whereas, non-responders showed a smaller increase of +0.72 
± 1.44 dBr.  Similarly, the ∆SI was +8.55 ± 1.84 dBr for responders and +4.40 ± 
1.62 dBr for non-responders.  The ∆SS was -0.12 ± 0.17 dBr/MHz for 
responders and -0.67 ± 0.14 dBr/MHz for non-responders.  Tests of significance 
are summarized in Table 3.5.      
     
  
Late Time Intervals (Week eight and Pre-op) 
 
After eight weeks of treatment, there were significant differences in the 
∆MBF and ∆SI parameters (p<0.001), but not the ∆SS (p=0.116).  For the 
∆MBF, responders and non-responders showed an increase of +10.02 ± 1.48 
dBr and +1.60 ± 1.39 dBr, respectively.  The ∆SI was +12.27 ± 2.02 dBr for 
                                            
18 dBr refers to decibels (normalized); it is a measurement of the acoustic 
intensity.    
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responders and +2.81 ± 1.58 dBr for non-responders.  The ∆SS was -0.41 ± 
0.21 dBr/MHz for responders and -0.22 ± 0.13 dBr/MHz for non-responders.  
Lastly, only the ∆MBF showed a statistically significant difference between 
response groups at the pre-operative time interval (p=0.020).  Here, the ∆MBF 
was +5.44 ± 2.53 dBr for responders and +0.51 ± 1.70 dBr for non-responders.   
The mean QUS changes for the MBF, SI and SS within the measured 
time intervals is presented in Figure 3.4.  Tests of significance are summarized 
in Table 3.5.      
      
 
Tests of Significance Over the Treatment Time Course 
 
 The significant QUS changes associated with a favourable 
chemotherapy response showed a similar trend for responders, i.e. for 
responders, there was an increase in QUS parameters over time (i.e. over 
course of chemotherapy).      
 
 Comparison between responders (R) 
and non-responders (NR) 
(Independent samples t-test)1 
Within-subjects 
comparison 
(ANOVA)2 
 Early  
Time Intervals 
Late  
Time Intervals 
All Time  
Intervals 
 Week 1 Week 4 Week 8 Pre-Op R NR 
 p-value p-value p-value p-value p-value p-value 
MBF 0.413 0.000 0.000 0.020 0.000 0.474 
SI 0.009 0.001 0.000 0.306 0.000 0.113 
SS 0.222 0.275 0.116 0.375 0.161 0.127 
       
Table 3.5.  1QUS parameters were also tested for significant differences 
between responders and non-responders using an independent t-test.  2A 
repeated-measures ANOVA was used to test for significant changes over time 
(i.e. repeated measures between time intervals) for QUS parameters. Bold and 
blue fonts indicate statistically significant results; p<0.05= statistically 
significant; p<0.01 very statistically significant.       
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Figure 3.4: QUS parameters measured.  Relative changes for all patients 
grouped by treatment response are presented.  Top, Mid-band Fit (MBF); 
Middle, 0-MHz Intercept (SI); Bottom. Spectral Slope (SS).  Error bars = 
Standard deviation, n = 14 responders and n = 8 non-responders.  Tests of 
significance are presented in Table 3.5. 
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3.2.6 Representative DOS and QUS Changes During Chemotherapy 
 
DOS and QUS imaging biomarkers demonstrated coincident changes 
during chemotherapy for patients who were pathologic responders (Miller-
Payne Scores 3-5), but not for non-responders (Miller-Payne Score 1,2).    
 
Representative Pathological Responder (Miller-Payne Pathology Response 
Score 4) 
 
This post-menopausal woman presented with a locally advanced breast 
tumour in the upper inner quadrant of the right breast that measured 9x9x6 cm 
by MRI.  Core biopsy revealed a high-grade invasive ductal carcinoma that was 
oestrogen receptor (ER) and progesterone receptor (PR) positive, and negative 
for HER2-Neu (HER2) overexpression.  Neoadjuvant chemotherapy consisted 
of AC-T.   Histological examination at the time of mastectomy revealed 
pathological response to treatment.  Figure 3.5 presents representative DOS 
and QUS data for this patient.  After four weeks of treatment, this patient 
demonstrated an increase in the mid-band fit (∆MBF) of +10.0 ± 1.4 dBr (±SD).  
At the same time interval, the DOS-measured haemoglobin concentration (Hb) 
decreased to 29.1% ± 9.5%, relative to the baseline. 
 
Representative Pathological Non-Responder (Miller-Payne Pathology 
Response Score 2) 
 
A post-menopausal woman presented with a tumour in the right breast, 
which measured 5 x 4 x 2 cm by MRI.  Core biopsy confirmed the presence of 
invasive ductal carcinoma that was positive for ER, PR negative, and positive 
for HER2.  Chemotherapy treatment consisted of AC-T+Herceptin.  Pathological 
examination after mastectomy demonstrated only minimal response to 
neoadjuvant treatment (no reduction in tumour size). Representative patient 
data is shown in Figure 3.6.  This patient, in contrast to the one above, 
demonstrated a smaller change in the MBF at week four (∆MBF  = +2.3 ± 1.8 
dBr), which was coincident with a reduction in haemoglobin to 64.4% ± 10.9% 
(SD), relative to baseline values. 
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Figure 3.5:  Representative DOS and QUS data of a responder (Miller-
Payne Pathology Score 4).  (Top) Representative B-mode images and DOS 
parametric maps are presented for baseline, mid-treatment (week four) and pre-
operative scans (with contours).  This responsive patient showed an overall 
increase in QUS MBF and an overall reduction in [Hb]. Error bars = Standard 
deviation, Scale bar; 2 cm. Deoxyhaemoglobin [Hb] colour bar = 0-15 µM 
(colour bar represents the concentration of deoxyhaemoglobin as shown in top 
figure; blue=low deoxy-haemoglobin concentration, red=high deoxy-
haemoglobin concentration).   
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Figure 3.6:  Representative DOS-QUS images and data for a non-
responder (MP2).  Normalized power spectra are presented for baseline and 
pre-operative scans.  This non-responsive patient demonstrated an insignificant 
change in the mid-band fit (dBr) and lesser changes in DOS parameters (deoxy-
haemoglobin presented) during treatment. Error bars = Standard deviation, 
Scale bar; 2 cm.  Deoxyhaemoglobin [Hb] colour bar = 0-15 µM (colour bar 
represents the concentration of deoxyhaemoglobin as shown in top figure; 
blue=low Hb concentration, red=high Hb concentration).  Contours are shown in 
the ultrasound and optical figures presented.   
 186 
3.2.7 Overview of Results: Subproject One, Research Question 2 
 
In this section, the following research question is addressed: “Can DOS 
and QUS imaging biomarkers be modelled using univariate and multivariate 
parameters to measure treatment response at early time intervals (i.e. after one 
or two cycles of chemotherapy)?”.  Evaluating early-response markers is 
important and clinically relevant because physicians need information at early 
time intervals in order to modify treatments as necessary.  In the following 
section, the results of both univariate and multiparametric models are 
presented.    
 
3.2.8 Univariate Analysis of DOS and QUS Parameters 
 
DOS and QUS Analysis at Early Time Intervals 
 
Linear discriminant analysis and ROC analysis of individual DOS and 
QUS parameters were undertaken to differentiate pathological response, as 
defined by Miller-Payne pathologic classification during treatment.  The area 
under the curves (AUCs) for individual DOS and QUS parameters (i.e. 
univariate analysis) during treatment are presented for early time intervals 
(weeks one and four) in Table 3.6.   After one week of treatment, the DOS and 
QUS parameters: SI, HbO2, and HbT indicated good response classification 
(AUC range=0.839-0.982), and this corresponded with 64.3-85.7% sensitivity, 
and 75.0-87.5% specificity.  Other DOS and QUS parameters were poorer 
predicators at this time interval, such as the SS, %Water, % Lipids, and SA 
(Table 3.6).  However, after four weeks of treatment, the QUS MBF and SI 
markers showed an increase in the AUC (range 0.920-0.982) and this 
corresponded with high sensitivity and specificity (range; 85.7-100.0%).  
DOS parameters related to tumour haemoglobin demonstrated high 
sensitivity and specificity (%Sn=85.7%, %Sp=87.5%), and an AUC of 0.911-
0.964.  Other DOS parameters such as the TOI demonstrated a sensitivity and 
specificity of 85.7% and 87.5% respectively, which corresponded to an AUC of 
0.973.   
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 Early Time Intervals  
Parameters 
Week 1  
(One Chemotherapy Cycle) 
 
Week 4  
(Two Chemotherapy Cycles) 
 
 
  %Sn %Sp AUC   %Sn %Sp AUC   
QUS         
MBF 50.0 50.0 0.607  92.9 100 0.982  
SI 64.3 87.5 0.839  85.7 87.5 0.920  
SS 28.6 25.0 0.201  57.1 62.5 0.643  
         
DOS         
Hb 64.3 62.5 0.616  85.7 87.5 0.911  
HbO2 85.7 87.5 0.982  85.7 87.5 0.938  
HbT 78.6 75.0 0.875  85.7 87.5 0.964  
%Water 50.0 50.0 0.589  85.7 75.0 0.848  
%Lipids 50.0 50.0 0.527  92.9 87.5 0.982  
SP 50.0 50.0 0.527  92.9 87.5 0.982  
SA 57.1 50.0 0.393  85.7 87.5 0.897  
TOI 64.3 62.5 0.625  85.7 87.5 0.973  
         
Table 3.6:  Sensitivity (%Sn), Specificity (%Sp), and Area Under Curve 
(AUC) for univariate DOS and QUS parameters.    DOS and QUS parameters 
were estimated from discriminant analysis, and receiver-operating characteristic 
analysis.  DOS and QUS parameters were analysed for weeks 1, 4 and 8 to 
correspond to response monitoring during treatment.  Markers for response 
classification were detected as early as one week relative to the start of 
chemotherapy.   Highlighted values indicate an AUC threshold of greater than 
0.8.   
 
3.2.9 Multivariate Analysis of Pairwise DOS-QUS Parameter Combinations 
 
Multivariate models were formulated using binary (pairwise) DOS and 
QUS parameters.  Pairwise combinations were determined from a statistical 
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framework that restricts the number of parameters that can be included in a 
model based on the number of subjects in a sample set19.       
  Table 3.7 present results of the ROC analyses of DOS-QUS pairwise 
combinations during early chemotherapy time intervals (Weeks 1, 4).  
Parametric combinations increased the sensitivity and specificity for response 
classification compared to univariate parameters alone after one week of 
chemotherapy and is represented in Figure 3.7.  At week one, combining the SI 
parameter with the %Water parameter demonstrated a sensitivity and specificity 
of 71.4-75.0% (AUC=0.866).  Also, combining the SS+TOI resulted in an AUC 
of (AUC=0.982).  At week one, the combination of the MBF with total 
haemoglobin (HbT) demonstrated an AUC value of 0.857.  All of these 
combinations demonstrated an increase in the classification performance 
compared to using the individual (univariate) parameters alone, i.e. the best 
univariate AUC was 0.839, compared to multivariate models which 
demonstrated an AUC of 0.857-1.0.   
At week four, response classification was enhanced when the MBF, SI, 
and SS were combined with the following DOS parameters: Hb, HbO2, %Water, 
SA, TOI.  Representative combinations are presented in Figure 3.8 and 
significant DOS and QUS combinations are presented in Table 3.7.   The 
combination of the MBF and Hb, or HbO2, or %Water resulted in an AUC of 1.0, 
and a sensitivity and specificity of 100% (Figure 3.8).  The SI showed an 
increase in sensitivity and specificity when combined with either HbO2, %Water, 
or SA.  Lastly, the SS showed an improvement with combinations with the TOI 
or %Water.  The performance of these combinations is presented in Table 3.7.    
 
 
 
                                            
19 This statistical framework indicates that the number of parameters permitted 
into a model is limited by the sample size; defined as 1/10 of the sample size 
Jain et al., 2000).  All possible forward combinations between DOS and QUS 
parameters were included in the statistical analysis using a brute-force search.  
Parametric combinations that yielded an AUC>0.8 were reported, as the 
likelihood ratio of 0.8 (true positive fraction)/0.2 (false positive fraction) was 
chosen (Zweig et al., 1993).    
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Multivariate Features %Sn %Sp AUC (Logistic) p-value 
     
Week 1 (One Cycle of Chemotherapy) 
   
MBF+HbO2 85.7 87.5 0.973 0.000 
MBF+HbT 71.4 75.0 0.857 0.006 
     
SI+HbO2 100 100 1.000 0.000 
SI+HbT 85.7 87.5 0.929 0.001 
SI+%Water 71.4 75.0 0.866 0.005 
     
SS+HbO2 100 100 1.000 0.000 
SS+HbT 85.7 87.5 0.955 0.000 
     
Week 4 (Two Cycles of Chemotherapy) 
   
MBF+Hb 100 100 1.000 0.000 
MBF+HbO2 100 100 1.000 0.000 
MBF+%Water 100 100 1.000 0.000 
     
SI+SA 100 100 1.000 0.000 
SI+HbO2 85.7 87.5 0.982 0.000 
SI+%Water 85.7 87.5 0.964 0.000 
     
SS+SA 100 100 1.000 0.000 
SS+TOI 92.9 87.5 0.982 0.000 
SS+%Water 85.7 87.5 0.955 0.000 
     
Table 3.7:  Sensitivity (%Sn), Specificity (%Sp) and AUC for representative 
multivariate (pairwise) DOS and QUS parameters.  Pairwise combinations 
were reported with AUC >0.8.  Analyses were performed at week one and 4 for 
combined parameters (i.e. during treatment).  Combining DOS and QUS 
parameters together demonstrated an increase in sensitivity and specificity 
compared to univariate models.   
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Figure 3.7:  Sensitivity (%Sn), Specificity (%Sp) and AUC for 
representative multivariate (pairwise) DOS and QUS parameters at week 
one. ROC curves: (Top) QUS alone; (Middle) DOS alone; (Bottom).  
Combination DOS+QUS.  Combining DOS and QUS parameters demonstrated 
an increase in sensitivity and specificity compared to the univariate parameters 
alone at this time interval.  The parameters presented here are representative; 
the performances of all multivariate models are presented in Table 3.7.   
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Figure 3.8:  Sensitivity (%Sn), Specificity (%Sp) and AUC for 
representative multivariate (pairwise) DOS and QUS parameters at week 
four. ROC curves: (Top) QUS alone; (Middle) DOS alone; (Bottom).  
Combination DOS+QUS. The parameters presented here are representative; 
the performances of all multivariate models are presented in Table 3.7.   
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3.2.10 Summary of Results and Responses to Research Questions 
(Subproject One)  
       
DOS and QUS imaging biomarkers were studied in breast cancer 
patients to report first accounts of coincident markers for tumour response 
during neoadjuvant chemotherapy.  The results of subproject one showed that 
the changes in DOS and QUS imaging biomarkers represented the biological 
alternations in the tumour and could be used to measure the tumour’s 
pathologic response.  The biological changes, as measured by QUS, include 
markers for cell death (i.e. MBF, SI); while DOS parameters showed that there 
were significant changes in the haematological properties (Hb, HbO2, HbT) and 
tissue composition (%Water, %Lipids, TOI).  The responses to the research 
questions are presented below:       
 
v Research Question 1: Do DOS and QUS imaging biomarkers demonstrate 
statistically significant changes over the course of chemotherapy? 
 
 
Over the entire course of chemotherapy (i.e. from pre-chemotherapy to pre-
surgery), the following QUS parameters showed significant increases in 
responders only: MBF and SI.  For DOS parameters, the following parameters 
showed significant decreases over chemotherapy in responders: Hb, HbO2, 
HbT, %Water, SP, TOI; while the following parameters showed significant 
increases in responders: SA, %Lipids.  There were parallel temporal changes in 
the DOS and QUS parameters.    
 
 
v Research Question 2: Can DOS and QUS imaging biomarkers be 
modelled together to measure treatment response at early time intervals (i.e. 
after one or two cycles of chemotherapy)?   
 
The results indicated that univariate DOS and QUS imaging parameters 
were good surrogate markers for pathologic endpoints (i.e. Miller-Payne 
pathologic response criteria) as early as one week after the start of 
chemotherapy (corresponding to one chemotherapy cycle).   At week one, the 
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QUS-spectral intercept (SI) showed a sensitivity of 64.3% and specificity of 
87.5% (AUC=0.839).  Similarly, the DOS-haemoglobin parameters, HbO2 
demonstrated a sensitivity of 85.6% and specificity of 87.5%, and the HbT had 
a sensitivity and specificity of 78.6% and 75%, respectively.  
In multivariate models, the results demonstrated that the following DOS 
and QUS values can be predictive of chemotherapy response at early time 
intervals, as measured after one week (i.e. one cycle) of chemotherapy:  QUS 
[MBF, SI, SS] and DOS [HbO2, HbT, %Water].  A logistic regression model was 
used for multivariate DOS and QUS models and showed that DOS and QUS 
parameters could be used as surrogate endpoint markers to Miller-Payne 
pathologic response criteria, which demonstrated an accuracy of up to 100%.  
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3.3 Results of Subproject Two  
 
3.3.1.  Overview and Link to subproject one 
 
 The aim of this thesis was to investigate DOS and QUS imaging 
biomarkers to detect early indicators of chemotherapy response defined as:  
1. Early-response markers after one or two cycles of chemotherapy;  
2. Predictive markers that are measured before starting chemotherapy.   
Subproject two was motivated from the results obtained from subproject one.  In 
subproject one, it was shown that early-response markers could be obtained by 
modelling DOS and QUS imaging biomarkers as univariate and multivariate 
models within one or two cycles of chemotherapy.  The results indicated that 
DOS and QUS imaging biomarkers demonstrated high sensitivity and specificity 
as early as one week after the start of chemotherapy.  Thus, the goal of 
subproject two was to then investigate predictive markers using DOS imaging 
only; using DOS alone was based on the following rationale: 
1. Previous studies have already investigated pre-treatment QUS imaging 
biomarkers (both mean QUS and texture-based QUS imaging 
biomarkers) and have shown a high prediction accuracy (88%) to 
treatment response (Tadayyon et al., 2017); thus, this area of research 
has already been studied with promising results.    
2. Previous studies have indicated that pre-treatment DOS parameters 
related to tumour haemoglobin and oxygen saturation can predict 
chemotherapy response; however, these studies had not investigated 
DOS-texture based imaging biomarkers (Ueda et al., 2012, Tromberg et 
al., 2016).  
Thus, the work in subproject two is motivated by exploring pre-treatment DOS-
texture features within a region-of-interest of the tumour-bed only. 
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3.3.2 Overview of Results: Subproject Two, Research Question 1 
 
The first research question for subproject two was: Do breast tumours 
demonstrate significant differences in DOS-texture parameters between 
responders and non-responders, as measured before chemotherapy? All DOS-
texture parameters were tested for statistically significant differences between 
Miller-Payne pathologic responders (MP 3-5) and non-responders (MP1,2).   
The results demonstrated that only DOS-haemoglobin parameters and DOS-
oxygen parameters demonstrated significant differences between responders 
and non-responders and are presented below.   
The data are presented as box-and-whisker plots, which show the 
median DOS-texture values, the lower extreme, the lower quartile, upper 
quartile and the upper extreme.  Since grey-level co-occurrence texture features 
do not have a unit of measure20, the DOS-texture values are indicated as A.U. 
(arbitrary units).  The data in the following section is presented in two parts:  1) 
DOS-haemoglobin parameters are presented and represented in Figures 3.9, 
3.10, 3.11 and; 2) DOS-oxygen features, which correspond to Figure 3.12 and 
Figure 3.13.   
 
3.3.3 Pre-treatment Tumour Haemoglobin-Texture Features Demonstrated 
Significant Differences Between Miller-Payne Pathologic Response 
Groups  
 
Pre-treatment Deoxy-haemoglobin (Hb) Texture Features 
 
The deoxyhaemoglobin-homogeneity (Hb-hom) feature demonstrated a 
significant difference between responders and non-responders; (p=0.030).  The 
Hb-hom feature was greater in non-responders (i.e. Miller-Payne pathology 
score 1-2) compared to responders (i.e., Miller-Payne pathology score 3-5).  
Non-responders had a median value of 0.351 A.U.; 95% CI [0.288, 0.370]; 
whereas responders had a median Hb-hom value of 0.275; 95% CI [0.260, 
                                            
20 The calculations for the grey-level co-occurrence matrix uses a probability 
score that is the sum of the elements in the matrix; thus, having no units and 
expressed as arbitrary units (A.U.).   
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0.304].  However, other texture features such as the deoxyhaemoglobin- 
contrast (Hb-con), correlation (Hb-cor) and energy (Hb-ene) did not 
demonstrate a significant difference between groups (p >0.05) (Figure 3.9).  
However, the Hb-con demonstrated near significance between response groups 
(p=0.066).     
 
 
Figure 3.9:  GLCM texture features for deoxy-haemoglobin texture features.  
Box-and-whisker plots showing significant differences in DOS textural markers 
for responders and non-responders (p values indicated).   
 
 
Pre-Treatment Oxy-haemoglobin (HbO2) Texture Features 
 
For the HbO2-texture features, the HbO2-cor feature was significantly 
different between response groups; the HbO2-cor was greater for responders 
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compared to non-responders (p<0.024) (Figure 3.10).  Responders had a 
median HbO2-cor value of 0.195 A.U.; 95% CI [0.182, 0.228] and non-
responders showed a median HbO2-cor value of 0.136 A.U.; 95% CI [0.118, 
0.193], p<0.024.  The HbO2-con approached a significant difference between 
response groups (p=0.058).  For responders, the median value for the HbO2-
con feature was 20.180 A.U.; 95% CI [19.191, 21.337]; whereas for non-
responders, the median value was 23.393 A.U.; 95% CI [20.018, 24.651].  The 
HbO2-ene and HbO2-hom was not significantly different between response 
groups (p>0.05).   
 
 
Figure 3.10:  GLCM texture features for oxy-haemoglobin texture features.  
Box-and-whisker plots showing significant differences in DOS textural markers 
for responders and non-responders (p values indicated).   
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Pre-Treatment Total Haemoglobin (HbT) Texture Features 
 
The total haemoglobin (HbT) texture measurements in tumours 
demonstrated significant differences in homogeneity (HbT-hom) (p = 0.047).  
The median HbT-hom value was 0.356 A.U.; 95% CI [0.340, 0.362] for 
responders and 0.373 A.U.; 95% CI [0.345, 0.377] for non-responders.   
Additionally, the HbT-con feature approached significance (p = 0.055); 
responders had a median value of 18.876 A.U.; 95% CI [17.729, 20.803]; 
whereas for non-responders, the median value was 16.399 A.U.; 95% CI 
[13.351, 19.353].    The HbT-con was close to being significantly different 
between responders and non-responders; the median value was 18.876 A.U.; 
95% CI [17.729, 20.803] for responders and non-responders had a median 
HbT-con value of 16.399 A.U.; 95% CI [13.351, 19.353].  The HbT-ene and 
HbT-cor features were not significantly different between response groups 
(p>0.05) (Figure 3.11).   
 
 199 
 
Figure 3.11:  GLCM texture features for total haemoglobin texture features.  
Box-and-whisker plots showing significant differences in DOS textural markers 
for responders and non-responders (p values indicated).   
 
3.3.4 Pre-treatment Tumour Oxygen-Texture Features Demonstrated 
Significant Differences Between Miller-Payne Pathologic Response 
Groups 
 
Oxygen Desaturation (St) Texture Features 
 
The St-con was significantly different between response groups (p = 
0.044); while other features such as St-hom were close to being significantly 
different (p = 0.058).  Features are presented in Figure 3.12.  St-con 
measurements were greater in responders (median value: 21.535 A.U.; 95% CI 
[20.800, 22.940] versus non-responders (median value: 20.306 A.U.; 95% CI 
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[19.416, 21.436], p=0.044).  The St-hom approached statistical significance 
between groups (p=0.058) and other features such as St-cor and St-ene were 
not statistically different between response groups (p>0.05).  
 
 
Figure 3.12:  GLCM texture features for oxygen desaturation.  The St-con was 
statistically different between response groups (p=0.044).   
 
Oxygen Saturation 
 Tumour oxygen saturation (StO2) texture features were analysed for 
significant differences between response groups and showed that only the 
StO2-con was significantly different (p=0.044) (Figure 3.13).  The StO2-con 
feature was 19.652 A.U.; 95% CI [18.681, 21.067] for responders and non-
responders had an StO2-con value of 21.932 A.U.; 95% CI [20.250-24.010].  
Other StO2 features (StO2-cor, StO2-ene, StO2-hom) were not significantly 
different between responders and non-responders (p>0.05).          
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Figure 3.13:  GLCM texture features for oxy-haemoglobin texture features.  
Box-and-whisker plots showing significant differences in DOS textural markers 
for responders and non-responders (p values indicated).   
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Representative Pre-Chemotherapy DOS Parametric Maps 
 
 Representative responder and non-responder pre-chemotherapy DOS 
images are presented in Figure 3.14 and Figure 3.15, respectively.  The 
corresponding MRI images that were also acquired before treatment are also 
presented for tumour referencing.  Case descriptions are presented below as 
typical patient pathways for locally advanced breast cancer.     
 
Responder Patient (Presented in Figure 3.14) 
 
 This patient was a 51-year-old woman with right sided breast cancer.  At 
the time of diagnosis her tumour measured 2.2 cm and involved lymph nodes, 
as indicated from her MRI scan.  The breast cancer was hormone receptor 
positive (oestrogen and progesterone positive), and HER2-negative.  
Histologically, it was an invasive ductal carcinoma.  The patient underwent AC-
T chemotherapy (Adriamycin, Cyclophosphamide for four cycles followed by 
four additional cycles of Taxol).  During the course of chemotherapy, the patient 
showed clinical response (i.e., the tumour was shrinking according to physical 
palpation).  At the time of surgery, the tumour was resected, and pathologic 
evaluation was completed; the results showed a Miller-Payne pathologic 
response grade of four (responder), i.e., having greater than a 90% loss of 
tumour cells.      
 
Non-Responder Patient (Presented in Figure 3.15).   
 
 This was a 38-year-old woman with a large 5.0 cm, left sided breast 
tumour at the time of diagnosis.  Her tumour was “triple negative” (ER-, PR-, 
HER2-) and was an invasive ductal carcinoma.  Her treatment consisted of four 
cycles of AC (Adriamycin, and Cyclophosphamide), followed by four cycles of 
Taxol.  Her tumour did not respond to chemotherapy, as assessed at the time of 
surgery.  Pathology evaluation of her tumour showed that there was no 
response to treatment and no overall reduction in the overall cellularity (i.e. 
Miller Payne grade 1). 
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Figure 3.14:  Representative DOS parametric maps and contrast-enhanced 
MRI for a responder, acquired before chemotherapy.  All parametric data were 
acquired and used for texture analyses. Colour washes and colour bars indicate 
the intensity and concentration of parameters in the image.    
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Figure 3.15:  Representative DOS parametric maps and contrast-enhanced 
MRI for a non-responder, acquired before chemotherapy.  All parametric data 
were acquired and used for texture analyses. Colour washes and colour bars 
indicate the intensity and concentration of parameters in the image.     
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3.3.5 Overview of Results: Subproject Two, Research Question 2 
 
 In this section the results of the following research question are 
presented:  Can DOS markers predict chemotherapy response before starting 
chemotherapy?  The results of the section are presented in two sections; 1) 
classification results for univariate DOS-texture features and; 2) classification 
results of multivariate DOS-texture features.  The models used to predict the 
classification of patients included a logistic regression model, a naïve Bayes 
model, and a k-NN model.  Results are presented below.   
 
3.3.6 Classification Results of Univariate DOS-texture features  
 
DOS-texture features that were significantly different between response 
groups (N versus NR) were analysed using the classifier models: Logistic 
Regression, naïve Bayes and k-NN (Table 3.8).  The naïve Bayes classification 
performed the best among the classifier models used in this study.   For the 
HbT-hom, naïve Bayes classification resulted in a sensitivity of 84%, and 
specificity of 85% (AUC = 0.813), in comparison to k-NN classification which 
resulted in a classification of only %Sn = 74%, %Sp = 47%, and AUC of 0.552 
(Table 3.8).     
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Significant 
Univariate 
Feature 
Classifier/Model %Sn %Sp AUC 
p-
value 
Statistical 
Power (n2) 
Hb-
Homogeneity 
Log. Regression 60.0 60.0 0.726 
0.030 71.8 (14) naïve Bayes 82.0 82.0 0.799 
k-NN 61.5 67.5 0.577 
HbO2-
Correlation 
Log. Regression 70.0  70.0 0.756 
0.024 78.9 (11) naïve Bayes 80.0 81.0 0.778 
k-NN 66.5 74.5 0.602 
HbT-
Homogeneity 
Log. Regression 60.0 60.0 0.657 
0.047 79.9 (11) naïve Bayes 84.0 85.0 0.813 
k-NN 74.0 47.0 0.552 
St-Contrast 
Log. Regression 60.0 63.0 0.670 
0.044 73.5 (13) naïve Bayes 79.5 82.0 0.779 
k-NN 70.5 64.5 0.582 
StO2-Contrast 
Log. Regression 70.0 63.0 0.715 
0.044 85.6 (Enough) naïve Bayes 83.0 85.5 0.803 k-NN 70.0 66.5 0.610 
Table 3.8: Results of univariate analysis using a logistic regression model, 
naïve Bayes and k-NN classifiers.  The bolded-blue values demonstrate the 
best predictors for each parameter.  The numbers in parenthesis indicate the 
required number of additional patients needed to reach a statistical power of 
80%). 
Analysis of all DOS-texture features was also performed, independent of 
statistical significance between groups, using the three classifiers (logistic 
regression analysis, the naïve-Bayes model, or k-NN classifier).  However, 
Table 3.9 presents the DOS-texture features that demonstrated the highest 
classification prediction from all possible univariate features (d=40) extracted 
from each classifier model (i.e. best predictive feature for logistic regression, 
naïve Bayes, and k-NN). 
 
Classifier Model Best Predictive Feature of Model %Sn %Sp %Acc 
Log. Regression HbO2-Correlation 70.0 70.0 70.0 
naïve Bayes HbO2-Homogeneity 86.5 89.0 87.8 
k-NN HbO2-Contrast 81.0 73.0 77.0 
Table 3.9: Model Prediction Parameters.  Summary of best predictive 
univariate features of each of the classification methods.  The corresponding 
AUCs are presented in Figure 3.16.     
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The corresponding ROC curves with AUCs are presented in Figure 3.16.  
Classification results from significant univariate-texture features indicated an 
AUC range between 0. 756-0.821 (Figure 3.16).  A maximum AUC was 
observed for HbO2-hom (AUC = 0.821) using a naïve Bayes model.  Cross 
validated %Sn and %Sp were 86.5%, and 89.0%, respectively and 
corresponded to an accuracy of 87.8% for the HbO2-homogeneity feature 
classified using the naïve Bayes model (Table 3.9). 
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Figure 3.16:  Receiver-Operating Characteristic (ROC) curves for univariate 
DOS-texture features.  ROC curves for the best-performing single DOS-texture 
parameter are presented according to the classification model.     
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3.3.7 Classification Results of Multivariate DOS-texture features  
 
Table 3.10 presents classification results for the maximum pairwise 
DOS-GLCM feature combinations.  The accuracy of optimal pairwise 
combinations was 77.8-79.5% for classifying Miller-Payne pathologic responses 
(responders versus non-responders).  Using a logistic regression analysis, the 
combination of HbO2-cor + Hb-hom demonstrated a sensitivity of 80%, and 
specificity of 78.0%.  This corresponded to an AUC of 0.815, and an accuracy 
of 79.5%.  In comparison to the naïve Bayes model, the optimal pairwise 
combination was observed using Hb-con + HbO2-hom, which indicated a 
sensitivity and specificity of 78.0%, and 81.0%, respectively.  The AUC for these 
combined parameters was 0.773, and the accuracy was 79.5% (Figure 3.17 
and Table 3.10).  Lastly, using the k-NN classifier, the best pairwise 
combination resulted from Hb-cor, and HbO2-con, which showed a sensitivity 
and specificity of 79.5%, and 76.0%, respectively.  The corresponding AUC was 
0.802 and the accuracy was 77.8%.   
 
 
Multivariate Features Classifier/Model %Sn %Sp %Acc 
HbO2-Correlation +  
Hb-Homogeneity 
Logistic Regression 80.0 78.0  79.5 
     
Hb-Contrast +  
HbO2-Homogeneity 
naïve Bayes 78.0 81.0 79.5 
     
Hb-Correlation +  
HbO2-Contrast 
k-NN 79.5 76.0 77.8 
     
Table 3.10: Multivariate Analysis for Optimal DOS-texture Pairwise 
Combinations.   Results of multivariate analysis (using three classification 
models: Logistic regression analysis, naïve Bayes classifier, and k-NN. 
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Figure 3.17:  Receiver-Operating Characteristic (ROC) curves for multivariate 
DOS-texture features.  ROC curves for the best-performing pairwise DOS-
texture parameters are presented. 
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3.3.8 Overview of Results of Subproject two, Research Question 3 
 
In this section, the results of the following research question are 
presented: Are there differences in DOS-texture prediction models for breast 
cancer subtypes (i.e., ER+ and triple negative) and chemotherapy treatments 
(i.e. FEC-D and AC-T)?  Firstly, the results of subgroup analysis are presented 
with respect to each tumour molecular subtype and treatment regimen.  The 
results of this section are presented using a logistic regression analysis, a naïve 
Bayes classifier and a k-NN algorithm.  Secondly, the results from a linear 
regression model are presented.  Here, DOS-GLCM features are tested for 
correlation to age, molecular and intrinsic subtype, tumour size and final 
pathological grading (Miller-Payne).   
 
3.3.9 Results of Subgroup Analysis 
 
Subgroup analysis showed that the HbO2-hom feature was the best 
predictor in ER+ patients using a naïve Bayes classifier (Table 3.11).  For 
patients with triple-negative tumours, the Hb-hom was the best predictor 
resulting in an AUC of 0.917 (%Sn=75.0%, 66.7%) using a k-NN classifier.  
Patients separated according to chemotherapy groups also showed variances 
in optimal features; FEC-D treated patients classified into responders and non-
responders with a sensitivity of 100.0% and specificity of 92.3% using a logistic 
regression analysis for TOI-hom.  Patients treated with AC-T based 
chemotherapy demonstrated an AUC of 0.896 using the HbO2-hom feature with 
k-NN classification (Table 3.11).             
 
 
 
 
 
 
 
 
 
 
 212 
Subgroup 
(n=sample size) 
Best 
Feature 
Model %Sn %Sp AUC 
      
ER+ Hb-con Log. Regression 76.2 66.7 0.746 
n=27  HbO2-hom Naïve Bayes 93.3 90.1 0.883 
  HBO2-con k-NN 85.8 82.5 0.851 
Triple Negative Hb-hom Log. Regression 100.0 33.3 0.917 
n=7 Hb-ene Naïve Bayes 100.0 66.7 0.667 
 Hb-hom k-NN 75.0 66.7 0.917 
FEC-D TOI-hom Log. Regression 100.0 92.3 0.949 
n=16 Hb-con Naïve Bayes 60.0 81.7 0.722 
 Hb-hom k-NN 80.0 80.0 0.806 
AC-T HbO2-cor Log. Regression 100.0 71.4 0.837 
n=21 HbO2-hom Naïve Bayes 96.4 90.7 0.882 
 HbO2-hom k-NN 83.6 85.0 0.896 
Table 3.11:  Subgroup analysis according to molecular subtype and 
chemotherapy treatment type. Three classification models were used (logistic 
regression, naïve Bayes and k-NN) and the best predictive features are 
presented.  The best features for each classification model are presented and 
bolded in blue for those parameters that showed an AUC of greater than 0.80. 
 
3.3.10 Results of Multiple Linear Regression Analysis  
 
 The results of the multiple linear regression demonstrated insignificant 
correlations between clinical features (Age, ER/PR status, HER2 status and 
tumour size) and DOS-GLCM features for this patient cohort.  In particular, the 
Hb-hom, HbO2-cor, and StO2-con features demonstrated significant 
correlations to Miller-Payne grading, corresponding to a regression coefficient 
value (r) of -0.358, +0.375 and -0.325 respectively (p<0.05).  Results of the 
multiple regression analysis are presented in Table 3.12.     
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DOS-GLCM Feature  Comparison r F Value P Value 
     
Hb-Homogeneity Age -0.130 0.599 0.444 
 ER/PR Status -0.087 0.267 0.608 
 HER2 Status -0.104 0.382 0.540 
 Tumour Size +0.231 1.967 0.170 
 Miller-Payne Grade -0.358 5.137 0.030 
     
HbO2-Correlation Age -0.116 0.475 0.495 
 ER/PR Status -0.003 0.000 0.988 
 HER2 Status -0.109 0.418 0.522 
 Tumour Size -0.295 3.335 0.076 
 Miller-Payne Grade +0.375 5.172 0.022 
     
HbT-Homogeneity Age -0.142 0.715 0.403 
 ER/PR Status +0.007 0.002 0.969 
 HER2 Status +0.206 1.544 0.222 
 Tumour Size +0.085 0.257 0.616 
 Miller-Payne Grade -0.233 2.015 0.165 
     
St-Contrast Age -0.231 1.972 0.169 
 ER/PR Status +0.056 0.111 0.741 
 HER2 Status +0.095 0.322 0.574 
 Tumour Size -0.164 0.971 0.331 
 Miller-Payne Grade +0.177 1.138 0.293 
     
StO2-Contrast Age -0.083 0.241 0.626 
 ER/PR Status -0.074 0.190 0.665 
 HER2 Status -0.213 1.661 0.206 
 Tumour Size +0.279 2.966 0.094 
 Miller-Payne Grade -0.325 4.140 0.050 
Table 3.12:  Regression coefficients (r) of the multiple regression analysis for 
DOS-GLCM features and corresponding regression F-value are presented.  
Significantly correlated features are bolded in blue.   
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3.3.11 Summary of Results and Responses to Research Questions 
(Subproject two)  
 
 Employing texture-based analyses of the DOS parameters showed 
significant differences in haemoglobin- and oxygen saturation-texture features 
using a grey-level co-occurrence matrix algorithm (GLCM features: contrast, 
correlation, energy and homogeneity).   Three classification methods were used 
to analyse data which included a logistic regression analysis (LRA), naïve 
Bayes classifier, and k-NN algorithm.  Both univariate and multivariate models 
were considered.  The results of subproject two are summarized according to 
the research questions below:      
 
v Research Question 1: Do breast tumours demonstrate significant 
differences in DOS-texture parameters between responders and non-
responders, as measured before chemotherapy?  
 
Texture analysis was completed on all DOS parameters using grey-level co-
occurrence (GLCM) algorithm, which included the following texture features: 
contrast, correlation, energy and homogeneity.  Texture analysis of the following 
DOS parameters were carried out:  deoxy-haemoglobin, oxy-haemoglobin, total 
haemoglobin, oxygen saturation, oxygen desaturation, lipid content, water 
content, scattering power, scattering amplitude, and the tissue optical index.   
The results showed that LABC tumours demonstrated significant differences in 
the following DOS-texture parameters between responders and non-
responders, as measured before chemotherapy: deoxy-haemoglobin-
homogeneity, oxy-haemoglobin-correlation, total haemoglobin-homogeneity, 
oxygen desaturation-contrast, oxygen saturation-contrast.    
 
 
v Research Question 2: Can DOS markers predict chemotherapy 
response prior to starting chemotherapy? 
 
The results of the subproject two study demonstrated that the pre-
chemotherapy DOS-texture parameters demonstrated high sensitivity and 
specificity for predicting Miller-Payne pathologic response endpoints.  The best 
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DOS-texture univariate model (predictor) was the HbO2-homogeneity feature 
using the naïve Bayes classifier; the sensitivity, specificity and accuracy was 
86.5%, 89.0% and 87.8%, respectively.  The best multivariate (pairwise) DOS-
texture models were the following:  HbO2-Correlation + Hb-Homogeneity 
(%Sn=80.0%, %Sp=78.0%, %Acc=79.5%) and Hb-Contrast + HbO2-
Homogeneity (%Sn=78.0%, %Sp=81.0%, %Acc=79.5%).   
 
 
v Research Question 3: Are there differences in DOS-texture prediction 
models for breast cancer subtypes (i.e., ER+ and triple negative) and 
chemotherapy treatments (i.e. FEC-D and AC-T)? 
 
Within each subgroup, as analysed by tumour molecular features and the 
treatment regimen, prediction models demonstrated that there were varying 
optimal DOS-texture features as surrogate markers for Miller-Payne pathologic 
endpoints.  The ER+ subgroup showed that the naive Bayes classifier using the 
HbO2-hom feature yielded an optimal AUC of 0.883.  Triple negative (i.e. basal-
like) patients (ER-/PR-/HER2-) had a maximum AUC of 0.917 using the Hb-hom 
feature, modelled with a logistic regression.  Patients treated with varying 
chemotherapies showed differences in the best prediction models; FEC-D 
patients optimal prediction results with the TOI-hom feature using a logistic 
regression (AUC=0.949); whereas, AC-T treated patients showed maximum 
results using the HbO2-hom feature with the k-NN algorithm (AUC=0.896). 
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Chapter 4 
 
Discussion 
 
 
4.0 Chapter Overview 
 
 Chapter 4 highlights the results of the study with a discussion of the 
significance of DOS and QUS measurements for breast tumour response 
evaluation to chemotherapy.   This chapter is divided into seven sections.  In 
the section one (Section 4.1), a thesis overview is presented to outline the 
research aims and underscore the clinical motivations behind the study.  In 
section two (Section 4.2), the results are compared to previous research from 
diffuse optical spectroscopy and quantitative ultrasound spectroscopy studies.  
Further to this, a summary of the new contributions to knowledge from this 
thesis are discussed.  In section three (Section 4.3), a discussion of DOS and 
QUS markers are examined with respect to the translational challenges, i.e. the 
present status of DOS and QUS imaging biomarker research and the steps 
needed for data validation before it can be implemented into the oncology clinic.  
Concepts such as, imaging biomarker statistical modelling and the translational 
gaps of current and previous studies are discussed.  In Section 4.4, the 
potential impact to patient care is discussed in terms of using DOS and QUS 
imaging biomarkers as a treatment decision-making tool by physicians. In 
Section 4.5 and Section 4.6, the limitations of the study and future work for 
DOS and QUS in breast cancer imaging are discussed, followed by the final 
conclusions to the study in Section 4.7.    
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4.1 Summary of Thesis and Study Motivations 
 
In this thesis, DOS and QUS imaging were studied to address two significant 
clinical problems for breast cancer patients treated with neoadjuvant 
chemotherapy:   
1. Breast cancer response to chemotherapy is variable and this 
negatively impacts subsequent treatment options and survival for 
patients.  New technologies, preferably non-invasive imaging would 
be advantageous in the clinic to guide clinicians and inform patients 
about the most appropriate treatment based on early-response 
biomarkers for the presumed pathological outcomes.  
2. Breast tumours are biologically heterogeneous; even so, a standard 
“one-size-fits-all” chemotherapy regime is given to patients. As 
patients respond to treatment in different ways, the overall effect of 
chemotherapy is that of variability in the treatment response 
outcomes.  Predictive markers are needed before the start of 
treatment to determine if the tumour is likely to respond favourably 
(tumour regression) or not, in which case the response to 
chemotherapy would be considered unfavourable.   
 
The uncertainties surrounding tumour responses to chemotherapy presents 
a real clinical problem, for the clinician as well as for the patient receiving the 
treatment, for their survival outcome will be determined by the chemotherapy’s 
efficacy.  In this study, the first approach to unravelling this treatment response 
uncertainty was to develop a framework for study and to begin with a systematic 
review of the literature; examining previous imaging methods, outcomes and 
research gaps from comparable studies using imaging biomarkers to measure 
breast tumour response to neoadjuvant chemotherapy.  The results of the 
literature review yielded 194 reports that had included MRI, PET, CT, 
conventional X-Ray and 99m-Tc imaging modalities as imaging options to 
measure the biological and functional activities of breast tumours treated with 
neoadjuvant chemotherapy.  Those studies showed variable accuracies for 
testing tumour response using imaging (AUC range=0.59-1.00).   The major 
limitations of previous studies included heterogeneities in the patient population, 
limited analyses completed in tumour subtypes, variable response endpoints 
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(i.e., radiological endpoints versus pathology endpoints) and differences in the 
statistical methods to discriminate responders and non-responders.  Technical 
limitations included imaging systems such as MRI and CT that are costly, 
require invasive procedures (i.e. injection of contrast agents) and the limited 
repeatability and reproducibility of results between studies.  However, the 
literature search also indicated that there were two major hallmarks of 
chemotherapy response mechanisms in tumours that could be detected using 
imaging: 1) QUS imaging biomarkers, previously shown to measure the rate of 
apoptotic cell death in cancer cells and; 2) DOS imaging biomarkers, shown to 
measure the changes to the tumour physiology, such vascular density and 
tissue composition (Czarnota et al., 1999, Cerussi et al., 2011).  Research has 
also suggested that both DOS and QUS imaging may help identify the changes 
in the tumour’s structural matrix during tumour response to chemotherapy.  
Therefore, the study here, aimed to combine these markers and map out 
statistical models using DOS and QUS to measure chemotherapy response.   
Therefore, the motivation of this study was to investigate the tumour response 
to chemotherapy using DOS and QUS and explore their role as putative 
biomarkers of tumour response mechanisms.  In this thesis, two approaches 
were used to address the following two overarching research questions: 
1) Can DOS and QUS imaging biomarkers be modelled to monitor 
chemotherapy response in breast cancer at early times after initiation of 
treatment intervals (i.e. after one or two cycles of chemotherapy)?  
2) Can pre-treatment DOS imaging be used to predict chemotherapy 
response before the initiation of treatment?   
 
To address the first research question (i.e. subproject one), patients were 
imaged at several time intervals during chemotherapy: before the start of 
chemotherapy (i.e. baseline), then at week one, week four, week eight during 
chemotherapy, and one week before surgery.  Locally advanced breast cancer 
patients demonstrated for the first time, coincident changes in the DOS and 
QUS imaging biomarkers during neoadjuvant chemotherapy.  Univariate and 
multivariate analyses indicated good sensitivity and specificity as early as one 
week after the start of chemotherapy.  The results of the first study (subproject 
one) indicated that markers of apoptotic cell death could be identified using 
QUS imaging and were associated with a decrease in tumour haemoglobin 
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markers on DOS imaging.  The results suggested that QUS cell death markers 
(i.e. DSI) increased in responsive tumours which was temporally aligned with a 
decrease in the haematological parameters (Hb, HbO2, HbT), as measured by 
DOS.  In the multivariate analyses conducted in the first subproject, the 
combination of DOS and QUS imaging markers provided a greater number of 
imaging signatures that could be used to measure early-responses in breast 
tumours; for example, after one week after initiating chemotherapy (i.e., one 
cycle of chemotherapy), there were seven DOS-QUS imaging signatures that 
classified tumour responses compared to only three univariate DOS or QUS 
parameters at the same time interval.  
 In subproject two of the study, pre-treatment DOS images were studied 
to predict the pathological response (i.e. Miller-Payne grade) to neoadjuvant 
chemotherapy. Here, LABC patients were imaged before treatment to measure 
the tumour’s physiological features such as, oxygenation, haemoglobin content 
and tissue composition (lipids and water content).   DOS data were analysed 
using a texture analysis approach (GLCM from second-order statistical 
methods).  The results demonstrated that DOS-texture maps of the tumour 
were significantly different between tumour's responding to chemotherapy (i.e. 
pathological responders) and non-responders as measured using Miller-Payne 
pathological response criteria. DOS-texture features showed a high 
discrimination performance between responders and non-responders using the 
following classification methods: a logistic regression model, a naïve Bayes 
machine-learning approach and a k-NN algorithm.  Additionally, in subproject 
two, a subgroup analysis was performed of tumours that were ER+, triple 
negative and patient groups that received either AC-T or FEC-D chemotherapy.   
Classification models such as Naive Bayes and k-NN machine-learning 
algorithms were also useful in discriminating patient responses (i.e. responders 
and non-responders) before treatment.  The results of subprojects one and two 
suggest a correlation between DOS and QUS imaging biomarkers and the 
tumour’s biological layout.  The results of subproject two also indicated that the 
pre-treatment DOS parameters can be used to predict breast tumour response 
to chemotherapy.   
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4.2 Comparison to Previous DOS and QUS Studies 
 
4.2.1 Overview 
 
The results presented in the thesis agree with previous reports that show 
a strong correlation between tumour biology, breast cancer response to 
chemotherapy, and imaging biomarkers obtained from DOS and QUS imaging.   
It has been shown that the tumour’s biological composition, as measured by 
DOS and QUS, over the course of chemotherapy or before treatment, can be 
used as early-response, or predictive markers to pathological endpoints as 
measured by Miller-Payne pathologic response criteria.  Underpinning these 
criteria, are a series of biological characteristics; haematological features, 
changes in tissue parameters (i.e., interstitial fluid (water content), lipid 
measurements and tumour cellularity). 
Of the 16 DOS studies identified in Chapter 1 (Literature Review), four 
studies demonstrated predictive DOS markers using various physiological 
measurements and one study showed that both predictive and early-response 
DOS markers were correlated with pathologic endpoints (various endpoints 
were used across several studies).  The remaining 11 DOS studies reported 
significant differences between responders and non-responders during 
treatment.  For QUS only, one study (Taddayyon et al. 2017) showed that QUS 
could be used to predict treatment response before starting chemotherapy; 
while the remaining five studies reported that QUS imaging biomarkers could be 
used as markers for final pathological outcomes21.   The present study 
(subproject one of this thesis) demonstrated for the first time, that there were 
coincident temporal changes in the DOS parameters with QUS imaging 
markers.  It was also shown that DOS and QUS parameters could be used to 
measure intra-treatment changes in the tumour as a link to the patient’s 
treatment response.  Also, for the first time, this was completed using a 
                                            
21 Pathologic response endpoints in these previous QUS studies were either 
systematically assessed (i.e. Miller-Payne pathologic response criteria) or by 
using non-systematic evaluation (assessment from pathologist based cellular 
features and identification of residual cancer cells).   
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systematic pathological response criteria endpoint and here, the Miller-Payne 
pathological response grading system was used.   
The work in subproject two in this thesis used a novel technique by 
employing a GLCM analysis (i.e. texture) to the tumour-only ROI of baseline 
(pre-treatment) DOS images.  The pre-treatment DOS-texture features were 
analysed and showed a correlation to Miller-Payne pathological response in 
patients with locally advanced breast cancer.  A discussion about this present 
study, in comparison to other major DOS and QUS works is presented in the 
following sections.     
 
4.2.2 Comparisons to other DOS Studies  
 
Previous DOS studies have confirmed that there are significant 
biophysical and biochemical alterations in breast tumours during chemotherapy 
that can be optically measured (Enfield et al., 2009).  Additionally, previous 
results have shown that the tumour’s biochemical composition, as measured by 
DOS before treatment, can be used to predict chemotherapy response in 
tumours, as measured either by radiological or pathological endpoints.  
However, this present study is unique from previous DOS studies in terms of 
using volumetric tumour analysis, GLCM-texture analysis in pre-treatment DOS 
images, using a systematic pathological response criteria and machine learning 
algorithms for predicting tumour response.  This following section compares the 
results of the present study and previous DOS studies.  A summary is 
presented at the end of the section, in Table 4.1A, B, C.   
 
Comparison of DOS-measured Haemoglobin Content 
 
  One significant alteration in the biology of the tumour during and after 
treatment includes significant reductions in haemoglobin content in tumours 
responding to chemotherapy.  These alterations represent a diminution in the 
vascular density and the decreased metabolic activity of tumours (Roblyer et al., 
2011). Thus, the reductions in deoxy-haemoglobin, oxy-haemoglobin and the 
total haemoglobin can be strong indicators for chemotherapy response.  
Several studies have indicated that these changes occur early, after the 
initiation of treatment.  Roblyer et al. (2011) reported an “oxy-haemoglobin flare” 
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in responsive tumours with an increase of 38% in HbO2 compared to non-
responders within the first 24 hours (p<0.0001) (Roblyer et al., 2011).  The data 
also showed a significant change in the HbO2 up to seven days after the start of 
chemotherapy for responders (Roblyer et al., 2011).  When whole-breast 
parametric haemoglobin maps were analysed using texture analysis, Sadeghi-
Naini et al. (2015) showed that the oxy-haemoglobin, deoxy-haemoglobin, and 
the total haemoglobin parameters could discriminate treatment responses with 
high sensitivities and specificities (80%-100%) within the first week of treatment 
(Sadeghi-Naini et al., 2015).  Cerussi et al. (2007) previously reported a 
significant difference in haemoglobin content between responders and non-
responders after 7 days of initiating chemotherapy. The relative (normalized) 
differences in deoxy-haemoglobin between responders and non-responders 
were 0.73 ± 0.17 and 1.02 ± 0.05, respectively, and the oxy-haemoglobin 
measured 15% less in responders compared to non-responders at the same 
time interval (Cerussi et al., 2007).  By comparison, the data from the present 
study supports previous work demonstrating a significant difference in the 
haemoglobin content between responders and non-responders (p<0.01). 
However, it should be noted that in the present study, the oxy-haemoglobin 
content for non-responders increased to 110.7% ± 5.4% after 7 days and this 
contrasts with a previous report by Cerussi et al. (2007) where increases in Hb 
(but not HbO2) were shown.  This is possibly explained by differences in the 
metabolic activity of tumours, as the rate by which the HbO2 converts to Hb 
during tumour activity (and metabolism) within the first week of therapy.      
The haematological differences between responders and non-
responders are also evident after chemotherapy.  The results from several 
studies have indicated a significantly higher haemoglobin content in patients 
who did not achieve pathological complete response (pCR) compared to those 
patients who had chemoresistant tumours (Cerussi et al., 2011).  Cerussi et al. 
(2011) showed that the deoxy-haemoglobin concentration significantly differed 
in pCR patients compared to non-pCR patients.  The relative changes were a 
1.01-fold in increase in pCR compared to a 1.32-fold increase in non-pCR 
patients (p<0.05); suggesting that a lower vascularity is associated with better 
pathologic response to chemotherapy.   Similar trends were also observed for 
oxy-haemoglobin after therapy and showed a 20% lower value in pCR patients 
compared to non-pCR patients (Cerussi et al., 2011).  A comparable report by 
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Soliman et al. (2010) and Falou et al. (2012) showed a reduction in 
haemoglobin parameters, however there was a notable difference in the 
measured values and thus showed that there was a greater reduction in 
haemoglobin measured at the end of chemotherapy compared to other groups.  
Responders’ deoxy-haemoglobin concentration reduced to 20%-25% of the 
baseline value (i.e. an ~80% reduction); while the oxy-haemoglobin dropped 
considerably more to only 5% of the baseline value (Soliman et al., 2010).  By 
contrast, although there was a change in the haemoglobin in non-responders, 
those changes were statistically insignificant  (Falou et al., 2012, Soliman et al., 
2010).  The results in this present study (subproject one of thesis) agreed with 
reports by Falou et al. (2012) and Soliman et al. (2010).  In this thesis, a 
significant reduction in haemoglobin was also observed after therapy and in 
general, responders had a lower tumour haemoglobin concentration compared 
to non-responders.  Tumour deoxy-haemoglobin was reduced to 25.39% ± 
4.50% in responders compared to non-responder tumours which showed a 
greater relative concentration of 82.99% ± 7.87%. Similarly, oxy-haemoglobin 
was 10.46% ± 2.57% for responders and non-responders had a relative 
concentration of 84.87% ± 7.63%.  Total haemoglobin at the end of 
chemotherapy was 13.85% ± 2.11% in responders and 84.36% ± 6.83% in non-
responders.  Although the measured haemoglobin concentrations varied 
between studies, it is important to note that there were similar trends observed 
in terms of an overall reduction in responders and insignificant changes in non-
responders after starting therapy.   
Some exploratory studies have indicated that pre-treatment DOS 
markers were good predictors for tumour response.  Zhu et al. (2013) used the 
pre-treatment HbT measurements and the data showed that the AUC reached 
as high as 0.87, which was a strong predictor to pathologic endpoints (Zhu et 
al., 2013).  Similarly, data from Jiang et al. (2014) showed that the pre-
treatment HbT was significantly different between responders and non-
responders; also showing that the HbT was a strong predictor for treatment 
response (AUC=0.92) (Jiang et al., 2014).  Other DOS studies that examined 
the pre-treatment haemoglobin content did not show a significant predictive 
value at the pre-treatment time interval (Sadeghi-Naini et al., 2015).  In 
comparison to these other studies, the average haemoglobin measurements 
from tumours did not demonstrate a significant result in this study.  However, by 
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employing texture analysis to the parametric maps of tumours, a significant 
difference was observed between responders and non-responders using the 
deoxy-haemoglobin-homogeneity (p=0.030), the oxy-haemoglobin-correlation 
(p=0.024) and the total haemoglobin-homogeneity (p=0.047) parameters.  To 
our knowledge, only one other study to date has used texture-based techniques 
to analyse DOS data for breast cancer response to chemotherapy (Sadeghi-
Naini et al., 2015).  In this previous study by Sadeghi et al. (2015), the baseline 
haemoglobin content did not demonstrate a significant difference between 
groups before chemotherapy (i.e. pre-treatment).  An important difference 
between this study and the previous work from colleagues at the University of 
Toronto include differences to their analysis approach.   Specifically, their work 
involved whole breast ROIs; whereas here, textural features were analysed 
within the parametric maps of tumours only (i.e. tumour-only ROI) (Sadeghi-
Naini et al., 2015, Tran et al., 2017).   Here, it is also reported that multivariate 
analysis using DOS-texture features demonstrated an increase in the predictive 
accuracy using DOS-haemoglobin parameters.  The best combination feature 
sets yielded an accuracy of 79.5% from the GLCM-deoxy-haemoglobin and 
oxy-haemoglobin parameters. Comparable studies that used multivariate DOS 
features were conducted by Cerussi et al. (2007) and Sadeghi-Naini et al. 
(2015).  Cerussi et al. (2007) used a discriminant function to predict treatment 
outcomes from multivariate DOS features.  Their analysis yielded an accuracy 
of 100% after one week of treatment (Cerussi et al., 2007) from the deoxy-
haemoglobin using binary DOS feature sets.  Similarly, Sadeghi-Naini et al. 
(2015) used multivariate texture features and showed a significant result after 
one week.  
 
Comparison of DOS Tissue Composition Parameters 
 
Tissue composition parameters included %Lipids, %Water, TOI, oxygen 
saturation (StO2) and oxygen desaturation (St).  In the present study, analysis 
of the absolute DOS parameters, %Lipids, TOI, oxygen saturation and oxygen 
desaturation demonstrated a significant difference (p<0.01) between 
responders and non-responders after the second cycle of chemotherapy (week 
four) and up to the pre-operative time-point (p<0.01).  The %Water was 
significantly different between response groups after week four, and at pre-
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surgery.  However, at week eight the water content only approached 
significance (p=0.062) between groups.  The research here also analysed 
tissue composition parameters at baseline (pre-treatment) using a GLCM 
algorithm.  Responders and non-responders had a significant difference in the 
baseline oxygen saturation-contrast (p=0.044) and the oxygen desaturation-
contrast (p=0.044).  In terms of classification results, univariate discriminant 
analysis of the absolute DOS parameters performed well at classifying 
responders from non-responders after four weeks of treatment.  The best DOS 
feature was the %Lipids which showed an AUC of 0.982.   For all time intervals, 
the maximum AUC was observed again in the %Lipids parameter after 
chemotherapy was completed (pre-surgery) (AUC=1.00).  Other analyses 
included studying the textural features of baseline oxygen saturation and 
oxygen desaturation parameters.  The results showed that the oxygen-
saturation-contrast was a good marker for pathologic response before 
chemotherapy (AUC=0.803; %Sn=83.0% and %Sp=85.5%).  
In comparison to other reports, the measured changes in tissue-based 
parameters, %Water and % Lipid did not agree with the results of two previous 
studies that measured those parameters during chemotherapy.  Cerussi and 
colleagues showed insignificant differences (z=0.41) after one week of 
treatment for %Water and % Lipid (Cerussi et al., 2007).  However, it should be 
noted that the same group reported a significant difference in the %Water at the 
end of treatment in a follow up study with a larger patient set (n=36) (Cerussi et 
al., 2011).  Results from the Dartmouth group (Jiang et al. (2009)) reported 
insignificant differences between response groups for the %Water (p=0.41) 
after four weeks of treatment (Jiang et al., 2009).  These results agreed with a 
previous report by Soliman et al. (2010) that demonstrated an insignificant 
difference (p<0.60) at the same time interval (Soliman et al., 2010).    Other 
parameters such as the TOI (tissue optical index), which is a ratio between 
the %Water, %Lipids and deoxy-haemoglobin showed similar data trends 
between this study, compared to others.  The present study showed that there 
were significant changes in the TOI in responsive tumours after four weeks of 
treatment (p<0.0001).  These results compliment previous findings from the 
ACRIN 6691 trial (Tromberg et al., 2016), that showed intra-treatment 
differences in the TOI between response groups (Tromberg et al., 2016).  
However, an important distinction in Tromberg et al.’s work included subjects 
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that were selected based on a StO2 threshold cut-off (StO2 >76.9%).  Effectively 
in that study, only tumours that had high baseline oxygen saturation were used 
in their analysis (Tromberg et al., 2016).    Indeed, tumour hypoxia and oxygen-
availability has been shown to affect tumour response to cytotoxic agents; i.e. 
hypoxic tumours are more chemoresistant compared to well-oxygenated 
tumours (Ward et al., 2013).  The intra-treatment changes in tumour oxygen 
content was correlated to pathologic response in one DOS study (Falou et al., 
2012).   Data from this small cohort of patients (n=15) showed that the oxygen 
desaturation (St) of the whole-breast was significantly different (p=0.0002) at 
intra-treatment (four weeks) between responders and non-responders (Falou et 
al., 2012).  Their study also showed that the tumour oxygen saturation (StO2) of 
the whole-breast was not significant between response groups (p=0.1) after four 
weeks of treatment and this agreed with a previous study by Jiang et al. (2009) 
(p=0.47).   
The pre-treatment analysis in the present study agrees with previous 
DOS data showing that baseline oxygen saturation can predict chemotherapy 
response (Ueda et al., 2012, Jiang et al., 2014).  Jiang et al. (2014) showed that 
the pre-treatment StO2 could reach an AUC of 0.8.  Similarly, data from Ueda et 
al. (2012) were comparable; the tumour StO2 showed an AUC of 0.72 (Ueda et 
al., 2012). In their study also, when the StO2 was modelled with intrinsic 
molecular features (ER+ and PR+) in a linear discriminant function, the AUC 
increased to 0.80-0.93 (Ueda et al., 2012). 
  
Data Comparison of Optical Scattering Parameters 
 
Optical scattering parameters included the scattering power (SP) and the 
scattering amplitude (SA).  These features correspond to the size of the 
scattering particle, relative to the wavelength (Cerussi et al., 2007).  Tumours 
have been shown to have higher optical scattering (i.e. larger scattering power) 
compared to the surrounding normal tissue and this is due to the complex 
cellular and stromal organization within the tumour’s microenvironment that act 
as scatterers (Tromberg et al., 2005, Cerussi et al., 2007, Soliman et al., 2010). 
In the present study, the scatter power and the scatter amplitude 
demonstrated a significant difference between response groups after four 
weeks of treatment (p<0.01) and there was a significant decrease in the scatter 
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power in responders during treatment.  This corresponded to a high predictive 
value (AUC range=0.897-0.982).  The results of this study agree with other 
studies that also showed a significant difference in the scattering power 
between responders and non-responders; Soliman et al. (2010) reported a 48% 
difference in the scattering power after four weeks of treatment (p<0.036).  In 
the present study, the difference in the scattering power parameter was 34.7% 
only between groups (p<0.05); in comparison to another study by Falou et al. 
(2012), their data indicated a difference of 35% between response groups after 
four weeks of treatment (p<0.046), which was similar to this present work 
(Falou et al., 2012).  On the other hand, in a study by Jiang et al. (2009), there 
was no difference in scattering parameters (scatter amplitude and scatter 
power) after four weeks of treatment, although the scattering power approached 
significance (p=0.06) at this time interval (Jiang et al., 2009).   Another study by 
Cerussi et al. (2007) examined earlier time intervals (i.e. after one week of 
treatment) in the scattering parameters and there were no significant results, 
differences in the scattering parameters, which corresponded with the data in 
this study (Cerussi et al., 2007).   
 
4.2.3 Analysis of Data Variances in DOS  
 
DOS Topography versus Tomography 
 
DOS systems can be built as topography systems (2D-image acquisition) 
or tomography systems (3D-image reconstructions) which can yield varying 
DOS datasets (i.e. 2D planar images may carry limited DOS data since only a 
portion of the tumour is measured, depending on the size).  Systems developed 
by the UC Irvine group (Cerussi, Tromberg, Ueda) and the University of 
Connecticut (Zhu, Hegde) used handheld topography devices that employs a 
reflectance geometry (Zhu et al., 2014).  Other research groups from Dartmouth 
University (Jiang, Paulsen, Pogue) and the University of Toronto (Falou, 
Soliman, Czarnota) used tomographic systems which provide cross-sectional, 
volumetric DOS datasets of the breast.  The differences between the two 
systems are that one produces 2-D maps (topographic); whereas the other, 3-D 
maps (tomographic) of the chromophores of interest (i.e. haemoglobin, water 
and lipids) are constructed.   
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Hand-held topography devices and DOS tomography systems have their 
respective advantages and disadvantages.  Hand-held systems are portable 
and are advantageous for imaging lesions in harder-to-reach areas such as the 
axilla.  It uses reflectance geometries that have an average imaging penetration 
depth of 10-22 mm below the skin surface (Cerussi et al., 2011).  As a result, 
the penetration depth limits the imaging of large locally advanced breast 
tumours that are bigger than 5 cm in the posterior dimension.  Since there are 
often intratumoural heterogeneities in breast tumours, topography systems are 
potentially constrained by under-sampling, i.e. the entire tumour volume is not 
measured due to limited penetration depth or limited field-of-view from the 
geometry of the imaging device.  Thus, errors can arise for tumours with deep 
posterior margins and the major consequence is that it may not represent the 
tumour’s entire biological properties given the limitations in device geometry.  In 
contrast, tomographic systems provide volumetric data (3-D), for it uses light 
transport calculations that are captured across the breast tissue (Dehghani et 
al., 2009).   DOS tomography is capable of high imaging contrast and yields 
more data points; yet the major disadvantage is the coarse spatial resolution 
(i.e. large voxel sizes) as a result of limitations in reconstructing data from 
diffuse light propagation in tissue (i.e. greater scattering during light transport 
across the longer tissue distance) (Dehghani et al., 2009).  Given these 
differences in technology, 2-D versus 3-D DOS imaging can yield varying 
results and this was apparent between research studies.  Analysis conducted 
by the UC Irvine and University of Connecticut group, who used hand-held 2D-
planar imaging demonstrated higher haemoglobin levels at the conclusion of 
therapy.  This may have been caused by measuring only a fraction of the 
tumour’s total bulk volume (i.e. anterior aspect).  In those studies, tumour 
analysis was based on two-dimensional datasets that had a fixed depth and 
area.  In comparison, researchers at the University of Toronto (the present 
study) and at Dartmouth University used DOS tomography which measured the 
optical properties of the whole tumour and the entire breast; thus, the 
chromophore concentrations were based on the sum of measurements in all 
spatial directions across the entire breast volume in some studies.  Measuring 
the whole tumour (and whole breast) versus a smaller tumour segment may 
have resulted in the variances in changes at the end of treatment; known as 
signal “washout”.  Other contributing factors to data variance include a partial-
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volume effect which is the loss of quantitative accuracy based on the DOS 
resolution (Santago and Gage, 1995, Durduran et al., 2010).  The result is an 
underestimation of the chromophore concentration changes and problems with 
assigning absolute optical properties within the region of interest  (Durduran et 
al., 2010).  The lower haemoglobin values calculated from this present study 
and other studies by Soliman et al. (2010) and Falou et al. (2012) could have 
been caused by a partial-volume effect (Falou et al., 2012, Soliman et al., 
2010).  The partial-volume effect is highly possible given the resolution of the 
DOS tomography system used here (3 mm x 3 mm) is large in comparison to 
the size of chromophores (i.e. haemoglobin) (Durduran et al., 2010).  
 
 
DOS Regions of Interest 
 
An important comparison between research reports involves discussing 
the methods in selecting the region-of-interest.  Indeed, there is great interest in 
studying the effects of adjusting the size, boundary and computing methods to 
contour the ROI in DOS data processing and analysis since it can impact the 
measured and absolute DOS values (Hylton, 2009).  Jiang et al. (2009) report 
results on using two ROI segmentation schemes that compared fixed-sized 
versus variable-sized ROIs  (Jiang et al., 2009).  In the first approach, a 
radiologist selected the ROI with a priori knowledge of the tumour’s location 
based on MRIs.   The size and dimension of the ROI was kept constant for the 
duration of the imaging series during the patients’ treatment.  In the second 
approach, an automated and computer-assisted method was utilized using the 
intensity distribution of the DOS image maps. The ROI was determined based 
on the position of the chromophore’s maximum intensity and a contour 
boundary was calculated around that position for values that were above the 
half of the maximum value.  This method is referred to as the full-width-half-
maximum (FWHM) approach (Jiang et al., 2009).  In a small dataset (n=7), 
Jiang and colleagues showed that variable-sized ROIs showed a greater 
normalized decrease in the total haemoglobin in pCR patients compared to 
using a fixed-sized ROI (HbT fixed = -64.2 ± 50.8 versus HbT variable = -96.7 ± 
91.8) (Jiang et al., 2009).       
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Another study by Falou et al. (2012) reported results using whole-breast 
analysis versus volume-adjusted ROIs using tomographic datasets.  Whole-
breast analysis involved calculating the integrated optical parameters across the 
entire breast, which included tumour and normal breast tissue.  For volume-
weighted analysis, the tumour volume was determined by referencing clinical 
imaging (i.e. MRI, CT) and the ROI was placed manually.  The optical 
parameters were calculated within the region of interest only.  The major 
advantages to whole-breast analysis is that it can be done without any 
knowledge of the size and location of the tumour and thus mitigates inter-user 
variability.  A major disadvantage however is that as tumours regress during 
treatment the optical parameters may reflect a greater ratio of breast to the 
tumour optical properties, thus “washing out” the tumour optical measurements.  
Falou et al. (2012) showed a significant difference in optical properties between 
whole-breast analysis and volume-weighted analysis.  Measuring the deoxy-
haemoglobin in responders after four weeks of treatment showed a reduction to 
32% ± 7% for volume-weighted ROIs; while whole-breast ROIs showed an 
increase of 114% ± 6% relative to the baseline concentration (Falou et al., 
2012).  These studies demonstrated that ROI placement and contouring 
methods have a significant impact on the reported optical properties in tumours.  
Importantly, other tissue composition features such as %Lipids demonstrated 
insignificant changes over the course of treatment and did not discriminate 
responders and non-responders.  This could be explained since breast tissue is 
highly composed of adipose tissue which could “wash out” any measurable 
changes in the tumour.     
Schaafsma et al. (2015) showed that displacing the ROI by 5 mm could 
result in a 2% change in the deoxyhaemoglobin and oxy-haemoglobin 
measurements for tumours that are 30 cm3 and an 8% change for tumours 
approximately 5 cm3.  Their data suggests that smaller tumour sizes (either on 
initial presentation or regressing from treatment) are susceptible to greater 
variability depending on the ROI placement (Schaafsma et al., 2015).  This 
phenomenon may explain some of the data variability in the haemoglobin 
changes at the end of treatment since tumour dimensions are generally smaller 
(for responsive patients) and therefore positioning the ROI around these smaller 
lesions may cause variability; caused also by the lower resolution of DOS 
images.   
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Wavelength (nm) Near Infrared (600-1100) x x x x x x x 
Image Type Topographic (2D)  x x x  x  Tomographic (3D) x    x  x 
ROI Analysed Tumour x  x  x   x x  x  x  Whole-Breast         
Time Measures Pre-Treatment x  x x  x  x Intra-Treatment   x  x   x  x  x   
Imaging Parameters 
Studied 
Haemoglobin  x  x  x  x  x  x x  
Oxygen Saturation x x  x      
Tissue Parameters x x  x x  x  
Scattering Parameters x x  x   x   
GLCM-Textures x       
Tumour Parameters 
ER/PR  x  x x x  x  
HER2 x  x x x  x 
Triple Negative x  x   x  x 
Multimodalities Other biomarkers  x        
Classification 
Models 
Logistic Regression x        
Linear Discriminant   x          
Machine 
Learning 
k-NN x         
SVM         
N. Bayes x        
Others         
Univariate Models x  x            
Multivariate Models x  x           
Tumour Response 
Endpoints 
RECIST 1.1 (Radiology)        
Miller-Payne (Pathology) x   x     
Residual Cancer Burden        
NSABP Protocol        
Other Radiological      x  
 Other Pathological  x  x x x x 
Table 4.1A.  Summary of comparisons between DOS studies.  A significant 
difference between the present study (thesis) and previous studies include 
using GLCM-texture analysis on baseline DOS parameters.   Yellow boxes 
represent the major differences and limitations of previous studies.   
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Wavelength (nm) Near Infrared (600-1100) x  x  x  x  x x  x 
Image Type Topographic (2D) x  x  x   Tomographic (3D)  x  x  x x 
ROI Analysed Tumour x  x x  x   x x    Whole-Breast  x       
Time Measures Pre-Treatment   x x  x   Intra-Treatment x   x      x x   
Imaging Parameters 
Studied 
Haemoglobin   x  x  x x  x  x  
Oxygen Saturation x x x x x  x   
Tissue Parameters  x    x  x  
Scattering Parameters  x     x   
GLCM-Textures        
Tumour Parameters 
ER/PR  x x x x  x x  
HER2 x x x x  x x  
Triple Negative x x x x   x x 
Multimodalities Other biomarkers     x     
Classification 
Models 
Logistic Regression    x x   x 
Linear Discriminant   x  x     x   
Machine 
Learning 
k-NN          
SVM         
N. Bayes         
Others         
Univariate Models   x  x      x   x 
Multivariate Models      x x        
Tumour Response 
Endpoints 
RECIST 1.1 (Radiology)       x 
Miller-Payne (Pathology)     x   x 
Residual Cancer Burden        
NSABP Protocol x       
Other Radiological     x   
Other Pathological   x x   x  
Table 4.1B.  Other DOS studies demonstrated significant differences in the 
classification algorithms used (i.e. machine learning) to predict treatment 
response.  Yellow boxes represent the major limitations and differences of 
previous studies.   
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Wavelength (nm) Near Infrared (600-1100) x   x x       
Image Acquisition Topographic (2D)  x x     Tomographic (3D) x       
ROI Analysed Tumour   x  x         Whole-Breast x        
Time Measures Pre-Treatment  x        Intra-Treatment x  x  x         
Imaging Parameters 
Studied 
Haemoglobin  x  x  x        
Oxygen Saturation x         
Tissue Parameters x x        
Scattering Parameters x         
GLCM-Textures x       
Tumour Parameters 
ER/PR  x  x      
HER2 x  x      
Triple Negative   x      
Multimodalities Other biomarkers          
Classification 
Models 
Logistic Regression         
Linear Discriminant x  x  x       
Machine 
Learning 
k-NN          
SVM         
N. Bayes         
Others         
Univariate Models x  x  x         
Multivariate Models x            
Tumour Response 
Endpoints 
RECIST 1.1 (Radiology)        
Miller-Payne (Pathology)         
Residual Cancer Burden        
NSABP Protocol        
Other Radiological x       
Other Pathological x  x x     
Table 4.1C:  The significant contribution of this thesis includes modelling QUS 
parameters with DOS features during chemotherapy.  Yellow boxes represent 
the major limitations and differences of previous studies.   
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4.2.4 Comparison of QUS studies 
 
 Quantitative ultrasound spectroscopy in breast cancer is a relatively new 
technique under clinical investigation.  Current research is underway for its use 
in classifying tumour response to treatment and also as a method for identifying 
malignant and benign breast lesions at diagnosis.   To our knowledge, the 
research group from the University of Toronto is unique in conducting clinical 
(human) research in breast cancer response to neoadjuvant chemotherapy.  
Indeed, other researchers have used QUS in the clinical research setting for 
other aims such as characterizing liver disease (Lu et al., 1999); (Lin et al., 
2015); however a large body of this other work is still focused on laboratory and 
animal-based research. 
 The previous breast studies presented from the University of Toronto 
demonstrated promising clinical results; the aims being to acquire both pre-
treatment and intra-treatment QUS parameters to measure breast cancer 
response to chemotherapy.  Taking the work of our group forward, the analysis 
in this thesis aimed to measure intra-treatment QUS changes and to use QUS 
parameters for combined DOS parametric models; whereas previously our 
group had included analysis of QUS alone, on both pre-treatment and intra-
treatment QUS parameters.  The forward innovation here, sought to correlate 
the biological measurements such as haemoglobin and tissue composition 
changes with the previous QUS work.  Additionally, this work differs from 
previous intra-treatment QUS studies since now, QUS imaging biomarkers were 
studied for correlation to a systematic pathological response criteria (i.e. Miller-
Payne grading); whereas previously QUS studies have used a non-standard 
pathological method or relied principally on radiological endpoints.   Table 4.2 
outlines the significant differences in methods and approaches between the 
present study, and previous QUS studies.  As indicated from Table 4.2. The 
work here is novel since to date, no other QUS study has included a 
multiparametric model using other imaging modalities.          
In comparing the QUS data only, the results here were consistent with 
data from Sadeghi-Naini et al. (2013), where there were similar temporal QUS 
changes observed in responders after four weeks of treatment.  Responders 
also showed a significant increase in the mid-band fit and spectral intercept; 
whereas non-responders showed insignificant change throughout the course of 
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treatment (Sadeghi-Naini et al., 2013b).  In comparison to the study by Sadeghi 
et al. (2013), there were two important distinctions in the methods and analysis; 
the first being a probability density function analysis of the MBF feature.  This 
analysis was carried out by analysing the MBF parametric maps and fitting a 
generalized gamma (GG) distribution of the MBF intensity histogram for feature 
extraction (Sadeghi-Naini et al., 2013b).  The second, multiparametric QUS-
features analysis was performed using combinations of QUS features only.  It 
was shown in their study that the generalized gamma distribution did not 
improve the accuracy of measuring chemotherapy response at intra-treatment; 
the sensitivity and specificity of the MBF was 100% and 72.2% at week four, 
respectively, compared to the 66.7% and 66.7% for the generalized gamma 
model (Sadeghi-Naini et al., 2013b).  Also, by using a multiparametric model 
(mid-band fit and the 0-MHz intercept), their study showed an improvement in 
discriminating responses (%Sn=100.0% and %Sp=83.3), compared to using 
those individual features alone (Sadeghi-Naini et al., 2013b).  A follow-up study 
by the same author used QUS-texture analysis and showed that alterations in 
the texture features separated responders and non-responders as early as one 
week after starting chemotherapy (Sadeghi-Naini et al., 2014).  This study also 
showed that QUS-textural biomarkers were significantly correlated to patient 
survival (p=0.0007) (Sadeghi-Naini et al., 2014).  By comparison, in this thesis, 
texture analyses were not completed since the focus here, was to explore the 
coincidence between mean DOS and QUS biomarkers only.  Additionally, 
survival analysis could not be completed for this patient cohort since the current 
follow up time is insufficient for long-term analysis (i.e. a minimum of 5-years is 
typically reported). 
Recently, Tadayyon et al. (2016) examined a larger patient cohort (n=58) 
and expanded QUS analysis to include predictive modelling with acoustic 
backscatter parameters (Tadayyon et al., 2016).  This analysis was developed 
from a previous study by Sannachi et al. (2015) where 30 LABC patients were 
studied.   The methods included a machine-learning algorithm (k-NN) for 
tumour-response classification, in addition to modelling intra-treatment and pre-
treatment QUS parameters together.  The results of that study showed a 
significant increase in QUS parameters (MBF, SI, ACE) after one week of 
treatment for responders; however, the diagnostic accuracies were poor for 
measuring treatment response (%Acc range = 54%-61%).  When more than 
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one parameter was employed (multiparameters), it was shown that the 
combination of intra- (week one)- and pre-treatment QUS features improved the 
diagnostic accuracy (%Acc=70.0%) (Tadayyon et al., 2016).  It should be noted 
however that this combination model did not show a significant result after four 
weeks of treatment.  In a subsequent QUS-based study by Tadayyon et al. 
(2017), pre-treatment QUS parameters were studied further to improve QUS 
analysis techniques (Tadayyon et al., 2017).  There were three important 
methodological differences to this present study:  1) a modified segmentation 
scheme of the tumour was used in their study, which included an expansion 
margin (5-10 mm) around the peritumour region (Tadayyon et al., 2017); 2) 
molecular tumour markers were used in their predictive models; and 3) machine 
learning techniques were used for response classification.  Their study showed 
that expanding the ROI margin by 5 mm around the tumour predicted response 
with an accuracy of 88%; yet including molecular subtypes did not improve the 
accuracy (%Acc=82%) (Tadayyon et al., 2017).  The ROI-expansion technique 
was not employed in the current study since the scope of the research was to 
compare coincident DOS and QUS markers of the tumour-volume only.  
Additionally, the image resolution for QUS is finer compared to DOS; where the 
in-plane resolution for DOS was 3 x 3 mm2 and thus an expansion margin 
would not permit a geometric comparison between DOS and QUS images.      
 Other QUS studies in breast cancer include a study by Gangeh et al. 
(2015); where the focus was based on using QUS parameters within the 
framework of computer-assisted theragnostics (CAT) (Gangeh et al., 2016).  
CAT is centred around complex machine-learning computations that are used to 
measure tumour response to therapies (i.e. theragnosis) (Gangeh et al., 2016).  
It works by implementing pattern-recognition algorithms within a feature space; 
using attributes or biomarkers, such as those found in QUS parameters, texture 
features, or morphological tumour characteristics (Gangeh et al., 2016).  The 
scope of that study was primarily exploratory and focused on computational 
theory that is beyond the scope of the current thesis.  In the next section, is a 
summary of comparisons between this present study and previous QUS studies 
presented.     
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4.2.5 Analysis of data variances in QUS Studies 
 
 The data variance between the results presented in this thesis and 
previous QUS reports can be explained by the different methodological 
approaches used.   
 
Ultrasound Imaging Parameters 
 
Two reports (Tadayyon et al., 2016, 2017) used lower-frequency 
ultrasound (transducer frequency = 6 MHz, central frequency = 5.5 MHz), 
compared to the present study that used a transducer frequency of 10 MHz, 
central frequency = 7 MHz.  The differences in ultrasound parameters changes 
the resolution and thus affects the absolute changes measured in the QUS 
parameters.   
In terms of ROI selection, all studies analysed the tumour volume except 
for one study by Tadayyon et al. (2017) which used an expansion volume (3-10 
mm) around the peritumour region.  This method contributed to a better 
prediction value for pre-treatment QUS parameters based on backscatter co-
efficient parameters and spectral parameters.  The data variance between this 
study and the work by Tadayyon et al. (2017) was due to the differences in 
computing different anatomical volumes.  In their study, QUS parameters were 
calculated on both malignant lesions and the normal breast parenchyma which 
alters the acoustic scattering measurements.   
 
Parameters of Interest and Modelling Features 
 
All studies but one (Sannachi et al., 2016) reported the linear fit 
parameters of the power spectrum (MBF, SI, SS).  The linear-fit model 
parameters that were measured in patients for this present study agreed with 
previous studies in terms of the observed trends and relative changes 
measured in response groups during chemotherapy.  However, there were 
variances in the predictive values for univariate and multivariate models 
between studies (sensitivity, specificity, accuracy, AUC) and this was caused 
from differences in the statistical frameworks used (i.e. classification algorithms 
used).  Univariate and multivariate analysis of the QUS linear-fit parameters 
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included a linear discriminant function, a logistic regression model and a k-
nearest neighbour classification algorithm among studies (Sadeghi-Naini et al., 
2013b, Tadayyon et al., 2016).  The predictive values are calculated from 
several factors: 1) the number of variables included into the model; 2) the 
sample size; and 3) the distribution of data samples.  Multivariate models from 
previous reports have included tumour molecular features and a combination of 
other QUS features together (Tadayyon et al., 2017, Sadeghi-Naini et al., 
2013b) 
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US Transducer 
Frequency (MHz) 
10 MHz (central f = 7 MHz) x x x x  x  
 6 MHz (central f = 5.5 MHz)     x  x 
ROI Analysed Tumour Volume x x x x x x x Other Volumes       x 
Time Measures Pre-Treatment       x Intra-Treatment x x x x x x  
Imaging 
Parameters 
Studied  
(Spectral 
Analysis) 
Linear Fit (MBF, SI, SS) x x x  x  x 
Backscatter 
coefficient 
model 
parameters 
ACE     x  x 
ASD    x x   
AAC    x x   
BSC    x    
SAS     x   
GLCM-Textures   x    x 
LBP-Textures      x  
Tumour 
Parameters 
ER/PR  x x x x x x x 
HER2 x x x x x x x 
Triple Negative x x x x x x  
Multimodalities Other imaging  x       
Classification 
Models 
Logistic Regression x       
Linear Discriminant x x x x   x 
Machine 
Learning 
k-NN     x  x 
SVM       x 
N. Bayes      x  
Other      x  
Univariate Models x x x x x x x 
Multivariate Models x x x x x  x 
Tumour 
Response 
Endpoints 
RECIST 1.1 (Radiology)  x   x x  
Miller-Payne (Pathology) x      x 
Other Radiological    x    
Other Pathological   x   x  
Table 4.2: QUS study comparisons.  Significant differences between the 
present study and previous QUS studies include the methods for spectral 
analysis (linear fit model compared to backscatter co-efficient model).  Other 
major differences include using concurrent DOS imaging and statistical 
modelling.  Lastly, this study used a systematic approach to pathological 
response criteria (i.e., Miller-Payne criteria).  LBP=local binary pattern.   Yellow 
boxes represent the major differences and limitations of previous studies.  
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4.2.6 Modelling DOS and QUS Parameters as Complementary Response 
Markers 
 
In the present study, combined analysis was completed for DOS-QUS 
parameters to measure NAC response at early time intervals in locally 
advanced breast cancer.  To our knowledge, this is the first study that has 
completed serial and coincident imaging with DOS and QUS in locally advanced 
breast cancer.  The coincident biomarkers measured from DOS and QUS show 
that there are also coincident cellular, biochemical, haematological and 
morphological changes with treatment (Jakubowski et al., 2004, Srinivasan et 
al., 2006, Jiang et al., 2009).  Of note, QUS parameters have been 
demonstrated in tumours that exhibit apoptotic cell death from chemotherapy 
(Kolios et al., 2002, Sadeghi-Naini et al., 2013b).  These DOS and QUS 
parameters have also been correlated to pathologic characteristics and 
outcomes (Cerussi et al., 2011, Cerussi et al., 2007, Sadeghi-Naini et al., 
2013b, Tadayyon et al., 2014).  Previous work by Cerussi et al., (2011) used 
DOS to measure tumour water content, and tumour haemoglobin concentration 
at multiple times during chemotherapy treatment (Cerussi et al., 2011).  The 
results of that study indicated a significant reduction in %Water and tumour 
haemoglobin at the end of chemotherapy when compared to the baseline 
measurements, and this corresponded to patients who demonstrated 
pathological complete response  (Cerussi et al., 2011).  The results in the study 
here are consistent with their findings and in addition, DOS data is 
supplemented with QUS biomarkers (MBF, SI) that indicated an increase in cell 
death within the tumour region.  Specifically, after four weeks, where there is an 
increase in the MBF and SI in responders, the total haemoglobin (HbT) in 
responders reduced significantly.  A possible explanation in responders could 
be due to decreased vessel viability within the tumour (measured by DOS), 
which also corresponded to an increase in cell death that resulted in spatial 
changes within the tumour (measured by QUS) (Zhu et al., 2008, Ueda et al., 
2012).  Conversely, non-responding patients may have had tumours with more 
aggressive malignant cells that prompted blood vessel growth to support the 
metabolic demands.   
In principle, tumour metabolic information, reflected by markers for 
deoxy-haemoglobin and oxy-haemoglobin parameters is closely linked to 
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tumour cellular activity (Roblyer et al., 2011, Falou et al., 2012).  This is 
explained by the conversion of oxy-haemoglobin to deoxy-haemoglobin during 
tumour cell cycling, and activity (i.e. metabolism).  After eight weeks of 
treatment, responders demonstrated a significant reduction of HbO2 and Hb and 
this corresponded with an increase in MBF of +10.0 ± 1.5 dBr, suggesting a 
coincident increase in dying cells within the tumour bed.  Non-responders 
however, demonstrated less significant decreases in the tumour haemoglobin, 
relative to the pre-treatment value and this was also correlated to a lesser 
change in the MBF and SI.  Together, DOS and QUS data suggest that 
chemotherapy-responsive tumours decrease in metabolism as linked to blood-
based parameters in comparison to non-responding tumours; potentially 
because of dying tumour cells.  QUS parameters, such as the SI and SS were 
not significantly different at the pre-operative time-point. This was expected 
since QUS measurement are sensitive to cell death induced by treatment which 
occurs in responsive patients early on, rather than many months later after 
chemotherapy.  Pre-operative measurements were obtained 4-6 weeks after the 
last chemotherapy infusion and therefore, cell death is expected to diminish 
within the tumour bed in responsive patients, due to a large reduction in tumour 
cells after many months of chemotherapy. 
Tumour structure was further characterized by measuring the tissue 
optical index (TOI) parameter which has been shown to demonstrate contrast 
between tissue types (Fantini and Sassaroli, 2012, Cerussi et al., 2006).  The 
TOI reflects the optical properties of breast tumours in reference to its 
pathological state (Fantini and Sassaroli, 2012).  In the work here, the TOI 
demonstrated significant differences (p=0.000) between responders and non-
responders after four weeks of chemotherapy and differed significantly 
(p<0.001) after completing chemotherapy (pre-surgery).  The change in TOI is 
dependent on the concentration of water and lipid content within the tumour and 
thus responsive tumours that demonstrated a larger reduction in water content 
would also result in a diminished TOI value (Fantini and Sassaroli, 2012, 
Tromberg et al., 2005).  Cerussi et al. 2007 previously suggested that this 
reduction in water fraction in responsive tumours might represent variations in 
tumour cell density, and cellularity within the tumour bed (Cerussi et al., 2007), 
and this was supported by clinically reported histological data that 
demonstrated cellular changes in the tumour after NAC.  Although the 
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relationship between water fraction and tumour cellularity is not entirely clear; it 
may be related to inflammatory response mechanisms within the tumour 
parenchyma (Coussens and Werb, 2002).  Further, in the work here the %Lipid 
also increased for responders, which can affect the TOI.  The increase in lipid 
content within the tumour bed could represent the changes in lipid composition 
closer to that of normal breast tissue and its relationship to QUS markers would 
suggest that there were cellular changes concurrently.           
DOS-QUS combined parameters enhanced chemotherapy response 
classification in comparison to single modality parameters as early as one week 
after the start of NAC.  However, it should be noted that not all combinations 
increased the sensitivity and specificity of response assessment, and this could 
likely be caused by the relatively small sample size in this first study.  Many 
single parameters classified patients with higher accuracy at weeks four and 
eight.   This is likely due to the cumulative effects of treatment and the 
concurrent biological changes in tumours at those times.  However, some 
parameters such as the SS benefited from multivariate DOS-QUS 
combinations.   It was expected that combining highly sensitive and/or specific 
parameters would increase the accuracy and prediction of treatment outcomes.  
In contrast, weaker predictors (such as the slope) would benefit from pairing 
with stronger predictive parameters with increases in sensitivity and specificity 
because more parameters carry complementary information about tumour 
physiology or cell death.  The results of this study suggest that DOS-QUS 
pairwise combinations may be useful for clinical application when modelled at 
one week of NAC treatment, using a combination of parameters that include: SI, 
SS, HbO2, HbT, SP, SA, %Water, and TOI, since many of these parameters 
demonstrate poor sensitivity and specify on their own at that time.  This may 
potentially be followed by treatment response verification and validation by 
using several other DOS-QUS parameters at weeks four and eight.   
Other strategies for combined systems to compliment tumour response 
measurements include US-guided optical imaging developed by Zhu et al., from 
the University of Connecticut (Xu et al., 2015, Zhu et al., 2013, Zhu et al., 
2008).  These systems have been studied to measure NAC response in breast 
tumours.  US grey-scale imaging was used there to localize breast tumours, 
and optical tomography to map tumour haemoglobin changes during treatment 
(Zhu et al., 2013, Zhu et al., 2008).  The technical benefits of that approach use 
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co-registered US images to verify posterior (deeper) tumour margins, where 
optical image resolution is poorer (Zhu et al., 2008).   For the current study, 
conventional US and DOS images were not co-registered since there were 
differences in the spatial geometries of the DOS and QUS images but averaged 
values over the tumour volume were used.  This was due to patient positioning 
for each scan modality (i.e. supine versus prone), and breast shape from DOS 
breast compression.  Another study from Ueda et al. used multivariate analyses 
for baseline DOS parameters combined with tissue biomarkers from 
immunohistochemistry (Ueda et al., 2012).   Markers for cell proliferation (Ki67), 
and molecular features (oestrogen and progesterone receptor) were combined 
with optical measurements such as (HbO2), (Hb), or the tumour oxygen 
saturation (StO2).  Multivariate discriminant analysis of the combined 
parameters demonstrated an increase in the sensitivity and specificity for 
predicting NAC response.  The results of this study from Ueda et al. support the 
need for further exploration into combination analysis to improve the predictive 
performance of multiple imaging and clinical biomarkers (Ueda et al., 2012).   
 
4.2.7 Significance of Texture-Analysis of Pre-Treatment DOS parameters 
 
Texture analysis is a general term for mathematical methods and models 
used to analyse images based on the image pixels’ spatial relationship to other 
neighbouring pixels (Davnall et al., 2012).  It has been used as a second-order 
statistical approach to analyse DOS parametric images; yielding DOS-texture 
features to aid in discriminating tumour response during NAC (Sadeghi-Naini et 
al., 2015, Davnall et al., 2012).  Texture feature-extraction methods such as 
those based on grey-level co-occurrence matrices (GLCM) can be applied to 
compute the probabilities of relative pixel intensities of images from the spatial 
distribution of their voxels (Haralick et al., 1973).  In discussing the advantages 
of applying texture analysis to DOS images, it is important to emphasize that 
the texture of the image carries important information about the images’ 
properties; specifically, between one pixel region to the next and giving insight 
about the “roughness”, “softness” or “smoothness” of the image itself.  In 
medical imaging, these qualities can help discern tumour heterogeneity which is 
represented by the biological measurements captured within the breast image 
(Gupta and Undrill, 1995). 
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There are several GLCM texture features but recently studied 
parameters in DOS include the following GLCM-textural features: contrast 
(con), correlation (cor), homogeneity (hom), and energy (ene).  These features 
are dependent on the number of grey-levels (Ng) in the image or within the 
region of interest (ROI).  Such techniques have been applied in computer-
assisted diagnostics in mammographic imaging and have been extended for 
use in several modalities, such as X-ray mammography (Li et al., 2005), MRI 
(Chen et al., 2007, Lerski et al., 1993), positron-emission tomography (PET) 
(Chicklore et al., 2013), and ultrasound (Yang et al., 2012).   Its use has also 
shown promising results for discriminating and characterizing tissue types 
(Castellano et al., 2004).  In breast studies, GLCM analysis has been able to 
classify benign and malignant lesions using planar (2D) and volumetric (3D) 
MRI images (Chen et al., 2007, Gibbs and Turnbull, 2003).  For X-ray 
mammography, GLCM analysis has been used to segment lesion borders of 
stellate (malignant) breast masses (Gupta and Undrill, 1995).  As previously 
shown, it was also reported that texture-based features from quantitative 
ultrasound (QUS) imaging can be used to classify responders and non-
responders early during NAC treatment (Sadeghi-Naini et al., 2014).  These 
previous findings suggested that textural features may detect the acute, 
heterogeneous microstructural features carried in the parametric layout not 
otherwise detected using the mean measurements (Sadeghi-Naini et al., 2014).    
 
4.2.8 Summary of Novel Contributions  
 
Novel contributions for Subproject One 
 
In terms of the novelty of the work presented in this thesis, there were three 
significant and new contributions in subproject one22: 
 
1. New DOS and QUS imaging marker signatures were identified for the 
first time, at early treatment time intervals (i.e. after one cycle of 
chemotherapy), by combining DOS and QUS parameters together in a 
                                            
22 A summary of published contributions for subproject one is presented in 
Appendix 4 and Appendix 5.   
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pairwise model; these included, MBF+HbO2, MBF+HbT, SI+HbO2, 
SI+HbT, SI+%Water, SS+HbO2, SS+HbT.   
 
2. Intra-treatment DOS and QUS parameters were used to demonstrate the 
likelihood of patients achieving pathologic endpoints, as defined 
systematically by Miller-Payne pathological response criteria, for the first 
time. This is novel compared to other QUS studies using radiological 
endpoints (Sadeghi-Naini et al., 2013b).   
 
3. Combining DOS and QUS parameters into pairwise models improved the 
classification performance compared to using the univariate parameters 
alone at early time intervals.  For example, the AUC of the QUS-SS 
parameter was 0.201 after one cycle (i.e. one week) of chemotherapy. 
The HbO2 AUC was 0.982 and the HbT AUC was 0.875; whereas 
combining the SS+HbO2 resulted in an increase of the AUC to 1.00 and 
the SS+HbT resulted in an increase of the AUC to 0.955.      
 
The coincident DOS and QUS parameters may have represented concurrent 
biological responses in the tumour.  The findings would suggest that the 
following coincident biological changes were processed in responsive tumours:  
1) tumour cell death; 2) haematological and vascular regression and; 3) tumour 
morphological changes (i.e. decreases in stromal and cellular properties) and 
thus suggests that tumour responses to cytotoxic agents involves multiple 
biological processes as mentioned above  (Coley, 2008). 
 
Novel Contributions for Subproject Two23 
 
In terms of novel work in subproject two, there were three new and significant 
contributions:  
 
1. For the first time, a tumour ROI-only GLCM analysis was completed on 
DOS tomographic images using machine learning classifiers.  The pre-
                                            
23 A summary of published contributions for subproject two is presented in 
Appendix 4 and Appendix 5.   
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treatment DOS parameters were studied using GLCM texture analysis 
and showed that for the first time, that there were significant differences 
between pathologic non-responders (MP1,2) and pathological 
responders (MP3-5) from DOS-texture features: Hb-homogeneity, HbO2-
correlation, total-haemoglobin-homogeneity, oxygen desaturation-
contrast, oxygen saturation-contrast.      
 
2. The second novel contribution included identifying DOS-texture 
signatures that could predict breast cancer response according to 
chemotherapy types; for FEC-D chemotherapy, the DOS-texture 
parameter, TOI-homogeneity demonstrated the highest predictive value 
(AUC=0.949), whereas the HbO2-homogeneity showed an optimal AUC 
of 0.896 for AC-T chemotherapy.        
 
3. The third novel contribution included analysis of DOS-texture parameters 
to characterize the likelihood of pathological response according to the 
tumour molecular subtypes. The results demonstrated for the first time, 
that the HbO2-homogeneity could optimally predict response in ER+ 
breast cancers (AUC=0.883) and that the Hb-homogeneity parameter 
could optimally predict tumour response in triple negative breast cancers 
(AUC=0.917).     
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4.3 DOS and QUS Clinical Translation 
 
4.3.1 Current Challenges for DOS and QUS Imaging as a Clinical Tool 
 
 Developing imaging biomarkers to produce a clinical decision-making 
tool (i.e. using biomarker information to guide and adapt treatments) requires 
several steps that begin with biomarker discovery, followed by validation in the 
clinical research setting.  Subsequently, further steps are needed to test the 
imaging biomarkers within heterogeneous tumour subtypes in order to 
determine if the biomarkers are generalizable.  These steps are referred to as 
the imaging biomarker pathway and this is analogous to the processes involved 
in clinical and translational research.  The similarities include moving laboratory-
based discoveries along a pipeline that is ultimately validated for either 
diagnostic or therapeutic interventions in patients and diseases (Drucker and 
Krapfenbauer, 2013, O'Connor et al., 2016).  The processes involved in the 
imaging biomarker pathway require a discussion about the current demand by 
physicians and patients for using imaging biomarkers as a clinical tool to help 
guide physicians and inform patients about the progress of chemotherapy 
treatments.  Also, it is pertinent to explore the challenges in study design and 
validation from laboratory testing to clinical implementation within the context of 
DOS and QUS imaging biomarkers.    
The clinical demand for imaging biomarkers, and thus using DOS and QUS 
in oncology, has been highlighted recently by a UK-based working group which 
identified critical research gaps and translational priorities for breast cancer.  
Their report highlighted the importance of exploiting both biospecimen-based 
markers and imaging for guiding breast cancer treatment.  Below are the major 
considerations outlined by their group (Eccles et al., 2013): 
 
1. Selection of therapies should be offered on an individual basis and 
using level one evidence.  Personalized treatments are the best 
approach.  Important considerations include optimizing the treatment 
time-course from individual tumour and patient data.  Currently, 
overtreatment is a clinical challenge. 
2. An assessment for the tumour’s underlying biology is essential.  
Tumour metrics may help assess the patient’s metastatic risk and 
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predict drug resistance.  The tumour’s behaviours from its cellular 
characteristics, molecular features, angiogenic pathways and stromal 
conditions (i.e. hypoxia, altered metabolism) may aid in understanding 
the impact on therapeutic interventions.  This may be achieved by using 
functional and metabolic medical imaging modalities.   
3.  Clinical decision-making tools will be integral in the management and 
treatment of breast cancer patients.  For example, imaging biomarkers 
could be used to predict prognosis and response to chemotherapy.  
Imaging modalities will permit potentially non-invasive, serial 
measurements that show the dynamic tumour changes over time.          
4. High risk populations include triple negative breast cancer patients and 
research needs to address prognostic and predictive biomarkers for this 
patient population.  In general, tumour heterogeneity is a treatment 
challenge and stratification of patients is needed in future studies for 
better treatment strategies.  
5. Both clinical and financial effectiveness should be considered while 
implementing new decision-making tools for clinical use.  
 
The need for biomarkers in medicine have been identified for decades.  In 
the early 2000s, the human genome project was completed to identify and map 
out thousands of genes in human cells (Cooper and Psaty, 2003, Chin et al., 
2011).   Since then, great efforts have been made in cataloguing and identifying 
gene signatures involved in disease progression, drug metabolism and 
treatment resistance across several disorders like cardiovascular disease, 
infectious diseases and cancer (Wang et al., 2011).  A major focus in genomic 
oncology has been to identify predictors for chemotherapy-resistance in breast 
cancer (Wang et al., 2011, Straver et al., 2010).  Indeed, thousands of genes 
have been studied as predictors to therapy response in cancer.  Yet, one 
notable example of these studies includes the validation of a 21-gene assay 
(Oncotype-DX) that predicts the probability of patients that would benefit from 
adjuvant chemotherapy.  The assay studies genes that have been shown to 
potentiate higher prognostic risk factors (Straver et al., 2010).  The 21-gene 
signatures included have undergone validation in over 10,000 patients.  The 
NSABP study B-14 trial demonstrated that Oncotype DX shown to predict 
recurrence in patients treated with Tamoxifen (Paik et al., 2004); while a parallel 
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study (NSABP study B-20) showed the benefit of the assay for predicting 
chemotherapy response (Paik et al., 2006).   Yet, a meta-analysis demonstrated 
variability in recurrence data between 23 studies and there were concerns over 
the test’s generalizability (Straver et al., 2010, Carlson and Roth, 2013).   
Patients who had intermediate risk breast cancer were not shown to benefit 
from Oncotype DX and it was also shown that only a subset of breast patients 
benefits from the assay; namely, in hormone-receptor-positive, HER2-negative, 
axillary node-negative breast cancer (Sparano et al., 2015, Carlson and Roth, 
2013).  The Oncotype-DX assay is one example of how biomarker discoveries 
have been adopted by clinicians to guide treatment.  It also demonstrates that 
biomarkers themselves may not be generalizable for all breast cancer subtypes 
and that it may not be suitable for all patients.  To date, no imaging biomarkers 
(excluding imaging tumour size) have reached the clinical adoption stage 
equivalent to biospecimen-based markers to monitor or predict breast cancer 
response to neoadjuvant chemotherapy.  The reasons for this are because 
imaging biomarkers have yet to undergo large-scale clinical studies and the 
availability of imaging technologies across geographical regions is still limited 
due to their high costs.  Additionally, advancing the use of imaging biomarkers 
also requires personnel expertise that are not always available (O'Connor et al., 
2016).  Thus, despite great efforts to investigate imaging biomarkers for clinical 
use, many studies involving novel imaging methods have not surpassed initial 
research hypothesis testing; thus, never reaching large-scale clinical trials for 
robust validation and translation into the clinic.  In fact, emerging research that 
could potentially guide treatments often fall through translational gaps, defined 
as not sufficiently meeting the following criteria and stages below (O'Connor et 
al., 2016).    
 
Discovery 
  
This involves the identification, selection and derivation (i.e. calculation) 
of imaging biomarkers from the imaging modality.  Biomarker discovery can be 
driven by computer-assisted technologies that permit high computing tasks, 
such as spectral analysis for MRI, CT or US data, which was not possible 
before the recent developments in high-throughput computing.  Other examples 
of extracting imaging biomarkers include the development of mathematical 
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models, for example using texture analysis that emerged in the 1970s (Haralick 
et al., 1973).  Only after several years, has texture analysis of medical images 
been applied to modern imaging from MRI and ultrasound.  Thus, biomarker 
discovery is dependent on technological advances and imaging constraints 
such as resolution and sensitivity of the detection system (e.g. detection of 
radiotracers).    
 
Technical Validation  
 
This stage involves ascertaining the repeatability and reproducibility of 
the imaging biomarkers.  Repeatability validation involves measuring the 
imaging biomarkers from the same subject (i.e. patient), equipment, software 
and by employing only one operator to ensure that the measurements are 
similar from one test series to the next.  In contrast, reproducibility uses the 
same subject or multiple subjects, tests multiple imaging devices of the same 
technology, studies the measurement accuracy with different users, or uses 
various software.  Reproducibility can be evaluated by conducting studies at 
multiple clinical research sites.  Also, system- and user-dependent errors can 
cause technical biases, defined as the difference between the measured 
biomarker value and the true value for example, the concentration of a 
substance such as oxy-haemoglobin in tissue (Kessler et al., 2015).  These 
biases must be reduced within the study design and can be achieved by 
conducting experiments in phantoms where the measurements can be 
confirmed based on reference values known about the phantom’s imaging 
properties (O'Connor et al., 2016).     
Lastly, technical validation requires that the imaging biomarkers are 
tested for safety for the intended patient population.  For example, important 
safety considerations include assessing if the imaging modality can induce 
harmful biological changes (e.g. ionizing radiation causing genetic mutations) or 
if the imaging procedure causes other health risks or effects (i.e. nausea, 
physical discomfort, allergies).   Subsequently, as the studies become validated 
for safety, approval for its use in patients must be obtained from the appropriate 
regulatory bodies such as, Health Canada, The Food and Drug Administration 
of the United States (FDA), or The Medicines and Healthcare Products 
Regulatory Agency of the United Kingdom (MHPRA).  
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Biological Validation, Clinical Validation and Evaluation of Clinical Utility  
 
 Biological validation confirms that the imaging biomarker represents an 
underlying biological process, for example, measuring the rate of apoptosis in 
tumour cells that have been treated with chemotherapy.  An extension of 
biological validation is clinical validation, which is defined as evidence of a link 
between the measured imaging biomarkers and the clinical outcomes, such as 
pathology endpoints (i.e. pathological complete response , defined as a 
complete disappearance of tumour cells after chemotherapy).  Biological and 
clinical validation lead to building evidence for clinical utility which evaluates the 
clinical benefits of using the imaging biomarkers in patient care.  Clinical utility is 
measured by improvements in patient outcomes, such as longer survival 
periods (i.e. >5-year intervals); or by optimizing the therapeutic effect by 
choosing therapies that are indicated for specific tumour types, for example 
using antivascular drugs in tumours where imaging biomarkers indicate high 
vascular density.  Recommendations and guidelines to achieve robust clinical 
validation were previously outlined by the National Cancer Institute and the 
European Organization for Research and Treatment of Cancer (NCI-EORTC) 
(McShane et al., 2005).  The NCI-EORTC guidelines made recommendations 
such that results could be compared across multiple studies and that 
conclusions could be drawn from multiple studies with the same imaging 
objectives.  The recommendations included the following highlights (McShane 
et al., 2005):    
1. Describing the clinical characteristics of patients (i.e. age, sex, disease 
stage, and the disease laterality where relevant, such as breast 
cancer). 
2. Indicate all treatments to patients. 
3. The method for case selection (inclusion and exclusion criteria) and 
stratification of disease types. 
4. Precisely defining the clinical endpoints, for example, pathologic 
complete response (pCR) and indicate the standard grading systems 
used.  If the endpoints are survival, the survival data should include 
time intervals from at least 3-5 year intervals (O'Connor et al., 2016).   
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5. Indicate the statistical methods used.  This includes an analysis of the 
relation of the imaging markers to the endpoints, as defined within the 
study.   
Lastly, for clinical validation and clinical utility, a consensus statement that 
includes all disciplines (medicine, scientific, technical) should be developed to 
establish standard imaging protocols that can be used and adapted across any 
treatment site (O'Connor et al., 2016).   
 
Cost Effectiveness Analysis 
 
 Using imaging biomarkers should be aimed for cost-savings to the 
healthcare system.  Using imaging biomarkers to guide chemotherapy and 
adapt treatments could potentially confer an economic benefit since imaging 
biomarkers could potentially identify ineffective chemotherapies; therefore, 
eliminating unnecessary treatments.   Additionally, in cases where tumours are 
highly responsive, the number of chemotherapy cycles could be potentially 
reduced since the desired therapeutic effect may be achieved earlier than 
conventionally scheduled treatments.  In developing imaging biomarkers, it is 
important to consider that the costs of imaging should not exceed the cost of 
the therapy or medical procedure itself.  Cost effectiveness analysis also 
includes a careful evaluation of the research costs associated with developing 
the imaging biomarkers.  Imaging studies are by its inherent nature, very 
expensive to conduct since there are high costs associated with imaging 
equipment.  With the expenses associated with high equipment costs, and the 
considerable research time involved in developing imaging biomarkers, 
translating imaging biomarkers to clinical implementation are a very costly 
endeavour (O'Connor et al., 2016).  
 
Conclusions of Biomarker Discovery Pathway 
 
Taken together, integrating and using imaging biomarkers in clinical 
practice requires robust marker validation through single- and multi-institutional 
testing, establishing the generalizability of the tests to the patient population 
and cost effectiveness analysis to demonstrate that the imaging biomarkers will 
have an economic benefit to the healthcare system (O'Connor et al., 2016, 
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Eccles et al., 2013).  These translational stages and the associated challenges 
are discussed further below with respect to the status of DOS and QUS imaging 
within the imaging biomarker development pathway.     
 
4.3.2 Status of DOS and QUS Biomarkers for Breast Cancer Treatment 
 
 The status of DOS and QUS imaging biomarkers have not reached 
clinical implementation for locally advanced breast cancer, i.e. clinicians are not 
currently using DOS and QUS as clinical decision-making tools for guiding and 
adapting chemotherapy treatments in locally advanced breast cancer.  To date, 
the advantages of using DOS and QUS imaging biomarkers have been well 
established for locally advanced breast cancer, which include: 1) non-invasive 
imaging; 2) minimal risk for adverse reactions because contrast agents are not 
required; 3) no exposure to ionizing radiation; 4) lower-cost instrumentation that 
permit serial imaging during chemotherapy; and 5) whole-tumour analysis that 
permits measurements across the heterogeneous tumour volume.  Despite 
these advantages, DOS and QUS studies to date have not undergone sufficient 
validation and large-scale studies to have gained physician confidence to use 
as a clinical decision-making tool, i.e. to adapt treatments based on the imaging 
biomarker information provided by DOS and QUS.  The criteria considered for 
the imaging biomarker development pathway are outlined below with respect to 
DOS and QUS.  
 
DOS and QUS Biomarkers Discovery 
 
 Previous DOS imaging biomarker discoveries originated from continuous 
wave, time-domain and frequency-domain imaging techniques that emerged in 
the 1990s (Tromberg et al., 2008).  DOS biomarker discoveries at that time 
included measurements of intrinsic (i.e. naturally occurring) optical absorbers 
that could be used to characterize tissue components and optical scattering 
(previously outlined in Chapter 1) (Tromberg et al., 2008).  The present status of 
DOS imaging biomarkers, in terms of new discoveries, has shown new DOS 
biomarker discoveries that measure metabolic activity.  These include the 
bound water index (BWI), which measures the quantity of bound water 
molecules to macromolecules such as protein (Chung et al., 2008). Kukreti et 
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al. (2010) identified another new imaging biomarker, termed the specific tumour 
component parameter (STC).  The STC is capable of characterizing tissue 
types by comparing the spectral patterns, i.e. the shape of the absorption 
spectral form between normal breast tissue and tumours  (Kukreti et al., 2010).   
To date however, the BWI and STC have not been used to measure 
chemotherapy response in breast cancer.  It is also important to mention 
discoveries in exogenous fluorophores (i.e. probes that emit light after optical 
excitation) used as DOS imaging biomarkers.  Exogenous agents in DOS 
imaging (within the near-infrared spectrum, NIR) include excitable fluorescent 
agents (NIR-EFAs) (Sevick-Muraca et al., 2002).  Examples of NIR-EFAs 
include tricarbocyanine dye, which absorb NIR wavelengths at ~800-840 nm.  
Tricarbocyanine dye is readily taken up by blood albumin and thus can serve as 
a vascular tracer, but has not been found to be useful in cancer studies 
(Richards-Kortum and Sevick-Muraca, 1996).         
Other recent DOS discoveries are using texture-based analysis which 
can yield hundreds of texture parameters from the DOS parametric layout.  The 
number of possible texture features is dependent on the statistical technique 
used such as: 1) histograms; 2) absolute gradients; 3) run-length matrix, 4) 
auto-regressive model; and 5) wavelets (Castellano et al., 2004).  Recently, 40 
additional texture features were yielded from GLCM analysis of DOS breast 
images (Sadeghi-Naini et al., 2015).     
 Previous QUS biomarker discoveries include parameters from the 
spectral form of the backscatter signal, which was first introduced by Frederic 
Lizzi in the 1970s (Mamou and Oelze, 2013, Feleppa et al., 2011).  Subsequent 
works by Insana et al. (1990) continued to develop spectral analysis to obtain 
parameters that represented the scatterer properties, i.e. size, concentration 
and distribution of scattering particles in tissue, by using estimates of the 
backscatter co-efficient from the power spectra (Insana and Hall, 1990).  The 
present status of QUS imaging biomarkers, in terms of new discoveries, involve 
improvements in mathematical models that estimate the size and concentration 
of scatterers in tissue (Oelze and Mamou, 2016).  Other innovative techniques 
are using texture-based analysis as previously described with DOS features 
above (Sadeghi-Naini et al., 2014).     
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DOS and QUS Technical Validation 
 
 In terms of technical validation, both DOS and QUS imaging biomarkers 
have been tested in laboratory studies for decades, thus having shown 
repeatability and robust methodologies in measuring and extracting biomarkers 
from biological specimens (Feleppa et al., 2011, Tromberg et al., 2008).  
Indeed, the evidence supporting the reliability of DOS imaging measurements 
has led to commercially available DOS mammography systems manufactured 
from Imaging Diagnostic Systems, (Florida, USA), Philips Healthcare 
(Amsterdam, Netherlands) and Advanced Research Technologies (Montreal, 
Canada, currently discontinued) (Leo et al., 2017). However, these devices 
have been classified under regulatory bodies for use in diagnostic 
mammography and are not indicated for evaluating treatment response.  
Similarly, ultrasound imaging systems are ubiquitous in radiology clinics, but are 
not yet approved for using QUS imaging biomarkers for treatment response 
assessment.    
 Validating the utility of DOS and QUS imaging biomarkers for 
chemotherapy response evaluation is still in its research phase.  A limitation of 
translating these imaging biomarkers into clinical implementation is the need to 
validate the data reproducibility through multicentre clinical trials.  This was 
identified in the early 2000s for DOS imaging in which the National Cancer 
Institute (NCI) initiated a consortium of health institutions, physicians and 
scientists to further develop DOS imaging for breast cancer (Network for 
Translation Research for Optical Imaging, NCI-NTROI) (Clarke et al., 2003).  
The NCI-NTROI is currently supporting multicentre trials in the United States by 
funding core institutions at Washington University, University of Texas, 
University of Michigan, and Stanford University.   Other networks include the 
American College of Radiology Imaging Network (ACRIN).  The ACRIN 6691 
trial was completed in 2013 and included six clinical research sites across the 
USA (Tromberg et al., 2016).  The aim of the ACRIN 6691 trial was to measure 
intratreatment chemotherapy response in LABC patients at the following time 
intervals: pre-treatment,  5-10 days after the first cycle, mid-therapy, and before 
surgery (American College of Radiology Imaging Network, 2017).  The study 
however, only reported evaluable cases of only 34 patients; thus, not having 
sufficient statistical power to translate the results for clinical implementation 
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(Tromberg et al., 2016).  To date, the ACRIN 6691 trial is the only DOS-based 
multisite trial for LABC response evaluation.   
 QUS studies for measuring chemotherapy response in LABC is currently 
led by the University of Toronto (Ontario, Canada).  Studies to date have only 
indicated results from single-institution trials.  However, for other disease types 
such as prostate cancer, and for the purpose of diagnostics, QUS trials have 
been conducted at other institutions led by Riverside Research (New York, 
USA) (Feleppa et al., 2011).    
 
DOS and QUS Biological Validation and Clinical Validation 
 
DOS measurements to quantify biological chromophores in tissue, such 
as haemoglobin, lipids and water are based on mathematical modelling that 
uses a photon transport model and diffusion theory24 (Dehghani et al., 2009, 
Gibson et al., 2005).  Biological and clinical validation studies using DOS have 
indicated that DOS measurements for haemoglobin are linked to vascular 
abundance in tumours and can serve as indicators for final pathologic endpoints 
such as pCR at mid-treatment (Choe et al., 2005, Cerussi et al., 2007, Cerussi 
et al., 2011).  There are previous studies that have shown a correlation between 
DOS imaging parameters and tissue features, as tested histologically (Pogue et 
al., 2001). Pakalnikis et al. (2011) reported that the total haemoglobin measured 
in breast tumours (HbT=45 µmol/L) was significantly correlated (p=0.001) with 
the tumour’s vascular density as measured using histology (CD105 blood 
vessel staining) (Pakalniskis et al., 2011).  Similarly, data by Zhu et al. (2008) 
demonstrated a nearly significant correlation (P=0.056) between DOS-
measured HbT and vascular density, as stained with CD-31 in the post-
treatment breast samples (Zhu et al., 2008).  
 For QUS studies, biological validation was completed both in vitro and in 
vivo.  Previous in vitro experiments demonstrated an increase in QUS 
parameters which corresponded to an increase in apoptosis in acute myeloid 
leukaemia cells treated with chemotherapy (Czarnota et al., 1999, Kolios et al., 
2002).  Also, Brand et. al (2008) showed that other cancer cell types such as, 
                                            
24 These models are used to determine the scattering and absorption co-
efficient to measure tissue parameters.   
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HeLa (human cervical cancer) cells treated with chemotherapy were linked to 
an increase in QUS features (SI and MBF) (Brand et al., 2008)  In vivo studies 
used mouse models that were transplanted with human breast tumours; 
Tadayyon et al. (2015) showed that QUS biomarkers, such as the average 
acoustic concentration (AAC) were correlated to increases in cell death, as 
demonstrated in histological analysis of excised tumours (r2=0.40) (Tadayyon et 
al., 2015).  Similarly, Sadeghi-Naini et al. (2013) showed that texture analysis of 
QUS parameters (MBF, SI) demonstrated a high correlation (r2=0.97) to cell 
death using the same experimental mouse and treatment model (Sadeghi-Naini 
et al., 2013a).  
 
DOS and QUS Cost-Effectiveness Analysis 
 
 A recent study demonstrated that Americans pay about $34,000 USD per 
chemotherapy visit for drugs and medical care to treat advanced breast cancer 
(i.e. stage 3) (Blumen et al., 2016).  Over the entire course of the chemotherapy 
treatment, over $200,000 USD would be spent for 6-8 chemotherapy cycles.  
Indeed, the cost of health care is dramatically lower in Canada and the United 
Kingdom; a study by Hall et al. (2015) reported significantly lower costs for the 
entire chemotherapy treatment for breast cancer, on average, approximately 
£16,000 GBP (Hall et al., 2015).  It can be appreciated that there is a huge 
economic problem when ineffective chemotherapies are given to cancer 
patients.  Therefore, using imaging biomarkers to evaluate the efficacy of 
chemotherapy, i.e. prognosticate if the tumours will respond to treatment, has 
an enormous economic benefit to the health system.    
To date, no cost-effectiveness analysis has been completed for QUS 
imaging.  However, Schegerin et al. (2009) previously analysed the cost 
effectiveness of prognostic DOS imaging in LABC patients treated with 
neoadjuvant chemotherapy (Schegerin et al., 2009).  The cost-effectiveness 
model was used to test if implementing DOS in the patient’s chemotherapy 
treatment would be cost-beneficial and included the following variables in their 
cost-model:     
1. The cost of the device (operational and capital) 
2. The chemotherapy treatment course 
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3. The prevalence of chemotherapy response in women, defined as 
pathologic complete response.  
4. The sensitivity and specificity of the imaging device and the 
potential gains in lives saved from adapting treatment based on 
biomarker information. 
5. The life expectancy of patients   
 
The results of their study indicated that a device cost of $1M for a DOS 
system would be cost-effective under the condition that DOS imaging could 
increase the cure rate by at least 1%, and that chemoefficacy rates would not 
exceed 90% (i.e. there is no utility for using DOS imaging biomarkers to guide 
treatment if chemotherapies are already effective) (Schegerin et al., 2009).       
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4.4 Potential Impact to Patient Care 
 
The body of research to support using DOS and QUS imaging 
biomarkers by physicians to evaluate breast tumour response to NAC is limited 
by small datasets (i.e., not enough patients for sufficient statistical power), 
variable imaging protocols and identifying biomarkers that yield an optimal 
correlation to final pathologic endpoints such as, Miller-Payne grade or the 
Residual Cancer Burden Index.   
However, using DOS and QUS parameters to accurately screen patients 
either before or during chemotherapy for treatment endpoints such as, pCR and 
partial pathologic response (pPR) can be achieved by increasing multicentre 
studies with sufficient power and sample size.  This will also lead to identifying 
salient DOS and QUS imaging biomarkers that can be used clinically; in 
contrast to the current status, where there are hundreds of experimental DOS 
and QUS imaging biomarkers available for analysis.  Before clinical 
implementation, it is also important to develop a consensus statement from an 
expert panel that may include imaging scientists, radiologists, oncologists, 
nurses and technicians.  This multidisciplinary approach will result in compiling 
a standard imaging protocol that outlines the imaging procedures, interpreting 
test cut-off points and optimal imaging time intervals.  This will effectively 
establish a decision-making algorithm that outlines how physicians would use 
DOS and QUS biomarker information to guide their treatment decisions.   The 
potential impact of prediction-guided and response-adaptive chemotherapy 
treatments could significantly improve treatment outcomes for patients, for 
example, increased pCR rates and improved patient survival from more 
efficacious treatments.  The approach by which treatments are customized for 
each individual based on biological and patient-based information is termed 
personalized medicine.         
  
4.4.1 Using Biomarkers to Make Treatment Decisions for Personalized 
Medicine 
 
 Personalized medicine refers to using biological, imaging, or individual 
patient characteristics to customize and administer the most precise diagnostic 
procedure or therapeutic intervention in medicine.   Personalized medicine is 
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predicated on gathering the most sensitive, specific and individualized 
information obtainable. Indeed, access and availability of useful and meaningful 
information (i.e. biomarkers) is the rate limiting factor since biomarker discovery 
and validation is highly dependent on the available technology. 
In current oncology practice, treatments that are given to patients are to 
some degree personalized, for example, tailoring the chemotherapy dose based 
on the patient’s height and weight, or discontinuing chemotherapy due to a 
patient’s low blood counts or other toxicities.  Medical imaging continues to play 
an important role in personalized treatments in other specialties like radiation 
oncology.  Imaging modalities like CT, MRI, and PET are being used in the 
clinic to map tumour response (i.e. size changes, and metabolic data) during 
radiation treatments and the information is used to adapt radiation treatment 
plans to conform to the dynamic changes in the tumour (Metcalfe et al., 2013).  
For personalized treatment in locally advanced breast cancer, existing methods 
include collecting tissue samples to extract biomarkers such as HER2-
expression.  Tailored treatments for HER2-overexpressed tumours (i.e. HER2+) 
include prescribing targeted therapies such as Trastuzumab.  Other biomarker 
screening approaches include testing for oestrogen-receptor positive (ER+) 
tumours, where endocrine therapies are administered to increase the 
therapeutic efficacy.  In these examples, biomarkers can be used to personalize 
drugs and the treatment course for patients; yet the challenge currently is to 
also understand if anticancer therapies are optimally effective.  Within this 
framework, biomarkers can be used in three ways to personalize treatment 
(below).  Understanding the different biomarker types will facilitate the 
discussion on the potential and future impact of DOS and QUS biomarkers for 
personalized treatments for patients with locally advanced breast cancer  
(Hricak, 2011): 
 
1) Prognostic biomarkers:  Indicators for the likelihood of the tumours 
to progress (i.e. identifies aggressive disease) without considering 
treatment interventions.  Population-based statistics can be used to 
identify prognostic biomarkers, for example, observing biomarkers for 
high proliferation (Ki67) and the prevalence of aggressive cancers 
within the sample population.     
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2) Predictive biomarkers: Predictive biomarkers indicate the probability 
of the tumour’s response to treatment (usually before treatment), for 
example, tumours with biomarkers for hypoxia are susceptible to 
chemoresistance.    
3) Early-response biomarkers:   Early response biomarkers are 
collected during the treatment course and indicates the likelihood of 
the tumour’s response to the post-treatment gold-standard 
assessment.   For example, breast tumours could be measured using 
DOS after the 2d cycle of chemotherapy and the output parameters 
are used to statistically evaluate a link to pathologic complete 
response in the tumour.        
 
Potential Impact to Patients: Confirming chemotherapy response before and 
during treatment using DOS and QUS imaging biomarkers 
 
Not all patients are good candidates for chemotherapy because of 
tumour heterogeneity.  The response to chemotherapy can influence the 
subsequent treatment course for patients, as outlined by the NCCN (USA) or 
NICE (UK) (National Comprehensive Cancer Network, 2016, National Institute 
for Health and Care Excellence, 2017, National Institute for Health and Clinical 
Excellence (NICE), 2009b, National Institute for Health and Clinical Excellence 
(NICE), 2009a) (Figure 4.2).  Since these standard therapies are not always 
effective, clinicians are interested in confirming chemoefficacy for their patients 
either before or during treatment.  To address this problem, this study 
demonstrated that DOS and QUS imaging biomarkers were potentially useful as 
either predictive biomarkers or early-response biomarkers in LABC.   Here, pre-
treatment DOS parameters were shown to be predictive biomarkers for 
chemotherapy response; whereas both DOS and QUS were modelled as early-
response biomarkers (i.e. intratreatment response evaluation).  The potential 
impact to patients by using DOS and QUS imaging biomarkers could 
personalize the patient’s treatment course by mapping out the best therapy at 
the early onset of treatment planning.  Additionally, serial DOS and QUS 
measurements during chemotherapy can provide physicians with real-time 
“feedback” to confirm that the treatment is appropriate for the patient and that 
the course can continue as planned.   
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 In comparison to other biomarker technologies, predictive biomarkers 
using genes, are currently personalizing the treatment course for patients with 
early stage breast cancer who undergo surgery first, then are considered for 
chemotherapy (Straver et al., 2010).  Predictive biomarkers include the 
MammaprintTM assay, which is a clinically validated assay that extracts 70 gene 
markers from the surgical tumour specimen.  The MammaprintTM assay 
provides physicians with an analysis about the potential risk of breast tumour 
recurrence.   Doctors use this analysis to decide on the potential benefit of 
patients receiving chemotherapy since the risk of recurrence is also linked to 
lower chemosensitivity and more aggressive tumours (Straver et al., 2010).  
The MammaprintTM test provides a framework for using pre-treatment DOS 
biomarkers to non-invasively evaluate LABC patients before chemotherapy to 
test if there is a potential clinical benefit for patients.  As can be seen in Figure 
4.1, patients who do not respond to chemotherapy in their “first-line” may go on 
to receive additional chemotherapy.  DOS and QUS imaging biomarkers could 
also be used to assess the potential clinical benefit during each phase of 
treatment.     
 It should be noted that other markers such as the tumour’s grade are 
associated with pathological response to neoadjuvant chemotherapy (Huober et 
al., 2010).  Research from the GeparTrio trial investigated 2,072 breast cancer 
patients treated with neoadjuvant anthracycline-taxane chemotherapy.   The 
results showed a higher pCR rate in grade three tumours (211 patients, 28.1%) 
compared to grade one and grade two tumours (156 patients, 13.0%, p<0.001) 
(Huober et al., 2010).  The results of the study suggest that there are several 
biological and clinical variables that are involved in tumour response; thus, 
using this framework as a guiding principle for well-designed clinical trials can 
significantly improve the quality of imaging biomarker research.  Such 
frameworks could include stratifying patients by initial tumour grade, hormone-
receptor status or by tumour size at the time of diagnosis.     
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Figure 4.1.  LABC patients are treated using a complex treatment decision-tree 
as outlined by the NCCN (USA) and NICE (UK). For patients who do not 
respond to first-line chemotherapy, additional chemotherapies may be given, or 
other targeted therapies (e.g. endocrine therapy) may be offered.  
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4.4.2 Adapting Chemotherapy Dosing Schedules to Optimize Tumour 
Response and Survival Outcomes 
 
 Using DOS and QUS as early-response biomarkers could help adapt 
chemotherapy doses (i.e. frequency of dose scheduling) according to tumour 
response.  Tumours that demonstrate early response could be given fewer 
chemotherapy cycles in contrast to non-responding tumours that could be 
recommended for more chemotherapy.  Adapting the chemotherapy dose 
according to response using information from radiology, biomarkers, or physical 
examination is called response-guided therapy (von Minckwitz et al., 2013).  A 
recent phase three randomized study (GeparoTrio) from the German Breast 
Group recently reported an increase in survival for patients who underwent 
response-guided neoadjuvant chemotherapy in breast cancer (von Minckwitz et 
al., 2013).  The GeparoTrio study included analysis of 2,072 breast cancer 
patients who received neoadjuvant chemotherapy.  In this study, the standard 
chemotherapy was defined as 6 cycles of anthracycline-taxane (TAC).  Patients 
were assessed as early responders or early non-responders using conventional 
ultrasound; early responders were defined as a having a reduction of at least 
50% of the tumour size after the second cycle of chemotherapy.  Early 
responders were then randomized into two arms. In the first arm, patients 
completed the conventional chemotherapy (6 cycles of TAC in total).  In the 
second arm (response-guided arm), patients were given two additional TAC 
chemotherapy cycles (8 cycles total).  For early non-responders, patients were 
randomized to receive the conventional chemotherapy (6 cycles of TAC) in the 
first arm; whereas the response-guided arm, patients were switched to other 
chemotherapy types (vinorelbine and capecitabine) for 4 cycles (von Minckwitz 
et al., 2013).  There were two significant outcomes from this study:  
 
1) Early response group: Patients that were randomized to the response-
guided treatments (i.e. 8 cycles of TAC) compared to those in 
conventional treatments, had better survival outcomes (Hazard ratio, 
0.78; P=0.026).            
2) Early non-response group:  Patients that were randomized to the 
response-guided treatments (2 cycles of TAC, then switched to 4 cycles 
of vinorelbine and capecitabine) lived longer compared to patients who 
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were randomized to receive the conventional treatment (Hazard ratio, 
0.59; P=0.001).      
 
The results presented by the German Breast Group suggested that response-
guided, and response-adapted chemotherapy may improve survival outcomes 
for patients.  Their study has also opened potential opportunities for further 
studies on using imaging biomarkers to guide chemotherapies, instead of using 
conventional imaging (e.g. grey-scale ultrasound) that was used previously to 
guide treatments (von Minckwitz et al., 2013).  Using imaging biomarkers such 
as from DOS and QUS during treatment, that are more sensitive and specific 
compared to conventional imaging, could thus optimize treatment endpoints 
such as survival, for both responding and non-responding patients.  In terms of 
adapting the GeparoTrio study’s framework into the current study, using DOS 
and QUS imaging biomarkers after two cycles of chemotherapy (in this present 
study, indicated as “Week 4”), could potentially impact patients by 
intratreatment response monitoring and by administering either more 
chemotherapy or adjusting the types of chemotherapies that could increase the 
therapeutic index.        
 
4.4.3 Potential Applications for Chemotherapy Drug Trials 
 
 Each year, approximately 10,000 new biochemical compounds are 
identified for potential drug development. It costs $800,000 million USD to 
develop the compounds into pharmaceutical agents which includes extensive 
testing and validation along the development pipeline (Willmann et al., 2008).  
DOS and QUS imaging biomarkers can be a cost-effective validation tool to test 
drug effectiveness and safety.  Implementing DOS and QUS imaging 
biomarkers during animal and human testing can help measure the biological 
effects of anticancer drugs such as cell death, vascular regression and changes 
to tissue composition (Pien et al., 2005).   DOS and QUS imaging biomarkers 
could be used along-side traditional evaluation methods such as biospecimen-
based immunohistochemistry to help identify and select those compounds that 
demonstrate a high therapeutic potential.  The impact to patient care includes 
expediting the drug-development process to bring new anticancer drugs to 
patients faster (Rudin and Weissleder, 2003).  Increased use of imaging 
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biomarkers in the drug development process has resulted from technological 
advances; for example, the ability for radiolabelled PET imaging to measure the 
accumulation of candidate drug compounds in tissue and permitting 
pharmacokinetic measurements (Pien et al., 2005).  Other methods, such as 
MRI have also been used to measure the reduction in the tumour blood flow 
and changes to the vascular volume from testing anti-vascular drugs (O'Connor 
et al., 2008).     
 The specific uses for DOS and QUS imaging biomarkers in cancer drug 
development include investigating drug effects in pre-clinical (i.e. animal) 
models to detect the cellular and physiological characteristics of tumours 
treated by the new drug compounds.  Previous animal experiments using 
xenografted human tumours have shown that QUS imaging biomarkers could 
be used for high resolution tumour imaging (50 microns), and that the spectral 
parameters were correlated to an increase in tumour cell death after 24 hours of 
treatment from radiation, chemotherapy and novel antivascular agents, such as 
microbubbles  (Vlad et al., 2011, Sadeghi-Naini et al., 2013a, Tran et al., 2016).   
Thus, QUS analysis of new drug candidates in animal models could permit non-
invasive and serial imaging of tumours to understand the effective doses 
needed to achieve a useful therapeutic index in tumours.  For applications in 
drug development trials in humans, the work presented in this present study 
could provide a framework to monitor tumour responses to new drug 
compounds and could provide a useful adjunct tool to assess the physical 
properties that are related to tumour cellularity.  To demonstrate other important 
tumour-response features such as vascular density, DOS imaging can play an 
important role in clinical trials by measuring the effects of new drugs to the 
tumour vasculature.  Other parameters such as the scattering power could be 
used to measure the tumour cellularity and the models presented in this current 
study could be used to measure the intratreatment response.  Therefore, DOS 
(like QUS) can also evaluate important resistance factors in tumours such as 
hypoxia and interstitial fluid and this can potentially affect the validation and 
interpretation of results in drug trials, not otherwise detectable serially using 
traditional invasive procedures such as biopsies.     
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4.5 Study Limitations 
 
4.5.1 Sample Size 
 
Limitations for subproject one included a small study (n=22 patients), 
which could have resulted in an overestimation of the sensitivity and specificity 
and this is an inherent statistical limitation.   For subproject two, a small sample 
size of n=37 was also an important limitation to the subproject in terms of 
statistical testing, i.e., the statistical test of significance was performed with a 
relatively small sample size in each responding group (n1 = 27 and n2 = 10) 
(Siegel and Castellan, 1988, de Winter, 2013). To evaluate the reliability of the 
performed tests, the statistical power was calculated using PASS14 (NCSS, 
LLC. Kaysville, Utah, USA).  As can be seen from the results, the statistical 
power for the statistically significant parameters varied between 71.8% and 
85.6%. This was one of the limitations of this study, as a threshold of 70% was 
chosen for the statistical power, instead of a commonly used threshold of 80%. 
By fixing the number of responders (n1 = 27), we have also estimated the 
number of non-responders (n2) required to achieve a minimum statistical power 
of 80%.  Analysis showed that at minimum, 4 additional non-responders were 
needed to achieve an 80% statistical power. This change would permit stronger 
conclusions to be drawn from this subproject.  This limitation could have been 
addressed by approaching the study in two ways: 1) increasing the recruitment 
period in order to enrol four non-responders using the chosen Miller-Payne 
response criteria or; 2) redefining the ground-truth labels; i.e. a modified cut-off 
point in the Miller-Payne grade to classify responders and non-responders.     
 
4.5.2 Sample Heterogeneity 
 
 Patient-related factors that could affect DOS measurements include 
increased body mass index (BMI25), higher breast density, and the larger 
breasts for imaging (Srinivasan et al., 2003, Intes, 2005, O'Sullivan et al., 2013).  
A study by Srinivasan et al. (2003) showed a significant negative correlation 
                                            
25 Body mass index (BMI) was not recorded in the patient’s medical record. 
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(p<0.05) between BMI and the total haemoglobin, breast size and the scattering 
amplitude, and age with the scattering power (Srinivasan et al., 2003).  Also, 
women with radiologically dense breasts showed an increase in the scattering 
power and scattering amplitude (Srinivasan et al., 2003).  The results of these 
studies demonstrate some potential limitations in the present study in terms of 
breast and patient heterogeneity that can affect the DOS measurements.  
However, the advantage of using the DOS tomographic device in the present 
study is the ability to apply a soft compression to the breast, as to maintain an 
equal breast thickness during the scanning process to mitigate the scattering 
effects from light transport across larger distances in the breast.          
 Patients included in this study also demonstrated differences in 
molecular features (oestrogen receptor, progesterone receptor, and HER2 
status).  The major limitations to tumour heterogeneity include patients who 
were HER2+, who also received Trastuzumab during their second phase 
(taxane) therapy.  Improved treatment response has been observed in HER2+ 
patients for two reasons: 1) HER2+ tumours are highly responsive to 
anthracycline and taxane chemotherapies and; 2) data from the German Breast 
Group (GeparoQuattro trial) showed that targeted therapies given in the 
neoadjuvant setting, such as Trastuzumab, demonstrate a 16% increase in pCR 
rates in breast cancer treatment (Untch et al., 2010, Andre et al., 2008).  
Therefore, the major limitations in having variable tumour subtypes within the 
study population, and the consequences of variable responses within these 
tumour subtypes can affect the DOS and QUS measurements.   
 
4.5.3 Pathologic Endpoints (Ground Truth Labels) 
 
 Another limitation in this study included classifying patients into binary 
response categories (i.e. responders versus non-responders) and this approach 
was necessary for statistical modelling.  However, in clinical practice, tumours 
do not respond to chemotherapy in a binary mode; rather, tumour response to 
chemotherapy is dynamic and graded within a continuum, i.e. there is a 
spectrum between pathological complete response (pCR), to partial response, 
to progressive disease (Marchio and Sapino, 2011).  There is added complexity 
since other classification systems such as the residual cancer burden index 
(RCBI) and TNM system (tumour, node, metastasis) include lymph node status 
 269 
within their definitions of pathological complete response and in pathological 
complete response (Symmans et al., 2007, von Minckwitz et al., 2012).   Some 
response criteria, such as the RCBI and TNM are useful endpoints since those 
scores have been linked also to long-term survival in some cancer subtypes 
such as triple negative breast cancers and HER2+ breast cancers (Symmans et 
al., 2007, von Minckwitz et al., 2012).    
 In this study, Miller-Payne (MP) response criteria was used.  As 
previously discussed in Chapter 2 (Methods), Miller-Payne response criteria is a 
five-scale system that measures the reduction in cellularity from before and 
after chemotherapy in the primary tumour (Ogston et al., 2003).   It is defined 
as:  grade 1 (no change to cellularity); grade 2 (up to 30% loss in cellularity); 
grade 3 (between 30-90% reduction in cellularity); grade 4 (small clusters of 
tumour cells and greater than 90% loss in cellularity) and; grade 5 
(disappearance of tumour cells).  In this study, responders were defined as 
having a MP grade of 3-5; whereas non-responders were defined as having an 
MP grade of 1-2.  This was chosen based on the advice and discussion with the 
host institution’s breast pathologist and also demonstrated good statistical 
modelling from other DOS studies (Zhu et al., 2014).  Also, Miller-Payne criteria 
is used to evaluate tumour-only response and thus provided a good system as 
DOS and QUS imaging analysis was only of the tumour alone.   Using Miller-
Payne criteria here, still has important clinical relevance, i.e., clinicians will still 
indicate continuing with chemotherapy, if there is partial response in the tumour.  
The natural follow-up question to this limitation is to inquire about the link 
between pCR/ pPR and long-term survival and if measuring partial response is 
still a clinical benefit in terms of survival outcomes to patients.  Indeed, pCR has 
been shown to be linked to long term (+5 years) survival by the German Breast 
Group (von Minckwitz et al., 2012).  However, achieving partial response is also 
an important clinical indicator; a study by Symmans et al. (2007) showed that up 
to 80% of patients who achieved partial response to chemotherapy may still live 
up to 5 years without distant relapse (Symmans et al., 2007).     
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4.5.4 Limitations of DOS and QUS Imaging 
 
Signal-to-Noise Ratio 
 
 A major challenge with all types of imaging (i.e. MRI, CT, PET, 
ultrasound, optical imaging) involves optimizing the signal-to-noise ratio (SNR) 
to obtain the intrinsic or “true” measurement.  The SNR is defined as the ratio 
between the strength (power) of the image signal to the strength of the 
unwanted signal (noise); thus, a greater SNR is desirable in medical imaging.  
Obtaining a high SNR in DOS imaging can be a challenge since light from the 
surrounding environment (i.e. room light or background illumination) can cause 
unwanted light signals detected and this can result in a contaminated DOS 
measurements or low SNR (Gibson et al., 2005)26.  Other challenges 
associated with optimal SNR in optical imaging include measuring the 
absorption co-efficient across large tissue distances (Gibson et al., 2005).  
Measurements of DOS imaging parameters such as the total haemoglobin 
concentration are dependent on the absorption co-efficient; yet the limitation is 
that scattering dominates over absorption as the photon path length increases 
(Gibson et al., 2005).  It has been shown previously that there is a negative 
correlation between the path length and the total haemoglobin measurement 
(r=-0.34); thus, as the photon path length (e.g. breast thickness) increases, the 
total haemoglobin decreases (Intes, 2005, Gibson et al., 2005).  To limit these 
challenges, a maximum breast thickness of 80 mm was used with the DOS 
tomography system in this thesis study.   Another limitation with DOS systems 
include the need to ensure adequate surface coupling between the light source 
and the breast.  In this study, optical compensation medium was used; but 
heterogeneities in the medium, such as air bubbles, inhomogeneous distribution 
of its components (lipid and dye), may result in a lower SNR.  However, a 
quality check was completed before each scan to remove air bubbles in the 
imaging aquarium and each OCM batch was characterized as described by 
Intes et al. (2005) prior to DOS imaging (Intes, 2005).  One major limitation for 
                                            
26  
Note that in this thesis study, DOS data was acquired in a dark-room. 
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optical imaging is skin pigmentation since intrinsic chromophores such as 
melanin in the skin can absorb the transmitted light at the skin surface.  
 For QUS, a low SNR can be caused by imaging deep (posterior) tumours;  
large breast tumours that extend into the posterior margin results in increased 
acoustic attenuation which can affect the quality of the echo signal (Lizzi et al., 
1983).  The study here used an attenuation correction (i.e. an attenuation co-
efficient was calculated per unit depth of QUS imaging) to compensate for the 
attenuation effects of deeply-located tumours (Lizzi et al., 1997b).    
    
Image Resolution and Region of Interest 
 
The accuracy of DOS and QUS imaging modalities is limited by the finite 
resolution size, which is greater than the physiological structures being 
measured (i.e. blood vessels, haemoglobin, cell substructures).  In medical 
imaging, this limitation is called the “partial volume effect”; defined as an 
underestimation of the measured value (i.e. concentration of a tracer or signal 
strength) due to the finite information that can be carried within the resolution 
parameters of a pixel or voxel.  For example, high resolution imaging can carry 
greater information compared to lower resolution imaging since in high 
resolution imaging,  the greater number of pixels (or voxels) within the image 
can better represent the spatial layout (Soret et al., 2007).  For DOS, the voxel 
size was 3 mm x 3 mm, which can capture information on larger blood vessels 
and even represent clusters of smaller blood vessels.  The limitation here is that 
image reconstruction is poor, yet the quantitative measurements may still 
represent the biological properties very well.     
 Another limitation for DOS and QUS imaging is the repeatability and 
reproducibility in ROIs; as the resolution of the images were relatively lower 
compared to other modalities such as MRI and CT imaging.  Variations in 
contouring the ROI could have resulted in differing results.  In this study, we 
employed a semi-automated contouring approach which was software driven 
(thus, minimizing potential user-variations).  Additionally, interuser variability 
testing was completed to ensure that there was consistency between readers.    
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Cross-validating DOS and QUS Parameters with Biospecimen Assays 
 
An important limitation was that it was not possible to validate intratreatment 
tumour biology with histology.  Using immunohistochemistry could have 
correlated biospecimen evaluation of tumour cell death, cell proliferation, 
vascular changes or hypoxia with DOS and QUS measurements.  For example, 
biological assays for apoptotic cell death could have used TUNEL (Terminal 
deoxynucleotidyl transferase (TdT) dUTP Nick-End Labelling); while using Ki-67 
could have been used to assess the proliferative rate in tumour cells.  Vascular 
assessment could have included serial biopsies to stain tumours with CD-31 
(Cluster of differentiation-31); whereas using CA-9 (carbonic anhydrase-9) 
could have been used to validate hypoxia and tumour oxygenation.  The above 
biological assays could have been used to compare with DOS and QUS 
markers.  However, it should be noted that serial biopsies during chemotherapy 
is difficult for patients and may also cause discomfort, pain and inflammation in 
the tumour site which may also cause the patient undue harm.  Also, in some 
patients, invasive procedures such as biopsies may cause breast swelling and 
injury to the breast which could also affect haematological measurements from 
DOS.      
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4.6 Future Work 
 
4.6.1 Future work for Locally Advanced Breast Cancer 
 
 Future work could be directed to allow stratification of patients to tumour 
subtypes based on measures/markers of the tumour responses to 
chemotherapy using DOS and QUS.  Such work could further examine the DOS 
and QUS imaging biomarker signatures associated with NAC responses in 
tumour subtypes27 such as triple negative breast cancer, luminal A, luminal B 
breast cancer, HER2-positive breast cancer and by tumour grade.  This future 
work is important since previous study results by the German Breast Group 
indicated that there were significant increases in long-term survival (10 years) 
for patients with HER2-positive (non-luminal), and triple negative breast 
tumours (von Minckwitz et al., 2012).  Thus, further studies using DOS and 
QUS could be used to measure the responses in these subtypes and link DOS 
and QUS imaging biomarkers to other endpoints such as overall survival.   
 With a larger patient cohort, further work could be completed correlating 
DOS and QUS parameters within multinomial categories; for example, 
classifying patients into MP1, MP2, MP3, MP4, and MP5.  This graded 
response classification could increase the information given to clinicians.  Also, 
other response classification models could be used such as TNM, Sataloff 
index, or residual cancer burden index.  These response indices are important 
since they also consider lymph node status in their response criteria, as 
involved lymph nodes after chemotherapy have been shown to decrease overall 
survival (von Minckwitz et al., 2012).  Thus, future work could also include DOS 
and QUS measurements of lymph nodes as surrogate endpoints for overall 
survival.  Evaluating lymph nodes would also give further insight to the risk of 
metastatic disease.  Assessing the risk of metastatic lymph node involvement 
after neoadjuvant chemotherapy is a subject of great interest to clinicians; as 
lymph node metastasis after primary treatment is linked to higher mortality 
(Symmans et al., 2007).  A recent study by Hieken et al. (2013) studied sentinel 
                                            
27 The subtypes are defined as: Luminal A: ER+/PR+/HER2-; Luminal B: 
ER+/PR+/HER2+/-/Ki67 high; Triple Negative: ER-/PR-/HER2- 
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lymph node involvement after NAC using conventional ultrasound, MRI, and 
PET and showed low sensitivity (range; 61.0%-69.8%) to gold-standard biopsy 
evaluation (Hieken et al., 2013).  Thus, there is an opportunity to improve the 
accuracies from current imaging techniques to assess lymph node metastasis 
after NAC using QUS.  
In terms of developing further clinical relevance using DOS and QUS, 
further work can be completed for analysing patients who are pCR and non-
pCR; since pCR patients have been shown to demonstrate a lower tumour 
recurrence rate and are also more likely to live longer (i.e. >5 years) (von 
Minckwitz et al., 2012).   
 
4.6.2 Applications to Early Stage Breast Cancer and Other Cancers 
 
 Neoadjuvant chemotherapy is becoming increasingly indicated for early 
(stage 1 and stage 2), operable invasive breast cancer (Cain et al., 2017).  
Patients with early breast cancer (EBC) are recommended for neoadjuvant 
chemotherapy upon presentation of the following clinical characteristics (Cain et 
al., 2017):  
1. large tumours relative to the breast size; as to downstage the tumour for 
either total mastectomy or lumpectomy (breast conserving surgery) 
2. higher risk breast cancer, i.e., positive lymph node status 
3. high grade tumours, HER2+ and triple negative disease 
4. women of younger age.   
In a Japanese study, women with HER2-negative breast cancer (median age; 
48 years old) were also indicated for neoadjuvant chemotherapy since in this 
tumour subgroup, the risk of tumour relapse is high and there is a low rate of 
pathological complete response (Masuda et al., 2017).  The opportunity for 
future work includes using DOS and QUS to measure the chemotherapy 
responses in early breast cancer with the primary endpoint of surrogate imaging 
biomarkers for incomplete pathologic response28, as opposed to measuring for 
complete pathologic response.  Identifying patients for incomplete pathologic 
response, (i.e., residual tumour cells after NAC) could build on the recent 
                                            
28 Incomplete pathological response is defined as the presence of residual 
cancer cells after primary treatment. 
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CREATE-X study by Masuda et al. (2017).  In this study, it was shown that 
incomplete responders benefited from additional chemotherapies, such as 
capecitabine29 after surgery (Masuda et al., 2017).  The results indicated that 
the major benefit to administering adjuvant capecitabine increased overall 
survival (the hazard ratio was 0.70 for patients who received capecitabine 
versus control group) (Masuda et al., 2017).  The potential benefit of using DOS 
and QUS to collect early-response markers could identify incomplete 
responders early, so that patients could potentially receive capecitabine upfront 
before surgery, to downstage tumours and improve tumour response.    
QUS could be used to monitor treatment response in other tumours.  
QUS is more ideal than DOS for imaging in other tumour types, since QUS 
imaging can achieve high resolution imaging in comparison to the current 
technology for DOS imaging that has a low resolution.  Indeed, current studies 
are underway to use QUS imaging biomarkers to measure radiotherapy 
response in head and neck cancer (Tran et al. (2017), unpublished data, under 
review).  Other disease sites, such as prostate cancer and bladder cancer could 
potentially benefit from using QUS imaging biomarker assessment for 
radiotherapy response, as pre-clinical studies are demonstrating promising 
results in mice models (Kim et al., 2014, Tran et al., 2016).  However, one major 
consideration for future projects is the requirement to use high resolution QUS 
imaging, due to the disease presentation in prostate and bladder tumours (i.e., 
diffuse cancer cells), which would require intensive work on partitioning the 
QUS signals between normal and tumour cells.      
 
4.6.3 Other Frameworks for Future Studies   
 
Collaborative Frameworks Toward Biomarkers Validation and Clinical 
Implementation 
 
Using DOS and QUS as a routine decision-making tool to guide therapy 
in oncology will require further investigation in terms of validating the results 
with a greater sample size.  Therefore, there is a motivation for future work to 
                                            
29 Capecitabine is an antimetabolite chemotherapy drug. 
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confirm DOS and QUS data reproducibility across several research centres and 
hospitals.  To achieve this, collaborations through imaging networks such as the 
NCI-based, Quantitative Imaging Network (QIN), Quantitative Imaging 
Biomarkers Alliance (QIBA), and the American College of Radiology Imaging 
Network (ACRIN) and Cancer Research UK (CRUK) could help with linking 
expertise and future work with collaborating scientists and physicians (O'Connor 
et al., 2016).  Collaborative multicentre trials have been carried out to 
investigate DOS imaging in breast cancer through the ACRIN network.  Future 
work could include participating in those multicentre trials with other research 
groups (Tromberg et al., 2016).   
 
Technical Frameworks 
 
 To address the limitations of correlating DOS and QUS measurements 
with histological assays during treatment, potential cross validation could be 
completed by performing parallel imaging with other modalities such as BOLD-
MRI30; to measure tumour blood perfusion and oxygenation to complement the 
physiological inferences by DOS parameters that measure haemoglobin and 
oxygen saturation (Jiang et al., 2013).  Additionally, some early imaging studies 
have shown a link between 99mTcAnnexin V imaging biomarkers and the rate of 
apoptosis; thus, it would be interesting if complementary QUS and 99mTcAnnexin 
V imaging biomarkers could be modelled together in multivariate analyses 
(Blankenberg et al., 1999).         
 A potential opportunity for future work could be to explore image co-
registration using other modalities such as MRI and conventional ultrasound.  In 
previous studies, US-guided optical imaging has been studied and developed 
by Zhu et al., from the University of Connecticut (Xu et al., 2015, Zhu et al., 
2013, Zhu et al., 2008).  In these studies, US grey-scale imaging was used to 
localize breast tumours, and diffuse optical imaging to map tumour haemoglobin 
changes during treatment (Zhu et al., 2013, Zhu et al., 2008, Xu et al., 2015, 
                                            
30 MRI-based functional imaging techniques, such as blood oxygenation-level 
dependent (BOLD) contrast, have indicated some promising results to measure 
vascular oxygenation as a marker for treatment response in tumours (Jiang et 
al. 2013). 
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Zhu et al., 2014).  The technical benefits of that approach use US guidance to 
verify posterior (deeper) tumour margins, where optical image resolution is 
poorer (Zhu et al., 2008).  Due to the differences in patient positioning in this 
present study (i.e. prone and supine for DOS and QUS, respectively), it was not 
possible to use ultrasound images to guide DOS, but MRIs were used to help 
demonstrate the extent of the tumour since patients were positioned in prone 
position for both imaging techniques.  A future project would investigate image 
co-registration and fusion, which is different from image guidance.   Image co-
registration and fusion involves correcting for the geometric transformations 
between two images; as to match the spatial coordinates between objects in the 
images.   
 Lastly, an opportunity exists for modelling DOS and QUS imaging 
markers with bio-specimen markers, such as oestrogen receptor, progesterone 
receptor, HER2, proliferation markers such as Ki67, or vascular markers such 
as CD-31 using the pre-treatment breast biopsies.  Previous work by Ueda et al. 
(2012) used multivariate analyses for baseline DOS parameters combined with 
tissue biomarkers from immunohistochemistry (Ueda et al., 2012).   Markers for 
cell proliferation (Ki67), and molecular features (oestrogen and progesterone 
receptor) were combined with optical measurements such as HbO2, Hb, or the 
tumour oxygen saturation (StO2).  Multivariate discriminant analysis of the 
combined parameters demonstrated an increase in the sensitivity and specificity 
for predicting NAC response.  The results from Ueda et al. (2012) support the 
need for further exploration into combination analysis to improve the predictive 
performance of multiple imaging and clinical biomarkers (Ueda et al., 2012).   
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4.7 Conclusion 
 
In this study, DOS and QUS imaging was explored for the potential to 
extract imaging biomarkers in locally advanced breast cancer patients to report 
first accounts of coincident expression during neoadjuvant chemotherapy.  The 
results from the present study support, and build on, the previous body of work 
suggesting that DOS and QUS imaging biomarkers may be extracted from 
breast tumours either before, or during, chemotherapy.   
In this study, baseline DOS functional maps were also examined using 
GLCM-texture analysis to predict patient response to NAC.  The results of this 
study demonstrated that an increase in cell death markers from QUS correlated 
with a decrease in tumour haemoglobin markers from DOS; suggesting that cell 
death and vascular remodelling were typically predictive of a favourable 
treatment response.  The results of subproject two also indicated that DOS-
texture features differentiated between response groups before the start of 
treatment, based on the biological features of breast tumours. Here, high 
sensitivity and specificity with pathologic endpoints as measured using Miller-
Payne pathologic response criteria were shown in this study.  
 Using DOS and QUS imaging modalities together and deriving 
combined acoustic and optical spectral data could provide more powerful 
imaging signatures to help guide treatment decisions and improve outcomes for 
patients.  With further validation studies, it would be plausible to use DOS-QUS 
markers as biological surrogates to predict tumour response to neoadjuvant 
chemotherapy.  These imaging modalities are lower in cost compared to MRI 
and CT, non-invasive and can be acquired quickly and in series within the 
patient’s treatment schedule.  Coincident DOS and QUS changes are important 
to understand the pathophysiological traits in tumours for better treatment 
response evaluation.  Although further studies are required, this first report 
demonstrates promising potential for DOS-based textural parameters to 
evaluate baseline tumour vascular heterogeneity, and subsequently as markers 
for response to chemotherapy.  The use of DOS and QUS markers may help 
guide treatments to personalize patient care plans by potentially predicting 
chemoresponse and to extract early-response indicators to help physicians 
make decisions about the patient’s treatment.  Ultimately if used to guide 
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therapy, validated DOS and QUS imaging biomarkers may help improve breast 
cancer therapeutics and may be further studied to potentially improve overall 
disease-free survival.      
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Appendix 1 
 
Supplementary Information to Chapter 1 
 
A1.1 Radiological Tumour Response Endpoints 
 
A1.1.1 WHO Tumour-response Imaging Guidelines 
 
 The standards set by the WHO were developed in the early 1980s and 
measures the changes in tumour dimensions to classify treatment response 
(Figure A1.1) (Park et al., 2003).  Tumour measurements are taken from 
radiographs, and a value is calculated from the product of the longest overall 
tumour diameter, and the longest perpendicular diameter (mm x mm).   This 
calculation is known as the sum of the products of diameters (SPD) (Figure 
A1.1).  In order to quantify tumour response, a relative percent change from the 
baseline SPD is computed.   Response categories are based on the overall 
percent changes and are classified as (Tirkes et al., 2013):  
1. Complete response (CR).  There is no detectable tumour on 
imaging for at least four weeks.  
2. Partial response (PR).  There is a ³50% reduction in the SPD at four 
weeks relative to baseline.  
3. Progressive disease (PD).  There is a ³25% increase in the SPD.  
4. Stable disease (SD).  There is no significant change; neither partial 
response, or progressive disease.   
 
A1.1.2 RECIST 1.1 Guidelines 
 
 RECIST guidelines were introduced in the early 2000s and have been 
updated recently to simplify the recommendations on tumour measurement 
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techniques and to include CT-based imaging (RECIST Version 1.1)(Eisenhauer 
et al., 2009, Therasse et al., 2000).  Significant differences between RECIST 
1.1 and WHO guidelines include changes in the classification cut-off points and 
modifying the way tumours are measured. For breast tumours, RECIST 1.1 
guidelines require only unidimensional tumour measurements and optimal 
analysis is recommended on axial CT images (Figure A1.1).  Tumour response 
is classified based on the relative percent changes from the baseline 
(Eisenhauer et al., 2009): 
1. Complete Response (CR): Disappearance of all target lesions.  Any 
pathological lymph nodes (both target and non-target lesions) have been 
reduced to less than 10 mm in the short axis.   
2. Partial Response (PR):  ³30% decrease in the sum of the longest 
diameter of the target lesion compared to baseline.   
3. Progressive Disease (PD):  ³20% increase in the sum of the shortest 
diameter of the target lesion compared to baseline   
4. Stable Disease (SD): No significant change to tumour dimension.  
Neither PR or PD.   
 
Figure A1.1: CT of the chest indicating a right breast tumour.   (Left) WHO 
guidelines use the cross-product of the longest tumour measurement (Arrow A) 
and the perpendicular longest measurement (Arrow B).  The sum of the 
product of diameters (SPD) is used to measure relative percent changes from 
baseline.  (Right) RECIST 1.1 guidelines measure the sum of the longest 
tumour dimension to calculate the relative changes in tumour size during 
treatment (Arrow A). (Image taken from clinical breast patient at Sunnybrook 
Health Sciences Centre, Toronto, Canada).       
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A1.1.3 Limitations of using Radiological Response Endpoints 
 
Limitations for WHO and RECIST 1.1 methods include variability among 
readers were previously shown in determining the longest tumour measurement 
and errors increased when readers were measuring multifocal malignant lesions 
(Kang et al., 2012). Also WHO guidelines have been limited in describing the 
utility of three-dimensional imaging such as computed tomography (CT) and 
magnetic resonance imaging (MRI) (Kang et al., 2012).  Size-based 
measurements to monitor treatment response have shifted towards using 
updated guidelines such as RECIST since it has shown greater applicability 
with newer imaging modalities such as MRI and CT (Schwartz et al., 2016).  
Limitations for RECIST criteria include the spatial resolution constraints for CT 
imaging which restrict imaging for lesions > 1 cm only (Eisenhauer et al., 2009).  
Other significant limitations include the overestimation of the tumour’s size on 
imaging due fibrosis and scattered residual nodules that can appear as 
enhanced imaging features on MRI and CT (Pritt and Weaver, 2005). 
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Appendix 2 
 
Supplementary Information to Chapter 2 
 
A2.1 Institutional Ethics Review Board Approval Letters 
 
Inquiries regarding ethics approval may be sent to: 
 
Human Research Protections Program, Sunnybrook Health Sciences Centre 
C825, 2075 Bayview Avenue 
Toronto, Ontario, M4N3M5 
Tel: 416 480 6100 x 88144 
Fax: 416 480 5385 
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A2.2 Image Processing 
 
A2.2.1 Fast Fourier Transform (FFT) (QUS) 
 
Fast Fourier Transform (FFT) of the amplitude line spectrum; 
 
Al(f,zl)= γ22 As(f,zl)Ar(f,zl)     
Calculation of the power spectrum is done by applying a fast Fourier 
transform (FFT, As(f,zl)) of a gated radiofrequency data line segment (zl) to 
obtain the amplitude line spectrum (Al(f,zl)) 
 
To reduce spectral-noise artefacts, a sliding window algorithm was used 
with the settings of a Hamming window function for gating, where there was an 
80% overlap between adjacent windows in the axial direction.  A reference 
phantom technique was used to remove system transfer effects from the data 
using a tissue-mimicking agar-embedded glass-bead phantom with known 
acoustic properties (Tadayyon et al., 2014).  
 
Calibration using a reference signal; 
S(f)= log10 1Nn|Al(f,zl)|2e-4(αs-αr)(R+∆z2 )N
l=1
 
 
To normalize the tissue sample signal to the reference phantom, the 
amplitude line spectrum is calculated in the same manner; where Ar(f,zl) is the 
FFT of the gated radiofrequency signal from the ROIs of the reference phantom.  
The log power spectrum S(f) is computed by the average of the squared 
magnitudes of the amplitude line spectra by lateral windowing.  The depth-
dependent acoustic attenuation (α) is employed for calculating the power 
spectrum, where αs and αr refer to the attenuation of the tissue and reference, 
respectively.     The resulting normalized power spectrum was calculated; where 
R is the on-axis distance between the transducer and the proximal gated 
window, and ∆z is the range of the axial distance of the gated window (Insana 
and Hall, 1990).  
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A2.2.2 Calculation for Sound Intensity (dB) 
 𝑑𝐵 = 10𝑙𝑜𝑔r ()()	  
 
where; 𝑍r and 𝑍_  corresponds to the characteristic impedance of a medium (1) 
and medium (2), respectively.  The characteristic impedance, Z, is defined as;  
 𝑍 = 𝜌𝑐 
 
where 𝜌	= density of the material, and 𝑐 = speed of sound in the medium.   
 
 
A2.2.3 Calculation for Average Speed of Sound in Soft Tissue 
 𝑐 =  r     (Madsen et al., 1978):  
 
 
A2.2.4 QUS Axial Resolution 
 
The SPL is expressed as; 
 𝑆𝑃𝐿 = 𝑁𝜆   
 
To determine the “best” axial resolution, a mathematical function is expressed 
that is derived from the SPL:  
 𝑅() ) = 	 ¡¢∆¤ 	(𝑚𝑚)    
   
Axial resolution was calculated as:  
  𝑅() ) = 	 .¦¦∆¤ 	  ;   
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where the frequency bandwidth was 3-8 MHz, (∆𝑓)	= 5 MHz 
 𝑅() ) = 	 .¦¦§	¨©ª  ;   
therefore,  𝑹(𝒂𝒙𝒊𝒂𝒍) = 	𝟎. 𝟏𝟓𝟒	𝒎𝒎    
 
Assumptions: The average speed of sound in soft tissue (i.e. breast) is 1540 
m/s, the best axial resolution would be expressed mathematically as,  𝑅() ) =	.¦¦∆¤ 		(O'Brien, 2007), where ∆𝑓 is equal to the system bandwidth (frequency 
range) in MHz.    
 
A2.2.5 QUS Lateral resolution (at focus) 
 𝑅 067  = 𝐹	 × 	𝜆   ;   
 
where the speed of sound was 1540 m/s and central frequency was 7 MHz and 
F31 is the Fnumber: 
 𝑅 067  = 0.98	𝑥	0.22	𝑚𝑚  ;   
therefore, 𝑹𝒍𝒂𝒕𝒆𝒓𝒂𝒍 = 𝟎. 𝟐𝟏	𝒎𝒎  
 
 
The optimal lateral resolution of the imaging system used was 0.21 mm.   
 
 
 
 
 
                                            
31 The F number was obtained from the settings profile of the ultrasound 
system. 
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Appendix 3 
 
Supplementary Information to Chapter 3 
 
A3.1.   Pathological Assessment 
A.3.1.1 Pathological responder versus Pathological non-responder 
Representative immunohistochemistry staining.   
 
      
 
Figure A3.1. Light microscopy of a responder’s breast tumour (Patient #10) 
and a non-responder’s breast tumour after chemotherapy (Study Patient # 
21).   Tumour specimens were stained with haematoxylin and eosin and cluster 
of differentiation-31 (CD-31) for vascular detection.   Biophysical features 
demonstrated differences in the tissue composition. Spatial heterogeneity 
between responders and non-responders were observed. Legend: (A) 
Adipocyte; (B) Blood Vessels; (F) Fibroblasts; (T) (Tumour Cells).       
A.3.1.2 Mastectomy histology demonstrated a significant difference in vascular 
density between responders and non-responders as assessed by CD31 
immunohistochemistry staining.  
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Appendix 4 
 
Supplementary Information to Chapter 4  
A4.3 Summary of Contributions of Thesis Study 
 
Description of Studies Published from Thesis 
No. Reference Summary of Work/Significant Findings/Optimal 
Markers 
23 Tran et al.  
(2016) 
• DOS and QUS measurements were obtained in 
parallel, at the same time intervals (baseline, week 
one, week four, week eight, preoperatively).  
• Results demonstrated that univariate QUS (SI) and 
DOS (HbO2) markers were significantly different 
between responders and non-responders after one 
week of treatment (p<0.01).  The %Sn and %Sp for 
the SI was 64.3% and 87.5%, respectively and for 
HbO2, the %Sn and %Sp was 85.7% and 87.5%, 
respectively.   
• The best multivariate (pairwise) combinations 
included the SI + HbO2 which resulted in an AUC of 
1.00 after one week (p<0.001) 
24 Tran et al.  
(2017) 
• Pre-treatment DOS-texture markers demonstrated 
significant differences between responders and non-
responders.   
• The HbO2 homogeneity resulted in the highest 
accuracy among univariate parameters in predicting 
response to chemotherapy; corresponding to a %Sn 
and %Sp were 86.5% and 89.0%, respectively, and 
accuracy was 87.8%. The highest predictors using 
multivariate (binary) combination features were the 
Hb-contrast + HbO2-homogeneity, which resulted in 
a %Sn/ %Sp¼78.0/81.0% and an accuracy of 79.5%. 
 
Table A4.4:  Significant contributions related to the work outlined in the thesis.  
The major contributions include using DOS and QUS at the same temporal time 
intervals, and using pre-treatment DOS-texture features to predict 
chemotherapy response.   
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Appendix 5 
 
Academic Output from PhD 
A5.1 Overview and Summary 
 
OUTPUT TYPE COUNT 
Primary Author Publications 3 
Contributing Author Publications 9 
Book Chapters 1 
Conference Presentations 6 
 
A5.2 Publications (Primary Author) 
 
1. Tran WT, Gangeh MJ, Sannachi L, Chin L, Watkins E, Bruni SG, 
Rastegar RF, Curpen B, Trudeau M, Gandhi S, Yaffe M, Slodkowska E, 
Childs C, Sadeghi-Naini A, Czarnota GJ. Predicting breast cancer 
response to neoadjuvant chemotherapy using pre-treatment diffuse 
optical spectroscopic texture analysis. Br J Cancer. 2017 Apr 18. doi: 
10.1038/bjc.2017.97. [Epub ahead of print] PubMed PMID: 28419079. 
Impact Factor: 5.57 
 
2. Tran WT, Childs C, Chin L, Slodkowska E, Sannachi L, Tadayyon H, 
Watkins E, Wong SL, Curpen B, El Kaffas A, Al-Mahrouki A, Sadeghi-
Naini A, Czarnota GJ. Multiparametric monitoring of chemotherapy 
treatment response in locally advanced breast cancer using 
quantitative ultrasound and diffuse optical spectroscopy. 
Oncotarget. 2016 Apr 12;7(15):19762-80. doi: 
10.18632/oncotarget.7844. PubMed PMID: 26942698; PubMed Central 
PMCID: PMC4991417.  Impact Factor: 5.00 
 
3. Tran WT, Childs C, Probst H, Farhat G, Czarnota GJ.  Commentary:  
Imaging Biomarkers for Precision Medicine in Locally Advanced Breast 
Cancer.  Accepted September 2017.  In Press.  Journal of Medical 
Imaging and Radiation Sciences.  Impact Factor:  N/A  
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A5.3 Publications (Contributing Author) 
 
1. Sadeghi-Naini A, Sannachi L, Tadayyon H, Tran WT, Slodkowska E, 
Trudeau M, Gandhi S, Pritchard K, Kolios MC, Czarnota GJ.  
Chemotherapy-Response Monitoring of Breast Cancer Patients Using 
Quantitative Ultrasound-Based Intra-Tumour Heterogeneities.  Sci 
Rep. 2017 Sep 4;7(1):10352. doi: 10.1038/s41598-017-09678-0.  
PMID: 28871171. Impact Factor: 5.23  
 
2. Tadayyon H, Sannachi L, Gangeh MJ, Kim C, Ghandi S, Trudeau M, 
Pritchard K, Tran WT, Slodkowska E, Sadeghi-Naini A, Czarnota GJ. 
A priori Prediction of Neoadjuvant Chemotherapy Response and 
Survival in Breast Cancer Patients using Quantitative 
Ultrasound. Sci Rep. 2017 Apr 12;7:45733. doi: 10.1038/srep45733. 
PubMed PMID: 28401902; PubMed Central PMCID: PMC53 50. 
Impact Factor: 5.23 
 
3. Pasternak M, Doss L, Farhat G, Al-Mahrouki A, Kim CH, Kolios M, 
Tran WT, Czarnota GJ. Effect of chromatin structure on 
quantitative ultrasound parameters. Oncotarget. 2017 Mar 
21;8(12):19631-19644. doi: 10.18632/oncotarget.14816. PubMed 
PMID: 28129644; PubMed Central PMCID: PMC5386710. 
Impact Factor: 5.00 
 
4. Tadayyon H, Sannachi L, Gangeh M, Sadeghi-Naini A, Tran W, 
Trudeau ME, Pritchard K, Ghandi S, Verma S, Czarnota GJ. 
Quantitative ultrasound assessment of breast tumour response 
to chemotherapy using a multi-parameter approach. Oncotarget. 
2016 Jul 19;7(29):45094-45111. doi: 10.18632/oncotarget.8862. 
PubMed  PMID: 27105515; PubMed Central PMCID: PMC5216708. 
Impact Factor: 5.00 
 
5. Tadayyon H, Sannachi L, Sadeghi-Naini A, Al-Mahrouki A, Tran WT, 
Kolios MC, Czarnota GJ. Quantification of Ultrasonic Scattering 
Properties of In Vivo Tumour Cell Death in Mouse Models of 
Breast Cancer. Transl Oncol. 2015 Dec;8(6):463-73.  doi: 
10.1016/j.tranon.2015.11.001. PubMed PMID: 26692527; PubMed 
Central PMCID: PMC4701005. 
Impact Factor: 3.01 
 
6. Gangeh MJ, Tadayyon H, Sannachi L, Sadeghi-Naini A, Tran WT, 
Czarnota GJ. Computer Aided Theragnosis Using Quantitative 
Ultrasound Spectroscopy and Maximum Mean Discrepancy in 
Locally Advanced Breast Cancer. IEEE Trans Med Imaging. 2016  
Mar;35(3):778-90. doi: 10.1109/TMI.2015.2495246. Epub 2015 Oct 
27. PubMed PMID: 26529750. 
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Impact Factor: 3.76 
 
7. Sadeghi-Naini A, Vorauer E, Chin L, Falou O, Tran WT, Wright FC, 
Gandhi S, Yaffe MJ, Czarnota GJ. Early detection of 
chemotherapy-refractory patients by monitoring textural 
alterations in diffuse optical spectroscopic images. Med Phys. 
2015 Nov;42(11):6130-46. doi: 10.1118/1.4931603. PubMed PMID: 
26520706. 
Impact Factor: 2.64 
 
8. Sannachi L, Tadayyon H, Sadeghi-Naini A, Tran W, Gandhi S, Wright 
F, Oelze M,  Czarnota G. Non-invasive evaluation of breast cancer 
response to chemotherapy using quantitative ultrasonic 
backscatter parameters. Med Image Anal. 2015 Feb;20(1):224-36. 
doi: 10.1016/j.media.2014.11.009. Epub 2014 Nov 25. PubMed 
PMID: 25534283.  
Impact Factor: 4.57 
 
9. Sadeghi-Naini A, Falou O, Tadayyon H, Al-Mahrouki A, Tran W, 
Papanicolau N, Kolios MC, Czarnota GJ. Conventional frequency 
ultrasonic biomarkers of cancer treatment response in vivo. 
Transl Oncol. 2013 Jun 1;6(3):234-43. Print 2013 Jun. Erratum in: 
Transl Oncol. 2013 Dec;6(6):erratum. PubMed PMID: 23761215; 
PubMed Central PMCID: PMC3678128. 
Impact Factor: 3.01 
 
A5.4 Conference Presentations and Posters 
 
1. Tran W. and Czarnota GJ.  DOS and QUS imaging biomarkers in 
locally advanced breast cancer. Canadian Consensus Meeting on 
Locally Advanced Breast Cancer. 2017.  Podium Presentation.  
 
2. Tran WT, Gangeh M, Suraweera H., Hadizad F., Watkins E.,  
Czarnota GJ.  DOS and QUS multiparametric modelling to measure 
neoadjuvant chemotherapy response in locally advanced breast 
cancer.  Terry Fox Research Institute Cancer Symposium.  
Vancouver BC.   2016.   Poster Presentation.     
 
3. Tran WT, Gangeh M, Suraweera H., Hadizad F., Watkins E., 
Czarnota GJ.  Multiparametric analysis of DOS and QUS imaging 
biomarkers to monitor chemotherapy response in breast cancer.  
Ultrasonic Imaging and Tissue Characterization Symposium.  
Washington DC, USA. 2015.   Podium Presentation.    
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4. Tran W., Kim C. Czarnota GJ.  Cell death detection in locally 
advanced breast cancer using quantitative ultrasound and diffuse 
optical spectroscopy.  IEEE International Ultrasonics Symposium, 
Chicago USA. 2014.   Poster Presentation 
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Monitoring.  IEEE International Ultrasonics Symposium, Chicago 
USA. 2014.   Poster Presentation 
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A5.5 Book Chapters 
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